,PageNo,Text
0,page_0,"P artici p ati n g N C T N Gr o u p s: Allia nce/ Allia nce f or Cli nical Trials i n O nc ol o gy(lea d), E C O G -A C RI N/ E C O G A C RI N Ca ncer Res earc h Gr o u p, N R G/ N R G O nc ol o gy, S W O G/ S W O G 1 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 A L LI A N C E F O R C LI NI C A L T RI A L S I N O N C O L O G Y A L LI A N C E A 1 7 1 6 0 1 A PH A S E II TRI A L AS S ES S I N G T H E TO L E R A BI LI T Y O F PA L B O C I C LI B I N CO M BI N A TI O N W I T H LE T R O Z O L E O R FU L V ES T R A N T I N PA TI E N TS AG E D 7 0 A N D OL D E R W I T H ES T R O G E N RE C E P T O R - PO S I TI V E , H E R 2 -N E G A TI V E ME T A S T A TI C BR E A S T CA N C E R C o m merci al a ge nt( s): P al b oci cli b; (I N D: exe m pt) C li ni c al Tri als. g o v I de ntifi er: N C T0 3 6 3 3 3 3 1. St u d y C hair Mi n a S. Se dra k M D , M S Cit y of H o p e Co mpre h e nsi v e Ca n c er Ce nt er St u d y Co -Ch air A mi n a h Jat oi M D M a y o Cli nic C o m m u nit y O n c ol o g y C o -C h air C orr elati v e St u d y C o -C h air P h ar m a c o ge n o mics St u d y C o -C h air I m a gi n g C o -C h air P h ar m a c o ki n etics St u d y C o -C h air Br e ast C o m mitt e e St u d y C o -C h air St u d y C o -C h air Ca n c er i n t h e El derl y C o m mitt e e C o -C h airs Br e ast C o m mitt e e C o -C h airs Dat a M a n a ger Pr ot o c ol Co or di nat or I n m e m ory of Dr. Arti H urri a Pri mar y St atisticia n Se c o n d ar y St atisticia n"
1,page_1,"Allia nc e A1 7 1 6 0 1 2 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 St u dy Res o u rces: Ex pe dit e d A dve rs e Eve nt Re porti n g Me di dat a R a ve   i Me di dat a port al O P E N ( O nc ol o g y P ati e nt Enr oll me nt Net wor k) Bi os pe ci m e n Ma n a ge me nt S yst e m Pr ot oc ol C o nt acts: A 1 7 1 6 0 1 N u rsi n g C o nt act A 1 7 1 6 0 1 P h ar m ac y C o nt act Alli a n ce Bi ore posit or y at Ma y o Cli ni c U ni ve rsit y of Pitts b u r g h C a n cer I nstit ute I R O C Pr ot oc ol -rel at e d q u esti o ns m a y be di re ct e d as f ollo ws : Q u esti o ns C o nt act ( vi a e m ail) Q uestio ns r e gar din g patie nt eligibilit y, tr eat m e nt, a n d d os e m o dific atio n: St u d y C hair, N ursin g C o nt act, Pr ot oc ol C o or dinat or, a n d ( w her e a p plic a ble) Dat a Ma na ger Q uestio ns r elat e d t o dat a s u b missio n, R A V E or patie nt f ollo w -u p: Dat a Ma na ger Q uestio ns r e gar din g t he pr ot oc ol d oc u m e nt a n d m o del inf or m e d c o ns e nt: Pr ot oc ol C o or dinat or Q uestio ns r elat e d t o I R B r e vie w Allia nc e Re g ulat or y I n b o x Q uestio ns r e gar din g C T E P -A E R S r e p ortin g: Allia nc e P har m ac o vigila nc e I n b o x Q uestio ns r e gar din g s peci m e ns/s peci m e n s u b missio ns: A p pr o priat e Allia nc e Bior e p osit or y Q uestio ns r e gar din g dr u g a d ministr atio n P har m ac y C o nt act"
2,page_2,"Allia nc e A1 7 1 6 0 1 3 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 C A N C E R T RI A L S S U P P O R T U NI T ( C T S U) A D D R E S S A N D C O N T A C T I N F O R M A TI O N F or re g ul at or y re q ui re me nts: F or pati e nt e n r oll me nts: F or dat a s u b missi o n: Re g ulat or y d oc u m e nt atio n m ust be s u b mitt e d t o t he C T S U via t he Re g ulat or y S u b missio n P ort al. ( Sig n in at a n d s elect t he Re g ulat or y > Re g ulat or y S u b missio n.) I nstit utio ns wit h patie nts w aitin g t hat ar e u na ble t o us e t he P ort al s h o uld alert t he C T S U Re g ulat or y Offic e i m m e diat ely at t o r ec eive f urt her instr uctio n a n d s u p p ort. C o nt act t he C T S U Re g ulat or y Help Des k at f or r e g ulat or y assist a nc e. Ref er t o t he patie nt e nr oll m e nt s ectio n of t he pr ot oc ol f or instr uctio ns o n usin g t he O nc olo g y P atie nt E nr oll m e nt Net w or k ( O P E N). O P E N is ac c ess e d at C o nt act t he C T S U Help Des k wi t h a n y O P E N-r elat e d q uestio ns b y p h o ne or e m ail : , or . Dat a c ollectio n f or t his st u d y will be d o ne e xclusively t hr o u g h Me didat a Ra ve. Ref er t o t he dat a s u b missio n s ectio n of t he pr ot oc ol f or f urt her instr uctio ns. D o n ot s u b mit st u d y dat a or f or ms t o t he C T S U. D o n ot c o p y t he C T S U o n dat a s u b missio ns. T he m ost c urr e nt versio n of t he st u dy pr ot oc ol a n d all s u p porti n g doc u m e nts m ust be d o w nloa de d fr o m t he pr ot oc ol-s pecific pa ge loc at e d o n t he C T S U m e m bers’ w e bsit e . Ac c ess t o t he C T S U m e m bers’ w e bsit e is m a na ge d t hr o u g h t he Ca nc er T hera p y a n d E valuatio n Pr o gr a m - I de ntit y a n d Ac c ess Ma na ge m e nt ( C T E P-I A M) r egistr atio n s yst e m a n d r e q uir es lo g in wit h a C T E P - I A M us er na m e a n d pass w or d. P er missio n t o vie w a n d d o w nloa d t his pr ot oc ol a n d its s u p p ortin g d oc u m e nts is r estrict e d a n d is bas e d o n pers o n a n d sit e r ost er assig n m e nt h o us e d in t he C T S U Re g ulat or y S u p p ort S yst e m ( R S S). Instit utio ns will or der t he f ollo win g s u p plies fr o m t he C T S U O per atio ns Offic e: Q uestio n na ir e b o o klets. S u p plies c a n be or der e d b y d o w nloa din g a n d c o m pletin g t he C T S U S u p ply Re q uest F or m ( a vaila ble o n t he pr ot oc ol-s pecific pa ge o n t he C T S U w e bsit e) a n d s u b mittin g it as instr uct e d o n t he f or m. F or cli ni c al q u esti o ns (i. e., pati e nt eligi bilit y or t re at me nt -rel at e d) s ee t he Pr ot oc ol C o nt acts, P a ge 2. F or n o n -cli ni c al q u esti o ns (i.e., u n rel ate d t o pati e nt eli gi bilit y, t re at m e nt, or cli ni c al dat a s u b missi o n) c o nt act t he C T S U Help Des k b y p h o ne or e m ail: C T S U Ge ner al I nf or m atio n Line – , or . All c alls a n d c orr es p o n de nce will be tria ge d t o t he a p pr o priat e C T S U r e pr es e nt ative."
3,page_3,"Allia nc e A1 7 1 6 0 1 4 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 A PH A S E II TRI A L AS S ES S I N G T H E TO L E R A BI LI T Y O F PA L B O C I C LI B I N CO M BI N A TI O N W I T H LE T R O Z O L E O R FU L V ES T R A N T I N PA TI E N TS AG E D 7 0 A N D OL D E R W I T H ES T R O G E N RE C E P T O R - PO S I TI V E , H E R 2 -N E G A TI V E ME T A S T A TI C BR E A S T CA N C E R E li gi bilit y Crite ri a ( S e e S e cti o n 3. 2 ) Estr o g e n re c ept or p ositi v e a n d/ or pr o gester o ne re c e pt or ( P R) p ositi ve, H E R2 n e g ati v e met astatic bre ast c a nc er Se e 3. 2. 1 M e as ura ble dis e ase or n o n -me as ura ble dis ease Se e 3. 2. 2 Pla n ni n g t o b e gi n p al b ocicli b f or met astatic dis e ase. Patie nts s h o ul d h a v e faile d o n e pri or li n e of e n d o cri n e t hera p y. Se e 3. 2. 3 N o p ri or t h era p y with a C D K i n hi bit or Se e 3. 2. 4 Res ol uti o n of all a c ut e t o xic effe cts of pri or t h era p y or s ur gic al pr o c e d ures t o C T C A E Gra d e ≤ 1 (e xc e pt al o p e cia) or t o b as eli n e t o xicities pri or t o pre vi o us t h erap y or s ur gic al pr o ce d ures. Se e 3. 2. 5 N o u ntre at e d brai n met astases Se e 3. 2. 6 N o k n o w n i nt erstitial l u n g dise ase. Se e 3. 2. 7. N o s e c o n d mali g n a n cies ot her t h an n o n -mela n o ma s ki n c a n c ers or c er vic al c arci n o ma i n sit u Se e 3. 2. 8. N o a cti v e i nfe cti o n re q uiri n g tre at me nt wit h a nti bi otics Se e 3. 2. 9 . Patie nts must b e a ble t o s wall o w a n d ret ai n oral me dic ati o n Se e 3 . 2.1 0 . Pa tie nt A g e: ≥ 7 0 y e ars Se e 3. 2. 1 1 . E C O G Per f or ma n c e St at us 0, 1 or 2 Se e 3. 2. 1 2 . Patie nts must b e a ble t o re a d a n d c o mpre he n d En glis h or S p a nis h Se e 3. 2. 1 3 Re q ui r e d I niti al La bor at or y V al ues A N C ≥ 1 5 0 0/ m m3 Plat elet c o u nt: ≥ 1 0 0, 0 0 0/ m m3 Cre ati ni n e: ≥ 3 0 ml/ mi n * T ot al s er u m bilir u bi n ≤ 1. 5 U L N ( < 3 U L N if Gil b ert’s dis e as e) A S T a n d/ or A L T ≤ 3 x U L N ( ≤ 5. 0 x U L N if li v er met ast ases prese nt) Al kali n e p h os p hatase ≤ 2. 5 x U L N ( ≤ 5 x U L N if b o n e or li v er met ast ases pres e nt) * Calc ulat e d usi n g t he Co c kcr oft -Ga ult f or mula S c h e m a 1 c ycle = 2 8 da ys Re gistratio n Tre at me nt: P al b o cicli b 1 2 5 m g a da y ( O nc e daily orally o n da ys 1 -2 1 of e a c h 2 8 -da y c ycle) a n d Letr o z ole o r F ul v e str a nt ( P er tre atin g in vestigat or dis cretio n) D osin g per pa c ket ins ert in e a c h 2 8 -da y c ycle C o ntin ue pr ot oc ol tr eat m e nt u ntil u nac c e pt a ble t o xicit y or dis eas e pr o gr essio n Pl e as e ref er t o t h e f ull pr ot oc ol t e xt f or a c o m pl ete des cri pti o n of t h e eligi bilit y crit eri a a n d t re at m e nt pl a n."
4,page_4,"Allia nc e A1 7 1 6 0 1 5 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 TA B L E O F CO N T E N TS 1. 0 B A C K G R O U N D ............................................................................................................... 7 1. 1 Agin g a n d a Decr eas e in P h ysiolo gic Res er ve: Ratio nale f or St u d yin g Ca nc er T her a p y in Older Ad ults .......................................................................................................................... 7 1. 2 F act ors Ot her t ha n C hr o n olo gic al Age t hat I mpact Dr u g T oler a nc e .................................. 7 1. 3 P alb ociclib ............................................................................................................... 8 1. 4 A Ratio nale f or C o m binin g P alb ociclib a n d E n d o crine T her a p y ....................................... 8 1. 5 Meas ur e m e nt of S ar c o pe nia .......................................................................................1 1 1. 6 Q ualit y of Lif e Q uestio n nair es: E ur o Q ol 5 D 3 L a n d E Q Vis ual Analo g Sc ale ( E Q V A S) ....1 2 1. 7 P R O -C T C A E ..........................................................................................................1 2 2. 0 O B J E C TI V ES .................................................................................................................1 3 2. 1 Pri m ar y O bjective ....................................................................................................1 3 2. 2 S ec o ndar y o bjectives ................................................................................................1 3 2. 3 C orr elative s cie nc e o bjectives ....................................................................................1 3 3. 0 P A TI E N T SE L E C TI O N .....................................................................................................1 5 3. 1 O n -St u dy G uidelines ................................................................................................1 5 3. 2 Eligib ilit y Crit eria ....................................................................................................1 6 4. 0 P A TI E N T RE GI S T R A TI O N ...............................................................................................1 7 4. 1 I n vestigat or a n d Res earc h Ass ociat e Re gistr atio n wit h C T E P .........................................1 7 4. 2 C T S U Re gistr atio n Pr oc e d ur es ...................................................................................1 8 4. 3 P atie nt Re gistr atio n Re q uir e m e nts ..............................................................................2 0 4. 4 P atie nt Re gistr atio n/ Ra n d o mizatio n Pr oc e d ur es ............................................................2 0 4. 5 Re gistr atio n t o C orr elative a n d C o m pa nio n St u dies .......................................................2 1 4. 6 Gr o u pin g F act or ......................................................................................................2 2 5. 0 S T U D Y CA L E N D A R ........................................................................................................2 3 6. 0 D A T A A N D SP E C I M E N SU B MI S S I O N .................................................................................2 4 6. 1 Dat a C ollectio n a n d S u b missio n .................................................................................2 4 6. 2 S peci m e n c ollectio n a n d s u b missio n ...........................................................................2 6 6. 3 Digit al I m a ge S u b missio n Usin g T RI A D .....................................................................2 9 7. 0 T R E A T M E N T PL A N/IN T E R V E N TI O N ................................................................................3 1 7. 1 P alb ociclib ..............................................................................................................3 1 7. 2 Letr oz ole ................................................................................................................3 2 7. 3 F ulvestr a nt ..............................................................................................................3 2 7. 4 Ad her e nc e, Geriatric Ass ess m e nt, an d P atie nt P ers pective .............................................3 2 8. 0 D O S E A N D TR E A T M E N T MO DI FI C A TI O N S ........................................................................3 3 8. 1 Ancillar y T her a p y, C o nc o mit a nt Me dic atio ns, a n d S u p p ortive Car e .................................3 3 8. 2 D os e M o dific atio ns ..................................................................................................3 5 9. 0 A D V E R S E EV E N TS .........................................................................................................3 6 9. 1 R o utine Ad vers e E ve nt Re p ortin g ..............................................................................3 6 9. 2 C T C A E R o utine Re p ortin g Re q uir e m e nts ....................................................................3 7 9. 3 E x pe dit e d Ad vers e E ve nt Re p ortin g ( C T E P -A E R S) ......................................................3 7 9. 4 C A E P R ..................................................................................................................4 2 1 0. 0 D R U G IN F O R M A TI O N ....................................................................................................4 5 1 0. 1 Ge ner al C o nsider atio ns: ............................................................................................4 5"
5,page_5,Allia nc e A1 7 1 6 0 1 6 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 1 0. 2 P alb ociclib ..............................................................................................................4 5 1 0. 3 F ulvestr a nt ..............................................................................................................4 6 1 0. 4 Letr oz ole ................................................................................................................4 8 1 1. 0 M E A S U R E M E N T O F EF F E C T ...........................................................................................4 9 1 1. 1 P atie nt r e p ort e d o ut c o m e m eas ur es .............................................................................4 9 1 1. 2 Meas ur e m e nt of t u mor r es p o ns e a n d sc he dule of e valuatio ns ..........................................5 0 1 1. 3 Definitio ns of Meas ur a ble a n d N o n -Meas ur a ble Dis eas e ................................................5 1 1 1. 4 G uidelines f or E valuatio n of Meas ur a ble Dis eas e .........................................................5 2 1 1. 5 Meas ur e m e nt of Tr eat m e nt/I nt er ve ntio n Eff ect .............................................................5 3 1 1. 6 Definitio ns of Analysis Varia bles ...............................................................................5 6 1 2. 0 E N D O F TR E A T M E N T /IN T E R V E N TI O N .............................................................................5 6 1 2. 1 D ur atio n of Tr eat m e nt ..............................................................................................5 6 1 2. 2 F ollo w -u p f or patie nts w h o dis c ontin ue pr otoc ol t her a p y ...............................................5 6 1 2. 3 Ma na gin g ineligible patie nts a n d r e gist er e d patie nts w h o ne ver r ec eive pr ot oc ol int er ve ntio n 5 7 1 2. 4 E xtr a or dinar y Me dic al Cir c u mst a nc es .........................................................................5 7 1 3. 0 S T A TI S TI C A L CO N S I D E R A TI O N S .....................................................................................5 8 1 3. 1 Pri m ar y E n d p oints: ..................................................................................................5 8 1 3. 2 Pri m ar y E n d p oint Analysis: .......................................................................................5 8 1 3. 3 S ec o ndar y E n d p oints: ...............................................................................................5 8 1 3. 4 S ec o ndar y E n d p oint Analys es ....................................................................................5 8 1 3. 5 S a m ple Size ............................................................................................................6 0 1 3. 6 I nt eri m a nalysis a nd st o p pin g r ules: ............................................................................6 0 1 3. 7 St u d y Re p ortin g ......................................................................................................6 1 1 3. 8 I nclusio n of W o m e n a n d Min orities ............................................................................6 2 1 4. 0 E X P L O R A T O R Y CO R R E L A TI V E AN D CO M P A NI O N ST U D I ES ...............................................6 3 1 4. 1 C orr elative S cie nc e: Cir c ulatin g m ar kers of infla m m atio n as p ot e ntial m ar kers pr e dictive of t o xicit y a m o n g elderly patie nts e nr olle d t o Allia nc e A1 7 1 6 0 1 ( Allia nc e A1 7 1 6 0 1-S T 1) ...................6 3 1 4. 2 P har m ac o ge n o mics: ( Allia nc e A1 7 1 6 0 1 -S T 2): Ge netic det er mina nts of P alb ociclib Effic ac y a n d t o xicit y in t he elderly .......................................................................................................6 7 1 4. 3 P har m ac o kinetics: ( Alli a nc e A1 7 1 6 0 1 -P P 1) P o p ulatio n P har m ac o kinetics of P alb ociclib ..7 2 1 5. 0 G E N E R A L RE G U L A T O R Y CO N S I D E R A TI O N S A N D CR E D E N TI A LI N G ....................................7 6 1 5. 1 Geriatric Ass ess m e nt Tr ainin g ...................................................................................7 6 1 6. 0 R E F E R E N C ES ................................................................................................................7 7 1 7. 0 MO D E L CO N S E N T F O R M ....................................................................................................8 7 AP P E N D I X I: P A TI E N T I N F O R M A TI O N S H E E T S .................................................................. 1 0 0 AP P E N D I X II: GE R I A T R I C AS S ES S M E N T ................................................................................... 1 0 4 AP P E N D I X III : WA S IT WO R T H IT QU ES TI O N N AI R E ................................................................. 1 2 4 AP P E N D I X I V: OV E R A L L TR E A T M E N T UTI LI T Y ........................................................................ 1 2 5 AP P E N D I X V: E Q -5 D -3 L HE A L T H QU ES TI O N N AI R E .................................................................. 1 2 7 AP P E N D I X VI: P R O -C T C A E * -N CI -P R O -C T C A E T M I T E M S ................................................. 1 2 9 A P P E N DI X VII: PA TI E N T ME DI C A TI O N DI A R Y - PA L B O C I C LI B ................................................. 1 3 6 AP P E N D I X VIII: TA B L E O F T A G S N P S F O R A 1 7 1 60 1 S T U D Y ........................................................ 1 3 8 AP P E N D I X I X: PA TI E N T P H A R M A C O KI N E T I C Q U ES TI O N N AI R E .................................................... 1 4 0
6,page_6,"Allia nc e A1 7 1 6 0 1 7 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 1. 0 B A C K G R O U N D T his pr ot oc ol a d dr ess es a ke y r esear c h priorit y of t he Ca nc er a n d Agin g Res ear c h Gr o u p, Natio nal Ca nc er I nstit ut e, Natio nal I nstit ut e o n Agin g, a n d t he I nstit ut e of Me dicin e: t he ass ess m e nt of c a nc er t her a p y in older a d ults6 , 7 P alb ociclib is a n o vel dr u g wit h t he p ot e ntial t o c ha n ge t he tr eat m e nt of m et ast atic br east c a nc er- a pri m ar y dis eas e of older a d ults. T he c o m binatio n of palb ociclib a n d e n d ocrine t her a p y ( t he ar o m at as e in hibit or , letr oz ole, or f ulvestr a nt) is ass ociat ed wit h a n i m pr o ve m e nt in pr o gr essio n -fr ee s ur vival ( P F S) c o m par e d t o e n d ocrine t her a p y alo ne.1 , 2 Ho w e ver, a s m all pr o p ortio n of patie nts e nr olle d in t hes e st u dies w er e a ge 7 5 a n d older. T he piv ot al trial of palb ociclib r e p ort e d in t he pac ka ge ins ert n ot es t hat o nly 3 7 patie nts ( 4 4 %) w er e ≥ 6 5 years of a ge a n d 8 patie nts ( 1 0 %) w er e ≥ 7 5 years of a ge. T he g oal of t his st u d y is t o fill t his ga p in k n o wle d ge b y utilizin g a p has e II desig n t o e xa mine t he t oler a bilit y of palb ociclib a n d e n d ocrine ther a p y a m o n g older a d ults a ge 7 0 a n d older wit h estr o ge n r ece pt or p ositive, H E R 2 ne gative br east t u m ors. A c o m pr e he nsive c a nc er-s pecific geriatric ass ess m e nt w hic h inclu des a n e valuatio n of f u nctio nal st at us, ot her m e dic al c o n ditio ns, c o g nitive f u nctio n, n utritio nal st at us, s ocial s u p p ort, ps yc h olo gic al st at e, a n d a r e vie w of m e dic atio ns will be inclu de d, as w ell as a n ass ess m e nt of a d her e nc e. 1. 1 A gi n g a n d a De cre as e i n P h ysi ol o gi c Res er ve: R ati o n ale f or St u dyi n g C a n cer T h e r a py i n Ol de r A d ults Agin g brin gs a b o ut a pr o gr essive decr eas e in p h ysiolo gic r es er ve t hat aff ects eac h in divid ual at a u niq u e pac e.8 , 9 T he a ge -r elat e d p h ysiolo gic al decline in or ga n s yst e ms t y pic ally be gins in t he 3r d dec a de of lif e a n d is n ot e vide nt at ti m es of r est b ut bec o m es m ost a p par e nt w he n t he b ody is str ess e d.1 0 Bot h c a nc er a n d c a nc er tr eat m e nt c a n be c o nsider e d a p h ysiolo gic al str ess or, and a ge-r elat e d decr eas es in p h ysiolo gic r es er ve m a y aff ect t oler a nc e t o ca ncer tr eat m e nt. A n u m ber of a ge -r elat e d c ha n ges in dr u g a bs or ptio n, distrib utio n, m et a b olis m, a n d e xcr etion wit h a gin g m a y c o ntrib ut e t o diff er e nc es in tr eat m e nt t oler a nc e bet w e e n older a n d y o u n ger patie nts. T he a bs or ptio n of dr u gs c a n be aff ect e d b y decr eas e d gastr oint estinal m otilit y, decr eas e d s pla nc h nic blo o d flo w, decr eas e d s ecr etio n of digestive e nz y m es, a n d m uc os al atr o p h y.1 1 , 1 2 Wit h t he incr eas e d us e of or al t her a p y, m e dic atio n c o m plia nc e is a n i m p ort a nt iss ue as w ell.1 3 As a pers o n a ges, b o d y c o m p ositio n c ha n ges, wit h a n incr eas e in b o d y f at a n d decr ease in lea n b o d y m ass a n d t ot al b o d y w at er. T he incr eas e in b o d y f at lea ds t o a ris e in t he v olu m e of d istrib utio n f or h y dr o p hilic dr u gs. I n t he p o p ulatio n of older a d ults wit h c a nc er, m aln utrition a n d h y p oalb u mine mia m a y r es ult in a n incr eas e d c o nc e ntr atio n of dr u gs t hat ar e alb u min - b o u n d.1 4 He patic m ass a n d blo o d flo w als o decr eas e wit h a ge.8 T he i m pact of t he decline in he patic m ass a n d blo o d flo w o n he patic e nz y m e f u nctio n is c o ntr o versial.1 5 I n a st u d y of 2 2 6 patie nts, t he c yt oc hr o m e P -45 0 c o nte nt in liver bio ps y s a m ples decr eas e d b y a p pr o xi m at ely 3 0 % in patie nts o ver t he a ge of 7 0.1 6 Re nal f u nctio n als o declines wit h a ge, a n d r e nal ins ufficie nc y is c o m mon in older a d ults.1 7 , 1 8 A pr o gr essive r e d uctio n in t he f u nctio nal r es er ve of vario us or ga n s yst e ms m a y alt er t he p har m ac o kinetics of a nti -c a nc er t her a pies11 , 19 a n d incr eas e t he s us c e ptibilit y of older in divid uals t o c o m plic atio ns of tr eat m e nt.1 4 , 2 0-22 N or m al tiss ues m a y be less a ble t o r e pair t he m olec ular da m a ge c a us e d b y a ntine o plastic a ge nts d ue t o cellular s e nes c e nce, res ultin g in gr eat er p ot e ntial c ar diot o xicit y, ne ur ot o xicit y, m uc ositis, a n d he m a t olo gic t o xicities.2 3 1. 2 F act ors Ot h e r t h a n C h r o n olo gi c al A ge t h at I m pact Dr u g Tol e r a n ce Agin g is a het er o ge ne o us pr oc ess. W hile c ert ain declines in or ga n f u nctio n ar e u nivers al as t he h u m a n b o d y a ges, t he r at e of t his decline a n d t he c o ns e q ue nc es of t his decline o n e ver y da y f u nctio n pr oc ee ds at a u niq ue pac e in eac h in divid ual. T her ef or e, c hr o n olo gic al a ge t ells us"
7,page_7,"Allia nc e A1 7 1 6 0 1 8 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 r elatively little a b o ut t he s pecific in divid ual. A m or e det aile d e valuatio n of a n older a d ult patie nt is nee de d in or der t o c a pt ur e f act ors ot her t ha n c hr o n olo gic al a ge t hat pr e dict f or m or bidit y a nd m ort alit y. A c o m pr e he nsive g eriatric ass ess m e nt m a y s er ve t his p ur p os e. T he c o mpr e he nsive geriatric ass ess m e nt inclu des a n e valuatio n of f u nctio nal st at us, c o -mor bid m e dic al c o n ditio ns, c o g nitive f u nctio n, n utritio nal st at us, s ocial s u p p ort a n d ps yc h olo gic al st at e , a n d a r e vie w of m e dic atio ns3 ,4. C o nclusio ns fr o m s e ver al st u dies ar e e m er gin g r e gar din g t he be nefits of perf or min g a c o m pr e he nsive geriatric ass ess m e nt f or older patie nts wit h c a nc er. 1. F act ors e valuat e d in a c o m pr e he nsive geriatric ass ess m e nt pr e dicts s ur vival . 2 4 2. F ac t ors e valuat e d in a c o m pr e he nsive geriatric ass ess m e nt pr e dicts t o xicit y t o c he m ot her a p y . 2 5 3. A c o m pr e he nsive geriatric ass ess m e nt u nc o vers pr o ble ms n ot det ect e d b y r o utine hist or y a n d p h ysic al in initial c o ns ult atio n a n d f ollo w -u p c ar e . 2 6 4. P atie nts u n der g oin g a c o m pr e he nsive geriatric ass ess m e nt a n d int er ve ntio n bas e d o n t he r es ults ha d i m pr o ve d pain c o ntr ol. 2 7 5. A c o m pr e he nsive geriatric ass ess m e nt a n d int er ve ntio n i m pr o ves a n older patie nt’s m e ntal healt h a n d w ell -bein g.2 7 6. C o ns e ns us g uidelines r ec o g nize t he be nefits a n d r ec o m m e n d t he inclusio n of a geriatric ass ess m e nt as part of t he e valuatio n of a n older patie nt.2 8 1. 3 P al boci cli b P alb ociclib is a r e versible, s elective, c yclin de pe n de nt kinas e ( C D K) 4 /6 in hibit or t hat is a ble t o st o p t he n or m al pr oc ess of t he c ell c ycle as t he c ell tr a vels fr o m G 1 p has e t o S p has e 1. I n t he a bs e nc e of palb ociclib, t hes e kinas es will p h os p h or ylat e t he r etin o blast o m a ( R b) pr ot ein t o c a use a r eleas e of tr a ns criptio n f act ors w hic h allo w s t he c ell t o m o ve t hr o u g h t he c ell c ycle, t h us allo win g t he gr o wt h of c a nc er o us c ells1. W he n palb ociclib in hibits C D K4 a n d C D K6, t he r etin o blast o m a pr ot ein is arr est e d at t he G 1 p has e, pr o hibitin g “ S-p has e e ntr y a n d c ell gr o wth” of t he c a nc er o us c ells2 9. 1. 4 A R ati o n al e f or C o m bi ni n g P al boci cli b a n d E n docri n e T h e r a py P alb ociclib in c o m binatio n wit h e n d ocrine t her a p y c o m par e d t o e n d ocrine t her a p y alo ne i m pr o ves pr o gr essio n-fr ee s ur vival. Dat a fr o m t he P A L O M A-1 trial de m o nstr at es t he efficac y o f palb ociclib wit h letr oz ole in t he first line tr eat m e nt of estr o ge n r ec e pt or p ositive m et ast atic br east c a nc er.1 I n t his ra n d o mize d o pe n-la bel p has e II st u d y, 1 6 5 w o m e n r a n gin g fr o m a ges 54- 7 2 ha d a d va nc e d estr o ge n r ec e pt or p ositive a n d H E R -2 ne gative br east c a nc er. O ne c o h ort of w o m e n ( m ea n a ge 6 5) w as e nr olle d bec a us e of t heir estr o ge n r ec e pt or p ositive a n d H E R 2 - ne g ative br east c a nc er, w her eas a sec o n d c o h ort ( mea n a ge 6 2. 5) was e nr olle d bec a us e t he y als o ha d c a nc ers wit h a m plific atio n of C C N D 1 a n d/ or loss of P 1 6. T hes e c o h orts r ec eive d eit her letr oz ole alo ne (or ally 2. 5 m g/ da y) or letr oz ole (or ally 2. 5 m g/ da y) wit h pa lb ociclib (or ally 1 2 5 m g/ da y f or t hr ee w ee ks o n a n d o ne w ee k off). Eig ht y -f o ur patie nts w er e assig ne d t o t he palb ociclib -letr oz ole gr o u p a n d 8 1 t o letr oz ole alo ne. T he m e dia n pr o gr essio n-fr ee s ur vival was 2 0. 2 m o nt hs f or t he palb ociclib a n d letr oz ole ar m, c o m par e d t o 1 0. 2 m o nt hs f or letr oz ole alo ne. C o m m o n side eff ects f or palb ociclib wit h letr oz ole c o m par e d t o letr oz ole alo ne ( T a ble 1) w er e: gr a de 3 -4 ne utr o pe nia ( 5 4 % vs. 1 %), le u k o pe nia ( 1 9 % vs. 0 %), a n d f atig ue ( 4 % vs. 1 %). Four per c e nt of patie nts r ec ei vin g palb ociclib wit h letr oz ole e x perie nc e d a p ul m o nar y e m b olis m. A m o n g patie nts in t he palb ociclib a n d letr oz ole gr o u p, 1 3 % dis c o ntin ue d d ue t o side eff ects w her eas o nly 2 % of t he letr oz ole gr o u p dis c o ntin ue d t he st u d y."
8,page_8,"Allia nc e A1 7 1 6 0 1 9 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 Ta bl e 1: C o m m o n A dve rs e Re acti o ns w it h a n I n ci de n ce of > 5 % i n P ati e nts w h o Re cei ve d P al boci cli b pl us Let r oz ol e or Let r oz ol e Al o ne i n P A L O M A -1 St u dy1 P al boci cli b pl us Let r oz ol e ( N = 8 3) Let r oz ol e ( N = 7 7) Gr a de 3 Gr a de 4 Gr a de 3 Gr a de 4 An y a d vers e e ve nt 4 9 ( 5 9 %) 1 4 ( 1 7 %) 1 6 ( 2 1 %) 0 Ne utr o pe nia 4 0 ( 4 8 %) 5 ( 6 %) 1 ( 1 %) 0 Le u k o pe nia 1 6 ( 1 9 %) 0 0 0 Ane mia 4 ( 5 %) 1 ( 1 %) 1 ( 1 %) 0 *Dat a ar e i n n ( %) u nless ot h er wise s p e cifie d P A L O M A -23 0 - w hic h w as desig ne d t o e x pa n d effic ac y a n d s af et y dat a f or palb ociclib a n d letr oz ole tr eat m e nt - ha d a s a m ple size of 6 6 6 p ost m e n o pa usal w o m e n wit h E R-p ositive, H E R 2 - ne gative, br east c a nc er. I n P A L O M A -2, t he m e dia n a ge of patie nts r ec eivin g palb ociclib - letr oz ole w as 6 2 wit h a r a n ge fr o m 3 0-8 9, wit h o nly 3 9. 3 % of participa nts a ge 6 5 a n d o ver wi th n o p u blis he d inf or m atio n f or patie nts older t ha n 7 5. A m o n g patie nts r ec eivin g plac e b o a n d letr oz ole t he m e dia n P F S w as 1 4. 5 m o nt hs ( 9 5 % CI 1 2. 9-1 7. 1). T his effic ac y i m pr o ve d wit h palb ociclib -letr oz ole t o 2 4. 8 m o nt hs ( 9 5 % CI 2 2. 1-N ot r eac he d). T he m ost c o m m o n gr ade 3 or 4 a d vers e e ve nts w er e ne utr o pe nia wit h 6 6. 4 % of patie nts tr eat e d wit h palb ociclib -letr oz ole e x perie ncin g t his c o m par e d t o 1. 4 % in t he plac e b o -letr oz ole gr o u p. Le u k o pe nia ( 2 4. 8 % vs. 0 %), a ne mia ( 5. 4 % vs. 1. 8 %) a n d f atig ue ( 1. 8 % vs. 0. 5 %) w ere als o r e p ort e d. F urt her s u p p ort f or use of palb oc iclib in c o nju nctio n wit h h or m o ne t her a p y w as c arrie d o ut in t he P A L O M A-3 trial.2 T his p has e III trial inclu de d 5 2 1 patie nts r a n d o mize d int o 2 gr o u ps: palb ociclib a n d f ulvestr a nt ( N = 3 4 7) or f ulvestr a nt alo ne ( N = 1 7 4). P atie nts w ere eligible t o participat e in t his st u d y if t he y w er e estr o ge n r ec e pt or p ositive. P atie nts e nr olle d in t his st u d y c o uld ha ve ha d prior e n d ocrine t her a p y ( 3 8. 8 % first line, 2 5. 5 % s ec o n d line, 1 0. 9 % t hir d line a n d a b o ve). I n a d ditio n, patie nts w er e allo w e d o ne prior line of c he m ot he r a p y. T he m e dia n pr o gr essio n -fr ee s ur vival w as 9. 2 m o nt hs f or t he palb ociclib a n d f ulvestr a nt ar m, c o mpar e d t o 3. 8 m o nt hs f or f ulvestr a nt alo ne. C o m m o n side eff ects f or palb ociclib a n d f ulvestr a nt c o m par e d t o f ulvestr a nt alo ne w er e: ne utr o pe nia ( 6 2 % vs. 6 % ), le u k o pe nia ( 2 5. 2 % vs. 0. 6 %), a ne mia ( 2. 6 % vs. 1. 7 % ), t hr o m b oc yto pe nia ( 2. 3 % vs. 0 %), f atig ue ( 2. 0 % vs. 1. 2 %), a n d f e brile ne utr o pe nia ( 0. 6 % f or b ot h gr o u ps). A m o n g patie nts in Gr o u p 1, 2. 6 % dis c o ntin ue d t he st u d y w hile 1. 7 % of patie nts in Gr o u p 2 dis c ontin ue d d ue t o side eff ects. 1. 4. 1 A ge S pe cifi c D at a f r o m P A L O M A -1, P A L O M A -2 a n d P A L O M A -3 Li mit e d e vide nc e e xists t o g uide t her a p y wit h palb ociclib a n d e n d ocrine t her a p y in older a d ults. I n P A L O M A-1, t he m ea n a ge of patie nts w as 6 4 wit h a r a n ge fr o m 5 4 -7 2 . I n P A L O M A -2, t he m e dia n a ge of patie nts r ec eivin g palb ociclib -letr oz ole w as 6 2 wit h a r a nge fr o m 3 0-8 9, wit h o nly 3 9. 3 % of participa nts a ge 6 5 a n d o ver wit h n o p u blis he d inf or m ation f or patie nts older t ha n 7 5. I n P A L O M A-3, t he m ea n a ge of patie nts w as 6 4 wit h a r a n ge fr o m 2 9 t o 8 8. I n P A L O M A-3, o nly 2 5 % of t he participa nts w er e a ge 6 5 a n d o ver. Re vie w of t he dat a o bt aine d fr o m 1 6 5 patie nts in t he P A L O M A -1 trial, as w ell as t he 5 2 1 patie nts in t he P A L O M A-3 trial, did n ot s h o w a n y a p par e nt diff er e nces in s yst e mic e x p os ur e r elated t o a ge. A s u b gr o u p a nalysis of t he effic ac y a n d s af ety of first-line palb ociclib plus letr oz ole c o m par e d wit h letr oz ole alo ne in patie nts in t he P A L O M A -1 st u d y e valuat e d 1 6 5 p ost m e n o pa us al w o m e n. Of t he 7 6 patie nts a ge 6 5 a n d o lder, 3 7 w er e tr eat e d wit h palb ociclib a n d letr oz ole, a n d t he r e m ain der r ec eive d letr oz ole alo ne. A m o n g patie nts r ec eivin g palb ociclib a n d letr oz ole t he m e dia n P F S f or patie nts a ge 6 5 a n d o ver w as 2 6. 6 m o nt hs ( 9 5 % CI 1 2. 6 -N R) in c o m paris o n t o 7. 7 m o nt hs ( 9 5 % CI 3. 7 -1 0. 9) f or patie nts w ho"
9,page_9,"Allia nc e A1 7 1 6 0 1 1 0 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 r ec eive d letr oz ole alo ne. Gr a de 3-4 ne utr o pe nia oc c urr e d in 5 6. 8 % of patie nts r ec eivin g palb ociclib a n d letr oz ole ( c o m par e d t o 2. 7 % in patie nts wit h letr oz ole alo ne). I n a d ditio n, gr a de 3 -4 le u k o pe nia oc c urr e d in 2 9. 7 % of t he patie nts r ec eivin g palb ociclib a n d letr oz ole, a n d gr a de 3 -4 f atig ue w as r e p ort e d in 1 0. 8 % of patie nts r eceivin g palb ociclib a n d letr oz ole. Neit her of t hes e a d vers e e ve nts oc c urre d in a n y patie nts t a kin g letr oz ole alo ne.3 1 An ot her s u bs et a nalysis of t he P A L O M A -1 st u d y e valuat e d t he ti m e t o o ns et of ne utr o pe nia, le u k o pe nia, a ne mia, a n d t hr o m b oc yt o pe nia. T he y f o u n d t hat 9 7. 9 % of all a d vers e e ve nts oc c urr e d wit hin t he first 6 m o nt hs a n d st a ye d r elatively st a ble or decr eas e d in incide nc e o ver ti m e. Wit hin t he first 6 m o nt hs, 6 9. 5 % of t he 9 5 participa nts pr es e nt e d wit h ne utr o pe nia, 3 3. 7 % wit h le u k o pe nia, a n d 2 2. 1 % wit h a ne mia. T he m e dia n ti m e t o o ns et f or ne utr o pe nia w as 2 0 da ys, f or le u k o pe nia w as 3 6 da ys, f or a ne mia w as 1 6 8 da ys , a n d f or t hr o m b oc yt o pe nia w as 1 4 0 da ys. T he y did n ot s ee a n y e vide nc e of s pecific c u m ulative or lat e o ns et of t o xicit y wit h tr eat m e nt o n palb ociclib a n d letr oz ole.3 2 1. 4. 2 Filli n g a Ga p i n K n o wl e dge P alb ociclib a n d e n d ocrine t her a p y is e m er gin g as a n o ve l tr eat m e nt f or estr o ge n r ec e ptor p ositive m et ast atic br east c a nc er. A ga p in k n o wle d ge s pecific ally e xists wit h r e gar d t o t he t oler a bilit y of t his c o m binatio n in a d ults a ge 70 a n d o ver. T his is a n i m p ort a nt r es ear c h ar ea, sinc e c a nc er is a dis eas e ass ociat e d wit h a gin g. T w e nt y per c e nt of patie nts wit h br east c ancer ar e a ge 7 0 a n d older. T his p has e II st u d y will e valuat e t he s af et y a n d t oler a bilit y of t he c o m binatio n of palb ociclib a n d letr oz ole o r f ulvestr a nt in patie nts a ge 7 0 a n d o ver, as w ell as des crib e t he f ull t o xicit y pr ofile, esti m at e t he o bjective r es p o ns e r at e a n d clinic al be nefit, as w ell as s ur vival. A geriatric ass ess m e nt a n d m eas ur es of a d her e nc e will be inclu de d wit hin t he st u d y. O ver all o ur g oal is t o clos e t his ga p in k n o wle d ge in older a d ults wit h m et ast atic br east c a nc er w h o m a y derive sig nific a nt be nefit fr o m t his n o vel tr eat m e nt o ptio n. 1. 4 . 3 R ati o n al e f or t h e St u dy Li mit e d e vide nc e e xists t o g uide t her a p y wit h t ar get e d a ge nts in t he older a d ult p o p ulatio n bec a us e older a d ults ha ve be e n u n der -r e pr es e nt e d in clinic al trials. Ad ults a ge 7 0 a n d older m a ke u p o nly 2 0 % of s u bjects e nr olle d in F D A r e gistr atio n trials b ut 4 6 % of all patie nts wit h c a nc er dia g n os es. D os e -fin din g st u dies s pecific ally in older a d ults ar e n ot r o utinely perf or m e d. T his is des pit e c ha n ges in dr u g m et a b olis m, a bs or ptio n, a n d distrib utio n wit h incr easin g a ge. T he c o m binatio n of palb ociclib a n d e n d ocrine t her a p y is a n o vel tr eat m e nt a p pr oac h f or p ost m e n o pa us al w o m e n wit h estr o ge n r ec e pt or p ositive, h u m a n e pider m al gr o w t h f act or r ec e pt or 2 ( H E R 2)-ne gative a d va nc e d br east c a nc er. T he c o m binatio n sig nific a ntly i m pr o ves pr o gr essio n-fr ee s ur vival c o m par e d t o e n d ocrine t her a p y alo ne. Ho w e ver, t hes e st u dies pri m arily f oc us e d o n w o m e n less t ha n a ge 7 5. F or e xa m ple, t he r a n d o mize d p has e II trial ( P A L O M A-1) of palb ociclib a n d letr oz ole c o m par e d t o letr oz ole alo ne ( m ea n a ge 6 3 a n d 6 4, r es pectively) o nly inclu de d 8 patie nts a ge 7 5 a n d older, a n d t he p has e III trial ( P A L O M A -3) of palb ociclib a n d f ulvestr a nt c o m par e d t o f ulvestr a nt al o ne ( m ea n a ge 5 7 a n d 5 6, r es pectively) inclu de d o nly 2 5 % of participa nts a ge 6 5 a n d older, w hile n ot r e p ortin g o n participa nts a ge 7 5 a n d older.1, 2 I n P A L O M A-2, t he m e dia n a ge of patie nts r ec eivin g palb ociclib -letr oz ole w as 6 2 wit h a r a n ge fr o m 3 0-8 9, wit h o nly 3 9. 3 % of participa nts a ge 6 5 a n d o ver wit h n o p u blis he d inf or m atio n f or patie nts older t ha n 7 5. I n a d ditio n, t he piv ot al trial of palb ociclib a n d letr oz ole r e p ort e d in t he pac ka ge ins ert n ot es t hat 3 7 patie nts ( 4 4 %) w er e ≥ 6 5 years of a ge a n d o nly 8 patie nts ( 1 0 %) w er e ≥ 7 5 years of a ge. T he m ost c o m m o n a d vers e e ve nts of palb ociclib in c o m binatio n wit h e n d ocrine t her a p y are ne utr o pe nia, le u k o pe nia, a n d f atig ue. I n partic ular, in P A L O M A -1 patie nts r ec eivin g t he"
10,page_10,"Allia nc e A1 7 1 6 0 1 1 1 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 c o m binatio n palb ociclib a n d letr oz ole e x p erie nc e d gr a de 3 or 4 ne utr o pe nia ( 5 4 %), le u k o pe nia ( 1 9 %), or f atig ue ( 4 %). I n P A L O M A-3, patie nts r ec eivin g palb ociclib a n d f ulvestr a nt e x perie nc e d gr a de 3 or 4 ne utr o pe nia ( 6 2 %), le u k o pe nia ( 2 5. 2 %), or f atig ue ( 2 %). T he pac ka ge ins ert s pecific ally w ar ns of p ot e ntial f e brile ne utr o pe nia a n d inf ectio n; alt h o u g h, ne utr o pe nic f e ver is ver y r ar e wit h t he c o m binatio n ( P A L O M A -1 wit h 0 %, P A L O M A -3 wit h 0. 6 %). I n a d ditio n, t he pac ka ge ins ert inclu des w ar nin g of t hr o m b oe m b olis m ( P A L O M A-1 wit h 4 %, P A L O M A-3 wit h 0 %). T hes e side eff ects are of partic ular c o nc er n in older a d ults. I n partic ular, t her e is a decr eas e in b o ne m arr o w r es er ve wit h a gin g, he nc e a m plif yin g t he p ot e ntial ris k of ne utr o pe nia a n d m yelos u p pr e ssion. F urt her m or e, older a d ults oft e n ha ve ot her c o -m or bid m e dic al c o n ditio ns w hic h m a y pr e dis p os e t he m t o t hr o m b oe m b olis m t her e b y incr easin g t he ris k. Bec a us e of t his, a definitive st u d y in t he older a d ult p o p ulatio n will di minis h a n y r es er vatio ns o nc olo gists m ay ha ve in pr es cribin g palb ociclib wit h letr oz ole or f ulvestr a nt a n d c a n pr o vide g uida nc e r e gar din g t he d osin g a n d t o xicit y m a na ge m e nt in older a d ults. T his is a n o pe n la bel, sin gle ar m, p has e II st u d y of t he c o m binatio n of palb ociclib a n d letr oz ole or f ulvestr a nt in 8 8 patie nts a ge 7 0 or o ver wit h estr o ge n r ec e pt or p ositive, H E R 2 ne gative m et ast atic br east c a nc er. T he pri m ar y g oal of t his st u d y is t o esti mat e t he s af ety a n d t oler a bilit y ( a d vers e e ve nt r at e) of t he c o m binatio n of palb ociclib a n d e n d ocrine t her a p y in older a d ults wit h es tr o ge n r ec e pt or p ositive, H E R 2 ne gative m et ast atic br east c a nc er. S ec o n dar y ai ms ar e t o des cribe t he f ull t o xicit y pr ofile, des cribe d os e m o dific atio ns, e valuat e dis eas e r es p o ns e in t his p o p ulatio n , e valuate patie nt a d her e nc e a n d tr eat m e nt pers pective, a n d t o e x plor e f act ors ot her t ha n c hr o n olo gic a ge t hat pr e dict t o xicit y usin g a c a nc er -s pecific geriatric ass ess m e nt. C orr elative st u dies in t his pr o p os al will als o ai m t o e valuat e cir c ulatin g m ar kers of infla m m atio n as p ot e ntial m ar kers pr e dictive of t o xicit y or p h ysic al f u nctio n as ass ess e d b y t he c a nc er -s pecific geriatric ass ess m e nt, a n d t o e xa mine sin gle n ucle otide p oly m or p his ms ( S N Ps) in c ell c ycle ge nes a n d ge nes t hat m et a b olize palb ociclib . 1. 5 Me as u re m e nt of S arc o pe ni a 1. 5. 1 B ac k gr o u n d a n d M et h o ds Age -r elat e d loss of m us cle m ass a n d f u nctio n, ot her wis e k n o w n as s ar c o pe nia, is hig hly pr e vale nt in older a d ults a n d ass ociat e d wit h f u nctio nal i m pair m e nt, dis a bilit y, loss of in de pe n de nc e, a n d m ort alit y.3 3 -3 5 L oss es in s kelet al m us cle m ass a n d str e n gt h ar e a p par e nt as early as t he 4t h dec a de of lif e a n d pr o gr ess linearly wit h incr easin g a ge.3 6 S ar c o pe nia in older a d ults wit h c a nc er is a d ditio nally c o m plic at e d b y c a nc er -r elat e d c ac he xia a n d fr ailt y.3 7, 3 8T he ele vat e d infla m m at or y r es p o ns e a n d alt er atio ns in m et a b olis m r elat e d t o c a nc er c ac he xia lea d t o f urt her loss es of m us cle m ass3 9, 40 T her e is a hig h pr e vale nc e of s ar c o pe nia in a d ults wit h br east c a nc er, partic ularly in older a d ults ( ~ 6 3 %) .41 S ar c o pe nia has bee n ass ociat e d wit h incr eas e d gr a de 3/ 4 c he m ot her a p y t o xicit y, h os pit alizatio ns, a n d a d vers e e ve nts in a d ults wit h m et ast atic br east c a nc er u n der g oin g t a xa ne -bas ed c he m ot her a p y4 2 T he pr es e nc e or a bs e nc e of s ar c o pe nia m a y help e x plain t he int er- in divid ual varia bilit y in tr eat m e nt t oler a bilit y of older a d ults wit h c a nc er a n d c o uld ulti m at ely be us e d t o in divid ualize tr eat m e nt pla n nin g. Alt h o u g h t her e ha ve bee n s e ver al st u dies e xa minin g t he ass ociatio n of s ar c o pe nia a n d c he m ot her a p y, t his u niq ue s m all st u dy will e x plor e its ass ociatio n wit h t ar get e d t her a p y in older a d ults. T his pr o p os al als o ai ms t o e valuat e t he i m pact of s ar c o pe nia o n t ar get e d t her a p y t o xicit y a n d a d vers e e ve nts in older a d ults wit h br east c a nc er u n der g oin g tr eat m e nt wit h pa lb ociclib a n d e n d ocrine t her a p y. Pr actic al a n d pr ecis e m eas ur e m e nt a p pr oac hes ha ve bee n de velo pe d t o q ua ntif y b o d y c o m p ositio n in patie nts wit h c a nc er usin g C T i m a ges ac q uir e d d urin g r o utine c ar e t hat"
11,page_11,"Allia nc e A1 7 1 6 0 1 1 2 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 r e q uir e mini m al a d ditio nal r es o ur c e alloc atio n.4 3 T he L 3 la n d m ar k fr o m cr oss -sectio nal i m a gin g has bee n ide ntifie d as t he str o n gest pr e dict or of w h ole b o d y f at a n d f at-fr ee m ass w he n c o m par e d t o d ual -e ner g y x -r a y a bs or ptio m etr y ( D X A).4 3 T he a d va nt a ge of usin g a d va nc e d i m a gin g m o dalities, s uc h as C T i m a gin g, is t he a bilit y t o pr o vide a d ditio nal q ualit ative m eas ur e m e nts of m us cle a n d f at be y o n d p ur ely q ua ntit ative m eas ur es4 4 1. 6 Q u alit y of Lif e Q u esti o n n ai res: E u r o Q ol 5 D 3 L a n d E Q Vis u al A n al o g S c al e ( E Q V A S) I n a d ditio n t o t he r e p ortin g of s y m pt o ms, u n derst a n din g h o w q ualit y of lif e m a y be aff ect e d by palb ociclib a n d h or m o nal t her a p y in t he m et ast atic s ettin g in older patie nts has n ot bee n e valuat e d pr e vio usly a n d will a d d i m p ort a nt inf or m atio n t o t his st u d y. T he E Q -5 D (Ap pe n dix V ) is a m eas ur e of healt h st at us f or us e in e valuatin g healt h a n d healt hc ar e. T he E Q-5 D -3 L is c o m pris e d of 2 pa ges: t he E Q -5 D des criptive s yst e m ( pa ge 1) a n d t he E Q vis ual a nalo g ue s c ale ( E Q V A S) ( pa ge 2). It pr o vides a si m ple des criptive pr ofile of five f u nctio nal di m e nsio ns: m o bilit y, s elf -c ar e, us ual activities, pain/ dis c o mf ort, a n d a n xiet y/ de pr essio n. It ge ner at es a sin gle in de x value f or healt h st at us o n w hic h f ull healt h is assig ne d a value of 1 a n d deat h a value of 0. T h us, t he in de x c a n be us e d t o o b t ain a utilit y f or t hes e di m e nsio ns f or us e in ec o n o mic a nalys es. T he E Q -5 D has bee n s pecially desig ne d t o c o m ple m e nt ot her q ualit y of lif e m eas ur es s uc h as t he S F -3 6, or c a nc er -s pecific m eas ur es. Eac h di m e nsio n has t hr ee le vels desig nat e d si m ply as ' n o pr o ble m', 's o m e pr o ble m', or ' e xtr e m e pr o ble m', wit h patie nts c hec king t he le vel m ost des criptive of t heir c urr e nt le vel of f u nctio n o n eac h di m e nsio n. Five di m e nsions, eac h wit h t hr ee le vels, yield 2 4 3 p ossible distinct healt h st at es c o m prisin g t he classifi c atio n s yst e m. T he classific atio n s yst e m has bee n assig ne d diff er e nt st a n dar dize d s c or es derive d t hr o u g h p o p ulatio n-bas e d s a m ples of r es p o nde nts w ho assig n values t o s u bs ets of t he 2 4 3 states usin g t he a nc h orin g la bels n ot e d a b o ve. F or e xa m ple, healt h st at e 1 1 2 1 2 r e pr es e nts a patie nt w h o in dic at es s o m e pr o ble ms o n t he us ual activities a n d a n xiet y/ de pr essio n di m e nsio ns. A s et of valuatio n w eig hts has t h us bee n derive d fr o m a U. S. s a m ple.4 5 T he Age nc y f or Healt hc ar e Res ear c h a n d Q ualit y has f u n de d a st u d y t o de velo p definitive w eig hts. E Q -5 D is desig ne d f or s elf-c o m pletio n b y patie nts a n d has bee n us e d e xt e nsively in m aile d s ur ve ys. It is c o g nitively si m ple, t a kin g n o m or e t ha n a f e w min ut es t o c o m plet e. 1. 7 P R O -C T C A E We will e valuat e h o w w ell s y m pt o ms r e p ort e d b y patie nts c orrelat e/ a gr ee wit h t h os e c o mpared t o w hat is r e p ort e d in clinic usin g tr a ditio nal A E e valuatio ns. P atie nt -r e p ort e d o ut c o m es ( P R O) ar e a n i m p ort a nt part of ne w dr u g e valuatio n a n d m a y pla y a r ole in r e g ulat or y a p pr o val of n o vel a ge nts in o nc olo g y 4 6. P R Os c a n be t he c o ns e q ue nc es of dis eas e a n d/ or its tr eat m e nt as r e p ort e d b y t he patie nt. P R Os ar e e valuat e d t hr o u g h t he us e of q uestio n nair es de velo pe d t o ass ess t o pics a patie nt c a n r e p ort a b o ut his or her o w n healt h a n d ar e oft e n c o m plet e d electr o nic ally. T his inclu des s y m pt o ms, p h ysic al f u nctio nin g, a n d m e nt al healt h. T he c urr e nt st a n dar d m ec ha nis m f or r e p ortin g t o xicities in c a nc er r es ear c h is clinicia n -o nly r e p ortin g usin g ite ms fr o m t he Natio nal Ca nc er I nstit ut e ( N CI) C T C A Es. I n m ultiple st u dies, P R O m eas ur es ha ve i m pr o ve d t he pr e dictive ac c ur ac y of clinicia n C T C A E r e p ortin g. I n a pr os pective st u d y inclu din g lu n g c a nc er patie nts’ P R O m eas ur e m e nts of t o xicities bett er r eflect ed patie nts’ u n derlyin g st at e a n d f u nctio nal st at us t ha n clinicia n’s e valuatio n 4 7. Alt h o u gh P R Os ha ve bee n w ell validat e d 4 8 , 4 9, 5 0, 5 1 , t hes e e xa minatio ns ha ve bee n mini m ally e valuat e d f or f easibilit y a n d ac c ur ac y in a n older patie nt gr o u p a n d will m ea nin gf ully a d d t o t he dat a c ollectio n o n t his st u d y."
12,page_12,"Allia nc e A1 7 1 6 0 1 1 3 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 We will f oc us o ur P R Os o n side eff ects m ost c o m m o nly r e p ort e d in prior st u dies wit h palb ociclib a n d h or m o nal t her a p y a n d w hic h of ar e of m ost int er est , inclu din g all s y m pt o ms list e d in Ap pe n dix V I. All s ur ve ys will be give n t o patie nts o n pa per, a t t he s a m e ti m e p oints as in-clinic e valuatio ns t hr o u g h c ycle 6, u nless patie nts c o m e off st u d y prior t o c ycle 6. We will us e t he P R O-C T C A E it e ms de velo pe d b y t he Natio nal Ca nc er Instit ut e in or der t o allo w patie nts t o s elf -r e p ort t he a b o ve s y m pt o m atic a d vers e e ve nts. T he pri m ar y p ur p ose of t he inclusio n of P R O -C T C A E is to e valuat e t he perf or m a nc e a n d a gr ee m e nt of patie nt -r e p ort e d o ut c o m es wit h t h os e c ollect e d as clinicia n -r e p ort e d C T C A Es. 2. 0 O B J E C TI V ES 2. 1 Pri m ar y O bje cti ve T o esti m at e t he s af et y a n d t oler a bilit y ( a d vers e e ve nt r at e) of t he c o m binatio n of palb ociclib a n d letr oz ole or f ulvestr a nt in a d ults a ge 7 0 or older wit h estr o ge n rec e ptor-p ositive, H E R 2 -ne gative m et ast atic br east c a nc er. 2. 2 S e c o n dar y o bje cti ves 2. 2. 1 T o des cribe t he f ull t o xic it y pr ofile inclu din g all gr a de 2 a n d hig her a d vers e e ve nts ( per N CI C T C A E v. 5 . 0), s pecific ally esti m at in g t he r at e of gr a de 2 a n d hig her m yelos u p pr ession (ne utr o pe nia, le u k o pe nia, t hr o m b oc yt o pe nia, a n d a ne mia), ne utr o pe nic f e ver , GI side eff ects ( na us ea, diarr hea, decr eas e d a p petit e, v o mitin g, m uc ositis -or al), f atig ue, ne ur o pat h y, and t hr o m b oe m b olis m. 2. 2. 2 T o des cribe r at es of d os e r e d uctio ns, d ose h olds, a n d h os pit alizatio ns . 2. 2. 3 T o esti m at e m e dia n ti m e t o tr eat m e nt f ailur e , inclu din g pr o gr essio n fr ee s ur vival a n d o ver all s ur vival. 2. 2. 4 T o esti m at e t he r at e of a d her e nc e t o palb ociclib , letr oz ole a n d f ulvestr a nt. 2. 2. 5 T o e x plor e f act ors ot her t ha n c hr o n olo gic a ge t hat c a n aff ect t o xicit y r at es as ide ntifie d usin g a c a nc er -s pecific geriatric ass ess m e nt. 2. 2. 6 T o des cribe t he r es ults of t he Was It W ort h It ( WI WI) Q uestio n nair e a n d t he O ver all Tr eat m e nt Utilit y ( O T U) . 2. 2. 7 T o det er m ine t he de gr ee of a gr ee m e nt bet w ee n patie nt -r e p ort e d A Es usin g P R O -C T C A E m eas ur es a n d t h os e r e p ort e d usin g tr a ditio nal c ollectio ns f or A Es . 2. 2. 8 T o e xa mine t he ass ociatio n bet w ee n s ar c o pe nia a n d t he de velo p m e nt of t o xicit y a n d a d verse e ve nts . 2. 3 C orrel at i ve s ci e n ce o bje cti ves 2. 3 . 1 T o e x plor e t he ass ociatio n bet w ee n bas eline c hr o nic infla m m at or y m e diat or le vels a n d de velo p m e nt of a d vers e e ve nts. 2. 3 . 2 T o e x plor e t he ass ociatio n bet w ee n bas eline c hr o nic infla m m at or y m e diat or le vels a n d tr eat m e nt m o dific atio n. 2. 3. 3 T o e x plor e t he ass ociatio n bet w ee n bas eline c hr o nic infla m m at or y m e diat or le vels a n d bas eline p h ysic al f u nctio n as ass ess e d b y t he c a nc er -s pecific geriatric ass ess m e nt."
13,page_13,"Allia nc e A1 7 1 6 0 1 1 4 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 2. 3. 4 T o e x plor e t he ass ociatio n bet w ee n bas eline c hr o nic infla m m at or y m e diat or le vels a n d decline in p h ysic al f u nctio n as ass esse d b y t he c a ncer -s pecific geriatric ass ess me nt. 2. 3. 5 T o e x plor e t he c orr elatio n bet w ee n in herit e d sin gle n ucle otide p oly m or p his ms ( S N Ps) in c ell c ycle pat h w a y ge nes a n d in ge nes t hat m et a b olize palb ociclib a n d tr eat m e nt effic ac y a n d t o xicit y ( clinic al o ut c o m es) in elderly patie nts u n der g oin g c o m bine d e n d ocrine t her apy plus palb ociclib f or estr o ge n r ec e pt or p ositive, H E R 2 ne gative m et ast atic br eas t c a nc er. 2. 3. 6 T o e x plor e w het her ge nes in C Y P 1 9 A , C Y P 2 A 6 a n d E S R 1 will als o c orr elat e wit h tr eat m ent effic ac y a n d t o xicit y ( clinic al o ut c o m es) in elderly patie nts u n der g oin g c o m bine d e n d ocrine t her a p y plus palb ociclib f or estr o ge n r ec e pt or p ositive, H E R 2 ne gative m et ast atic br east c a nc er. 2. 3. 7 T o r efine a p o p ulatio n p har m ac o kinetic m o del usin g N O N M E M f or palb ociclib bas e d on t hat of S u n a n d Wa n g ( E S M O P ost er Pr es e nt atio n 4 6 2 P 2 0 1 4) t a kin g ac c o u nt of r ele va nt intrinsic a n d e xtrinsic f act ors. 2. 3. 8 T o det er mine t he intr a patie nt a n d int er patie nt varia bilit y of palb ociclib e x p os ur e ( A U C) in older br east c a nc er patie nts r eceivin g palb ociclib plus letr oz ole/f ulvestr a nt. 2. 3. 9 T o e x plor e t he e x p os ur e ( A U C/ C ma x) t o xicit y ( ne utr o pe nia, t hr o m b oc yt o pe nia) r elatio ns hip f or palb ociclib w he n c o m bine d wit h letr oz ole/f ulvestr a nt in older br east c a nc er patie nts."
14,page_14,"Allia nc e A1 7 1 6 0 1 1 5 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 3. 0 P A TI E N T SE L E C TI O N F or q uestio ns r e gar din g eligibilit y crit eria, s ee t he St u d y Res o ur c es pa ge. Pl e as e n ot e t h at t he St u dy C h ai r c a n n ot gr a nt wai ve rs t o eligi bilit y re q ui re me nts. 3. 1 O n -St u dy G ui deli n es T his clinic al trial c a n f ulfill its o bjectives o nly if patie nts a p pr o pri at e f or t his trial ar e e nr olle d. All r ele va nt m e dic al a n d ot her c o nsider atio ns s h o uld be t a ke n int o ac c o u nt w he n decidin g w het her t his pr ot oc ol is a p pr o priat e f or a partic ular patie nt. P h ysicia ns s h o uld c o nsider t he ris ks a n d be nefits of a n y t her a p y, a n d t her ef or e o nly e nr oll patie nts f or w h o m t his tr eat m e nt is a p pr o priat e. P h ysicia ns s h o uld c o nsider w het her a n y of t he f ollo win g m a y r e n der t he patie nt ina p pr o priat e f or t his pr ot oc ol: • Ps yc hiatric illness w hic h w o uld pr e ve nt t he patie nt fr o m givin g inf or m e d c o ns e nt. • Me dic al c o n ditio n s uc h as u nc o ntr olle d inf ectio n (inclu din g HI V), u nc o ntr olle d dia bet es m ellit us or c ar diac dis eas e w hic h, in t he o pinio n of t he tr eatin g p h ysicia n, w o uld m a ke t his pr ot oc ol u nr eas o na bly hazar d o us f or t he patie nt. • C o nc o mit a nt m e dic atio ns : C hr o nic c o nc o mit a nt tr eat m e nt wit h str o n g in hibit ors of C Y P 3 A is str o n gly dis c o ur a ged o n t his st u d y. P atie nts o n str o n g C Y P 3 A in hibit ors m ust dis c o ntin ue t he dr u g prior t o r e gistr atio n o n t he st u d y. S ee s ectio n 8. 1. 1 0 f or m ore inf or m atio n. C hr o nic c o nc o mit a nt tr eat m e nt wit h str o n g C Y P 3 A in d uc ers is str o n gly dis c o ur a ged. P atie nts m ust dis c o ntin ue t he dr u g prior t o t he st art of st u d y tr eat m e nt. S ee s ection 8. 1. 1 1 f or m or e inf or m atio n. C hr o nic c o nc o mit a nt tr eat m e nt wit h C Y P 2 A6 s u bstr at es is str o n gly dis c o ur a ge d f or patie nts w h o ar e bein g tr eat e d wit h letr oz ole. P atie nts m ust dis c o ntin ue t he dr u g prior t o t he st art of st ud y tr eat m e nt. S ee s ectio n 8. 1. 1 2 f or m or e inf or matio n. • Lif e e x pect a nc y of less t ha n 6 m o nt hs"
15,page_15,"Allia nc e A1 7 1 6 0 1 1 6 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 3. 2 Eli gi bilit y Crit e ri a Us e t he s pac es pr o vide d t o c o nfir m a patie nt’s eligibilit y b y in dic atin g Yes or N o as a p pr o priat e. It is n ot r e q uir e d t o c o m plet e or s u b mit t he f ollo win g pa ge(s). W he n c alc ulatin g da ys of t ests a n d m eas ur e m e nts, t he da y a t est or m eas ur e m e nt is d o ne is c o nsider e d Da y 0. T her ef or e, if a t est w er e d o ne o n a M o n da y, t he M o n da y o ne w ee k lat er w o uld be c o nsider e d Da y 7. _ _ _ 3. 2 . 1 D oc u m e nt ati o n of Dis e as e: Est r o ge n re ce pt or positi ve a n d/ or pr o gest e ro ne re ce pt or ( P R) positi ve , H E R 2 n e g ati ve m et ast ati c b re ast c a n ce r. Hist olo gic c o nfir m atio n is r e q uir e d. _ _ _ 3. 2. 2 Me as u r a bl e dis e as e or n o n -me as ur a bl e dis e ase (s ee S ecti o n 1 1. 3 ) _ _ _ 3. 2. 3 Pl a n ni n g t o be gi n pal boci cli b f or m et ast ati c dis e as e. O n e pri or li n e of e n docri n e t h e r a py a n d/ or c h e m ot h er a py f or m et ast ati c dis e as e is all o we d. P atie nts m a y be gin or ha ve alr ea d y be g u n e n d ocrine t her a p y bef or e t he y st art palb ociclib tr eat m e nt, b ut n o m or e t ha n t w o w ee ks prior t o r e gistr atio n. _ _ _ 3. 2. 4 No p ri or t h e r a py wit h a C D K i n hi bit or . _ _ _ 3. 2. 5 Res ol uti o n of all ac ut e t o xic eff ects of pri or t h er a py or s u r gi c al pr oce d u res t o C T C A E Gr a de ≤ 1 ( e xce pt al o pe ci a) or t o bas eli n e t o xiciti es pri or t o pre vi o us t h era py or s u r g i c al pr oce d u res, pri or t o re gist r ati o n. _ _ _ 3. 2. 6 No u nt re at e d br ai n m et ast ases. P atie nts wit h tr eat e d br ain m et ast ases m ust have c o m plet e d tr eat m e nt wit h st er oids t o be eligible. _ _ _ 3. 2. 7 No k n o w n i nt e rstiti al l u n g dis e as e. _ _ _ 3. 2. 8 . No s e c o n d m ali g n a n ci es ot h e r t h a n n o n -m ela n o m a s ki n c a n ce rs or ce r vi c al c arci n o m a i n sit u . Ho we ve r, pati e nts are n ot c o nsi dere d t o h a ve a “c u rre ntl y active ” m ali g n a n c y if t h e y h a ve c o m pl ete d t h er a py a n d are f re e of dis e ase f or ≥ 3 ye ars. _ _ _ 3. 2. 9 No acti ve i nf e cti o n re q ui ri n g t re at m e nt wit h a nti bi otics. _ _ _ 3. 2. 1 0 P ati e nts m ust be a bl e t o s wall o w a n d ret ai n or al m e di c ati o n. _ _ _ 3. 2. 1 1 P ati e nt A ge: ≥ 7 0 ye ars _ _ _ 3. 2. 1 2 E C O G Pe rf or m a n ce St at us 0, 1 or 2. _ _ _ 3 . 2. 1 3 P ati e nts m ust be a bl e t o re a d a n d c o m pre h e n d E n glis h or S pa nis h. _ _ _ 3. 2. 1 4 Re q ui re d I niti al L a bor at or y V al u es: Abs olut e ne utr o p hil c o u nt ( A N C) ≥ 1 5 0 0/ m m3 ( 1. 5 x 1 09/ L) Plat elet c o u nt: ≥ 1 0 0, 0 0 0/ m m3 ( 1 0 0 x 1 09/ L) Cr eatinine clear a nc e: T ot al s er u m bilir u bin A S T a n d/ or A L T ≥ 3 0 ml/ min * ≤ 1. 5 U L N ( < 3 U L N if Gilbert’s dis eas e) ≤ 3 x U L N ( ≤ 5. 0 x U L N if liver m et ast as es pr es e nt) Alkaline p h os p hat as e ≤ 2. 5 x U L N ( ≤ 5 x U L N if b o ne or liver m et ast as es pr es e nt) * Calc ulat e d usin g t he C oc kcr oft -Ga ult f or m ula"
16,page_16,
17,page_17,"Allia nc e A1 7 1 6 0 1 1 8 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 • Assig n t he Clinic al I n vestigat or ( CI) r ole o n t he Dele gatio n of T as ks L og ( D T L). I n a d ditio n, all in vestigat ors actin g as t he Sit e-Pr ot oc ol PI (in vestigat or list e d o n t he I R B a ppr o val), c o ns e ntin g/tr eatin g/ dr u g s hip m e nt in vestigat or in O P E N, or as t he CI o n t he D T L m ust be r ost er e d at t he e nr ollin g sit e wit h a participatin g or ga nizatio n. Ad ditio nal inf or m atio n is loc at e d o n t he C T E P w e bsit e at F or q uestio ns, pleas e c o nt act t he R C R Hel p Des k b y e m ail at . 4. 2 C T S U Re gist r ati o n Pr oce d u res P er missio n t o vie w a n d d o w nloa d t his pr ot oc ol a n d its s u p p ortin g d oc u m e nts is r estrict e d and is bas e d o n pers o n a n d sit e r ost er assig n m e nt h o us e d in t he C T S U Re g ulat or y S u p p ort S yst e m ( R S S). T his st u d y is s u p p ort e d b y t he N CI Ca nc er Trials S u p p ort Unit ( C T S U). I R B A p pr o v al F or C T E P a n d Divisio n of Ca nc er Pr e ve ntio n ( D C P) st u dies o pe n to t he Natio nal Clinic al Trials Net w or k ( N C T N) a n d N CI C o m mu nit y O nc olo g y Res ear c h Pr o gr a m ( N C O R P) Res ear c h Bases aft er Mar c h 1, 2 0 1 9, all U. S. -bas e d sit es m ust be m e m bers of t he N CI Ce ntr al I nstit utio nal Re vie w Boar d ( N CI CI R B). I n a d ditio n, U. S. -bas e d sit es m ust ac c e pt t he N CI CI R B r e vie w t o activat e ne w st u dies at t he sit e aft er Mar c h 1, 2 0 1 9. L oc al I R B r e vie w will c o ntin ue t o be ac c e pt e d f or st u dies t hat ar e n ot r e vie w e d b y t he CI R B, or if t he st u d y w as pr e vio usly o pe n at t he sit e u n der t he loc al I R B. I nt er natio nal sit es s h o uld c o ntin ue t o s u b mit Res ear c h Et hics Boar d ( R E B) a p pr o val t o t he C T S U Re g ulat or y Offic e f ollo win g c o u ntr y-s pecific r e g ulatio ns . Sit es participatin g wit h t he N CI CI R B m ust s u b mit t he St u d y S pecific W or ks heet f or L oc al C o nt e xt ( S S W) t o t he CI R B usin g I R B Ma na ger t o in dic at e t heir int e nt t o o pe n t he st u d y loc ally. T he N CI CI R B’s a p pr o val of t he S S W is a ut o m atic ally c o m m u nic at e d t o t he C T S U Re g ulat or y Offic e, b ut sit es ar e r e q uir e d t o c o nt act t he C T S U Re g ulat or y Offic e at t o est a blis h sit e pr ef er e nc es f or a p plyin g N CI CI R B a p pr o vals acr oss t heir Sig nat or y Net w or k. Sit e pr ef er e nc es c a n be s et at t he net w or k or pr ot oc ol le vel. Q uestio ns a b o ut est a blis hin g sit e pr ef er e nc es c a n be a d dr ess e d t o t he C T S U Re g ulat or y Office b y e m a il or c allin g Sit es usin g t heir loc al I R B or R E B, m ust s u b mit t heir a p pr o val t o t he C T S U Re g ulat or y Office usin g t he Re g ulat or y S u b missio n P ort al loc at e d in t he Re g ulat or y s ectio n of t he C T S U w e bsite. Ac c e pt a ble d oc u m e nt atio n of loc a l I R B/ R E B a p pr o val inclu des: • L oc al I R B d oc u m e nt atio n; • I R B-sig ne d C T S U I R B Certific atio n F or m; a n d/ or • Pr ot oc ol of Hu m a n S u bjects Ass ur a nc e I de ntific atio n/I R B Certific atio n/ Declar atio n of E xe m ptio n F or m. I n a d ditio n, t he Sit e-Pr ot oc ol Principal I n vestigat or ( PI) (i. e. t he in vestigat or o n t he I R B/ R E B a p pr o val) m ust m eet t he f ollo win g crit eria in or der f or t he pr oc essin g of t he I R B/ R E B a p pr o val r ec or d t o be c o m plet e d: • Holds a n active C T E P st at us; • R ost er e d at t he sit e o n t he I R B/ R E B a p pr o val ( a p plies t o U S a n d C a n a di an sit es o nl y) a n d o n at least o ne participatin g r ost er; • If usin g N CI CI R B, r ost er e d o n t he N CI CI R B Sig nat or y r ec or d;"
18,page_18,"Allia nc e A1 7 1 6 0 1 1 9 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 • I nclu des t he I R B n u m ber of t he I R B pr o vidin g a p pr o val in t he F or m F D A 1 5 72 in t he R C R pr ofile; a n d • Holds t he a p pr o priat e C T E P r e gistr atio n t y pe f or t he pr ot oc ol. A d diti o n al Re q ui re m e nts : Ad ditio nal r e q uir e m e nts t o o bt ain a n a p pr o ve d sit e r e gistr atio n st at us inclu de: • An active F e der al Wide Ass ur a nc e ( F W A) n u m ber; • An active r ost er affiliatio n wit h t he Le a d Pr ot oc ol Or ga nizatio n ( L P O) or a P articipatin g Or ga nizatio n ( P O); a n d • C o m plia nc e wit h all pr ot oc ol -s pecific r e q uir e m e nts ( P S Rs). 4. 2. 1 Pr ot oc ol S pe cifi c Re q ui re m e nts f o r A 1 7 1 6 0 1 Sit e Re gistr atio n • E v ide nc e of Geriatric Ass ess m e nt Tr ainin g, as des cribe d in S ectio n 1 5. 0 I R O C cre de nti ali n g: T his is a st u d y wit h a r a diatio n a n d/ or i m a gin g ( R TI) c o m p o ne nt a n d t he e nr ollin g sit e m ust be alig ne d t o a n R TI pr o vider. T o m a na ge pr o vider ass ociatio ns or t o a d d or r e m o ve ass ociat e d pr o viders, ac c ess t he Pr o vider Ass ociatio n pa ge fr o m t he Re g ulat or y s ectio n o n t he C T S U m e m bers’ w e bsit e at . Sit es m ust be lin ke d t o at least o ne I m a gin g a n d Ra diatio n O nc olo g y C or e (I R O C) pr o vider t o participat e o n trials wit h a n R TI c o m p o ne nt. E nr ollin g sit es ar e r es p o nsible f or e ns urin g t hat t he a p pr o priat e a gr ee m e nts a n d I R B a p pr o vals ar e in plac e wit h t heir R TI pr o vider. An in divid ual wit h a pri m ar y r ole o n a n y r ost er is r e q uir e d t o u p dat e pr o vider ass ociatio ns, t h o u g h all in divid uals at a sit e m a y vie w pr o vider ass ociatio ns. T o fin d w h o h olds pri m ar y r oles at y o ur sit e, vie w t he P ers o n R ost er Br o w s er u n der t he R U M S s ectio n o n t he C T S U w e bsit e. 4. 2 .2 D o w nl o a di n g Sit e Re gist r ati o n D oc u me nts D o w nloa d t he sit e r e gistr atio n f or ms fr o m t he pr otoc ol -s pecific pa ge loc at e d o n t he C T S U m e m bers’ w e bsit e. P er missio n t o vie w a n d d o w nloa d t his pr ot oc ol a n d its s u p p orting d oc u m e nts is r estrict e d bas e d o n p ers o n a n d sit e r ost er assig n m e nt. T o participat e, t he instit utio n a n d its ass ociat e d in vestigat ors a n d st aff m ust be ass ociat e d wit h t he L P O or a Pr ot oc ol Or ga nizatio n ( P O) o n t he pr ot oc ol. O ne w a y t o s ear c h f or a pr ot oc ol is list e d belo w. • L o g in t o t he C T S U m e m bers’ w e bsit e usin g y o ur C T E P -I A M us er na m e a n d pass w or d; • Clic k o n Pr ot oc ols in t he u p per left of t he s cr ee n o E nt er t he pr ot oc ol n u m ber in t he s ear c h field at t he t o p of t he pr ot oc ol tr ee; o r o Clic k o n t he By Lea d Or ga nizatio n f older t o e x pa n d, t he n s elect [ Alli a nce], a n d pr ot oc ol n u m ber [A 1 7 1 6 0 1 ]. • Clic k o n D oc u me nts , s elect Sit e R e gistr ati o n , a n d d o w nloa d a n d c o m plet e t he f or ms pr o vide d. ( N ot e: F or sit es u n der t he CI R B, I R B dat a will loa d a ut o m atic ally t o t he C T S U.)"
19,page_19,"Allia nc e A1 7 1 6 0 1 2 0 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 4. 2. 3 S u b mitti n g Re g ul at or y Re q ui re me nts S u b mit r e q uir e d f or ms a n d d oc u m e nts t o t he C T S U Re g ulat or y Offic e usin g t he Re g ulat or y S u b missio n P ort al o n t he C T S U w e bsit e. T o ac c ess t he Re g ulat or y S u b missio n P ort al lo g in t o t he C T S U m e m bers’ w e bsit e, go to t he Re g ulat or y s ectio n a n d s elect Re g ulat or y S u b missio n. I nstit utio ns wit h patie nts w aitin g t hat ar e u na ble t o us e t he Re g ulator y S u b missio n P ort al s h o uld alert t he C T S U Re g ulat or y Offic e i m m e diat ely at in or der t o r ec eive f urt her instr uctio n a n d s u p p ort. 4. 2 . 4 C h e c ki n g Y o u r Site’s Re gistr ati o n St at us Sit e r e gistr atio n st at us m a y be verifie d o n t he C T S U m e m bers’ w e bsit e. • Clic k o n R e g ul at ory at t he t o p of t he s cr ee n; • Clic k o n Sit e R e gistr ati o n; a n d • E nt er t he sit es 5 -c har act er C T E P I nstit utio n C o de a n d clic k o n G o. o Ad ditio nal filt ers ar e a vaila ble t o s ort b y Pr ot oc ol, Re gistr atio n St at us, Pr ot oc ol St at us, a n d/ or I R B T y pe. N ot e: T he st at us s h o w n o nly r eflects instit utio nal c o m plia nc e wit h sit e r e gistr atio n r e q uir e m e nts as o utline d wit hin t he pr ot oc ol. It d oes n ot r eflect c o m plia nc e wit h pr ot oc ol r e q uir e m e nts f or in divid uals participatin g o n t he pr ot oc ol or t he e nr ollin g in vestigat or’s st at us wit h N CI or t heir affiliat e d net w or ks. 4 .2 . 5 Cre de nti ali n g S ee S ectio n 1 5. 0 f or cr e de ntialin g r e q uir e m e nts f or Geriatric Ass ess m e nt Trainin g. 4. 3 P ati e nt Re gistr atio n Re q ui re me nts I nf or m e d c o ns e nt: T he patie nt m ust be a w ar e of t he ne o plastic nat ur e of his/ her dis eas e a n d willin gly c o ns e nt aft er bein g inf or m e d of t he pr oc e d ur e t o be f ollo w e d, t he e x peri m e nt al nat ure of t he t her a p y, alt er natives, p ot e ntial be nefits, side -eff ects, ris ks, a n d dis c o mf orts. C urr ent h u m a n pr ot ectio n c o m mitt ee a p pr o val of t his pr ot oc ol a n d a c o ns e nt f or m is r e q uir e d prior t o patie nt c o ns e nt a n d r e gistr atio n. P ati e nt c o m pl et e d bo o kl ets : P atie nt q uestio n nair e b o o klets ar e t o be or der e d prior t o t he r e gistr atio n of a n y patie nts. P atie nt c o m plet e d b o o klets in E n glis h a n d S pa nis h c a n be or der ed b y d o w nloa din g a n d c o m pletin g t he C T S U s u p ply r e q uest f or m (loc at e d u n der t he sit e r e gistr atio n s ectio n of t he C T S U pr ot oc ol s pecific w e bsit e ) a n d s u b mittin g the f or m t hr o u gh the C T S U r e g ulat or y p ort al . S a m ples of t he b o o klets in E n glis h ar e f o u n d in Ap pe n dic es II-VII a nd electr o nic versio ns of t he b o o klets in S pa nis h ar e a vaila ble o n t he Allia nc e a n d C T S U w e b sit es. T hes e ar e t o be us e d f or r ef ere nce a n d I R B s u b missio n o nly. T he y ar e n ot t o be use d f or patient c o m pletio n. Pr ot e ct e d He alt h I nf or m ati o n : W h ole blo o d s a m ples c ollect e d f or t he p har m ac o kinetics sub- st u d y A1 7 1 6 0 1-P P 1 will be s e nt dir ectly t o t he Universit y of Pitts b ur g h Ca nc er Ce nt er. T hese s a m ples will be la bele d wit h patie nt initials, st u d y I D a n d c ollectio n dat e/ti m e. 4. 4 P ati e nt Re gistr atio n/ R a n do mi z atio n Pr oce d u res T he O nc olo g y P atie nt E nr oll m e nt Net w or k ( O P E N) is a w e b -bas e d r e gistr atio n s yst e m a vaila ble o n a 2 4/ 7 basis. O P E N is int e gr at e d wit h C T S U r e g ulat or y a n d r ost er dat a a n d wit h t he L P Os"
20,page_20,"Allia nc e A1 7 1 6 0 1 2 1 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 r e gistr atio n/r a n d o mizatio n s yst e ms or t he T her a de x I nt er active We b Res p o n s e S yst e m (I W R S) f or r etrie val of patie nt r e gistr atio n/r a n d o mizatio n assig n m e nt. O P E N will p o p ulat e t he patie nt e nr oll m e nt dat a in N CI’s clinic al dat a m a na ge m e nt s yst e m, Me didat a Ra ve. Re q uir e m e nts f or O P E N ac c ess: • A valid C T E P -I A M ac c o u nt; • T o perf or m e n r oll m e nts or r e q uest slot r es er vatio ns: M ust b e o n an L P O r ost er, E T C T N c orr es p o n din g r ost er, or participatin g or ga nizatio n r ost er wit h t he r ole of Re gistr ar. Re gistr ars m ust h old a mini m u m of a n Ass ociat e Plus ( A P ) r e gistr atio n t y pe; • If a Dele gatio n of T as ks L o g ( D T L) is r e q uir e d f or t he st u d y, t he r e gistr ars m ust h old t he O P E N Re gistr ar t as k o n t he D T L f or t he sit e; a n d • Ha ve a n a p pr o ve d sit e r e gistr atio n f or t he pr ot oc ol prior t o patie nt e nr oll m e nt. T o assig n a n I n vestigat or (I V R) or N o n -P h ysicia n I n vesti gat or ( N PI V R) as t he tr eatin g, cr e ditin g, c o ns e ntin g, dr u g s hip m e nt (I V R o nly), or r ec eivin g in vestigat or f or a patie nt tr a nsfer in O P E N, t he I V R or N PI V R m ust list t he I R B n u m ber us e d o n t he sit e’s I R B a p pr o val o n t heir F or m F D A 1 5 7 2 in R C R. If a D T L is r e q uir e d f or t he st u d y, t he I V R or N PI V R m ust be assig ned t he a p pr o priat e O P E N-r elat e d t as ks o n t he D T L. Prior t o ac c essin g O P E N, sit e st aff s h ould verif y t he f ollo win g: • P atie nt has m et all eligibilit y crit eria wit hin t he pr ot oc ol st at e d ti m efr a m es; a n d • Al l patie nts ha ve sig ne d a n a p pr o priat e c o ns e nt f or m a n d HI P A A a ut h orizatio n f or m (if a p plic a ble). • Sit e st aff ha ve c o m plet e d t he Geriatric Ass ess m e nt tr ainin g des cribe d in S ectio n 1 5. 0. N ot e: T he O P E N s yst e m will pr o vide t he sit e wit h a print a ble c o nfir m atio n of r e gistr atio n a n d tr eat m e nt inf or m atio n. Yo u m a y print t his c o nfir m atio n f or y o ur r ec or ds. Ac c ess O P E N at or fr o m t he O P E N lin k o n t he C T S U m e m bers’ w e bsi te. F urt her instr uctio nal inf or m atio n is in t he O P E N s ectio n of t he C T S U w e bsit e at F or a n y a d ditio nal q uestio ns, c o nt act t he C T S U Help Des k at T o r ec eive sit e r ei m b urs e m e nt f or s pecific t ests a n d/ or bio -s peci m e n s u b missio ns, c o m pletion dat es m ust be e nt er e d in t he O P E N F u n din g s cr ee n p ost r e gistr atio n. Pleas e r ef er t o t he pr ot oc ol - s pecific f u n din g pa ge o n t he C T S U m e m bers’ w e bsit e f or a d ditio nal inf or m atio n. Ti m ely e ntr y of c o m pletio n dat es is r ec o m m e n de d as t his will trig ger sit e r ei m b urs e m e nt. 4. 5 Re gist r ati o n t o C orrel ati ve a n d C o m pa ni o n St u di es 4. 5 . 1 Re gist r ati o n t o S u b st u di es descri be d i n S e cti o n 1 4. 0 T her e ar e 3 s u b st u dies wit hin Allia nc e A 1 7 1 6 0 1 . T hes e st u dies m ust be off er e d t o all patie nts e nr olle d o n Allia nc e A 1 7 1 6 0 1 (alt h o u g h patie nts m a y o pt t o n ot participat e). T hese s u b st udies d o n ot r e q uir e s e par at e I R B a p pr o val. T he s u b st u dies inclu de d wit hin Allia nc e A 1 7 1 6 0 1 ar e: • Cir c ulatin g m ar kers of infla m m atio n as p ot e ntial m ar kers pr e dictive of t o xicit y a m o ng elderly pat ie nts e nr olle d t o Allia nc e A1 7 1 6 0 1: Allia nc e A 1 7 1 6 0 1 -S T 1 ( S ectio n 1 4. 1 ) • Ge netic det er mina nts of P alb ociclib Effic ac y a n d t o xicit y in t he elderly: Al lia nc e A1 7 1 6 0 1 -S T 2 (S ectio n 1 4. 2 ) • P o p ulatio n P har m ac o kinetics of P alb ociclib: Allia nc e A1 7 1 6 0 1 -P P 1 (S ectio n 1 4. 3 )"
21,page_21,"Allia nc e A1 7 1 6 0 1 2 2 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 If a patie nt a ns w ers “ yes ” t o “I a gr ee t o ha ve m y s peci m e n c ollect e d a n d I a gr ee t hat m y s peci m e n s a m ple(s) a n d r elat e d inf or m atio n m a y be us e d f o r t he la b or at or y st u dies des cribed a b o ve. , ” Q uestio n # 1 in t he m o del c o ns e nt, t he y ha ve c o ns e nt e d t o participat e in t he s ub st u dies des cribe d in S ectio n 1 4. 1 , S ectio n 1 4. 2 a n d S ectio n 1 4. 3 . T he patie nt s h o uld be r e gist er e d t o Allia nc e A1 7 1 6 0 1 -S T 1 , A1 7 1 6 0 1 -S T 2 a n d A1 7 1 6 0 1 -P P 1 at t he s a m e ti m e t he y ar e r e gist er e d t o t he tr eat m e nt trial ( A1 7 1 6 0 1 ). S a m ples s h o uld be s u b mitt e d per S ectio n 6. 2 . 4. 6 Gr o u pi n g F act or 4. 6. 1 A ge 7 0 -7 4 vs. ≥ 7 5"
22,page_22,"Allia nc e A1 7 1 6 0 1 2 3 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 5. 0 S T U D Y CA L E N D A R T he pr e -st u d y t estin g int er vals ar e g uidelines o nly. La b or at or y a n d clinic al par a m et ers d urin g tr eat m e nt ar e t o be f ollo w e d usin g in divid ual instit utio nal g uidelines a n d t he best clinic al ju d g m e nt of t he r es p o nsible p h ysicia n. It is e x pect e d t hat patie nts o n t his st u d y will be c ar e d f or b y p h ysicia ns e x perie nc e d in t he tr eat m e nt a n d s u p p ortive c ar e of patie nts o n t his trial. Pre -St u dy Testi n g I nt er v als: To be c o m pl et e d ≤ 1 4 D A Y S bef ore re gist r ati o n : All la b or at or y st u dies, hist or y a n d p h ysic al , c o nc o mit a nt m e dic atio ns a n d bas eline a d vers e e ve nt ass ess m e nt . To be c o m pl et e d ≤ 4 2 D A Y S bef ore re gistr ati o n: C T a n d b o ne s ca n, or P E T s ca n * +/ - 2 da ys. 1 c y cle = 2 8 da ys. ( All Da y 1 baseli n e assess m e nt s m a y be c o m plet e d a n y ti m e aft er r e gistr ati o n b ut bef or e tr e at m e nt. H & P n e e d n ot be r e p e at e d f or Da y 1 if d o n e wit hi n a 3 0 da y wi n d o w pri or t o Da y 1 of C y cle 1.) * * Ne e d n ot be r e p e at e d if d o n e wit hi n t h e last 7 da ys * * * C M P i n cl u des ele ctr ol yt es (s o di u m, p ot assi u m, c hl ori de, bic ar b o n at e), r e n al f u n cti o n ( bl o o d ur e a nitr o ge n a n d cr e ati ni n e) li v er f u n cti o n t est s ( A S T, A L T, al k. p h os., t ot al bilir u bi n, dir e ct bilir u bi n o nl y if cli nic all y i n dic at e d), t ot al pr ot ei n, al b u mi n, a n d c alci u m † At t h e e n d of pr ot o c ol tr e at m e nt p atie nts will c o m plet e t h e Geriatric Assess m e nt a n d t h e e n d of tr e at m e nt b o o klet. P atie nts will t h e n be f oll o we d e v er y y e ar f or s ur vi v al o nl y, u p t o 5 y e ars 1 P R O -C T C A E a n d E Q -5 L -3 D r e q uir e d o nl y f or t h e first 6 c y cles of pr ot o c ol t h er a p y d uri n g t h e first y e ar of tr e at m e nt 2 D o es n ot n e e d t o be r e p e at e d if d o n e wit hi n t h e last 3 0 da ys. 3 Ra di o n ucli de b o n e sc a n is n ot r e q uir e d if baseli n e P E T sc a n was d o n e. B o n e sc a n aft er baseli n e is r e q uir e d o nl y if i n dic ati v e of m et ast ases at baseli n e or if si g ns or s y m pt o ms s u g gesti v e of m et ast ases de v el o p m e nt. A E n d of c y cle 1 a n d 2 B Da y 1, C y cle 4 o nl y C C y cle 1 o nl y D Da y 1 of C y cle 4 ( +/- 2 we e ks), t h e n e v er y 1 2 we e ks ( +/- 2 we e ks) u ntil e n d o f tr e at m e nt. Res p o nse assess m e nt s h o ul d i n cl u de assess m e nt of all sit es of dise ase a n d use t h e sa m e i m a gi n g m et h o d as was use d at baseli n e. Se e Se cti o n 6. 3 f or i nstr ucti o ns o n s u b missi o n of i m a ges. P ri o r t o r e gi st r ati o n C y cl e s 1 a n d 2 D a y 1 of e ve r y c y cl e st arti n g wit h C y cl e 3 f o r y e a r 1 of t r e at m e nt* Eve r y 3 mt h s f r o m y e a r 2 u ntil e n d of t r e at m e nt( +/-8 d a ys) At e n d of pr ot o c ol t r e at m e nt† Da y 1 * Da y 1 5 * Tests a n d O bs e r vati o ns Hist or y a n d P h ysic al X X X X A d h ere nc e e v al uati o n A B X A d v erse Ev e nt Re p orti n g X X X X X P R O -C T C A E X X X( 1) X( 2) Co n c o mit a nt me dic ati o ns X X X X Geriatric As sess me nt C B X( 2) E Q -5 D -3 L X X( 1) X( 2) W as It W ort h It a n d O v erall Tre at me nt Utilit y X La bor at or y St u di es C B C, Differe ntial, Plat elets X X * * X X X C M P * * * X X * * X X X St a gi n g C T c h est/a b d +/ - p el vis or P E T X D X Bo n e Sc a n, W h ole Bo d y X( 3) D X C or r el ati ve st u di es f or pati e nts wh o c o ns e nt t o parti ci pate T o b e c oll e ct ed at t h e ti me p oi nts d escri bed i n S ecti o n 6. 2 W h ole Bl o o d a n d Plas ma"
23,page_23,"Allia nc e A1 7 1 6 0 1 2 4 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 6. 0 D A T A A N D SP E C I M E N SU B MI S S I O N 6. 1 D at a C oll e cti o n a n d S u b missi o n 6. 1. 1 D at a s u b missi o n sc h e d ul e : A S c he d ule of F or ms is a vaila ble o n t he Allia nc e st u d y w e b pa ge, wit hin t he Cas e Re p ort F or ms s ectio n. T he S c he d ule of F or ms is als o a vaila ble o n t he C T S U sit e wit hin t he Cas e Re p ort F or ms t a b . 6. 1. 2 Me di dat a R a ve Me didat a Ra ve is a clinic al dat a m a na ge m e nt s yst e m bein g us e d f or dat a c ollectio n f or this trial/st u d y. Ac c ess t o t he trial in Ra ve is c o ntr olle d t hr o u g h t he C T E P -I A M s yst e m a n d r ole assig n m e nts. Re q ui r e m e nts t o ac c ess Ra ve via i Me didat a: • A valid C T E P -I A M ac c o u nt; a n d • Assig ne d a Ra ve r ole o n t he L P O or P O r ost er at t he e nr ollin g sit e of: Ra ve C R A, Ra ve Rea d O nly, Ra ve C R A ( La b Ad min), Ra ve S L A, or Ra ve I n vestigat or. Ra ve r ole r e q uir e m e nts: o Ra ve C R A or Ra ve C R A ( La b Ad min) r ole m ust ha ve a mini m u m of a n Ass ociate Plus ( A P) r e gistr atio n t y pe; o Ra ve I n vestigat or r ole m ust be r e gist er e d as a n N o n -P h ysicia n I n vestigat or ( N PI V R) or I n vestigat or (I V R); a n d o Ra ve Rea d O nly r ole m ust ha ve at a mini m u m a n Ass ociat e s ( A) r e gistr atio n t y pe. Ref er t o f or r e gistr atio n t y pes a n d d oc u m e nt atio n r e q uir e d. Up o n initial sit e r e gistr atio n a p pr o val f or t he st u d y in Re g ulat or y S u p p ort S yst e m ( R S S), all pers o ns wit h Ra ve r oles assig ne d o n t he a p pr o priat e r ost er will be s e nt a st u d y in vit atio n e-m ail fr o m i Me didat a. T o ac c e pt t he in vit atio n, sit e st aff m ust lo g in t o t he S elect L o gin usin g t heir C T E P-I A M us er na m e a n d pass w or d a n d clic k o n t he acce pt lin k in t he u p per rig ht-c or ner of t he i Me didat a pa ge. Sit e st aff will n ot be a ble t o ac c ess t he st u d y in Ra ve u ntil all r e q uir e d Me didat a a n d st u d y s pecific tr ainin gs ar e c o m plet e d. Tr ainin gs will be in t he f or m of electr o nic lear nin gs ( e Lear nin gs) a n d c an be ac c esse d b y clic kin g o n t he lin k in t he u p per rig ht pa ne of t he i Me didat a s cr een. If a n e Lear nin g is r e q uir e d a n d has n ot yet bee n t a ke n, t he lin k t o t he e Lear nin g will a p pear u n der t he st u d y na m e in i Me didat a inst ea d of t he R av e E D C lin k; o nc e t he s uc c essf ul c o m pletio n of t he e Lear nin g has bee n r ec or de d, ac c ess t o t he st u d y in Ra ve will be gr a nt e d, a n d a R av e E D C lin k will dis pla y u n der t he st u d y na m e. Sit e st aff t hat ha ve n ot pr e vio usly activat e d t heir i Me didat a/ Ra ve ac c o u nt at t he ti m e of initial sit e r e gistr atio n a p pr o val f or t he st u d y in R S S will r ec eive a s e par at e in vit atio n fr o m i Me didat a t o activat e t heir ac c o u nt. Ac c o unt activatio n instr uctio ns ar e loc at e d o n t he C T S U w e bsit e in t he Dat a Ma na ge m e nt s ectio n u n der t he Ra ve r es o ur c e m at erials ( Medidat a Ac c o u nt Activatio n a n d St u d y I n vit atio n Ac c e pt a nc e). Ad ditio nal inf or m atio n o n i Me didat a/ Ra ve is a vaila ble o n t he C T S U m e m bers’ w e bsit e in t he Dat a Ma na ge m e nt > Ra ve s ectio n at or b y c o nt a ctin g t he C T S U Help Des k at"
24,page_24,"Allia nc e A1 7 1 6 0 1 2 5 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 • P ati e nt -c o m pl ete d q u estio n n aire bo o kl ets f or t his st u d y ar e t o be or der e d prior t o t he r e gistr atio n of a n y patie nts (s ee S ectio n 4. 3 ). S a m ples of t he b o o klets in E n glis h ar e f o u n d in Ap pe n dic es II-VII a n d electr o nic versio ns of t he b o o klets in S pa nis h ar e a vaila ble o n t he Allia nc e a n d C T S U w e b sit es, f or r ef er e nc e a n d I R B s u b missio n o nly. T he y ar e n ot t o be us e d f or patie nt c o m pletio n. Bo o klets m ust be give n t o patie nts t o c o m plet e a n d patie nts s h o uld be instr uct e d t o r et ur n t he b o o klets t o sit e st aff eit her in pers o n or b y m ail a n d sit e st aff will e nt er patie nt a n d c ar e giver r es p o ns es int o Ra ve. 6. 1. 3 D at a Q u alit y P ort al: T he Dat a Q ualit y P ort al ( D Q P) pr o vides a c e ntr al loc atio n f or sit e st aff t o m a na ge u na ns w er e d q ueries a n d f or m delin q ue ncies, m o nit or dat a q ualit y a n d ti m eliness, ge ner at e r e p orts, a n d r e vie w m etrics. T he D Q P is loc at e d o n t he C T S U m e m bers’ w e bsit e u n der Dat a Ma na ge m e nt. T he Ra ve Ho m e s ectio n dis pla ys a t a ble pr o vidin g s u m m ar y c o u nts of T ot al Delin q ue ncies a n d T otal Q ueries. D Q P Q ueries, D Q P Delin q ue nt F or ms a n d t he D Q P Re p orts m o d ules ar e a vaila ble t o ac c ess det ails a n d r e p orts of u na ns w er e d q ueries, delin q ue nt f or ms, a n d ti m eliness r e p orts. Re vie w t he D Q P m o d ules o n a r e g ular basis t o m a na ge s pecifie d q ueries a n d delin q ue nt f or ms. T he D Q P is ac c essible b y sit e st aff t hat ar e r ost er e d t o a sit e a n d ha ve ac c ess t o t he C T S U w e bsit e. St a ff t hat ha ve Ra ve st u d y ac c ess c a n ac c ess t he Ra ve st u d y dat a usin g a dir ect lin k o n t he D Q P. T o lear n m or e a b o ut D Q P us e a n d ac c ess, clic k o n t he Help ic o n dis pla ye d o n t he Ra ve Ho m e, D Q P Q ueries, a n d D Q P Delin q ue nt F or ms m o d ules. N ot e: S o m e Ra ve pr ot oc ols m a y n ot ha ve delin q ue nt f or m det ails or r e p orts s pecifie d o n t he D Q P. A pr ot oc ol m ust ha ve t he Cale n dar f u nctio nalit y i m ple m e nt e d in Ra ve b y t he Lea d Pr ot oc ol Or ga nizatio n f or delin q ue nt f or m det ails a n d r e p orts t o be a vaila ble o n t he D Q P. Sit e s t aff s h o uld c o nt act t he L P O Dat a Ma na ger f or t heir pr ot oc ol r e gar din g q uestio ns a b o ut Ra ve Cale n darin g f u nctio nalit y. 6. 1. 4 S u p porti n g doc u m e nt ati o n T his st u d y r e q uir es s u p p ortin g d oc u m e nt atio n f or dia g n osis, r es p o ns e, pr o gr essio n a n d s ur vival. S u p p ortin g d oc u m e nt atio n will inclu de pat h olo g y a n d i m a gin g r e p orts a n d m ust be s u b mitt e d at t he f ollo win g ti m e p oints: B as eli n e: F or patie nts wit h m eas ura ble dis eas e o nly, pat h olo g y a n d i m a gin g r e p orts. At Pr o gressi o n a n d res po ns e : I m a gin g r e p orts a n d/ or clinic n otes, bas e d o n st a n dar d R E CI S T crit eria. All s u p p ortin g d oc u m e nt atio n s h o uld be de -ide ntifie d ac c or din g t o instit utio nal st a n dar ds prior t o u ploa d int o R A V E."
25,page_25,"Allia nc e A1 7 1 6 0 1 2 6 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 6. 2 S pe ci m e n c oll e cti o n a n d s u b missi o n F or patie nts r e gist er e d t o s u bst u d y A 1 7 1 6 0 1 -S T 1, A 1 7 1 6 0 1 -S T 2 a n d A1 7 1 6 0 1 -P P 1 : All participatin g instit utio ns m ust as k patie nts f or t heir c o ns e nt t o participat e in t he c orr elative s u bst u dies pla n ne d f or Allia nc e A1 7 1 6 0 1 -S T 1, A 1 7 1 6 0 1 -S T 2 a n d A1 7 1 6 0 1 -P P 1, alt h o u g h patie nt parti cipatio n is o ptio nal. Bio m ar ke r, p har m ac o ge netics st u dies a n d p har m ac o kinetic st u dies will be perf or m e d. Ratio nale a n d m et h o ds f or t he s cie ntific c o m p o ne nts of t hese st u dies ar e des cribe d in S ectio n 1 4. 0 . F or patie nts w h o c o ns e nt t o participat e, plas m a a n d w h ole blo o d will be c ollect e d at t he f ollo win g ti m e p oints f or t hes e st u dies: C ollectio n of plas m a f or t o xicity bio m ar ker c orr elative st u dies will c oincide wit h t he Geriatric ass ess m e nt o n c ycle 1 da y 1, a nd prior t o c ycle 4 . 1 W h ole blo o d f or Plas m a t o be us e d f or bio m ar ker a nalys es des cribe d in S ectio n 1 4. 1 . 2 W h ole blo o d t o be us e d f or p har m ac o ge n o mic a n alys es des cribe d in S ectio n 1 4. 2 . 3 P har m ac o kinetic a nalys es des cribe d in S ectio n 1 4. 3 . P atie nts will be as ke d t o c o m plet e a p har m ac o kinetics q uestio n nai r e (Ap pe n dix I X) t hes e visits ( Bas eline, C ycles 1 & 2 Da y 1 5, prior t o tr eat m e nt) . T he q uestio n nair e c a n be c o m plet e d bef or e or aft er t he blo o d dr a w. A c o p y of t he q uestio n nair e will be s e nt b y sit e st aff alo n g wit h t he s a m ples t o t he Universit y of Pitts b ur g h. Q uestio n nair e r es p o ns es ar e t o be e nt er e d int o Ra ve b y sit e st aff. Not e: S a m pl es f or A 1 7 1 6 0 1 - P P 1 s u bst u dy are o nl y re q ui re d f or pati e nts w h o are re gist e re d (a n d c o ns e nt t o parti ci pat e i n t h e s u bst u di es ) aft er U p dat e 1. P ati e nts e n r olle d pri or t o t h e rel e ase of U p dat e 1 will n ot be as k e d t o pr o vi de a d diti o n al s a m pl es. 6. 2. 1 S pe ci m e n S u b missi o n U si n g t h e Alli a nce Bi os pe ci me n Ma n a ge me nt S yst e m U S E O F T H E A L LI A N C E BI O S P E CI M E N M A N A G E M E N T S Y S T E M ( Bio M S) I S M A N D A T O R Y A N D A L L S P E CI M E N S M U S T B E L O G G E D A N D S HI P P E D VI A T HI S S Y S T E M. Bio M S is a w e b -bas e d s yst e m f or lo g gin g a n d tr ac kin g all bios peci m e ns c ollect e d o n Allia nc e trials. Aut h orize d in divid uals m a y ac c ess Bio M S at t he f ollo win g U R L: usin g m ost st a n dar d w e b br o w sers ( S af ari, Fir ef o x, I nt er net E x plor er). F or inf or m atio n o n usin g t he Bio M S s yst e m, pleas e r efer t o t he ‘ Help’ lin ks o n t he Bio M S w eb pa ge t o ac c ess t he o n -line us er m a n ual, F A Qs, a n d F or all pati e nts re gist ere d t o A 1 7 1 6 0 1 S T1, A 1 7 1 6 0 1 - S T2 a n d A 1 7 1 6 0 1 -P P 1 , s u b mit t h e f oll o wi n g: Pri or t o Tre at m e nt C ycl es 1 & 2 D a y 1 5 ( Pri or t o t re at m e nt) Pri or t o C ycl e 4 St or a ge/ S hi p pi n g c o n diti o ns S u b mit t o: W h ol e Bl o o d1 ( E D T A/la ve n der t o p) 1 0 m L 1 0 m L C o ol pac k /s hip o ver nig ht Ma y o B A P Fr eezer W h ol e Bl o o d2 ( E D T A/la ve n der t o p) 1 0 m L C o ol pac k/s hip o ver nig ht Ma y o B A P Fr eezer Pl as m a f r o m W h ol e Bl o o d3 ( E D T A/la ve n der t o p) 5 m L 5 m L Dr y ic e/ s hip o ver nig ht Universit y of Pitts b ur g h"
26,page_26,"Allia nc e A1 7 1 6 0 1 2 7 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 tr ainin g vide os. T o r e p ort t ec h nic al pr o ble ms, s uc h as lo gin iss ues or a p plic atio n err ors, pleas e c o nt act: . F or assist a nc e in usin g t he a p plic atio n or q uestio ns or pr o ble ms r elat e d t o s pecific s peci m e n lo g gin g, pleas e c o nt act: . Aft er lo g gin g c ollect e d s peci m e ns in Bio M S, t he s yst e m will cr eat e a s hip pin g m a nif est. T his s hip pin g m a nif est m ust be print e d a n d plac e d in t he s hip m e nt c o nt ainer wit h t he s peci m e ns. All s u b mitt e d s peci m e ns m ust be la bele d wit h t he pr ot oc ol n u m ber ( A 1 7 1 6 0 1 ), Allia nc e patie nt n u m ber, patie nt’s initials, dat e a n d t y pe of s peci m e n c ollect e d ( e. g., s er u m , w h ole blo o d). W he n s peci m e ns ar e ti m e -s e nsitive, a n d/ or ar e r e q uir e d f or c o m m u nic atio n of t est r es ults bac k t o instit utio ns a n d patie nts, t he y s h o uld be la bele d wit h patie nt initials a n d dat e of pr oc ur e m e nt, in a d ditio n t o pr ot oc ol n u m ber, Allia nc e patie nt n u m ber a n d s peci m e n t y pe. S peci m e ns t hat ar e n ot ti m e -s e nsitive, a n d/ or ar e n ot s u b mitt e d f or t he p ur p os e of perf or min g a n int e gr al t est t hat will be r e p ort e d bac k t o patie nts, s h o uld n ot inclu de patie nt initials or dat e of pr oc ur e m e nt. A c o p y of t he S hip m e nt P ac kin g Slip pr o d uc e d b y Bio M S m ust be print e d a n d plac e d in t he s hip m e nt wit h t he s peci m e ns. I nstr uctio ns f or t he c ollectio n of s a mples ar e inclu de d belo w. Pleas e be s ure t o use a m ethod of s hip pin g t hat is s ec ur e a n d tr ac ea ble. E xtr e m e heat pr ec a utio ns s h o uld be t a ke n w hen nec ess ar y. S peci m e ns f or t he A1 7 1 6 0 1 - S T 1 a n d A1 7 1 6 0 1 -S T 2 s u b -st u dies s h o uld be s hip pe d M o n da y t hr o u g h Frida y m ar ke d f or S at ur da y deliver y. S hip pin g b y o ver nig ht s er vic e t o ass ure r ec eipt is e nc o ur a ge d. D o n ot s hip s peci m e ns on S at ur da ys . S pe ci m e ns f or t h e A 1 7 1 6 01 -P P 1 s u bst u dy s h o ul d be s e nt t o t h e f oll o wi n g a d dress: All ot h e r s pe ci m e ns s h o ul d be s e nt t o t h e f oll o wi n g a d dress: 6. 2. 2 W h ol e Bl o o d s a m pl e s u b missi o n f or pl as m a ( A 17 1 6 0 1-S T1) F or patie nts w h o c o ns e nt t o participat e, w h ole blo o d c ollect e d f or plas m a s a m ples will be us e d f or t he bio m ar ker a nalys es des cribe d in S ectio n 1 4. 1 . F or E D T A plas m a, c ollect 1 0 m L of w h ole blo o d b y st a n dar d ve n o us p hle b ot o m y int o t he E D T A t u be , prior t o tr eat m e nt a n d prior t o c ycle 4. T he t u be s h o uld be in vert e d s e ver al"
27,page_27,"Allia nc e A1 7 1 6 0 1 2 8 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 ti m es t o mix t he E D T A a n d r efriger at e d u ntil s hip pe d o n c o ol pac k b y o ver nig ht m ail t o t he Allia nc e Bior e p osit or y ( M a y o B A P). T he s a m ples s h o uld be s hip pe d t he s a m e da y t hat t he blo o d is dr a w n per S ectio n 6. 2. 1 . La bel s a m ples wit h t he f ollo win g ide ntific atio n: 1) Pr oc ur e m e nt dat e/ti m e of c ollectio n 2) Allia nc e patie nt n u m ber 3) P atie nt initi als 4) Allia nc e st u d y n u m ber (i. e., A 1 7 1 6 0 1 -S T 1 ) 5) S peci m e n t y pe T he 1 0 ml of blo o d c a n be c ollect e d in o ne 1 0 ml t u be, or t w o 5 ml t u bes or t hr ee 3 ml t u bes, as lo n g as t he final v olu m e is ~ 1 0 ml. 6. 2. 3 W h ol e b l o o d s u b missi o n f or p h ar m ac o ge n o mi c st u di es ( A1 71 6 0 1 -S T2) F or patie nts w h o c o ns e nt t o participat e, w h ole blo o d s a m ples will be us e d f or t he p har m ac o ge n o mic s t u dies des cribe d in S ectio n 1 4. 2 . T his s a m ple s h o uld be c ollecte d prior t o t he initiatio n of pr ot oc ol tr eat m e nt. T he f ollo win g bio s peci m e ns will be c ollect e d at bas eline : C ollect 1 0 m L of w h ole blo o d b y st a n dar d ve n o us p hle b ot o m y int o t he E D T A t u be. T he t u be s h o uld be in vert e d s e ver al ti m es t o mix t he E D T A a n d r efriger at e d u ntil s hip pe d o n c o ol pac k b y o ver nig ht s hip pin g t o t he Allia nc e Bior e p osit or y ( Ma y o B A P). T he s a m ples s h o uld be s hip pe d t he s a m e da y t hat t he blo o d is dr a w n per S ectio n 6. 2. 1. La bel s a m ples wit h t he f ollo win g ide ntific atio n: 1) Pr oc ur e m e nt dat e/ti m e of c ollectio n 2) Allia nc e patie nt n u m ber 3) P atie nt initials 4) Allia nc e st u d y n u m ber (i. e., A 1 7 1 6 0 1 -S T 2 ) 5) S peci m e n t y pe T h e 1 0 ml of blo o d c a n be c ollect e d in o ne 1 0 ml t u be, or t w o 5 ml t u bes or t hr ee 3 ml t u bes, as lo n g as t he final v olu m e is ~ 1 0 ml. 6. 2. 4 Pl as m a s u b missi o n f or p h ar m ac o ki neti c st u di es ( A 1 7 16 0 1-P P 1) F or patie nts w h o c o nse nt t o participat e, blo o d s a m ples will be us e d f or t he p har m ac o kinetic a nalys es des cribe d in S ectio n 1 4. 3. Pl as m a f r o m W h ol e Bl o o d i n E D T A L a ve n de r To p T u be: Prior t o r ec eivin g pr ot oc ol t her a p y o n C ycle 1 da y 1 , C ycle 1 Da y 1 5, a n d C ycle 2 Da y 1 5, patie nts c o ns e nt e d t o t he A1 7 1 6 0 1 -P P 1 s u bst u d y will be as ke d t o c o m plet e a P atie nt P har m ac o kinetics F or m (s ee Ap pe n dix I X) w hic h will pr o vide inf or m atio n a b o ut t he pr e vio us 4 8 -h o urs of palb ociclib d osin g (i. e. det ails o n d os e a n d ti m e). Aft er c o m pletio n, t he f or m s h o uld be c ollect e d, a n d t he dat a s h o uld be r e p ort e d in Ra ve o n t he S peci m e n S u b missio n F or m f or A1 7 1 6 0 1 -P P 1. C oll ect 1 x 5 m L of perip her al ve n o us blo o d in a la ve n der t o p ( E D T A) t u be prior t o t he patie nt r ec eivin g t he daily d os a ge of palb ociclib o n C ycle 1 Da y 1 a n d Da y 1 5, a n d C ycle 2 Da y 1 5. I n vert t he t u bes a p pr o xi m at ely 8 -1 0 ti m es t o mix t he E D T A, a n d t he n c e ntrif u ge at r o o m t e m per at ur e f or 10 min ut es at 1 5 0 0 g. Aliq u ots of plas m a will t he n be plac e d in la belle d p oly pr o p yle ne t u bes ( 1 m L in eac h of t w o t u bes) a n d st or e d at -7 0 t o - 8 0 oC u ntil s hip pe d o n dr y ic e ."
28,page_28,"Allia nc e A1 7 1 6 0 1 2 9 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 La bel all plas m a s a m ples wit h t he f ollo win g ide ntifi c atio n inf or m atio n: 1) Dat e of C ollectio n 2) Ti m e of C ollectio n (i. e. act ual ti m e t he blo o d s a m ple w as o bt aine d) 3) Allia nc e P atie nt I D N u m ber 4) P atie nt I nitials 5) Allia nc e St u d y N u m ber (i. e. A1 7 1 6 0 1 -P P 1) 6) S a m ple T y pe ( e. g. Plas m a) If la bels ar e us e d, pleas e e ns ur e la bels ar e c ar ef ully att ac he d t o t he t u bes a n d ar e n ot likely t o f all off w he n fr oze n or d urin g s hip pin g. S hip s peci m e ns a n d c o pies of t he c o m plet e d P har m ac o kinetics q uestio n nair es t o t he Allia nc e La b or at or y at t he Universit y of Pitts b ur g h ( S ee S ectio n 6. 2. 1 ) wit h Priorit y O ver nig ht o n M o n da y t hr o u g h T h urs da y f or ne xt da y deliver y. D o n ot s hip s peci m e ns t he da y bef or e a h olida y. T he Universit y of Pitts b ur g h d oes n ot ac c e pt S at ur da y deliveries. 6. 3 Di git al I m a ge S u b missi o n Usi n g T RI A D Tr a nsf er of I m a ges a n d Dat a ( T RI A D) is t he A m eric a n C olle ge of Ra diolo g y’s ( A C R) i m a ge e xc ha n ge a p plic atio n. T RI A D pr o vides sit es participatin g in clinic al trials a s ec ur e m et h o d t o tr a ns mit i m a ges. T RI A D a n o n y mizes a n d validat es t he i m a ges as t he y ar e tr a nsf err e d. 6. 3. 1 T RI A D Access Re q ui re m e nts • A valid C T E P -I A M ac c o u nt. • Re gistr atio n a n d Cr e de ntial Re p osit or y ( R C R) r e gistr atio n t y pe of: Ass ociat e ( A), Ass ociat e Plus ( A P), N o n-P h ysicia n I n vestigat or ( N PI V R), or I n vestigat or (I V R) r e gistr atio n t y pe. Ref er t o t he C T E P Re gistr atio n Pr oc e d ur es s e ctio n f or instr uctions on h o w t o r e q uest a C T E P -I A M ac c o u nt a n d c o mplet e r e gistr atio n in R C R. • T RI A D Sit e Us er r ole o n a n N C T N or E T C T N r ost er. All in divid uals o n t he I m a gin g a n d Ra diatio n O nc olo g y C or e pr o vider r ost er ha ve access to T RI A D a n d m a y s u b mit i m a ges f or cr e de ntialin g p ur p os es, or f or e nr oll m e nts t o w hic h the pr o vider is lin ke d in O P E N. 6. 3. 2 T RI A D I nst all atio ns T o s u b mit i m a ges, t he in divid ual h oldin g t he T RI A D Sit e Us er r ole will nee d t o inst all t he T RI A D a p plic atio n o n t heir w or kst atio n. T RI A D inst allatio n d oc u m e nt atio n is a vaila ble at T his pr oc ess c a n be d o ne in par allel t o o bt ainin g y o ur C T E P -I A M ac c o u nt a n d R C R r e gistr atio n. F or q uestio ns, c o n t act T RI A D T ec h nic al S u p p ort st aff via e m ail 6. 3. 3 Pr oce d u res f or D at a S u b missi o n vi a T RI A D C ollectio n of C T/ P E T -C T a n d Bo ne i m a ges is r e q uir e d. I m a ges will be c ollect e d digit ally f or ar c hival a n d r etr os pective p ur p os es at t he f ollo win g ti m e p oints: • B as eli n e ( wit hin 2 8 da ys prior t o patie nt r e gistr atio n )"
29,page_29,"Allia nc e A1 7 1 6 0 1 3 0 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 • Rest a gi n g (Da y 1 of C ycle 4 ( ± 2 wee ks) t he n e ver y 1 2 w ee ks u ntil e n d of tr eat m e nt ) T he c o m plet e C T / P E T-C T an d Bo ne s c a n i m a gin g dat a in digit al DI C O M f or m at will be s u b mitt e d el e ct r o ni c all y t o t he I m a gin g a n d Ra diatio n O nc olo g y C or e at O hio (I R O C O hio) wit hi n n o m ore t h a n 3 b usi n ess da ys u p o n patie nt e nr oll m e nt ( at bas eline) or u p o n t he i m a ge ac q uisitio n c o m plet e ness ( at f ollo w-u ps). B M P files, J P G files, or har d c o pies (fil ms) ar e n ot ac c e pt a ble. I m a gin g dat a s h o uld be s u b mitt e d electr o nic ally t o I R O C O hio via T RI A D . T he st a n dar d T RI A D bas e d d at a tr a nsf er a p pr oac h will be pr o vide d s e par at ely t hr o u g h I R O C eff orts via t he s pecific trial e-m ail per t he r e q uest b y participatin g sit es bef or e t heir first dat a s u b mission. If T RI A D a p pr oac h is n ot ac hie va ble at sit e, alt er natively s it e nee ds t o de-ide ntif y t he patie nt dat a usin g instit utio nal pr oc e d ur es t o r e m o ve patie nt na m e a n d m e dic al r ec or d n u m ber w hile pr es er vin g t he Allia nc e patie nt I D n u m ber ( e. g., 1 1 2 1 3 6) a n d pr ot oc ol n u m ber ( e. g., A1 7 1 6 0 1 ), a n d us e t he f ollo win g electr o nic a p pr oac hes f or dat a s u b missio n: 1 ) We b Tr a nsf e r An y P Cs wit h int er net ac c ess a n d w e b br o ws er ( e. g., I nt er net E x plor er, M oz illa Fir ef o x) c an be us e d t o w e b tr a nsf er DI C O M i m a ges a n d ot her r e q uir e d files t o I R O C O hio. T he st a n dar d We b Tr a nsf er inf or m atio n will be pr o vide d s e par at ely t hr o u g h t he s pecific trial e -m ail , per t he r e q uest b y participatin g sit es bef or e t heir first dat a s u b missio n. 2) F T P Tr a nsf e r An y F T P s oft w ar e c a n be us e d t o initiat e ac c ess t o t he s ec ur e F T P S er ver of I R O C O hio. T he st a n dar d F T P ac c ess inf or m atio n will be pr o vide d s e par at ely t hr o u g h t he s pecific trial e-m ail , per t he r e q uest b y participatin g sit es bef or e t heir first dat a s u b missio n. Mail/ C D S hi p m e nt O nly if electr o nic dat a tr a nsf er a p pr oac hes c a n not be ac hie ve d, t he de-ide ntifie d i m a ges in digit al DI C O M f or m at c a n be b ur ne d t o a C D a n d m aile d t o I R O C O hio. S u b mit o nly o ne patie nt’s i m a ges per C D, wit h t he patie nt’s Allia nc e I D n u m ber, st u d y t y pe, dat e of s c a ns, a n d na m e of s u b mittin g instit utio n. S u b mit t hes e dat a t o: O nc e t he i m a gin g dat a s u b missio n is d o ne, s e n d a n e -mail t o I R O C O hio at t he s pecific trial e m ail t o inf or m t hat t he st u d y has bee n s u b mitt e d fr o m t he instit utio n. Pleas e inclu de t he basic inf or m atio n of s u b mitt e d dat a s ets as f ollo w s: 1) Allia nc e patie nt I D n u m ber 2) S c a n ti m e p oint (i. e., bas eline) 3) Dat e of s c a ns"
30,page_30,"Allia nc e A1 7 1 6 0 1 3 1 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 4) I nstit utio n na m e I R O C O hio will n otif y sit e wit hin 2 b usi n ess da ys of t he dat a r ec eipt, a n d t he n, wit hin 3 b usi n ess da ys f ollo win g t he dat a r ec eipt, of t he q ualit y c hec k r e p ort. An y q uestio ns or pr o ble ms a b o ut t he dat a s u b missio n t o I R O C O hio, c all I R O C O hio at f or help 7. 0 T R E A T M E N T PL A N/IN T E R V E N TI O N Pr ot oc ol tr eat m e nt is t o be gin wit h i n 1 4 da ys o f re gist r ati o n . F or q uestio ns r e gar din g tr eat m e nt, pleas e s ee t he pr ot oc ol c o nt acts o n pa ge 2 . It is ac c e pt a ble f or pr ot oc ol tr eat m e nt t o be deliver e d wit hin a 2 4-h o ur ( b usiness da y) win do w bef or e a n d aft er t he pr ot oc ol -define d dat e f or Da y 1 of a ne w c ycl e. F or e xa m ple, if t he tr eat m e nt d ue dat e is a Frida y, t he win d o w f or tr eat m e nt inclu des t he pr ec e din g T h urs da y t hr o u g h t he f ollo win g M o n da y. I n a d ditio n, patie nts ar e per mitt e d t o ha ve a ne w c ycle of pr ot oc ol tr eat m e nt dela ye d u p t o 7 da ys f or m ajor lif e e ve nts ( e. g., s erio us illness in a f a mily m e m ber, m ajor h olida y, vac atio n t hat c a n n ot be r es c he d ule d) wit h o ut t his bein g c o nsider e d a pr ot oc ol violatio n. D oc u m e nt atio n t o justif y t his dela y s h o uld be pr o vide d. T he st u d y will be a n o pe n la bel, sin gle ar m, p has e II s af et y a n d t oler a bilit y st u d y of t he c o m binatio n of palb ociclib a n d letr oz ole or f ulvestr a nt in patie nts a ge 7 0 or o ver wit h h or m o ne -r ec e pt or p ositive, H E R 2 -ne gative m et ast atic br east c a nc er. All patie nts w h o be gin st u d y tr eat m e nt will be inclu de d in t he a nalysis of all clinic al e n d p oints. A ge nt St arti n g D os e R o ut e of A d mi nist r ati o n Fre q u e n c y of A d mi nist r ati o n P al boci cli b 1 2 5 m g/ da y Or ally O nc e daily o n Da ys 1 -2 1 of eac h 2 8 -da y c ycle Let r oz ol e 2. 5 m g Or ally O nc e daily o n Da y s 1 -2 8 of eac h 2 8 da y c ycle O R P al boci cli b 1 2 5 m g/ da y Or ally O nc e daily o n Da ys 1 -2 1 of eac h 2 8 -da y c ycle F ul vest r a nt 5 0 0 m g I M injectio n Da y 1 a n d Da y 1 5 of C ycle 1, t he n Da y 1 of e ver y s u bs e q ue nt c ycle T r eat m e nt will c o ntin ue u ntil dis eas e pr o gr essio n or u nac c e pt a ble t o xicit y. 7. 1 P al boci cli b A c ycle will be f o ur w ee ks ( 2 8 da ys) in d ur atio n. Tr eat m e nt will be a d minist er e d in a n o ut patie nt s ettin g. P alb ociclib will be a d minist er e d per t he f ollo win g s c he d ule: 1. 2 1 c o ns ec utive da ys of 1 2 5 m g palb ociclib, t a ke n or ally wit h f o o d a n d t a ke n at a p pr o xi m at ely t he s a m e ti m e eac h da y . 2. F ollo win g t he 2 1 c o ns ec utive da ys, t her e will be 7 da ys off tr eat m e nt t o c o m pris e a c o m plet e c ycle of 2 8 da ys ."
31,page_31,"Allia nc e A1 7 1 6 0 1 3 2 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 If a patie nt v o mits or miss es a d os e, a n a d ditio nal d os e s h o uld n ot be t a ke n t hat da y. T he ne xt pr es cribe d d os e s h o uld be t a ke n at t he us ual ti m e. Miss e d d os es will n ot be m a de u p a n d c ycle le n gt h st a ys t he s a m e. P alb ociclib c a ps ules s h o uld be s w allo w e d w h ole a n d s h o uld be t a ke n in c o m binatio n wit h e n d ocrine t her a p y (if t a kin g letr oz ole). 7. 2 Let r oz ol e Letr oz ole will be pr es cribe d a n d a d minist er e d per M D dis cr etio n a n d d osin g s h o uld f ollo w t he pac ka ge ins ert g uidelines . T he r ec o m m e n de d d os e is 2. 5 m g daily . D os es miss e d f or t o xicit y will n ot be m a de u p. D osin g int err u ptio n a n d/ or d os e r e d uctio ns ar e r ec o m m e n de d bas e d o n in divid ual s af et y a n d t oler a bilit y. 7. 3 F ul vest r a nt F ulvestr a nt will be pr es cribe d a n d a d minist er e d per M D dis cr etio n a n d d osin g s h o uld f ollo w the pac ka ge ins ert g uidelines. T he r ec o m m e n de d d os e is 5 0 0 m g give n I M o n Da ys 1 a n d 1 5 of C ycle 1, a n d t he n give n e ver y 2 8 da ys. D os es miss e d f or t o xicit y will n ot be m a de u p. D osin g int err u ptio n a n d/ or d os e r e d uctio ns ar e r ec o m me n de d bas e d o n in divid ual s af et y a n d t oler a bilit y. 7. 4 A d h e re n ce , Ge ri atri c Ass ess m e nt , a n d P ati e nt Pe rs pe cti ve Pill di ari es will be c ollect e d at t he e n d of c ycles 1 -3 of tr eat m e nt t o as c ert ain d os e deliver e d a d her e nc e t o palb ociclib. Ad her e nc e t o palb ociclib will be m eas ur e d b y patie nt s elf -r e p ort in de dic at e d patie nt diaries at t he e n d of t he first 3 c ycles. A c a nc er s pecific geri atri c assess me nt will be c a pt ur e d pr e -tr eat me nt, aft er 3 c ycles, a n d at the e n d of tr eat m e nt. S ee S ectio n 1 1. 0. T o f urt her ass ess t he patie nt’s per c e ptio n of tr eat m e nt effic ac y of palb ociclib in a d ditio n t o e n d ocrine t her a p y, w e will as k o ur participa nts t o c o m plet e t he f ollo win g q uestio n nair es at t he e n d of tr eat m e nt : Was It W ort h It (Ap pe n dix III) a n d O ver all Tr eat m e nt Utilit y (Ap pe n dix I V ), t he E Q -5 D -3 L (Ap pe n dix V ) a n d P R O-C T C A E q uestio n nair e ( Ap pe n dix V I). T hese q uestio n n air es will pr o vide a bett er u n derst a n din g of t he patie nt’s pers pectives r e gar din g t he be nefits a n d side eff ects of tr eat m e nt, in c o m binatio n wit h a n ass ess m e nt of tr eat m e nt efficac y a n d t o xicit y. S ee S ectio n 1 1. 0."
32,page_32,"Allia nc e A1 7 1 6 0 1 3 3 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 8. 0 D O S E A N D TR E A T M E N T MO DI FI C A TI O N S 8. 1 A n cill ar y T h e r a py, C o n c o mit a nt M e di c ati o ns, a n d S u p porti ve C are 8. 1. 1 P ati e nts s h o ul d n ot re cei ve a n y ot h er a ge nt w hi c h wo ul d be c o nsi de re d t re at me nt f or t h e pri m ar y n e o pl as m or i m pact t h e pri m ar y e n d poi nt. 8. 1. 2 P ati e nts s h o ul d a v oi d i m m u ni z ati o ns wit h li ve vi r us v acci nes. 8. 1. 3 P ati e nts s h o ul d re cei ve f ull s u p porti ve c are w hil e o n t his st u dy. T his inclu des blo o d pr o d uct s u p p ort, a ntibiotic tr eat m e nt, a n d tr eat me nt of ot her ne wly dia g n os e d or c onc urrent m e dic al c o n ditio ns. All blo o d pr o d ucts a n d c o nc o mit a nt m e dic atio ns s uc h as a ntidiarr heals, a nalgesics, a n d/ or a ntie m etics r ec eive d fr o m t he first da y of st u d y tr eat m e nt a d ministr ation u ntil 3 0 da ys aft er t he fin al d os e will be r ec or de d in t he m e dic al r ec or ds . 8. 1. 4 Tre at m e nt wit h h or m o n es f or bre ast c a n ce r t re at m e nt or ot h e r c h e m ot h er a pe utic a ge nts m a y n ot be a d minist er e d . 8. 1. 5 A nti e m eti cs m a y be us e d at t he dis cr etio n of t he att e n din g p h ysicia n, wit h t he e xc e p tion of st er oids a b o ve. 8. 1. 6 Di arr h e a m a n a ge m e nt is per t he dis cr etio n of t he tr eatin g p h ysicia n. Diarr hea c o uld be m a na ge d c o ns er vatively wit h m e dic atio ns s uc h as lo per a mide. P atie nts wit h s e ver e diarr hea s h o uld be ass ess e d f or intr a ve n o us h y dr atio n a n d c orr ection of electr olyt e i m bala nc es. 8. 1. 7 P alli ati ve r a di ati o n t h er a py m a y n ot be a d mi nist ere d . P atie nts w h o r e q uir e r a diatio n t her a p y d urin g pr ot oc ol tr eat m e nt will be r e m o ve d fr o m pr ot oc ol t her a p y d ue t o dis eas e pr o gr essi o n. 8. 1. 8 Alli a n ce P oli c y C o n ce r ni n g t he Us e of Gr o wt h F act ors Blo o d pr o d ucts a n d gr o wt h f act ors s h o uld be utilize d as clinic ally w arr a nt e d a n d f ollo win g instit utio nal p olicies a n d r ec o m m e n datio ns. T he us e of c olo n y sti m ulatin g f act ors, filgr asti m ( G -C S F), pe gfilgr asti m a n d s ar gr a m osti m ( G M-C S F) is dis c o ur a ge d b ut m a y be us e d in patie nts w h o ha ve pr o g n ostic f actors t hat are pr e dictive of clinic al det erior atio n s uc h as p ne u m o nia, h y p ot e nsio n, m ulti -or ga n d ysf u nctio n (s e psis s y n dr o me) or f u n gal inf ectio n, as per A S C O g uidelines . I n vestigat ors s h o uld us e t heir o w n dis cr etio n in usin g t he C S Fs in t his s ettin g w hic h m ust be d oc u m e nted a n d r e p ort e d o n f or ms.5 3 8. 1. 9 Hy pe rs e nsiti vit y/i nf usi o n re actio ns Tr eat h y pers e nsitivit y a n d inf usio n r eactio ns t o ( dr u g[s]) as per instit utio nal st a n dar ds. 8. 1. 1 0 C Y P 3 A I n hi bit ors C hr o nic c o nc o mit a nt tr eat m e nt wit h str o n g in hibit ors of C Y P 3 A is str o n gly dis c o ur a ged w hile o n t his trial. T he f ollo win g dr u gs ar e E X A M P L E S of str o n g in hibit ors of C Y P 3 A a n d ar e n ot allo w e d d urin g tr eat m e nt wit h p alb ociclib. • I n dina vir • Clarit hr o m ycin • Ket oc o naz ole • Gr a pefr uit juic e"
33,page_33,"Allia nc e A1 7 1 6 0 1 3 4 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 Bec a us e lists of t hes e a ge nts ar e c o nst a ntly c ha n gin g, pleas e c o ns ult a n d r e vie w a n y dr u gs f or t heir p ot e ntial t o in hibit C Y P 3 A. E xa m ples of r es o ur c es t hat ma y be utilize d inclu de t he pr o d uct inf or m atio n f or t he in divid ual c o nc o mit a nt dr u g in q uestio n, m e dic al r ef er e nc e t e xts s uc h as t he P h ysicia ns’ Des k Ref er e nc e, t he F D A w e bsit e, or y o ur loc al instit utio n’s p har m acist. 8. 1. 1 1 C Y P 3 A I n d u ce rs C hr o nic c o nc o mit a nt tr e at m e nt wit h str o n g in d uc ers of C Y P 3 A is str o n gly dis c o ur a ged w hile o n t his trial. T he f ollo win g dr u gs ar e E X A M P L E S of str o n g in d uc ers of C Y P 3 A a n d ar e n ot allo w e d d urin g tr eat m e nt wit h palb ociclib . • Rif a m pin • Car ba m aze pine Bec a us e lists of t hes e a ge nts a r e c o nst a ntly c ha n gin g, pleas e c o ns ult a n d r e vie w a n y dr u gs f or t heir p ot e ntial t o in d uc e C Y P 3 A. E xa m ples of r es o ur c es t hat m a y be utilize d inclu de t he pr o d uct inf or m atio n f or t he in divid ual c o nc o mit a nt dr u g in q uestio n, m e dic al r ef er e nc e t e xts s uc h as t he P h ysicia ns’ Des k Ref er e nc e, t he F D A w e bsit e, or y o ur loc al instit utio n’s p har m acist. 8. 1. 1 2 C Y P 2 A 6 S u bst r at es C hr o nic c o nc o mit a nt tr eat m e nt wit h s u bstr at es of C Y P 2 A6 is str o n gly dis c o ur a ge d w hile o n t his trial. T he f ollo win g dr u gs ar e E X A M P L E S of C Y P 2 A6 s u bstr at es a n d ar e n ot allo w e d d urin g tr eat m e nt wit h letr oz ole. • De x m e det o midine • T e gaf ur Bec a us e lists of t hes e a ge nts ar e c o nst a ntly c ha n gin g, pleas e c o ns ult a n d r e vie w a n y dr u gs f or t heir p ot e ntial t o in d uc e C Y P 2 A6. E xa m ples of r es o ur c es t hat m a y be utilize d inclu de t he pr o d uct inf or m atio n f or t he in divid ual c o nc o mit a nt dr u g in q uestio n, m e dic al r ef er e nce t e xts s uc h as t he P h ysicia ns’ Des k Ref er e nc e, t he F D A w e bsit e, or y o ur loc al instit utio n’s p har m acist."
34,page_34,"Allia nc e A1 7 1 6 0 1 3 5 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 8. 2 D os e Mo difi c ati o ns P alb ociclib c ycle le n gt h w ill r e m ain 2 8 da ys ( ± 2 da ys) (des pit e a dela y in initiatin g a ne w c ycle of palb ociclib ); e n d ocrine t her a p y m a y c o ntin ue t o be a d minist er e d per t he pr e pla n ne d s c he d ule. • D os e h olds/r e d uctio ns of letr oz ole or f ulvestr a nt will oc c ur per t he pac ka ge ins ert an d t he tr eatin g in vestigat or’s dis cr etio n. • D os e es c alatio n will n ot be per mitt e d in t his st u d y. • P alb ociclib d os es miss e d f or t o xicit y will n ot be m a de u p. • T he initiatio n of a ne w c ycle m a y be dela ye d f or u p t o 7 da ys C T E P – A E R S r e p ortin g m a y be r e q uir e d f or s o m e a d vers e e ve nts. S ee S ectio n 9. 0. P R O - C T C A E dat a s h o uld n ot be us e d f or d os e m o dific atio ns. 8. 2. 1 D os e Le vels D os e Le vel P al boci cli b D os e St artin g D os e 1 2 5 m g/ da y -1 1 0 0 m g/ da y -2 7 5 m g/ da y 8. 2. 2 He m at ol o gi c a dve rs e e ve nts ( e xce pt l y m p h o pe ni a, u nl ess ass oci at e d wit h cli ni c al e ve nts, e. g., o p port u nisti c i nfe cti o ns ): M o nit or c o m plet e blo o d c o u nts prior t o t he st art of palb ociclib t her a p y a n d at t he be gin nin g of eac h c ycle, as w ell as o n Da y 1 5 of t he first 2 c ycles, a n d as clinic ally in dic at e d. F or patie nts w h o e x perie nc e a m a xi m u m of Gr a de 1 or 2 ne utr o pe nia in t he first 6 c ycles, m o nit or c o m plet e blo o d c o u nts f or s u bs e q ue nt c ycles e ver y 3 m o nt hs, prior t o t he be gin nin g of a c ycle a n d as clinic ally in dic at e d. F or gr a de 3 e ve nts: D a y 1 of c ycl e: O mit palb ociclib , r e peat c o m plet e blo o d c o u nt m o nit orin g wit hin 1 w ee k. Up o n r ec over y to Gr a de ≤ 2, st art t he ne xt c yc le at t he s a m e ( pr e vio us) d os e. D a y 1 5 of fi rst 2 c ycl es: • If Gr a de 3 o n Da y 1 5, c o ntin ue palb ociclib at c urr e nt d os e t o c o m plet e c ycle a n d r e peat c o m plet e blo o d c o u nt o n Da y 2 2. • If Gr a de 4 o n Da y 2 2, s ee Gr a de 4 d os e m o dific atio n g uidelines belo w. • C o nsider d os e r e d uctio n in c as es of pr olo n ge d ( > 1 w ee k) r ec o ver y fr o m Gr a de 3 ne utr o pe nia or r ec urr e nt Gr a de 3 ne utr o pe nia o n Da y 1 of s u bs e q ue nt c ycles. F or gr a de 3 n e ut r o pe ni a wit h f e ver ≥ 3 8. 5 º C a n d/ o r i nfe cti o n, a n d Gr a de 4 e v e nts: • O mit palb ociclib u ntil r ec o v er y t o Gr a de ≤ 2. • Res u m e at t he ne xt lo w er d os e."
35,page_35,"Allia nc e A1 7 1 6 0 1 3 6 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 8. 2. 3 No n He m at ol o gi c a dve rs e e ve nts: F or all g r a de 3 a n d hi g h e r e ve nts rel ate d t o pal boci cli b, o mit palb ocicli b u ntil r ec o ver y t o Gr a de ≤ 1 , or Gr a de ≤ 2 (if n ot c o nsider e d a s af et y ris k f or t he patie nt) . • R es u m e p alb ociclib at t he ne xt lo w er d os e at t he dis cr etio n of t he tr eatin g p h ysicia n. • P er m a ne ntly dis c o ntin uin g palb ociclib is r ec o m m e n de d in patie nts e x perie ncin g s e ver e I nt erstitial L u n g D is eas e/ p ne u m o nitis. 9. 0 A D V E R S E EV E N TS T he pr o m pt r e p o rtin g of a d vers e e ve nts is t he r es p o nsibilit y of eac h in vestigat or e n ga ge d in clinic al r es ear c h, as r e q uir e d b y F e der al Re g ulatio ns. Ad vers e e ve nts m ust be des cribe d a n d gr a de d usin g t he t er min olo g y a n d gr a din g c at e g ories define d in t he N CI’s C o m m o n T er minolo g y Crit eria f or Ad vers e E ve nts ( C T C A E), Versio n 5 . 0. T he C T C A E is a vaila ble at Attrib utio n t o pr ot oc ol tr eat m e nt f or eac h a d vers e e ve nt m ust be det er mine d b y t he in vestigat or a n d r e p ort e d o n t he r e q uir e d f or ms. Pleas e r ef er t he N CI G uidelines: Ad vers e E ve nt Re p ortin g Re q uir e m e nts f or f ur t her det ails o n A E r e p ortin g pr oc e d ur es. T o c o m ple m e nt C T C A E r e p ortin g, patie nts will s elf -r e p ort t heir side eff ects usin g t he P R O- C T C A E. T he s pecific P R O -C T C A E it e ms f or t his pr ot oc ol c a n be f o u n d in Ap pe n dix V I. P R O - C T C A E s h o uld n ot be us e d f or det er minin g attrib utio n or r e p ortin g of s erio us a d vers e e ve nts. 9. 1 R o uti n e A dve rs e E ve nt R e porti n g Ad vers e e ve nt dat a c ollectio n a n d r e p ortin g, w hic h ar e r e q uir e d as part of e ver y clinic al trial ar e d o ne t o e ns ur e t he s af et y of patie nts e nr olle d in t he st u dies as w ell as t h os e w h o will e nr oll in f ut ur e st u dies usin g si milar a ge nts. Ad vers e e ve nts ar e r ep ort e d in a r o utine m a n ner at s c he d uled ti m es ac c or din g t o t he st u d y c ale n dar in S ectio n 5. 0 . F or t his trial, t he Ad vers e E ve nt S olicit e d f or m is us e d f or r o utine A E r e p ortin g in Ra ve. S olicit e d Ad vers e E ve nts: T he f ollo win g a d ver s e e ve nts ar e c o nsider e d ""e x pect e d"" a n d t heir pr es e nc e/ a bs e nce s h o uld be s olicit e d, a n d s e verit y gr a de d, at bas eline a n d f or eac h c ycle of tr eat m e nt b y C T C A E, P R O-C T C A E, or b ot h. C T C A E v. 5 . 0 Te r m P R O -C T C A E v. 1. 0 Te r m C T C A E v. 5 . 0 S yst e m O r g a n Cl ass ( S O C) Ne utr o p hil c o u nt decr eas e d I n vestigatio ns Plat elet c o u nt decr eas e d I n vestigatio ns W hit e Blo o d c ell c o u nt decr eas e d I n vestigatio ns Ane mia Blo o d a n d ly m p hatic s yst e m dis or ders F e brile Ne utr o pe nia Blo o d a n d ly m p hatic s yst e m dis or ders Na us ea Na us ea Gastr oint estinal Dis or ders An or e xia Decr eas e d Ap petit e Met a b olis m a n d N utritio nal Dis or ders Diarr hea Diarr hea Gastr oint estinal dis or ders"
36,page_36,"Allia nc e A1 7 1 6 0 1 3 7 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 Vo mitin g Vo mitin g Gastr oint estinal dis or ders M uc ositis or al M o ut h/t hr oat s or es Gastr oint estinal dis or ders F atig ue F atig ue Ge ner al dis or ders P erip her al S e ns or y Ne ur o pat h y N u m b ness a n d Tin glin g Ge ner al dis or ders T hr o m b oe m b oli c e ve nt Vas c ular dis or ders Up per Res pir at or y I nf ectio n I nf ectio ns a n d I nf est atio ns Urinar y Tr act I nf ectio n I nf ectio ns a n d I nf est atio ns 9. 2 C T C A E R o uti n e Re porti ng Re q ui re me nts I n a d ditio n t o t he s olicit e d a d vers e e ve nts list e d in S ectio n 9. 1, t he f ollo win g t a ble o utlines t he c o m binatio ns of ti m e p oints, gr a des a n d attrib utio ns of A Es t hat r e q uir e r o utine r e p ortin g t o t he Allia nc e St atistics a n d Dat a Ce nt er. Q uestio ns a b o ut r o utine r e p ortin g s h o uld be dir ect e d t o t he Dat a Ma na ger. P R O -C T C A E dat a s h o uld n ot be us e d f or det er minin g attrib utio n, d ose m o dific atio ns, or r e p ortin g of s erio us a d vers e e ve nts. • C o m binatio ns of C T C A E Gr a de & Attrib utio n Re q uir e d f or R o utine A E Dat a S u b missio n o n Cas e Re p ort F or ms ( C R Fs) Att ri b uti o n Gr a de 1 Gr a de 2 Gr a de 3 Gr a de 4 Gr a de 5 Unr elat e d a a a a Unlikely a a a a P ossible a a, b a, b a, b Pr o ba ble a a, b a, b a, b Definit e a a, b a, b a, b • a) Ad vers e E ve nts: Ot her C R F - Ap plies t o A Es oc c urrin g bet w ee n r e gistr atio n a nd wit hin 3 0 da ys of t he patie nt’s last tr eat m e nt dat e, or as part of t he Clinic al F ollo w-Up P has e. • b) Ad vers e E ve nts: Lat e C R F - Ap plies t o A Es oc c urrin g gr eat er t ha n 3 0 da ys aft er t he patie nt’s last tr eat m e nt dat e. 9. 3 Ex pe dit e d A dve rs e Eve nt Re porti n g ( C T E P -A E R S) I n vestigat ors ar e r e q uir e d b y F e der al Re g ulatio ns t o r e p ort s erio us a d vers e e ve nts as define d in t he t a ble belo w. Allia nc e in vestigat ors ar e r e q uir e d t o n otif y t he Allia nc e Ce ntr al Pr ot oc ol O per atio ns Pr o gr a m, t he St u d y C hair, a n d t heir I nstit utio nal Re vie w Boar d if a patie nt has a r e p ort a ble s erio us a d vers e e ve nt. T he des criptio ns a n d gr a din g s c ales f o u n d in t he N CI C o m m on T er min olo g y Crit eria f or Ad vers e E ve nts ( C T C A E) versio n 5 will be utilize d f or A E r e p ortin g. T he C T C A E is ide ntifie d a n d loc at e d o n t he C T E P w e bsit e at: All a p pr o priat e tr eat m e nt ar eas s ho uld ha ve ac c ess t o a c o p y of t he C T C A E. All r eactio ns det er mine d t o be “r e p ort a ble” in a n e x pe dit e d m a n ner m ust be r e p ort e d usin g t he Ca nc er T her a p y E valuatio n Pr o gr a m Ad vers e E ve nt Re p ortin g S yst e m ( C T E P -A E R S)."
37,page_37,"Allia nc e A1 7 1 6 0 1 3 8 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 F or f urt her inf or m atio n o n t he N CI r e q uir e m e nts f or S A E r e p ortin g, pleas e r ef er t o t he ‘ N CI G uidelines f or I n vestigat ors: Ad vers e E ve nt Re p ortin g Re q uir e m e nts’ d oc u m e nt p u blis he d b y t he N CI. N ot e: All deat hs o n st u d y r e q uir e b ot h r o utine a n d e x pe dit e d r e p ortin g r e gar dless of c a us alit y. Attrib uti o n t o tr eat m e nt or ot her c a us e s h o uld be pr o vide d."
38,page_38,
39,page_39,"Allia nc e A1 7 1 6 0 1 4 0 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 9. 3. 2 Ex pe dit e d A E re porti n g ti m eli n es defi n e d “ 2 4 h o urs; 5 c ale n dar da ys ” – T he in vestigat or m ust initially r e p ort t he A E via C T E P -A E R S ≤ 2 4 h o urs of lear nin g of t he e ve nt f ollo w e d b y a c o m plet e C T E P -A E R S r e p ort ≤ 5 cale n dar da ys of t he initial 2 4 -h o ur r e p ort. “ 1 0 c ale n dar da ys ” - A c o m plet e C T E P -A E R S r e p ort o n t he A E m ust be s u b mitt e d ≤ 1 0 c ale n dar da ys of t he in vestigat or lear nin g of t he e ve nt. An y m e dic al e ve nt e q uivale nt t o C T C A E gr a de 3, 4, or 5 t hat pr ecipit at es h os pit alizatio n ( or pr olo n gatio n of e xistin g h os pit alizatio n) m ust be r e p ort e d r e gar dless of attrib utio n a n d desig natio n as e x pect e d or u ne x pect e d wit h t he e xc e ptio n of a n y e ve nt s ide ntifie d as pr ot oc ol-s pecific e x pe dit e d a d vers e e ve nt r e p ortin g e xclusio ns (see belo w). Us e t he N CI pr ot oc ol n u m ber a n d t he pr ot oc ol -s pecific patie nt I D pr o vide d d urin g trial r e gistr atio n o n all r e p orts. 9. 3. 3 A d diti o n al I nst r u cti o ns or Excl usi o n t o C T E P -A E R S Ex pe dit e d Re porti ng Re q ui re m e nts • All a d vers e e ve nts r e p ort e d via C T E P -A E R S (i. e., s erio us a d vers e e ve nts) s h o uld als o be f or w ar de d t o y o ur loc al I R B. • Gr a de 3/ 4 he m at os u p pr essio n a n d h os pit alizatio n r es ultin g fr o m s uc h d o n ot r e q uir e C T E P-A E R S, b ut s h o uld be s u b mitt e d as part of st u d y r es ults. All ot her gr a de 3, 4, or 5 a d vers e e ve nts t hat pr ecipit at e h os pit alizatio n or pr olo n g a n e xistin g h os pit alizatio n m ust be r e p ort e d via C T E P -A E R S . • Re p ortin g of c as es of s ec o n dar y A M L/ M D S is t o be d o ne usin g t he N CI/ C T EP S ec o n dar y A M L/ M D S Re p ort F or m. Ne w pri m ar y m alig na ncies s h o uld be r e p ort e d in Ra ve . • Deat h d ue t o pr o gr essive dis eas e s h o uld be r e p ort e d as Gr a de 5 “ Dis eas e pr o gr essio n” in t he s yst e m or ga n class ( S O C) “ Ge ner al dis or ders a n d a d ministr atio n sit e c o n ditio ns. ” E vide nc e t hat t he deat h w as a m a nif est atio n of u n derlyin g dis eas e ( e. g., r a diolo gic al c ha n ges s u g gestin g t u m or gr o wt h or pr o gr essio n: clinic al det erior atio n ass ociat e d wit h a d is eas e pr oc ess) s h o uld be s u b mitt e d. • An y deat h oc c urrin g wit hin 3 0 da ys of the last d os e, r e gar dless of attrib utio n to the in vestigatio nal a ge nt/int er ve ntio n r e q uir es e x pe dit e d r e p ortin g wit hin 2 4 h o urs. • An y deat h oc c urrin g gr eat er t ha n 3 0 da ys aft er t he last d os e of t he in vestigatio nal a ge nt/int er ve ntio n r e q uir es e x pe dit e d r e p ortin g wit hin 2 4 h o urs o nly if it is p ossibly, pr o ba bly, or definit ely r elat e d t o t he in vestigatio nal a ge nt/int er ve ntio n. • All ne w m alig na ncies m ust be r e p ort e d via C T E P -A E R S w h et her or n ot t he y ar e t h o u g ht t o be r elat e d t o eit her pr e vio us or c urr e nt tr eat m e nt. All ne w m alig na ncies s h o uld be r e p ort e d, i. e. s olid t u m ors (inclu din g n o n -m ela n o m a s kin m alig na ncies), he m at olo gic m alig na ncies, m yelo d ys plastic s y n dr o m e/ ac ut e m yelo ge n o us le u ke mia, a n d in sit u t u m ors. I n CT C A E versio n 5 . 0, t he ne w m alig na ncies ( b ot h s ec o n d a nd s ec o n dar y) m a y be r e p ort e d as o ne of t he f ollo win g: ( 1) Le u ke mia s ec o n dar y t o o nc olo g y c he m ot her a p y, ( 2) M yelo d ys plastic s y n dr o m e, ( 3) Tr eat m e nt -r elated s ec o n dar y m alig na nc y, or ( 4) Ne o plas ms be nig n, m alig na nt a n d u ns pecifie d-ot her. W he ne ver p ossible, t he C T E P -A E R S r e p orts f or ne w m alig na ncies s h o uld inclu de t u m or pat h olo g y, hist or y or prior t u m ors, prior tr eat m e nt/ c urr e nt tr eat m e nt inclu din g d ur atio n, a n y ass ociat e d ris k f act ors or e vide nc e r e gar din g h o w lo n g t he ne w m alig na nc y m a y ha ve bee n pr es e nt, w he n a n d h o w t he ne w m alig na nc y w as det ected,"
40,page_40,"Allia nc e A1 7 1 6 0 1 4 1 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 m olec ular c har act erizatio n or c yt o ge netics of t he original t u m or (if a vaila ble) a n d of a n y ne w t u m or, a n d ne w m alig na nc y tr e at m e nt a n d o ut c o me, if a vaila ble. • Tr eat m e nt e x pect e d a d vers e e ve nts inclu de t h os e list e d in S ectio n 1 0. 0 a n d in t he pac ka ge ins ert. • Gr a de 1 -3 na us ea or v o mitin g a n d h os pit alizatio n r es ultin g fr o m s uc h d o n ot r e q uir e A E R S r e p ortin g, b ut s h o uld be r e p ort e d via r o utine A E r e p ortin g • Gr a de 3 or 4 na us ea or v o mitin g d oes n ot r e q uir e A E R S r e p ortin g, b ut s h o uld be r e p ort e d via r o utine A E r e p ortin g. • Gr a de 1 -3 f atig ue a n d h os pit alizatio n r es ultin g fr o m s uc h d o n ot r e q uir e A E R S r e p ortin g, b ut s h o uld be r e p ort e d via r o utine A E r e p ortin g. • Gr a de 3 or 4 f atig ue d oes n ot r e q uir e A E R S r e p ortin g, b ut s h o uld be r e p ort e d via r o utine A E r e p ortin g • Gr a de 1 -3 diarr hea d oes n ot r e q uir e A E R S r e p ortin g, b ut s h o uld be r e p ort e d via r o utine A E r e p ortin g • Gr a de 3 or 4 diarr hea a n d h os pi t alizatio n r es ultin g fr o m s uc h d o n ot r e q uir e A E R S r e p ortin g, b ut s h o uld be r e p ort e d via r o utine A E r e p ortin g. • Gr a de 3 ne utr o pe nic f e ver a n d h os pit alizatio n r es ultin g fr o m s uc h d o n ot r e q uir e A E R S r e p ortin g, b ut s h o uld be r e p ort e d via r o utine A E r e p ortin g. • C T E P -A E R S r e p orts s h o uld be s u b mitt e d electr o nic ally."
41,page_41,
42,page_42,
43,page_43,"Allia nc e A1 7 1 6 0 1 4 4 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 H E P A T O BI LI A R Y DI S O R D E R S - He p atic fail ure; He p at o biliar y dis or ders - Ot h er ( bile d u ct o bstr u cti o n); He p at o biliar y dis or ders - Ot h er (ja u n dic e) I M M U N E S YS T E M DI S O R DE R S - Aller gic re a cti o n I N J U R Y , P OI S O NI N G A N D P R O C E D U R A L C O M P LI C A TI O N S - Fall; Fra ct ure I N V ES TI G A TI O N S - Al kali n e p h os p hat ase i n cre ase d; Bl o o d bilir u bi n i n cre ased; C P K i n cre as e d; Cre ati ni n e i n cre as e d; Eje cti o n fra cti o n d ecre ase d; G G T i n cre as e d; I N R i n cre ase d; W ei g ht l os s M E T A B O LI S M A N D N U T RI TI O N DI S O R D E R S - De h y drati o n; H y percalc e mia; H y per gl y c e mia; H y p er kale mia; H y p er ma g nese mia; H y p er uric e mia; H y p oal b u mi n e mia; H y p o calc e mia; H y p o kale mia; H y p o n atre mia; H y p o p h os p hate mia; M eta b olis m a n d n utriti o n dis or ders - O t h er (fail ure t o t hri v e) M US C U L O S K E L E T A L A N D C O N N E C TI V E TI S S U E DI S O R D E R S - Art hral gia; Ba c k p ai n; Fla n k p ai n; Ge n eralize d mus cle we a k n ess; M uscle cra mp; M uscul os keletal a n d c o n necti v e tiss u e dis or d er - Ot h er ( ost e o my elitis); M yal gia; Ne c k p ai n; Ost eo necr osis; Pai n i n e xtre mit y N E O P L A S M S B E NI G N, M A LI G N A N T A N D U N S P E CI FI E D (I N C L. C YS T S A N D P O L Y P S) - Tre at me nt relat e d s e c o n dar y mali g n a nc y N E R V O US S YS T E M DI S O R D E R S - Dizzi n es s; D ys est h esia; D ys p hasia; I ntra cra nial h e morr h a ge; Ner v o us s yste m dis or ders - Ot h er ( p er i p h eral n e ur o pat h y)5; S y nc o pe P S Y C HI A T RI C DI S O R D E R S - Co nf usi o n; I ns o mnia; Ps ychiatric dis or d ers - Ot h er (alt ere d me nt al st at us) R E N A L A N D U RI N A R Y DI S O R D E R S - A c ut e ki d n ey i nj ur y; He mat uria R E S PI R A T O R Y , T H O R A CI C A N D M E DI A S TI N A L DI S O R D E R S - Co u g h; D ys p ne a; H y p o xia; Or o p h ar y n ge al p ai n; Ple ural eff usi o n; P ost nasal dri p; P ul mo n ar y e d e ma; P ul mo nar y h y pert ensi o n S KI N A N D S U B C U T A N E O US TI S S U E DI S O R D E R S - H y p er hi dr osis; Pr urit us V A S C U L A R DI S O R D E R S - H y p ert e nsi o n; H y p ote nsi o n N ote : Pal b o cicli b ( P D-0 3 3 2 9 9 1) i n c o mbi n ati o n wit h ot her a g ents c o ul d c a use a n e xa c er b ati o n of a n y a d verse e ve nt c urre ntl y k n o w n t o b e c a use d b y t h e ot her a g ent, or t h e c o mbi n ati o n ma y res ult i n e v e nts n e ver pre vi o usl y as s o ciat ed wit h eit h er a g e nt."
44,page_44,"Allia nc e A1 7 1 6 0 1 4 5 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 1 0. 0 D R U G IN F O R M A TI O N 1 0. 1 Ge n e r al C o nsi de r ati o ns: All st u d y a ge nts ar e t o be a d minist er e d at t he r e gist erin g instit utio n. 1 0. 2 P al boci cli b I N D E xe m pt: P alb ociclib is I N D e xe m pt as us e d in t his trial. T his e xe m ptio n has bee n det er mine d b y att est atio n t hat neit her t he in vestigat or n or s p o ns or int e n ds t o s ee k a ne w in dic atio n f or us e or t o s u p p ort a n y ot her sig nific a nt c ha n ge in t he la belin g or pr o d uct a d vertising f or P alb ociclib ; t his in vestigatio n will us e a n a p pr o ve d r o ut e of a d ministr atio n a n d d os a ge of P alb ociclib a n d has n o f act ors t hat incr eas e t he ris k of t he pr o d uct; t his in vestigatio n will be in c o m plia nc e wit h 2 1 C F R parts 5 6, 5 0, a n d 3 1 2. 7; a n d neit her t he i n vestigat or n or s p o ns or will pr o m ot e or r e pr es e nt t hat P alb ociclib is s af e or eff ective f or t he c o nt e xt t hat is u n der in vestigatio n in t his st u d y. Pr oc ure me nt P alb ociclib is a c o m m er cially a vaila ble a ge nt a n d fille d wit h pr es criptio n. F or m ul ati o n P alb ocicl ib is s u p plie d as a 1 2 5 m g, 1 0 0 m g, or 7 5 m g t a blet. P alb ociclib is a yello w t o or a n ge p o w der a n d t he 1 2 5 m g ca ps ule is a n o pa q ue har d gelatin, size 0 c a ps ules wit h a c ara m el c ap and b o d y , print e d wit h w hit e in k “ Pfizer ” o n t he c a p, a n d “ P B C 1 2 5 ” o n t he b o d y. T he 1 0 0 m g c a ps ules ar e o pa q ue har d gelatin c a ps ules, size 1, wit h c ar a m el c a p a n d lig ht or a n ge b o d y, print e d wit h w hit e in k “ Pfizer ” o n t he c a p a n d “ P B C 1 0 0” o n t he b o d y. T he 7 5 m g ca ps ules are o pa q ue har d gelatin c a ps ules, size 2, wit h lig ht or a n ge c a p a n d b o d y, printe d wit h w hit e in k “ Pfizer ” o n t he c a p a n d “ P B C 7 5” o n t he b o d y. I nactive in gr e die nts pr es e nt in t he c a ps ule inclu de: Micr ocr yst alline c ellulos e, lact ose m o n o h y dr at e, s o diu m st ar c h glyc olat e, c olloidal silic o n dio xide, m a g nesiu m st ear at e , a n d har d gelatin c a ps ule s hells T he lig ht or a n ge, lig ht or a n ge/ c ar a m el a n d c ar a m el o pa q ue c a ps ule s hells c o nt ain gelatin, r e d ir o n o xide, yello w ir o n o xide, a n d tit a niu m dio xide; a n d t he printin g in k c o nt ains s hellac, tit a niu m dio xide, a m m o niu m h y dr o xide, pr o p yle ne glyc ol a n d si m et hic o ne St or a ge a n d St a bilit y T he int act b ottles s h o uld be st or e d at 2 00C t o 2 5oC ( 6 8oF t o 7 7oF); e xc ursio ns per mitt e d bet ween 1 5 t o 3 0oC ( 5 9 t o 8 6oF) A d mi nistr ati o n D os e: 1 2 5 m g of palb ociclib a d minist er e d or ally o nc e a da y ar o u n d t he s a m e ti m e e ver y da y f or 2 1 c o ns ec utive da ys f ollo w e d b y 7 da ys off t o c o m pris e a c ycle of 2 8 da ys. R o ut e of Ad ministr atio n: Or ally wit h m eals a n d patie nts s h o uld be e nc o ur a ge d t o t a ke t h eir d ose at a p pr o xi m at ely t he s a m e ti m e eac h da y. If a patie nt v o mits or miss es a d os e, a n a d ditio nal d ose s h o uld n ot be t a ke n t hat da y. I nst ea d t he ne xt pr es cribe d d os e s h o uld be t a ke n at t he us ual ti m e. P alb ociclib c a ps ules s h o uld be s w allo w e d w h ole ( d o n ot c he w, cr us h, or o pe n t he m prior t o s w allo win g). N o c a ps ule s h o uld be in gest e d if it is br o ke n, cr ac ke d, or ot her wis e n ot int act. P atie nts s h o uld a v oid c o ns u m ptio n of gr a pefr uit or gr a pefr uit juic e."
45,page_45,"Allia nc e A1 7 1 6 0 1 4 6 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 Dr u g I nt er acti o ns P alb ociclib is pri m arily m et a b olize d b y C Y P 3 A a n d s ulf otr a nsf er as e ( S U L T) e nz y m e S U L T 2 A1. P alb ociclib int er acts wit h C Y P 3 A in hibit ors a n d C Y P 3 A in d uc ers. Av oid c o nc urr e nt use of palb ociclib wit h str o n g C Y P 3 A in hibit ors or in d uc ers. A dv erse E v e nts T he f ollo win g ar e c o m m o n (≥ 1 0 %) ad vers e e v e nts oc c urrin g in at least o ne patie nt w ho r ec eive d palb ociclib plus letr oz ole in clinic al trials. I nf ectio ns a n d I nf est atio ns: Up per Res pir at or y I nf ectio n Blo o d a n d L y m p hatic S yst e m Dis or ders: Ne utr o pe nia, Le u k o pe nia, Ane mia, T hr o m b oc yt o pe nia Met a b olis m a n d N utritio n Dis or ders : Decr eas e d Ap petit e Ner v o us S yst e m Dis or ders: P erip her al Ne ur o pat h y Res pir at or y, T h or acic, a n d Me diastinal Dis or ders: E pist a xis Gastr oint estinal Dis or ders : St o m atitis, Na us ea, Diarr hea, Vo mitin g S kin a n d S u bc ut a ne o us Ti ss ue Dis or ders : Alo pecia Ge ner al Dis or ders a n d Ad ministr atio n Sit e C o n ditio ns: F atig ue, Ast he nia N ursi n g G ui deli nes 1. Age nt s h o uld be a d minist er e d wit h f o o d. D o n ot cr us h, br ea k or o pe n c a ps ules prior to a d ministr atio n. 2. M o nit or C B C w/ diff as c yt o pe nias ar e c o m m o n a n d r e q uir e d os e r e d uctio ns. I nstr uct patie nts t o r e p ort sig ns or s y m pt o ms of inf ectio n a n d/ or a n y u n us ual br uisin g or blee din g t o t he st u d y t ea m. 3. GI s y m pt o ms ar e c o m m o n, inclu din g na us ea/ v o mi tin g, st o m atitis a n d diarr hea. Tr eat s y m pt o m atic ally a n d m o nit or f or eff ective ness. S o m e side eff ects m a y r e q uir e d ose r e d uctio ns. 4. P atie nts s h o uld a v oid gr a pefr uit a n d gr a pefr uit juic e, d ue t o p ossible incr eas e in t he s er u m c o nc e ntratio n of palb ociclib. 5. T her e ar e dr u g t o dr u g int er a ctio ns wit h C Y P 3 A4 s u bstr at es . O bt ain a c o m plet e list of patie nt m e dic atio ns inclu din g O T C a n d her bal pr o d ucts. I nstr uct patie nts t o r e p ort any ne w m e diatio ns t o t he st u d y t ea m i m m e diat ely. 6. War n patie nt of ris k of t hr o m b oe m b olic e ve nts, s pecific ally p ul m o nar y e m b olis m. 7. War n patie nts of p ossibilit y of alo pecia. 8. P atie nts m a y e x perie nc e u p per r es pir at or y inf ectio n. I nstr uct patie nts t o r e p ort U RI s y m pt o ms t o st u d y t ea m. 9. Rar ely patie nts m a y e x perie nc e perip her al ne ur o pat h y. M o nit or patie nts clos ely w ho m a y ha ve pr ee xistin g CI P N fr o m pr e vi o us t her a p y. 1 0. 3 F ul vest r a nt Pleas e r ef er t o t he F D A -a p pr o ve d pac ka ge ins ert f or f ulvestr a nt f or pr o d uct inf or m atio n, e xt e nsive pr e par atio n instr uctio ns a n d a c o m pr e he nsive list of a d vers e e ve nts. Ot her na m es: F aslo de x"
46,page_46,"Allia nc e A1 7 1 6 0 1 4 7 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 Classific atio n: Estr o ge n r ec e pt or a nt a g o nist M olec ular F or m ula: C 3 2H4 7F5O3S M. W.: 6 0 6. 7 7 Ap pr o xi m at e S olu bilit y: Eac h injectio n c o nt ains as inactive in gr e die nts alc o h ol, U S P, be nz yl alc o h ol, N F, a n d be nz yl be nz oat e, U S P as c o -s olve nts a n d c ast or oil, U S P as a c o-s olve nt a nd r eleas e r at e m o difier. T he s olutio n is a clear, c olorless t o yello w, vis c o us liq uid. Pr oc ure me nt F ulvestr a nt is a c o m m er cially a vaila ble a ge nt a n d fille d wit h pr es criptio n . St or a ge: T he s yrin ges of f ulvestr a nt f or all c ycles of tr eat m e nt s h o uld be st or e d in t he original c o nt ainer a n d r efriger at e d at 2° - 8° C ( 3 6° - 4 6° F). A d mi n istr ati o n: R o ut es of Ad ministr atio n: I M I njectio n Met h o d of Ad ministr atio n: Re m o ve glass s yrin ge barr el fr o m tr a y a n d c hec k t hat it is n ot da m a ge d. P eel o pe n t he s af et y nee dle ( S af et y Glide ™) o ut er pac ka gin g. Br ea k t he s eal of t he w hit e plastic c o ver o n t he s yrin ge luer c o n nect or t o r e m o ve t he c o ver wit h t he att ac he d r u b ber tip c a p. T wist t o loc k t he nee dle t o t he luer c o n nect or. Re m o ve nee dle s heat h. Re m o ve e xc ess air fr o m t he s yrin ge ( a s m all gas b u b ble m a y r e m ain). F or t his st u d y, f ulvestr a nt will be a d minist er e d at a d os e of 5 0 0 m g ( 2 X 2 5 0 m g injectio ns) I M or as in dic at e d per t he pac ka ge ins ert o n Da y 1 a n d Da y 1 5 of C ycle 1 a n d t he n o n Da y 1 of eac h c ycle in eac h s u bs e q ue nt c ycle. Ad minist er intr a m us c ularly slo wly in t he b utt oc k. ( N O T E: 5 0 0 m g d os e will r e q uir e o ne 2 5 0 m g injectio n in eac h b utt oc k.) I m m e diat ely activat e nee dle pr ot ectio n de vic e u p o n wit h dr a w al fr o m patie nt b y p us hin g le ver ar m c o m plet ely f or w ar d u nti l nee dle tip is f ully c o ver e d. Vis ually c o nfir m t hat t he le ver ar m has f ully a d va nc e d a n d t he nee dle tip is c o ver e d. If u na ble t o activat e, dis c ar d i m m e diat ely int o a n a p pr o ve d s har ps c o nt ainer. T oxi cit y: T he m ost c o m m o n t o xicities r e p ort e d in trials of f ulvestr a nt t o dat e inclu de gastr oint estinal s y m pt o ms, m e n o pa usal s y m pt o ms a n d injectio n sit e r eactio ns. Na us ea a n d v o mitin g ha ve bee n t he pri m ar y GI s y m pt o ms, occ urrin g in a p pr o xi m at ely 5 0 % of patie nts in p has e III trials. T hey w er e ge ner ally of mild t o m o der at e s e verit y. Hot flas hes w er e r e p ort e d in a p pr o xi m at ely 2 0 % of patie nts. I njectio n sit e r eactio ns inclu de pain, he m orr ha ge a n d infla m m atio n. S uc h r eactions m a y be m or e fr e q ue nt w he n f ulvestr a nt is a d minist er e d as 2 injectio ns of 2. 5 ml ( 1 2 5 m g) eac h, as c o m par e d wit h 1 injectio n of 5 ml ( 2 5 0 m g). P ot e ntial Dr u g I nt er actio ns: I n i n vitr o st u dies usin g h u m a n he pat oc yt es, f ulvestr a nt w as m et a b olize d pr e d o mina ntly b y c o nju gatio n. T he m et a b olit es t h us f or m e d ar e t h o u g ht t o p ossess n o estr o ge nic activit y a n d mini m al a nti-estr o ge nic activit y. I n st u dies usin g h u m a n liver micr os o m es, f ulvestr a nt in hibit e d t he activit y of C Y P 1 A2, 2 C 9 a n d 3 A4 mini m ally. C Y P 3 A4 did m et a b olize f ulvestr a nt in t hes e st u dies, b ut t he h u m a n he pat oc yt e st u dies n ot e d a b o ve in dic at e c o nju gatio n is a m or e i m p ort a nt m et a b olic pat h w a y. I n a d ditio n, st u dies in healt h y v olu nt eers in dic at e t hat f ulvestr a nt m et a b olis m is n ot sig nific a ntly aff ect e d b y in d uc ers or in hibit ors of C Y P 3 A4, n or d oes f ulvestr a nt aff ect t he m et a b olis m of 3 A4 s u bstr at es. T hus, f ulvestr a nt is n ot e x pect e d t o be in v olve d in sig nific a nt dr u g int er actio ns m e diat e d b y C Y P 3 A4. N ursi n g g ui deli nes"
47,page_47,"Allia nc e A1 7 1 6 0 1 4 8 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 1 Rar ely a blo o d -tin ge d va ginal dis c har ge has bee n r e p ort e d infr e q ue ntly d urin g t her a p y. Ad vis e patie nts t hat t his is a p ossibilit y a n d t hat st u dies ha ve s h o w n n o eff ects o n va gina or e n d o m etriu m. 2 M o nit or L F T’s bas e d o n pr ot oc ol r e q uir e m e nts. Re p ort increas e d L F T’s t o tr eatin g p h ysicia n. 3 Hot pac kin g t he injectio n sit e f or a s h ort w hile aft er injectio n m a y pr e ve nt t he p ossible br uisin g, t e n de r ness, a n d/ or er yt he ma at t he I M injectio n sit e. 4 I nstr uct patie nt t o r e p ort a n y sig ns or s y m pt o ms of blo o d clots. P atie nts wit h c alf t e n der ness or b ur nin g, a n d/ or c hest pain ( p ul m o nar y e m b olus) s h o uld be e valuat e d b y a p h ysicia n i m m e diat ely. 5 War n patie nt of p ossible h ot flas hes. Ass ess s e verit y a n d dis c uss n o n -h or m o nal tr eat m e nts wit h tr eatin g p h ysicia n. Ass ess tr eat m e nt f or efficac y. 6 Ma y c a us e mild GI s y m pt o ms ( na us ea, a n ore xia, v o mitin g, c o nstipatio n). Treat s y m pt o m atic ally a n d m o nit or f or eff ective ness of int er ve ntio n. 1 0. 4 L et r oz ol e Pleas e r ef er t o t he F D A -a p pr o ve d pac ka ge ins ert f or letr oz ole f or pr o d uct inf or m atio n, a n d a c o m pr e he nsive list of a d vers e e ve nts. Ot her na m e: F e m ar a ® Classific atio n : Ar o m at as e in hibit or M olec ular f or m ula: C 1 7H1 1N5 Pr oc ure me nt Letr oz ole is c o m m er cially a vaila ble a n d fille d wit h pr es criptio n. F or m ul ati o n: Letr oz ole is s u p plie d as 2. 5 m g, dar k yello w, fil m -c oate d t a blets in b ottles of 3 0 t a blets. St or a ge a n d St a bilit y I nt act b ottles of letr oz ole s h o uld be st or e d at 2 5 °C ( 7 7 °F), e xc ursio n s per mitt e d t o 1 5 t o 3 0 °C ( 5 9 t o 8 6°F) A d mi nistr ati o n Letr oz ole will be t a ke n or ally, at a d os e of 2. 5 m g o nc e daily wit h o ut r e gar d t o m eals. T oxi citi es T he m ost c o m m o n a d vers e e ve nts r e p ort e d inclu de art hr algia, flus hin g, ast he nia, e de m a, hea dac he, dizziness, h y per c h olest er ole mia, b o ne pain . Of c o nc er n, pri m arily wit h lo n g -t er m use of ar o m at as e in hibit ors inclu din g letr oz ole, ar e eff ects o n lipid m et a b oli s m wit h s u bs e q uent c ar dio vas c ular e ve nts a n d o n b o ne r es or ptio n. Ot her less fr e q ue nt a d vers e e ve nts inclu de b o ne a n d m us cle pain. N ursi n g g ui deli nes 1 Ma na ge h ot flas hes wit h n o n -h or m o nal int er ve ntio ns (ie: ve nlaf a xine X R 7 5 m g daily). 2 Ma na ge pain ( art hr algias). I nstr uct patie nt t o r e p ort u nr elie ve d pain. 3 Ma y t a ke wit h f o o d if nee de d f or na us ea. I nstr uct patie nt t o r e p ort u nr elie ve d na us ea or v o mitin g."
48,page_48,"Allia nc e A1 7 1 6 0 1 4 9 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 4 Ass ess f or c ha n ges in b o w el patt er ns. Ma na ge diarr hea or c o nstipatio n wit h n o n - pr es criptio n dr u gs. T ell patie nts t o r e p ort u nr elie ve d diarr hea or c o nstipatio n. 5 If patie nt e x perie nc es diffic ult y br eat hin g or s u d de n o ns et c hest pain, instr uct t he m t o s ee k e m er ge nc y m e dic al att e ntio n i m m e diat ely. 6 M o nit or f or sig ns of e de m a, instr uct patie nt t o r e p ort a n y s wellin g in le gs, f eet, or ha n ds. 1 1. 0 M E A S U R E M E N T O F EF F E C T 1 1. 1 P ati e nt re port e d o ut c o m e m e as u res 1 1. 1. 1 Ge ri at ri c ass ess me nt A c a nc er -s pecific c o m pre he nsive geriatric ass ess me nt will be give n at bas eline, t he first r est a gin g (i. e., aft er 3 c ycles of tr eat m e nt a n d prior t o c ycle 4 ), a n d at t he e n d of tr eat m e nt (s ee Ap pe n dix II f or Geriatric Ass ess m e nt S ur ve y). T he c a nc er-s pecific c o m pr e he nsive geriatric ass ess m e nt inclu des a n e valuatio n of f u nctio nal st at us, c o -m or bidit y, c o g n ition, ps yc h olo gic al st at us, s ocial f u nctio nin g a n d s u p p ort, a n d n utritio nal st at us.3 T his ass ess ment has be e n pilot e d in t he Allia nc e ( in le gac y Ca nc er a n d Le u ke mia Gr o u p B [C A L G B ]). C A L G B 3 6 0 4 0 1 e valuat e d t he f easibilit y of inc or p or atin g t he Geriatric Ass ess m e nt T o ol int o o nc olo g y c o o per ative gro u p trials.5 2 P atie nts w er e eligible t o participat e if t he y w ere age ≥ 6 5 a n d ha d sig ne d c o ns e nt f or a c o o per ative gr o u p tr eat m e nt trial. T he Geriatric Ass ess m e nt T o ol w as c o m plet e d prior t o initiatio n of t he pr ot oc ol -s pecifie d tr eat m e nt. Ninet y -t hr ee patie nts e nr olle d in t his st u d y. T he m e dia n ti m e t o c o m plet e t he ass ess ment w as 2 2 min ut es, 8 8 % of patie nts c o m plet e d t he patie nt p ortio n wit h o ut assist a nc e, 88 % s atisfie d wit h t he ass ess m e nt le n gt h, 9 8 % r e p ort e d t her e wer e n o u ps ettin g it e ms, a n d 95 % s aid t he ass ess m e nt w as eas y t o c o m pr e he n d. T he Geriatric Ass ess m e nt T o ol m et t he pr ot oc ol s pecifie d f easibilit y crit eria f or inc or p or atio n in o nc olo g y c o o per ative gr o up trials.5 2 S e ver al st u dies ar e e m er gin g r e gar din g t he be nefits of perf or min g a c o m pr e he nsive geriatric ass ess m e nt f or older patie nts wit h c a nc er. F act ors e valuat e d in a c o m pr e he nsive geriatric ass ess m e nt c a n pr e dict s ur vival, pr e dict t o xicit y t o c he m ot her a p y, a n d u nc o ver pr o ble ms n ot det ect e d b y a r o utine hist or y a n d p h ysic al in initial c o ns ult atio n a n d f ollo w -u p c ar e.53, 5 4, 5 5 C o ns e ns us g uidelines r ec o g nize t he be nefits a n d r ec o m me n d t he inclusio n of a geriatric ass ess m e nt as part of t he e valuatio n of a n older patie nt.5 6 1 1. 1. 2 O ve r all t re at me nt utilit y We will be inclu din g a m eas ur e of O ver all Tr eat m e nt Utilit y ( O T U) t o ass ess t he “ o bjective a n d s u bjective m eas u r es of t oler a bilit y a n d ac c e pt a bilit y”. T his is ac c o m plis he d wit h a n a nalysis of clinic al be nefits in c o nju nctio n wit h a n a nalysis of w het her t o xicit y a n d s erio us a d vers e e ve nts aff ect o ne’s daily f u nctio ns. T his pr o vides a wa y t o q ua ntif y a d va nt a ges and d is a d va nt a ges fr o m r ec eivin g tr eat m e nt in t his st u d y, as w ell as a n u n derst a n din g of h o w patie nts m a y r es p o n d t o tr eat m e nt. O T U is us ef ul in a ns w erin g t he f ollo win g h y p ot hetic al q uestio n fr o m t he patie nt’s pers pective: “ Wit h t he be nefit of hin dsig ht, ar e y o u gla d y o u r ec eive d tr eat m e nt?” By inclu din g t he O T U in t his st u d y, r es ear c hers a n d o nc olo gists will be a ble t o bett er u n derst a n d t he patie nt’s pers pectives r e gar din g t he be nefits a n d side effects of tr eat m e nt, in c o m binatio n wit h a n ass ess m e nt of tr eat m e nt effic ac y a n d t o xicit y. O T U is a n o vel c o m p osit e e n d p oint de velo pe d b y in vestigat ors of t he F O C U S 2 trial t o ass ess t he o ut c o m e of palliative c he m ot her a p y5 7. T he int er pr et atio n of clinic al trials, es pecially in t he palliative s ettin g, oft e n r e q uir es s u bjective s y nt hesis of o bject dat a. Meas ur es of effic ac y ar e w eig ht e d a gainst t he t o xic eff ects, c o n ve nie nc e, a n d ot her varia bles bef or e decidin g w hic h tr eat m e nt is best. O T U helps int e gr at e t hes e m eas ur es int o a sin gle"
49,page_49,"Allia nc e A1 7 1 6 0 1 5 0 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 c o m p osit e e n d p oint. O T U c o m bines clinic al effic ac y ( “Is m y patie nt alive wit h o ut dis eas e pr o gr essio n?”), clinic al t oler a bilit y ( “ Did w e a v oid c a usin g m ajor har m ”), a n d patie nt o pinio n ( “ Was m y tr eat m e nt w ort h w hile a n d ac c e pt a ble?”). I n t he original st u d y usin g O T U, t he c o m p osit e e n d p oint w as f o u n d t o be partic ularly us ef ul w hen c o n ve ntio nal o ut c o mes w er e diver ge nt ( O xaliplatin i m pr o ve d r es p o ns e r at es a n d pr o gr essio n fr ee s ur vival, yet r es ult e d in incr eas e d t o xicit y), a n d helpe d c o nfir m t he be nefit of O xaliplatin5 7. We will m eas ur e O T U b y ass essin g clinic al be nefit a n d t oler a bil it y/ ac c e pt a bilit y at t he e n d of tr eat m e nt. ( S ee St u d y c ale ndar S ectio n 5. 0 a n d Ap pe n dix I V ). O T U is s c or e d as Go o d O T U ( clinic al or r a dio gr a p hic e vide nc e or dis eas e pr o gr essio n, n o m ajor negative tr eat m e nt eff ects in t er ms of t o xicit y or patie nt ac c e pt a bilit y), I nt e r m e di at e O T U ( eit her clinic al det erior atio n b ut n o ne gative tr eat m e nt eff ect, or a sig nific a nt ne gative tr eat m e nt eff ect but n o clinic al det erior atio n), or P o or O T U ( b ot h clinic al det erior atio n a n d a major ne gative tr eat m e nt eff ect, or deat h). 1 1. 1. 3 W as it wort h it q u esti o n n ai re T he Was It W ort h It instr u m e nt (Ap pe n dix III) w as de velo pe d t o lear n m or e a b o ut t he e x perie nc e of patie nts participatin g in clinic al trials. It is c o m pris e d of f our brief q uestions, a n d it has als o bee n c alle d t he “ Trial S atisf actio n” s ur ve y.5 8 Alt h o u g h f or m al validit y a n d r elia bilit y dat a f or t his instr u m e nt ar e n ot yet a vaila ble, m ultiple c o o per ative gr o u p st u dies ha ve us e d it t o m eas ur e h o w s atisfie d patie nts e n d u p wit h t heir decisio n t o e nr oll o n a clinic al trial.5 9 -6 3 1 1. 1. 4 . Q u alit y of lif e All participa nts will be as ke d t o fill o ut a s h ort Q O L s ur ve y a n d o n pa per at eac h pr o vider ass ess m e nt visit at bas eline t hr o u g h t he st art of c ycle 6 ( u nless patie nts c o m e off st u dy tr eat m e nt bef or e t hat ti m e). Ap pe n dix V has t he r e q uir e d E Q -5 D -3 L s ur ve y. ) 1 1. 1. 5 A d h e re n ce e v al u atio n Pill diaries will be c ollect e d at t he e n d of eac h c ycle of tr eat m e nt t o as cert ain d os e deliver ed a d her e nc e t o palb ociclib f or a m a xi m u m of t hr ee c ycles fr o m initiatio n of pr ot oc ol tr eat m e nt. Ad her e nc e t o palb ociclib will be m eas ur e d b y patie nt s elf-r e p ort in de dic at e d patie nt diaries. ( Ap pe n dix V II). P atie nts will be as ke d t o brin g t heir pill diaries t o e ver y clinic visit. 1 1. 2 Me as u re m e nt of t u m or res po nse a n d s c h e d ul e of e v al u ati o ns Res p o ns e a n d pr o gr essio n will be e valuat e d in t his st u d y usin g t he ne w int er natio nal crit eria pr o p os e d b y t he r e vis e d Res p o ns e E valuatio n Crit eria in S olid T u m ors ( R E CI S T) g uidelines ( versio n 1. 1). P er t he ne w R E CI S T crit eria, as dis eas e r es p o ns e is n ot t he pri m ar y e n d p oint of t his trial, c o nfir m at or y s c a ns f ollo win g d oc u m e n t atio n of pr o gr essio n or r es p o ns e will n ot be r e q uir e d. Rat her, pr o gr essio n/r es po ns e will be det er mine d bas e d o n r es ults of t he sin gle s c a n. C ha n ges in t he lar gest dia m et er ( u nidi m e nsio nal m eas ur e m e nt) of t he t u m or lesio ns a n d t he s h ort a xis m eas ur e m e nts in t he c as e of ly m p h n o des ar e us e d in t he R E CI S T g uideline.6 4 S c h e d ul e of Ev al u ati o ns F or t he p ur p os es of t his st u d y, patie nts s h o uld be r ee valuat e d f or t u m or r es p o ns e e ver y 1 2 w eeks. W hile o n st u d y, a C T of t he c hest, a b d o m e n, wit h or wit h o ut pelvis ( or P E T -C T as a b o ve) will be perf or m e d e ver y 1 2 w ee ks ( ± 2 w ee k s). A b o ne s c a n will be d o ne at r est a gin g ti m e p oints if clinic ally in dic at e d ( or t o c o nfir m a c o m plet e r es p o ns e)."
50,page_50,"Allia nc e A1 7 1 6 0 1 5 1 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 To xi cit y Ev al u ati o n T o xicit y e valuatio ns will be perf or m e d Da ys 1 ( ± 2 da ys), 8 ( ±2 da ys), a n d 1 5 ( ± 2 da ys) of C ycles 1 a n d 2. F or s u bse q ue nt c ycles, t o xicit y e valuatio ns will be d o ne o n Da y 1 ( ± 2 da ys). Ad ditio nal a d vers e e ve nts c a pt ur e d in -bet w ee n will als o be r ec or de d. ( Pleas e s ee st u d y c ale n dar S ection 5. 0 ) All t o xicit y r elat e d d os e int err u ptio ns or r e d uctio ns, h os pit alizatio ns, a n d a d vers e e ve nts will be n ot e d. P atie nts will be f ollo w e d f or t o xicit y o ut c o m es f or a n a d ditio nal 3 0 da ys aft er st o p ping t he dr u g a n d u ntil r es olutio n of all gr a de > 2 t o xicities. An y t o xicities will be r ec or de d in t he patie nt’s m e dic al r ec or d a n d hig hest gr a de of t hat t o xicit y will be r e p ort e d o n t he c as e r e p ort f or ms. 1 1. 3 Defi niti o ns of Me as ur a bl e a n d No n -Me as u r a bl e Dise ase 1 1. 3. 1 Me as u r a bl e Dis e ase Meas ur a ble lesio ns ar e define d as t h os e t hat c a n be ac c ur at ely m eas ur e d in at least o ne di m e nsio n (lo n gest dia m et er t o be r ec or de d) as > 1 0 m m wit h c o n ve ntio nal t ec h niq ue s (C T, or c aliper m eas ur e m e nt). L y m p h n o des gr eat er t ha n 1 5 m m o n s h ort a xis ar e c o nsider ed m eas ur a ble as w ell. All t u m or m eas ur e m e nts m ust be r ec or de d in milli m et ers ( or deci m al fr actio ns of c e nti m et ers). T u m or lesio ns in a pr e vio usly irr a diat e d ar ea ar e n ot c o nsider e d m eas ur a ble dis eas e. 1 1. 3. 2 No n -Me as u r a bl e Dis e ase All ot her lesio ns ( or sit es of dis eas e ), ar e c o nsider e d n o n-m eas ur a ble dis eas e. Or ga n o m e galy, le pt o m e nin geal dis eas e, as cit es, ple ur al/ peric ar dial eff usio ns, ly m p ha n gitis c utis/ p ul m o nis, infla m m at or y br east dis eas e, a n d a b d o minal m ass es ( n ot f ollo w e d b y C T ar e all n o n -m eas ur a ble. T ar get lesio ns : All m eas ur a ble lesio ns u p t o a m a xi m u m of 2 lesio ns per or ga n a n d 5 lesio ns in t ot al, r e pr es e nt ative of all in v olve d or ga ns, s h o uld be ide ntifie d as t ar get l esi o ns a nd r ec or de d a n d m eas ur e d at bas eline. L y m p h n o des less t ha n 1 5 m m in t he s h ort a xis c a n n ot be us e d as t ar get lesio ns. T ar get lesio ns s h o uld be s elect e d o n t he basis of t heir size (lesions wit h t he lo n gest dia m et er) a n d t heir s uit a bilit y f or ac c ur at e r e peat e d m eas ur e m e nts ( eit her b y i m a gin g t ec h niq ues or clinic ally). A s u m of t he lo n gest di a m et er ( L D) f or all t ar get lesio ns will be c alc ulat e d a n d r e p ort e d as t he bas eline s u m L D. T he bas eline s u m L D will be us e d as r ef er e nc e b y w hic h t o c har act erize t he o bjective t u m or r es p o ns e. N o n -t ar get lesio ns: All ot her lesio ns ( or sit es of dis eas e) inclu din g a n y m eas ur a ble lesio ns o ver a n d a b o ve t he 5 t ar get lesio ns s h o uld be ide ntifie d as n o n -t ar get l esi o ns a n d s h o uld als o be r ec or de d at bas eline. Meas ur e m e nts of t hes e lesio ns ar e n ot r e q uir e d, b ut t he pr es e nc e or a bs e nc e of eac h s h o uld be n ot e d t hr o u g h o ut f ollo w -u p. All ot her lesio ns ( or sit es of dis eas e) ar e c o nsider e d n o n -m eas ur a ble dis eas e, inclu din g pat h olo gic al n o des (t h os e wit h a s h ort a xis ≥ 1. 0 t o < 1. 5 c m). Bo ne lesio ns, le pt o m e nin geal dis eas e, as cit es, ple ur al/ peric ar dial eff usio ns, ly m p h a n gitis c utis/ p ul m o nis, infla m m at or y br east dis eas e, a n d a b d o minal m ass es ( n ot f ollo w e d b y C T), ar e c o nsider e d as n o n - m eas ur a ble as w ell. N ot e: ‘ C ystic lesio ns’ t h o u g ht t o r e pr es e nt c ystic m et ast as es c a n be c o nsider e d as m eas ur a ble lesio ns, if t he y m eet t h e definitio n of m eas ur a bilit y des cribe d a b o ve. Ho w e ver, if n o n-c ystic lesio ns ar e pr es e nt in t he s a m e patie nt, t hes e ar e pr ef err e d f or s electio n as t ar get lesio ns. I n a d ditio n, ly m p h n o des t hat ha ve a s h ort a xis < 1. 0 c m ar e c o nsider e d n o n- pat h olo gic al (i . e., n or m al) a n d s h o uld n ot be r ec or de d or f ollo w e d."
51,page_51,"Allia nc e A1 7 1 6 0 1 5 2 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 1 1. 4 G ui deli n es f or Ev al u ati o n of Me as u r a bl e Dis e ase 1 1. 4 . 1 Me as u re m e nt Met h o ds All m eas ur e m e nts s h o uld be r ec or de d in m etric n ot atio n (i. e., deci m al fr actio ns of c e nti m et ers) usin g a r uler or c alipers. T he s a m e m et h o d of ass ess m e nt a n d t he s a m e t ec h niq ue m ust be us e d t o c har act erize eac h ide ntifie d a n d r e p ort e d lesio n at bas eline a n d d urin g f ollo w-u p. F or patie nts ha vin g o nly lesio ns m eas urin g at least 1 c m t o less t ha n 2 c m m ust us e C T i m a gin g f or b ot h pr e- a n d p ost -tr eat m e nt t u m or assess me nts. I m a gin g-bas e d e valuatio n is pr ef err e d t o e valuatio n b y clinic al e xa minatio n w he n b ot h m et h o ds ha ve bee n us e d at t he s a m e e valuatio n t o ass ess t he a ntit u m or eff ect of a tr eat ment. 1 1. 4 . 2 Acce pt a bl e Mo d aliti es f or Me as u r a bl e Dis e ase • C o n ve nti o n al C T: T his g uideline has define d m eas ur a bilit y of lesio ns o n C T s can bas e d o n t he ass u m ptio n t hat C T slic e t hic k ness is 5 m m or less. If C T s c a ns ha ve slice t hic k ness gr eat er t ha n 5 m m, t he mini m u m size f or a m eas ur a ble lesio n s h o uld be t wice t he slic e t hic k ness. • P E T -C T: If t he sit e’s pr ot oc ol is t o us e a P E T-C T, t he n a P E T -C T wit h or wit h o ut I V a n d or al c o ntr ast, c a n be us e d int er c ha n gea bly wit h c o n ve ntio nal C T in ac c ur at ely m eas urin g c a nc er lesio ns o ver ti m e . • P h ysi c al Ex a mi n ati o n: F or s u perficial n o n -n o dal lesio ns, p h ysic al e xa minatio n is ac c e pt a ble, b ut i m a gin g is pr ef er a ble, if b ot h c a n be d o ne. I n t he c as e of s kin lesio ns, d oc u m e nt atio n b y c olor p h ot o gra p h y, inclu din g a r uler t o esti m at e t he size of t he lesion, is r ec o m m e n de d. • F D G -P E T: F D G -P E T s c a n nin g is allo w e d t o c o m ple m e nt C T s c a n nin g in ass ess ment of pr o gr essive dis eas e [ P D] a n d partic ularly p ossible ' ne w' dis eas e. A ‘ p ositive’ F D G - P E T s c a n ne d lesio n is define d as o ne w hic h is F D G a vid wit h a n u p dat e gr eat er t ha n t wic e t hat of t he s urr o u n din g tiss ue o n t he att e n uatio n c orr ect e d i m a ge; ot her wis e, an F D G -P E T s c a n ne d lesio n is c o nsider e d ‘ ne gative.’ Ne w lesio ns o n t he basis of F D G - P E T i m a gin g c a n be ide ntifie d ac c or din g t o t he f ollo win g alg orit h m: • Ne gative F D G -P E T at bas el ine wit h a p ositive F D G-P E T at f ollo w -u p is a sig n of P D bas e d o n a ne w lesio n. • N o F D G -P E T at bas eline a n d a p ositive F D G -P E T at f ollo w -u p: • If t he p ositive F D G-P E T at f ollo w -u p c orr es p o n ds t o a ne w sit e of dis eas e c o nfir m e d b y C T, t his is P D. • If t he p ositive F D G-P E T at f ollo w -u p is n ot c o nfir m e d as a ne w sit e of dis eas e on C T at t he s a m e e valuatio n, a d ditio nal f ollo w -u p C T s c a ns (i. e., a d ditio nal f ollo w - u p s c a ns at least 4 wee ks lat er) are nee de d t o det er mine if t her e is tr uly pr o gr ession oc c urrin g at t hat sit e. I n t his sit uatio n, t he dat e of P D will be t he dat e of t he initial a b n or m al P D G -P E T s c a n. • If t he p ositive F D G-P E T at f ollo w -u p c orr es p o n ds t o a pr e -e xistin g sit e of dis ease o n C T t hat is n ot pr o gr essin g o n t he basis of t he a nat o mic i m a ges, it is n ot classifie d as P D."
52,page_52,"Allia nc e A1 7 1 6 0 1 5 3 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 1 1. 4 . 3 Me as u re m e nt at F oll o w -u p Ev al u ati o n: T he c yt olo gic al c o nfir m atio n of t he ne o plastic origin of a n y eff usio n t hat a p pears or w orsens d urin g tr eat m e nt w he n t he m eas ur a ble t u m or has m et crit eria f or r es p o ns e or st a ble dis ease is m a n dat or y t o diff er e ntiat e bet w ee n r es p o ns e or st a ble dis eas e ( a n eff usio n m a y be a side eff ect of t he tr eat m e nt) a n d pr o gr essive dis eas e. C yt olo gic a n d hist olo gic t ec h niq ues c a n be us e d t o diff er e ntiat e bet w ee n P R a n d C R in r are c as es ( e. g., r esid ual les io ns in t u m or t y pes s uc h as ger m c ell t u m ors, w her e k n o w n r esid ual be nig n t u m ors c a n r e m ain.) 1 1. 5 Me as u re m e nt of Tre at m e nt/I nter ve nti o n Eff e ct 1 1. 5 . 1 Tar get Lesi o ns & Tar get L y m p h No des Meas ur a ble lesio ns ( as define d in S ect io n 1 1. 3 . 1) u p t o a m a xi m u m of 5 lesio ns in t ot al, r e pr es e nt ative of all in v olve d or ga ns, s h o uld be ide ntifie d as “ T ar get Lesio ns ” a n d r ec or ded a n d m eas ur e d at bas eline. T hes e lesio ns c a n be n o n -n o dal or n o dal ( as define d in 1 1. 3 . 1), w her e n o m or e t ha n 2 lesio ns ar e fr o m t he s a m e or ga n a n d n o m or e t ha n 2 m alig na nt n o dal lesio ns ar e s elect e d. Not e : If f e w er t ha n 3 t ar get lesio ns a n d tar get ly m p h n o des ar e ide ntifie d ( as t her e oft e n will be), t her e is n o r eas o n t o perf or m a d ditio nal s t u dies be y o n d t h os e s pecifie d in t he pr ot oc ol t o dis c o ver ne w lesio ns. T ar get lesio ns a n d t ar get ly m p h n o des s h o uld be s elect e d o n t he basis of t heir size, be r e pr es e nt ative of all in v olve d sit es of dis eas e, b ut in a d ditio n s h o uld be t h os e t hat le n d t he ms elves t o r e pr o d ucible r e peat e d m eas ur e m e nts. It m a y be t he c as e t hat, o n oc c asion, t he lar gest lesio n ( or m alig na nt ly m p h n o de) d oes n ot le n d its elf t o r e pr o d ucible m eas ur e m e nts in w hic h cir c u mst a nce t he ne xt lar gest lesio n ( or m alig na nt ly m p h n o de) w hic h c a n be m eas ur e d r e pr o d ucibly s h o uld be s elect e d. Bas eline S u m of Di m e nsio ns ( B S D): A s u m of t he lo n gest dia m et er f or all t ar get lesio ns plus t he s u m of t he s h ort a xis of all t he t ar get ly m p h n o des will be c alc ulat e d a n d r e p ort ed as t he bas eline s u m of di m e nsio ns ( B S D). T he B S D will be us e d as r ef er e nc e t o f urt her c har act erize a n y o bjective t u m or r es p o ns e in t he m eas ur a ble di m e nsio n of t he dis eas e. P ost -Bas eline S u m of t he Di m e nsio ns ( P B S D): A s u m of t he lo n gest dia m et er f or all t ar get lesio ns plus t he s u m of t he s h ort a xis of all t he t ar get ly m p h n o des will be c alc ulat e d a n d r e p ort e d as t he p ost-bas eline s u m of di m e nsio ns ( P B S D). If t he r a diolo gist is a ble t o pr o vide a n act ual m eas ur e f or t he t ar get lesio n ( or t ar get ly m p h n o de), t hat s h o uld be r ec or de d, even if it is belo w 0. 5 c m. If t he t ar get lesio n ( or t ar get ly m p h n o de) is belie ve d t o be pr es e nt and is f aintly s ee n b ut t o o s m all t o m eas ur e, a def a ult value of 0. 5 c m s h o uld be assig ne d. If it is t he o pinio n of t he r a diolo gist t hat t he t ar get lesio n or tar get ly m p h n o de has likely dis a p pear e d, t he m eas ur e m e nt s h o uld be r ec or de d as 0 c m. T he mini m u m s u m of t he di m e nsio ns ( M S D) is t he mini m u m of t he B S D a n d t he P B S D. 1 1. 5 . 2 No n -Tar get Lesi o ns & No n -Tar get L y m p h No des N o n -m eas ur a ble sit es of dis eas e ( S ectio n 1 1. 3 . 2) ar e classifie d as n o n- t ar get lesio ns or n o n- t ar get ly m p h n o des a n d s h o uld als o be r ec or de d at baseline. T hes e lesio ns a n d ly m p h n odes s h o uld be f ollo w e d in ac c or d wit h 1 1. 5 . 3."
53,page_53,"Allia nc e A1 7 1 6 0 1 5 4 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 1 1. 5 . 3 Res po ns e Crit eri a All t ar get lesio ns a n d t ar get ly m p h n o des f ollo w e d b y C T/ P E T -C T / p h ysic al e xa minatio n m ust be m eas ur e d o n r e -e valuatio n at e valuatio n ti m es s pecifie d in S ectio n 1 1. 2. S pecific ally, a c ha n ge in o bjective st at us t o eit her a P R or C R c a n n ot be d o ne wit h o ut r e - m eas urin g t ar get lesio ns a n d t ar get ly m p h n o des. Not e: N o n -t ar get lesio ns a n d n o n-t ar get ly m p h n o des s h o uld be e valuat e d at eac h ass ess m e nt, es pecially in t he c as e of first r es p o nse or c onfir m atio n of res p o nse. I n selected cir c u mst a nces, c ert ain n o n -t ar get or ga ns m a y be e valuat e d less fr e q ue ntly. F or e xa m ple, b o ne s c a ns m a y nee d t o be r e peat e d o nly w he n c o m plet e r es p o ns e is ide ntifie d in t ar get dis eas e or w he n pr o gr essio n in b o ne is s us pect e d. Ev al u ati o n of Tar get Lesi o ns • C o m plet e Res p o ns e ( C R): All of t he f ollo win g m ust be tr ue: ▪ Dis a p pear a nc e of all t ar get lesio ns. ▪ Eac h t ar get ly m p h n o de m ust ha ve r e d uctio n in s h ort a xis t o < 1. 0 c m. • P artial Res p o ns e ( P R): At least a 3 0 % decr eas e in P B S D (s u m of t he lo n gest dia m et er f or all t ar get lesio ns plus t he s u m of t he s h ort a xis of all t he t ar get ly m p h n o des at c urr ent e valuatio n) t a kin g as r ef er e nc e t he B S D (s ee S ectio n 1 1. 5 . 1). • Pr o gr essio n ( P D): At least o ne of t he f ollo win g m ust be tr ue: ▪ At least o ne ne w m alig na nt lesio n, w hic h als o inclu des a n y ly m p h n o de t hat was n or m al at bas eline ( < 1. 0 c m s h ort a xis) a n d incr eas e d t o ≥ 1. 0 c m s h ort a xis d urin g f ollo w-u p. ▪ At least a 2 0 % incr eas e in P B S D (s u m of t he lo n gest dia m et er f or all t ar get lesio ns plus t he s u m of t he s h ort a xis of all t he t ar get ly m p h n o des at c urr e nt e valuatio n) t a kin g as r ef er e nc e t he M S D (S ectio n 1 1. 5 . 1). I n a d ditio n, t he P B S D m ust als o de m o ns tr at e a n a bs olut e incr eas e of at least 0. 5 c m fr o m t he M S D. ▪ S ee S ectio n 1 1. 4 . 2 f or det ails in r e gar ds t o t he r e q uir e m e nts f or P D via F D G-P E T i m a gin g. • St a ble Dis eas e ( S D): Neit her s ufficie nt s hrin ka ge t o q ualif y f or P R, n or s ufficie nt incr eas e t o q ualif y f or P D t a kin g as r ef er e nc e t he M S D. Ev al u ati o n of No n -Tar get Lesi o ns & No n -t ar get L y m p h No des • C o m plet e Res p o ns e ( C R): All of t he f ollo win g m ust be tr ue: ▪ Dis a p pear a nc e of all n o n -t ar get lesio ns. ▪ Eac h n o n -t ar get ly m p h n o de must ha ve a r e d uctio n in s h ort a xis t o < 1. 0 c m. • N o n -C R/ N o n -P D: P ersist e nc e of o ne or m or e n o n -tar get lesio ns or n o n-t ar get ly m p h n o des • Pr o gr essio n ( P D): At least o ne of t he f ollo win g m ust be tr ue: ▪ At least o ne ne w m alig na nt lesio n, w hic h als o inclu des a n y ly m p h n o de t hat was n or m al at bas eline ( < 1. 0 c m s h ort a xis) a n d incr eas e d t o ≥ 1. 0 c m s h ort a xis d urin g f ollo w-u p. ▪ Une q uiv oc al pr o gr essio n of e xistin g n o n -t ar get lesio ns a n d n o n-t ar get ly m p h n o d es. ( N O T E: Une q uiv oc al pr o gr essio n s h o uld n ot n or m ally tr u m p t ar get lesion"
54,page_54,
55,page_55,
56,page_56,"Allia nc e A1 7 1 6 0 1 5 7 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 1 2. 2 . 3 Ot h e r re as o ns f or dis c o nti n uati o n of pr ot oc ol t h er a py P atie nts w h o dis c o ntin ue tr eat m e nt f or a n y ot her r eas o n t ha n pr o gr essio n or u nac c e pt a ble t o xicit y s h o uld c o ntin ue t o be f ollo w e d f or pr o gr essio n. F ollo win g pr o gr essio n, patie nts will be f ollo w e d e ver y year f or s ur vival. T he r eas o n f or dis c o ntin uatio n of pr ot oc ol tr eat m e nt m ust be d oc u m e nt e d o n t he “ Off tr eat m e nt ” f or m. 1 2. 2. 4 Dis c o nti n u ati o n of Ge ri at ri c Ass ess me nt a n d S pe ci m e n S u b missi o n Ge ri at ri c Ass ess me nt: P atie nts will c o m plet e t he geriatric ass ess m e nt at t he e n d of tr eat m e nt. If e n d of tr eat m e nt oc c urs prior t o t he e n d of C ycle 3, t he e n d of c ycle 3 ass ess m e nt nee d n ot be s u b mitt e d. ( T hat is, patie nts w h o dis c o ntin ue pr ot oc ol tr eat m e nt prior t o t he e n d of c ycle 3 will ha ve c o m plet e d a geriatric ass ess m e nt at bas eline a n d at t he e n d of tr eat m e nt.) S pe ci m e n S u b missi o n: P atie nts w h o dis c o ntin ue pr ot oc ol tr eat m e nt prior t o t he e n d of C ycle 3 m ust still be as ke d t o s u b mit a n e n d of tr eat m e nt blo o d s a m ple r at her t ha n t he prior t o C ycle 4 blo o d s a m ple list e d in S e ctio n 6. 2 . 1 2. 3 Ma n a gi n g i n eli gi bl e pati e nts a n d re giste re d pati e nts w h o n e ver re cei ve pr ot oc ol i nt e r ve nti o n Defi niti o n of i n eligi bl e pati e nt A st u d y participa nt w h o is r e gist er e d t o t he trial b ut d oes n ot m eet all of t he eligibilit y crit eria is dee m e d to be ineligible. F oll o w -u p f or i n eli gi bl e pati e nts w h o c o nti n ue wit h pr ot oc ol t re at me nt P atie nts w h o ar e dee m e d ineligible aft er r e gist erin g m a y c o ntin ue pr ot oc ol tr eat m e nt, pr o vided t he tr eatin g p h ysicia n, st u d y c hair, a n d e xec utive offic er a gr ee t her e ar e n o s af et y c o nc er ns if t he patie nt c o ntin ues pr ot oc ol tr eat m e nt. All s c a ns, t ests, a n d dat a s u b missio n ar e t o c o ntinue as if t he patie nt w er e eligible. N otific atio n of t he loc al I R B m a y be nec ess ar y per loc al I R B p olicies. F oll o w -u p f or i n eli gi bl e pati e nts w h o dis c o nti n u e pr ot oc ol t re at m e nt F or patie nts w h o ar e dee m e d ineligible aft er r e gist erin g t o t he trial, w h o st art tr eat me nt, b ut then dis c o ntin ue st u d y tr eat m e nt, t he s a m e dat a s u b missio n r e q uir e m e nts ar e t o be f ollo w e d as f or t h os e patie nts w h o ar e eligible a n d w h o dis c o ntin ue st u d y tr eat m e nt. F oll o w -u p f or pati e nts w h o are re gistere d, b ut w h o n e ver st art st u dy t re at m e nt F or all st u d y participa nts w h o ar e re gist er e d t o the trial b ut w h o ne ver r eceive st u d y int er ve ntion (r e gar dless of eligibilit y), t he f ollo w -u p r e q uir e m e nts ar e s pecifie d belo w. Bas eline a n d off -tr eat m e nt n otic e dat a s u b missio n r e q uir e d. S ee t he Dat a S u b missio n S c he d ule ac c o m pa n yin g t he All F or ms P ac ket. 1 2. 4 Ext r a or di n ar y Me di c al Ci rc u mst a n ces If, at a n y ti m e t he c o nstr aints of t his pr ot oc ol ar e detri m e nt al t o t he patie nt's healt h a n d/ or t he patie nt n o lo n ger wis hes t o c o ntin ue pr ot oc ol t her a p y, pr ot oc ol t her a p y s hall be dis c o ntin ued. I n t his e ve nt: • D oc u m e nt t he r eas o n(s) f or dis c o ntin uatio n of t her a p y o n dat a f or ms . • F ollo w t he patie nt f or pr ot oc ol e n d p oints as r e q uir e d b y t he St u d y Cale n dar."
57,page_57,"Allia nc e A1 7 1 6 0 1 5 8 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 1 3. 0 S T A TI S TI C A L CO N S I D E R A TI O N S 1 3. 1 Pri m ar y E n d poi nts : T he pri m ar y e n d p oint is t he a d vers e e ve nt r at e at 6 m o nt hs, define d as the pr o p ortio n of patients wit h d oc u m e nt at io n of gr a de 3 - 5 t o xicit y (r e gar dless of attrib utio n usin g t h e N CI C T C A E v. 5 . 0 crit eria). 1 3. 2 Pri m ar y E n d poi nt A n al ysis : A 9 5 % bin o mial c o nfide nc e int er val f or sin gle pr o p ortio ns will be c o nstr ucte d f or t he s e vere t o xicit y r at e oc c urrin g t he first 6 m o nt hs of tr eat m e nt. Univariat e r elatio ns hips bet w ee n t he pri m ar y e n d p oint a n d vario us pr e -tr eat m e nt patie nt c har act eristics s uc h as a ne mia, s elf-assessed f u nctio nal st at us, or s ocial s u p p ort will be des cribe d via cr oss -t a b ulatio n a n d Fis her’s e xact t esting. E x plor at or y lo gistic r e gr essio n m o delin g, wit h li mit e d ge ner aliza bilit y d ue t o t he m o dest s a m ple size, will be us e d t o ass ess t he r elative c o ntrib utio ns of t hes e varia bles i m pact t he likelih o o d of de velo pin g a s e ver e t o xicit y d urin g tr eat m e nt. T he str en gt h of t his ass ociation will be e x pr ess e d in t er ms of a n o d ds r atio a n d its ass ociat e d 9 5 % c o nfide nc e int er val. As a s ec o n dar y a nalysis f or t his e n d p oint, w e will als o lo o k at gr a de 3 -5 t o xicities oc c urrin g wit hin t he first 6 m o nt hs of tr eat m e nt t hat ar e at least p ossibly r elat e d t o palb ociclib. T his a nalysis will be c o n d uct e d in a si milar f as hio n as t he pri m ar y e n d p oint. T o e x plor e t he r elatio ns hip bet w een t he s e ver e t o xicit y r at e oc c urrin g wit hin t he first 6 m o nt hs of tr eat m e nt in t his p o p ulatio n a n d t he t y pe of e n d ocrine t her a p y us e d (letr oz ole vs. f ulvestr a nt), w e will c o n d uct a c hi-s q uar e test or Fis her’s e xact t est as a p pr o priat e. 1 3. 3 S e c o n dar y E n d poi nts : • All t o xicities ass ociat e d wit h t he c o m binatio ns as m eas ur e d b y N CI C T C A E v. 5 . 0 • D os e r e d uctio ns, d os e h olds, a n d h os pit alizatio ns • Ti m e t o tr eat m e nt f ailur e ( a n d r eas o n f or c o min g off st u d y – t o xicit y, patie nt pr ef er e nc e, pr o gr essio n) • T he per c e nt a ge of d os es of palb ociclib t a ke n eac h c ycle f or t he first 3 c ycles • Res ults of t he geriatric ass ess m e nt, Wa s It W ort h It ( WI WI) Q uestio n nair e, a n d O ver all Tr eat m e nt Utilit y ( O T U) 1 3. 4 S e c o n dar y E n d poi nt A n al ys es 1 3. 4. 1 P al boci cli b Tol e r a bilit y C o nclusio ns c o nc er nin g t he t oler a bilit y of t his r e gi m e n in elderly patie nts will t a ke int o ac c o u nt t he per c e nt a ge of patie nts w h o de velo p gr a de 2 a n d hig her t o xicities inclu din g f e brile ne utr o pe nia, le u k o pe nia, t hr o m b oc yt o pe nia, a n d a ne mia, GI side eff ects ( na us ea, diarr hea, decr eas e d a p petit e, v o mitin g, st o m atitis), f atig ue, ne ur o pat h y, a n d t hr o m b oe m b olis m , t he per c e nt a ge of patie nts w h o r e q uir e d os e m o dific atio ns a n d t he per c e nt a ge of patie nts w h o r ef us e t o c o ntin ue o n st u d y tr eat m e nt f or a n y r eas o n. 1 3. 4. 2 Re as o ns f or D os e Re d u cti o n, D os e Hol ds, a n d Hos pit ali z ati o ns S u m m aries of r eas o ns f or d os e r e d uctio ns, d ose h olds, a n d h os pit alizatio ns will be pr e par e d. An y d os e r e d uctio n will be c o nsider e d a n d r eas o n f or d os e r e d uctio n will be n ot e d. Sinc e palb ociclib is give n in c o m binatio n wit h e n d ocrine t her a p y as per st a n dar d of c ar e, w e are e valuatin g clinic al e n d p oints bas e d o n t oler a bilit y of t he c o m binatio n. I n t he c as e r e p ort f or ms, w e will c a pt ur e w het her t he t o xicit y is d ue t o t he e n d ocrine t her a p y or t he palb ociclib."
58,page_58,"Allia nc e A1 7 1 6 0 1 5 9 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 1 3. 4. 3 Ti m e t o Tre at m e nt F ail u re Distrib utio ns ti m e t o tr eat m e nt f ailur e will be esti m at e d usin g Ka pla n -Meier m et h o d olo g y. Tr eat m e nt f ailur e is define d as a s e ver e a d vers e e ve nt, dis eas e pr o gr essio n or patie nt r ef usal t o c o ntin ue assig ne d tr eat m e nt. We w o uld inclu de a n y r eas o n t hat tr eat m e nt is dis c ontin ued t o ti m e t o tr eat m e nt f ailur e a n d n ot c e ns or patie nts. T he r eas o n f or tr eat m e nt dis c o ntin uation will be c a pt ur e d. 1 3. 4. 4 A d h e re n ce t o P al boci cli b P atie nts t o be inclu de d in t he a nalysis c o h ort will be t h os e patie nts w h o ha ve t a ke n o ne or m or e d os es of t he st u d y tr eat m e nt . T h os e patie nts will be c o nsider e d a d her e nt t o st u dy tr eat m e nt. F or eac h of t he first 3 c ycles, a n esti m at e of t he pr o p ortio n of patie nts w h o m ee t t he crit eria f or a d her e nc e a n d its c orr es p o n din g 9 5 % c o nfide nce int er val will be det er mine d. 1 3. 4. 5 Res po ns e R at e as Det er mi n e d by R E CI S T T he r es p o ns e r at e is define d as t he pr o p ortio n of patie nts w h os e dis ease st at us m et R E CI S T crit eria f or c o m plet e r es p o ns e ( C R) or partial r es p o ns e ( P R) o n 2 c o nsec utive e valuatio ns at least 8 w ee ks a part. A 9 5 % bin o mial c o nfide nc e int er val f or t he r es p o ns e r at e will be c o nstr ucte d. 1 3. 4. 6 Pr o gressi o n Fre e S ur vi v al ( P F S) a n d O ve r all S u r vi v al ( O S) Distrib utio ns of P F S a n d O S ti m es will be esti m at e d usin g Ka pla n -Meier m et h o d olo g y. Pr o gr essio n fr ee s ur vival is define d as f ollo w s: “t he ti m e fr o m st art of tr eat m e nt t o t he first of t he f ollo win g dis eas e e ve nts: loc al/r e gio nal/ dist a nt r ec urr e nc e, in vasive c o ntr alat er al br east dis eas e, s ec o n d pri m ar y or deat h d ue t o a n y c a us e”. 1 3. 4. 7 Ge ri at ri c Ass ess m e nt, WI WI Q u esti o n n aire, a n d O T U Des criptive st atistics will be pr o vide d f or r es p o ns es fr o m t he WI WI Q uestio n nair e a n d t he O T U. Ge ner al linear m o dels a n d gr a p hic al m et h o ds will be u s e d t o e x plor e f act ors as ide ntifie d b y a c a nc er-s pecific geriatric ass ess m e nt t hat m a y be pr e dictive of t o xicit y/ d ose r e d uctio n, d os e h olds, or h os pit alizatio ns. Re peat e d m eas ur es m o dels a n d gr a p hic al m et h o ds will als o be utilize d in a n e x plor at or y f as hio n t o ass ess t he i m pact of t he le n gt h of tr eat ment o n t he r es ults of t he geriatric ass ess m e nt. 1 3. 4. 8 S arc o pe ni a a n al ysis Ab d o minal or t h or acic C T i m a ges perf or m e d as part of r o utine c ar e f or st a gin g a n d dis ease m o nit orin g d urin g t he trial, ( w hic h is e ver y 1 2 w ee ks -See St u d y cale n dar S ectio n 5. 0) will be ac q uir e d fr o m st u d y sit es. Usin g t he tr a ns vers e s ectio n at t he L 3 le vel f or a b d o minal i m a gin g ( as m ost hig hly c orr elat e d wit h t ot al b o d y m us cle m ass [r 2 = 0. 8 6]6 5) or at L 1 le vel f or t h or acic i m a gin g ( as most hig hly c orr elat e d wit h L 3),66 s kelet al m us cle ar ea ( S M A) will be q ua ntifie d wit hin a Ho u nsfield u nit ( H U) r a n ge of -2 9 t o + 1 5 0 H U usin g Slic e -O -Matic s oft w ar e ( v. 4. 3; T o m ovisio n, M o ntr eal, Q ue bec, Ca na da). A S kelet al M us cle I n de x ( S MI) will t he n be c alc ulat e d usin g t he f ollo win g f or m ula: S MI = S M A ( c m 2) / patie nt heig ht ( m 2). Esti m at e d L B M will als o be c alc ulat e d usin g t he f ollo win g f or m ula: [ L B M ( k g) = 0. 3 0 × [ S M A ( c m 2)] + 6. 0 6]. 1 5 Mea n s kelet al m us cle de nsit y ( S M D) will be derive d b y a ver a gin g H U of s k elet al m us cle. S kelet al m us cle ga u ge ( S M G) will t he n be c alc ulat e d b y m ultiplyin g S MI x S M D. S u bc ut a ne o us a dip os e tiss ue ( S A T) ar ea will als o be c alc ulat e d fr o m e xtr a-m us c ular tiss ue wit h de nsit y bet w ee n − 1 9 0 a n d -3 0 H U, a n d vis c er al a dip os e tiss ue ( V A T) fr o m n o n-s u bc ut a ne o us tiss ue wit h de nsit y bet w ee n -1 5 0 a n d -5 0 H U. T he pri m ar y m eas ur e of s kelet al m us cle m ass will be S MI, a n d ot her m eas ur es will be ass essed s ec o n darily."
59,page_59,"Allia nc e A1 7 1 6 0 1 6 0 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 Des criptive st atistics will be pr o vide d f or b o d y c o m p ositio n varia bles inclu din g S MI , S M D, S M G, a n d L B M. S ar c o pe nia will be tr eat e d as a binar y varia ble ( bas e d o n c ut -p oints of S MI fr o m prior lit er at ur e ; S MI < 4 1c m 2/ m 2 = s ar c o pe nic 7 0) a n d diff er e nc es in gr a des 6 7 -69 c he m ot her a p y t o xicit y a n d a d vers e e ve nts will be a nalyze d usin g t w o gr o u p t -t ests a n d Fis her’s e xact t est. De pe n din g o n t he n u m ber of a b d o minal vers us t h or acic s c a ns t hat are utilize d, a nalys es m a y be str atifie d b y loc atio n of S M A m eas ur e m e nt ( L 3 vers us L 1). Relative ris ks ( R R) a n d 9 5 % C o nfide nc e I nt er val ( CI) will be r e p ort e d f or ass ociatio ns bet w ee n s ar c o pe nia a n d gr a de 3 -5 t o xicit y a n d h os pit alizatio n, a n d s ec o n darily f or S M D a n d S M G ( bas e d o n lit er at ur e bas e d c ut -p oints).7 0, 7 1 Bot h u na djust e d a n d a djus t e d R R will be c alc ulat e d usin g P oiss o n r e gr essio n m o dels wit h r o b ust varia nc e.7 2 C o variat es in t he m o del inclu de a ge, a n d r ac e/ et h nicit y. Rec eiver o per atin g c har act eristic ( R O C) c ur ves will be ge ner at e d, as w ell as t he ar ea u n der t he c ur ve ( A U C), t o e valu at e t he pr e dictive a bilit y of eac h b o d y c o m p ositio n m eas ur e wit h gr a des 3 -5 t o xicit y. De pe n din g o n t he a vaila bilit y of s u bs e q ue nt f ollo w u p i m a gin g aft er 3 tr eat m e nt c ycles, we will des cribe c ha n ges in b ody c o m p ositio n fr o m bas eline t o st art of c ycle 4. We will e xa mine varia bles ass ociat e d wit h s kelet al m us cle loss d urin g tr eat m e nt a n d w het her s kelet al m us cle loss d urin g tr eat m e nt is ass ociat e d wit h t he pr es e nc e of gr a de 3 -5 t o xicit y a n d a d vers e e ve nts. 1 3. 4. 9 E u r o Q ol 5 D 3 L q u esti o n n ai re: T he E Q -5 D -3 L will be s c or e d a n d t he r es ults will be e valuat e d des criptively a n d gr a p hic ally. 1 3. 4. 1 0 P R O -C T C A E: We will e valuat e f easibilit y of P R O -C T C A E r e p ortin g in t his p o p ulatio n b y lo o kin g at t he c o m plia nc e r at es of t he P R O -C T C A E. T he P R O -C T C A E will be c o nsider e d f easible if 7 5 % of t he patie nts c o m plet e d 7 5 % of t he P R O -C T C A E q uestio n nair es. We will als o c o m pare s y m pt o ms r e p ort e d b y patie nts o n t heir P R O-C T A E in p uts c o m par e d t o w hat is r e p ort e d in clinic usin g tr a ditio nal A E e valuatio ns. P R O -C T C A E r es ults will be s u m m arize d a n d pr es e nt e d des criptively. 1 3. 5 S a m pl e Si ze T he s a m ple size w as det er mine d bas e d o n T ur ner et al .’s fin din g t hat t he s e ver e t o xicit y r at e in patie nts a ge 2 9 – 8 8 ( a p pr o xi m at ely 2 5 % a ge ≥ 7 0 ) w as 7 0 %.2 T he s a m ple size is 8 8 patie nts w hic h will t a ke int o ac c o u nt p ot e ntial dr o p o ut w hic h will allo w f or 8 0 e valua ble patie nts. Give n a s a m ple of 8 0 patie nts, t he widest half -widt h of t he 9 5 % c o nfide nce li mits f or t he r at e of se vere t o xicities will be less t ha n or e q ual t o 0. 1. Ass u min g a r at e of s e ver e t o xicities of 7 0 %, o ur 95 % c o nfide nc e int er val will r a n ge fr o m 0. 6 t o 0. 8. Ad ditio nally, t o e ns ur e w e ha ve s ufficie nt patie nts w h o ar e a ge d 7 5 + t o esti m at e t he s e ve re t o xicit y r at e a n d s af et y of palb ociclib, w e will ac cr ue patie nts u ntil w e ha ve 4 0 patie nts w h o are 7 5 or older. Give n a s a m ple of 4 0 patie nts, t he widest half -widt h of t he 9 5 % c o nfide nc e li mits f or t he r at e of s e ver e t o xicities will be less t ha n or e q ual t o 0. 1 4 2 . Ass u min g a r at e of s e vere t o xicities of 7 0 %, o ur 9 5 % c o nfide nce int er val will r a n ge fr o m 0. 55 8 t o 0. 84 2 . 1 3. 6 I nt e ri m a n al ysis a n d st o p pi n g r ul es: Aft er a p pr o xi m at ely 2 0 patie nts ha ve c o m plet e d o ne f ull c ycle, t he st u d y t ea m will r e vie w t he dat a (inclu din g t he t o xicit y pr ofile, r at es of d os e r e d uctio n, h olds a n d h os pit alizatio ns) a n d ass ess if t he d os e bein g st u die d is t o o hig h, t hat is if m or e t ha n 5 0 % of patie nts e x perie nc e a d os e r e d uctio n. If s o, a r e d uctio n of t he d os e will be c o nsider e d, ot her wis e t he st u d y wi ll c o ntin ue t o c o m pletio n at t he pla n ne d d os e."
60,page_60,"Allia nc e A1 7 1 6 0 1 6 1 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 P er c orr es p o n de nce wit h N CI, w e inclu de a s e par at e st o p pin g r ule f or patie nts wit h a perf or m a nc e st at us of 3 or 4 t o m o dif y eligibilit y crit eria if t her e is e vide nc e t hat patie nts wit h P S 3 or 4 d o n ot s ee m to t oler at e t he r e gi m e n. If, in t he r e vie w des cribe d a b o ve of t he first 2 0 patie nts, m or e t ha n 5 0 % of t he patie nts wit h perf or m a nc e st at us 3 or 4 e x perie nc e a n a d verse e ve nt, w e will c o nsider c ha n gin g t he eligibilit y r e q uir e m e nts t o pr eclu de patie nts wit h P S 3or 4 fr o m participatin g in t he st u d y. Wit h Up dat e 2 t o t he st u d y, w e ha ve r e vis e d eligibilit y crit eria t o r estrict st u d y participatio n to patie nts wit h E C O G perf or m a nc e st at us 0 -2. ( S ee S ectio n 3. 2. 1 1 ) 1 3. 7 St u dy Re porti n g T his st u d y will be m o nit or e d b y t he st u d y t ea m (inclu din g t he St u d y C hair, C o m mitt ee C hair, st u d y st atisticia ns, pr ot oc ol c o or dinat or, a n d Allia nc e E xec utive Offic er) o n a m o nt hly basis, to ass ess s e ver e a d vers e e ve nts. Re p orts c o nt ainin g a s u m m ar y of a d vers e e ve nts will be r e vie w ed o n t hes e c alls. T he st u d y t ea m will als o m o nit or t he ac cr ual r at e ."
61,page_61,
62,page_62,"Allia nc e A1 7 1 6 0 1 6 3 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 1 4. 0 E X P L O R A T O R Y CO R R E L A TI V E AN D CO M P A NI O N ST U DI ES T her e will b e 3 s u b st u dies a n d all patie nts ar e e nc o ur a ge d t o participat e. 1 4. 1 C orrel ati ve S ci e n c e: Ci rc ul ati n g m ar k ers of i nfl a m m ati o n as pot e nti al m ar k ers pre di cti ve of t o xi cit y a m o n g el de rl y pati e nts e n r oll e d t o Alli a n ce A 1 7 1 6 0 1 ( Alli a nce A 1 7 1 6 0 1 -S T1 ) Allia nc e A1 7 1 6 0 1 -S T 1 will e valuat e cir c ulatin g m ar kers of infla m m atio n as p ot e ntial m ar kers pr e dictive of t o xicit y a m o n g older patie nts wit h Estr o ge n r ec e pt or p ositive, H E R 2 ne gative m et ast atic br east c a nc er. 1 4. 1 . 1 B ac k gr o u n d T her e is gr eat het er o ge neit y in t he a bilit y of older a d ults t o t oler at e c a nc er tr eat m e nt. So me older patie nts t oler at e tr eat m e n t w ell a n d derive as m uc h be nefit fr o m tr eat m e nt as y o u nger patie nts, w hile ot hers ha ve incr eas e d r at es of t o xicit y r es ultin g in tr eat m e nt r e d uctions a n d/ or c ess atio n of tr eat m e nt. T he best -st u die d t o ols t o pr e dict t o xicit y ar e c o m pr e he nsive geriatric ass e ss m e nts, w hic h r e q uir e ti m e a n d r es o ur c es t hat li mit t heir us e in r o utine o nc olo g y pr actic e. A m eas ur e of cir c ulatin g bio m ar kers t o pr e dict t o xicit y w o uld be a n e xtr e m ely valua ble t o ol t o c o m ple m e nt t he c a nc er -s pecific geriatric assess m e nt t o g uide the clinicia n in m a kin g tr eat m e nt decisio ns a n d a v oid e xc essive t o xicit y in t his p o p ulatio n. T his pr o p os al ai ms t o e valuat e cir c ulatin g m ar kers of infla m m atio n as p ot e ntial m ar kers pr e dictive of t o xicit y a m o n g older w o m e n wit h m et ast atic br east c a nc er . T his class of m ar kers w as c h os e n bas e d o n t heir c orr elatio n wit h p h ysic al f u nctio n, f u nctio nal decline, a n d m ort alit y in t he ge ner al geriatric p o p ulatio n , as w ell as e m er gin g e vide nc e of t heir s ecr etio n b y s e nes c e nt c ells ass ociat e d wit h t he a gin g pr oc ess. I n a d ditio n t o t o xicit y, t his st u d y will als o ass ess f or a c orr elatio n bet w ee n bas eline m ar kers of c hr o nic infla m m atio n a n d ot her i m p ort a nt o ut c o m es s uc h as f u nctio nal decline, a n d tr eat m e nt m o dific atio n. Le vels of cir c ulatin g pr o -infla m m at or y m e diat ors s uc h as I L -6 a n d T N F -alp ha, D -di m er, a n d plas min o ge n activat or in hibit or ( P AI) -1, incr eas e wit h a ge.7 3 -7 5 T hes e m ar kers ar e pr o p os e d t o ac c eler at e t he a gin g pr oc ess a n d e xac er bat e m ultiple a ge -r elat e d dis eas es.76-78 T her e is a c o -sti m ulat or y aff ect bet w ee n m ar kers of infla m m atio n a n d pr o -t hr o m b otic f act ors. C yt o kines s uc h as T N F-α a n d I L -6 sti m ulat e pr o d uctio n of pr o -t hr o m b otic f actors s uc h as P AI-1 a n d fibrin o ge n.7 9 I n t ur n, D-di m er, a m ar ker of t he clottin g pr ocess, has been s h o w n t o in d uc e s y nthesis a n d r eleas e of c yt o kines I L -1 B, I L -6, a n d P AI -1.8 0 Like wis e, w he n vas c ular c ell a d hesio n m olec ule ( V C A M) is e x p os e d t o infla m m at or y m ar kers T N F - α a n d I L -1 B, it is clea ve d t o s olu ble (s) -V C A M, w hic h is ele vat e d in patie nts wit h a ge - r elat e d dis eas es.8 1 T h us, w e r ef er t o m ar kers of infla m m atio n a n d c oa g ulatio n dis c uss e d in t his pr o p os al c ollectively as ‘infla m m at or y m e diat ors’. S e ver al st u dies ha ve s h o w n t hat infla m m at or y m e diat ors c orr elat e wit h m eas ur es of p h ysical f u nctio n, a n d ar e ele vat e d t o a gr eater de gr ee in fr ail patie nts t ha n in a ge -m at c he d, n o n -fr ai l c o ntr ols.1 0-1 6 A st u d y of 1 1 0 patie nts > 7 5 years de m o nstr at e d t hat a c o m binatio n of infla m m at or y m ar kers ( T N F-α, I L -6, C R P) a n d lo w alb u min c orr elat e d wit h lo w er p h ysical f u nctio n s c or es, in de pe n de nt of a ge, s e x, b o d y m ass in de x ( B MI), s m o kin g st at us, n u m ber of c o -m or biditie s a n d n u m ber of m e dic atio ns8 2 I n t he ge ner al geriatric p o p ulatio n, ele vat e d c hr o nic infla m m at or y a n d pr o -c oa g ula nt m ar kers pr e dict f u nctio nal decline.8 3 -9 0 An a nalysis of dis a ble d w o m e n ≥ 6 5 years s h o wed hig her I L -6 le vels at bas eline w er e ass ociat e d wit h hig her le vels of f u nctio nal decline inclu din g decr eas e d m o bilit y, activities of daily livin g deficits, incr eas e d w alkin g li mit atio ns a n d decr eas e d w alkin g s pee d, c o m pare d t o w o m e n wit h lo w I L-6 le vels.8 7 T hese"
63,page_63,"Allia nc e A1 7 1 6 0 1 6 4 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 m ar kers als o c orr elat e wit h f u nctio nal decline aft er h os pit alizatio n a n d p ost o per ative c o m plic atio ns fr o m o nc olo gic s ur ger y.85, 91 Mar kers of c hr o nic infla m m atio n a n d c oa g ulatio n ar e als o ass ociat e d wit h all -c a us e m ort alit y ris k in t he elderly8 3, 8 4, 8 8, 9 0 I n a p o p ulatio n of c o m m u nit y dw ellin g a d ults ( m ea n a ge 7 8), s olu ble (s) -V C A M w as in de pe n de ntly c orr elat e d wit h p o or er f u nctio nal st at us at bas eline ( H R 1. 2, p = 0. 0 0 2).8 8 Aft er a djustin g f or f u nctio nal st at us, de m o gr a p hic f actors a n d c o m or bidities, hig her plas m a s -V C A M, D -di mer, a n d I L -6 c o nc e ntr atio ns w ere in de pe n de ntly r elat e d t o m ort alit y wit hin 4 years. I nfla m m at or y m e diat ors c a n ha ve gr eater pr e dictive a bilit y a m o n g patie nts wit h o ut bas eline f u nctio nal i m pair m e nts, s u g gestin g t hey m a y ide ntif y pr e -fr ail patie nts t hat m a y n ot ot her wis e ha ve bee n ide ntifie d wit h o ut e xt e nsive geriatric ass ess m e nt t estin g8 3, 9 0, a n d 9 2 Pr e vio us st u dies ha ve de m o nstr at e d t he utilit y of infla m m at or y m ar ker m eas ur e m e nt in c a nc er patie nts. I n a st u d y e valuatin g gait s pee d of 3 2 9 older participa nts wit hin t w o p h ysic al activit y int er ve ntio n st u dies, t h os e wit h a n incr easin g n u m ber of ele vat e d infla m m at or y m ar kers (I L-6, T N F R 2, a n d D -di mer) ha d lo w er gait s pee ds ( linear tr e n d p < 0. 0 0 0 1; T a ble 1). T his eff ect w as m or e pr o n o unce d a m o n g t he 6 % of patie nts t hat w er e c a nc er s ur viv ors (linear tr e n d p = 0. 0 0 9). T he patie nts wit h a c a nc er dia g n osis a n d t w o ele vat e d bio m ar kers ha d a gait s pee d of 0. 8 8 m et ers/s ec o nd ( +/ -0. 3 7), w hic h is w ell belo w t he n or m al gait s pee d of 1. 0 m/s ec. T he gr o u p of c a nc er s ur viv ors als o ha d a clinic ally m ea nin gf ul slo w er gait s pee d c o m par e d t o t he gr o u p wit h o ut a c a nc er dia g n osis a n d t hr ee ele vat e d bio m ar kers ( -0. 2 0 m/s ec). T his st u d y in dic at es cir c ulatin g m ar kers of infla m m atio n c a n ide ntif y c a nc er patie nts in nee d of t ar get e d int er ve ntio ns t o pr e ve nt f urt her f u nctio nal decline.9 3 I n vestigat ors o utside of t he Unit e d St at es ha ve r ec o g nize d t hat s yst e mic infla m m atio n pla ys a m ajor r ole in t he decline of c a nc er patie nts, es pecially in t er ms of n utritio n a n d p h ysic al f u nctio n. T he s yst e mic inflam m atio n -bas e d Glas g o w Pr o g n ostic S c or e ( G P S), bas ed on le vels of C-r eactive pr ot ein ( C R P) a n d h y p oalb u mine mia, w as derive d as a s urr o gat e of s yst e mic infla m m at or y st at us. Dat a fr o m 8, 3 3 3 patie nts fr o m 2 8 st u dies in patie nts wit h o per a ble c a nc er de m o nstr at e t he G P S w as a n in de pe n de nt pr e dict or of s ur vival ( H R r a n ge 1. 5 – 5. 1).9 4 F o urt ee n of t hes e st u dies in v olve d patie nts wit h c olor ect al c a nc er a n d t he pr o g n ostic sig nific a nc e of t he G P S w as in de pe n de nt of st a ge, pat h olo gic al f eat ur es, a nd c o m or bidit y. Si milar pr o g n ostic a bilit y of t he G P S w as s ee n in 1 1 st u dies in v olvin g 1, 5 04 patie nts wit h m et ast atic c a nc er. I n a st u d y of 5 6 patie nts wit h a d va nc e d -st a ge c olor ect al c a nc er, t he G P S n ot o nly pr e dict e d s ur vival, b ut it als o pr e dict e d t o xicit y t o c he m other apy95 A hig her G P S s c or e c orr elat e d wit h hig her gr a de 2/ 3 diarr hea a n d hig her incide nc e of grade 2/ 3 t o xicit y c o m par e d t o t h os e wit h lo w er s c or es ( p = 0. 0 23 a n d 0. 0 1 5 r es pectively). Ot her c yt o kines inclu din g I L-1 β, I L -6, I L -2, I L -1 2, I L -8, T N F -α, MI P -1 α, a n d MI P -1 β c orr elated wit h clinic al o ut c o m es. E m er gin g da t a s u g gest c ellular s e nes c e nc e is a n u n derlyin g pr oc ess c o ntrib utin g t o t he incr eas e in cir c ulatin g infla m m at or y a n d pr o-t hr o m b otic f act ors ass ociat e d wit h f u nctio nal decline a n d m ort alit y in t he elder ly.1 8, 2 9 S e nes c e nt c ells ac c u m ulat e wit h a ge as a r eactio n t o lif e-lo n g c ellular str ess. Alt h o u g h s e nes c e nt c ells ar e n ot mit otic ally active, t he y ac q uir e a s e nes c e nc e-ass ociat e d s ecr etor y p he n ot y pe ( S A S P), wit h incr ease d pr o ductio n of pr oteins in v olve d in c hr o nic infla m m atio n a n d c oa g ulatio n, ver y si milar t o t he m ar kers ass ociat ed wit h p o or er p h ysic al f u nctio n a n d m ort alit y in t he elderl y.9 6 -9 7 T her ef or e, t his pr o p os al inclu des s o m e m ar kers of c hr o nic infla m m atio n t hat ar e part of t he S A S P t o e valuat e if t hey ar e ele vat e d in patie nts w h o e x perie nc e d a d vers e o ut c o mes wit h c a ncer tr eat m e nt."
64,page_64,"Allia nc e A1 7 1 6 0 1 6 5 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 Alt h o u g h c hr o nic infla m m at or y m e diat ors ha ve n ot bee n est a blis he d as tr ue a gin g bio m ar kers, t he f act t hat t he y c orrelat e wit h m eas ur es of p h ysic al st at us, f u nctio nal decline, a n d m ort alit y in t he older a d ult p o p ulatio n s u g gests t he y m a y r eflect u n derlyin g biolo gic pr oc ess es t hat c o uld pr e dict a patie nt’s ris k of t o xicit y fr o m ca ncer treat m e nt a n d t her ef ore, t heir a bilit y t o t oler at e it. T he le vels of infla m m at or y m e diat ors c a n be m eas ur e d wit h E LI S A ass a ys o n plas m a s a m ples c ollect e d d urin g blo o d dr a w s r o utinely d o ne f or c a ncer m a na ge m e nt. T her ef ore, t he m eas ure m e nt of t hes e le vels c o uld bec o m e a n efficie nt way of pr o vidin g t he o nc olo gist insig ht int o p ot e ntial t oler a nc e of c a nc er t her a p y a n d pr o vide g uida nc e as t o t he m ost a p pr o priat e r e gi m e ns a n d d os es t o pre ve nt e xcessive t o xicit y f or the older patie nt. 1 4. 1. 2 O bje cti ves • T o e x plor e t he ass ociatio n bet w ee n bas eline c hr o nic infla m m at or y m e diat or le vels a n d de velo p m e nt of a d vers e e ve nts. • T o e x plor e t he ass ociatio n bet w ee n bas eline c hr o nic infla m m at or y m e diat or le vels a n d tr eat m e nt m o dific atio n. • T o e x plor e t he ass ociatio n bet w ee n bas eline c hr o nic infla m m at or y m e diat or le vels a n d bas eline p h ysic al f u nctio n as ass ess e d b y t he c a nc er -s pecific geriatric ass ess m e nt. • T o e x plor e t he ass ociatio n bet w ee n bas eline c hr o nic infla m m at or y m e diat or le vels a n d decline in p h ysic al f u nctio n as ass ess e d b y t he c a nc er -s pecific geriatric ass ess m e nt. 1 4. 1 . 3 Met h o ds V -Ple x pa nels ar e 1 0 -s p ot 9 6-w ell plat es. I n divid ual pa nels m eas ur e 1 0 c yt o kines i m p ortant in infla m m at or y r es p o ns es a n d i m m u ne s yst e m r e g ulatio n, a n d w e a nticipat e r u n nin g t hr ee V -ple x pa nels f or a t ot al of 3 0 a nalyt es t est e d. T hes e 1 0 -s p ot ass a ys c a n detect s ecr eted bio m ar kers a n d ass ess c yt o kines i m p ort a nt in c har act erizin g T H1 a n d T H2 s u bs ets of T c ells i m p ort a nt in s e ver al infla m m at or y dis or ders. We will als o r u n n o n 1 0-s p ot pa nels f or T N F R- 1, T N F R -2, a n d D -di m er. T he Mes o S c ale Dis c o ver y ( M S D) platf or m will be utilize d f or t estin g ( Mes o S c ale Dis c o ver y R oc k ville, Mar yla n d). O ur pr o p os e d st u dies r e q uir e 1 0 0 u L of s a m ple per 1 0 a nalyt es t est e d o n t he V-Ple x 1 0 -s p ot platf or m. Sinc e w e pla n t o us e 3 s e par at e V-Ple x pa nels, w e a nticipat e usin g a p pr o xi m at ely 3 0 0 u L of s a m ple t o c har act erize e x pr essio n of 3 0 c yt o kines. Ad ditio nal m ar kers bein g t est e d in s e par at e kits inclu de T N F R -1 a n d T N F R - 2, as w ell as D -di m er, w hic h will a d d a n ot her 2 0 0 u L of s a m ple r e q uir e m e nt. T her ef ore, the t ot al mini m u m s a m ple r e q uir e m e nt is 5 0 0 u L of plas m a. Ad ditio nal s a m ple w o uld be f a v or e d, sinc e at least 2 0 % a d ditio nal s a m ple m a y be r e q uir e d f or err or a n d or pipettin g loss es. T he V-Ple x kits ar e desig ne d f or t he a nalysis of all or a n y c o m binatio n of t hes e c yt o kine bio m ar kers in c ell c ult ur e s u per nat a nts, s er u m, plas m a, a n d urine. P las m a s a m ples ar e r e q uir e d f or all t estin g , w hic h will be r u n in d u plic at e usin g t he f ollo win g kits:"
65,page_65,"Allia nc e A1 7 1 6 0 1 6 6 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 KI T# 1: I F N-g a m m a, I L -1 bet a, I L -2, I L -4, I L -6, I L -8, I L -1 0, I L -1 2 p7 0, I L -1 3, T N F -al p h a Le vel of det e ctio n : I F N-γ: 0. 0 4 p g/ m L I L-2: 0. 2 2 p g/ m L I L-4: 0. 1 4 p g/ m L I L-5: 0. 0 7 p g/ m L I L-6: 0. 6 1 p g/ m L K C/ G R O: 0. 2 4 p g/ m L I L-1 0: 0. 9 5 p g/ m L I L-1 2 p 7 0: 9. 9 5 p g/ m L T N F -α: 0. 1 3 p g/ m L KI T# 2: Eot a xi n, MI P -1 bet a, Eot a xi n -3, T A R C, I P -1 0, MI P -1 al p h a, I L -8, M C P -1, M D C, M C P -4 Le vel of det e ctio n: E ot a xin: 3. 2 6 p g/ m L MI P -1 β: 0. 3 7 p g/ m L E ot a xin -3: 1. 7 7 p g/ m L T A R C: 0. 2 2 p g/ m L I P-1 0: 0. 3 7 p g/ m L MI P -1 α: 3. 0 2 p g/ m L I L-8( H A): 9 5. 6 p g/ m L M C P -1: 0. 0 9 p g/ m L M D C: 1. 2 2 p g/ m L M C P -4: 1. 6 9 p g/ m L KI T# 3: C R P, I C A M -1, S A A, V C A M -1 Le vel of det e ctio n: S A A: 1 0. 9 p g/ m L C R P: 1. 3 3 p g/ m L V C A M -1: 6. 0 0 p g/ m L I C A M-1: 1. 0 3 p g/ m L KI T# 4: T N F R 1 a n d T N F R 2 T N F -R 1: I ntr a-ass a y C. V.'s ar e 6. 9 %, 3. 1 %, a n d 4. 2 % at 6 1. 0 1, 4 4 2 6. 3, a n d 3 8 4 1. 2 p g/ m L r es pectively. T N F -R 2 : I ntr a-ass a y C. V.'s ar e 2. 6 %, 3. 6 %, a n d 3. 4 % at 1 2 6. 6, 7 1 5 8. 6, a n d 6 1 2 0. 5 p g/ m L r es pectively."
66,page_66,"Allia nc e A1 7 1 6 0 1 6 7 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 KI T# 5: D -di m e r Le vel of det e ctio n: 1 1 0 - 2, 0 0 0 n g/ m L T he I m m u n oc he mic al C or e La b or at or y at Ma y o Clinic. T he I C L is c ertifie d by b ot h t he C olle ge of A m eric a n P at h olo gists ( C A P # 1 8 0 8 2 0 1, A U I D # 1 1 8 3 8 32) a n d t he De part m e nt of Healt h a n d Hu m a n S er vic es ( C LI A I D # 2 4 D 0 8 6 1 2 6 5). Re g ulat or y r e q uir e m e nts inclu de t h or o u g h t est validatio n, d oc u m e nt ation, st a n dar dize d t est pr oc e d ur es a n d r e vie w of q ualit y c o ntr ol m ar kers. 1 4. 1. 4 A n al ys es Bas eline c hr o nic infla m m at or y m e diat or le vels will be s u m marize d a n d pr es e nt ed des criptively f or all patie nts. T he ass ociatio n bet w ee n bas eline c hr o nic infla m m at or y m e diat or le vels a n d t he r at e of a d vers e e ve nts a n d tr eat m e nt m o dific atio ns will be ass essed gr a p hic ally. L o gistic r e gr essio n m o dels will als o be utilize d in a n e x plor at or y f as hio n t o ass ess t hes e ass ociatio ns. T o e xa mine t he ass ociatio n bet w ee n bas eline c hr o nic infla m m at or y m e diat or le vels a n d t he bas eline geriatric ass ess m e nt s c or es, w e will us e gr a p hic al m ea ns a n d S pear m a n’s c orr elatio n c oefficie nt. E x plor at or y linear r e gr ession m o dels will als o be utilize d f or t his ai m. T he ass ociatio n bet w ee n bas eline c hr o nic infla m m at or y m e diat or le vels a n d t he c ha n ge in t he geriatric ass ess m e nt t hr o u g h ti m e will be a nalyze d gr a p hic ally a n d wit h e x plor at or y r e peat e d m eas ur es m o dels. 1 4. 2 P h ar m ac o ge n o mi cs : ( Alli a n ce A1 7 1 6 0 1 -S T2 ): Ge n eti c de t er mi n a nts of P al boci cli b Effi c ac y a n d t o xi cit y i n t h e el derl y Allia nc e A1 7 1 6 0 1 -S T 2 will e valuat e ge netic det er mina nts of palb ociclib effic ac y a n d t o xicit y in elderly patie nts wit h estr o ge n r ec e pt or p ositive, H E R 2 ne gative m et ast atic br east c a ncer 1 4. 2 . 1 B ac k gr o u n d M ultiple e n d ocrine t her a p y o ptio ns e xist f or tr eat m e nt a n d pr e ve ntio n of br east c a nc er in p ost -m e n o pa us al w o m e n wit h estr o ge n r ec e pt or p ositive br east (H R p ositive) c a nc ers.98- 1 0 0Ar o m at as e in hibit ors ( AI) s uc h as letr oz ole, a nastr oz ole a n d e xe m est a ne w hic h f u nction b y in hibitin g t he ar o m at as e e nz y m e ( C Y P 1 9), ha ve i m pr o ve d t he r ec urr e nc e r at es of br east c a nc er aft er 5 years of t a m o xif e n tr eat m e nt c o m par e d t o plac e b o.1 0 0 Ho w e ver, sid e eff ects n ot a bly m us c ulos kelet al s y m pt o ms, fr o m AI t her a p y ha ve le d t o int oler a nc e a n d s u bse q uent dis c o ntin uatio n of tr eat m e nt.1 0 1-10 2 Dat a ac c u mulat e d o ver t he perio d n o w s u g gests t hat the be nefits ass ociat e d wit h pr olo n ge d e n d ocrine t her a p y s h o uld be ba la nc e d wit h tr eat m e nt t oler a bilit y a n d fr act ur e ris ks1 03 P ost -m e n o pa us al w o m e n wit h m et ast atic H R p ositive br east c a nc ers ar e tr eat e d wit h fulvestr a nt w hic h acts diff er e ntly fr o m t he AIs b y t ar getin g t he estr o ge n r ec e pt or. As a n a nt a g o nist, f ulvestr a nt bin ds t o estr o ge n r ec e ptors c o mpetitively o n t u m ors a n d ot her tiss ue t ar gets, pr o d ucin g a n uclear c o m ple x t hat c a us es a d os e-r elat e d d o w n-r e g ulatio n of estr o gen r ec e pt ors a n d in hibits t u m or gr o wt h.10 4 F or a d va nc e d m et ast atic br east c a nc ers e x hibitin g b ot h H R -p ositive a n d h u m a n e pider m al gr o wt h f act or r ec e pt or 2 ( H E R 2) -ne gative c har act eristics, i m pr o ve d pr o gr essio n fr ee s ur vival has bee n ass ociat e d wit h tr eat m e nt o ptio ns t hat inclu de a n AI or f ulvestr a nt t o get her wit h a c yclin -de pe n de nt kinas e ( C D K) 4/6 in hibit or s uc h as p alb ociclib.1 0 5 -10 7 P alb ociclib has bee n s h o w n t o s pecific ally in hibit C D K 4/ 6 b y bloc kin g t he pr o gr essio n of c ells fr o m G 1 int o S p has e of t he c ell c ycle a n d r es ultin g in r e d uc e d c ellular pr olif er atio n of E R -p ositive br east c a nc er c ell lines 1 0 8, 1 0 9 . Re p orts in dic at e t hat palb ociclib e n ha nc es t he"
67,page_67,"Allia nc e A1 7 1 6 0 1 6 8 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 effic ac y of c yt ost atic a ge nts, s uc h as e n d ocrine t her a p y or H E R 2 -t ar get e d t her a p y, b ut decr eas es t he effic ac y of c ytot o xic c he m ot hera p y s uc h as wit h c ar bo platin a n d d o x or u bicin 1 1 0 -1 1 2 . Clinic al trials ha ve s h o w n sig nific a nt be nefit in pr o gr essio n fr ee s ur vival f or w o men wit h m et ast atic br east c a nc er o n palb ociclib wit h or wit h o ut prior AI (letr oz ole) or f ulvestr a nt tr eat m e nt. T he variatio n in m e dia n P F S a m o n g t he patie nts ha ve r a n ge d fr o m 1 0. 2 m o nt hs ( 9 5 % CI, 5. 7 – 1 2. 6) f or t he letr oz ole gr o u p t o 2 0. 2 m o nt hs ( 9 5 % CI, 1 3. 8 – 2 7. 5) f or t he palb ociclib -letr oz ole gr o u p s u g gestin g t hat ot her f act ors ass ociat e d wit h palb ociclib c o uld be c o ntrib utin g t o t he clinic al o ut c o m es.10 5 Si milar P F S tr e n ds w er e s een in t he st u d y of palb ociclib wit h/ wit h o ut f ulvestr a nt 1 06, 107. T ur ner et al.1 0 6 r e p orte d a m e dian P F S of 9. 2 m o nt hs ( 9 5 % CI, 7. 5 – n ot esti m a ble) f or palb ociclib -f ulvestr a nt gr o u p a n d 3. 8 m o nt hs ( 9 5 % CI, 3. 5 – 5. 5) f or t he plac e b o -f ulvestr a nt gr o u p,1 0 6, w hile Crist of a nilli et al1 0 7r e p ort e d a m e dia n P F S of 9 .5 m o nt hs ( 9 5 % CI, 9 .2 – 1 1.0) in t he palb ociclib -f ulvestr a nt gr o u p a n d 4 .6 m o nt hs ( 9 5 % CI, 3 .5– 5 .6) in t he plac e b o -f ulvestr a nt gr o u p. All of t hes e trials ha ve s h o w n variat io ns in t he clinic al o ut c o m es 1 0 5-1 07. O ne f act or t hat c o uld in part e x plain s o m e of t hes e variatio ns mig ht be t he r ole of in herit e d ge netic varia nts w h ose pr ot eins m a y be r es p o nsible f or t he biotr a nsf or m atio n of t he AIs, f ulvestr a nt a n d palb ociclib. S e ver al r e p orts o n c a n didat e ge nes a n d ge n o m e wide ass ociatio n st u dies ( G W A S) ha ve c orr elat e d sin gle n ucle otide p oly m or p his ms ( S N P) in t he estr o ge n m et a b olis m r elat e d pat h w a y ge nes wit h r es p o ns e t o e n d ocrine t her a p y f or br east c a ncer. 1 14 -1 18 T o dat e, t here is n o st u d y t hat has lo o ke d at ge netic varia nts ass ociat e d wit h palb ociclib biotr a nsf or m ation pat h w a y ge nes wit h r es p o nse t o t he treat m e nt in m et astatic br east ca ncer, let alo ne elucidat e h o w t hes e p oly m or p his ms ar e ass ociat e d wit h t oler a bilit y a n d r es p o ns e t o palb ociclib t her a p y in t he elderly, s pecific ally w o m e n a ge d 7 0 years a n d o ver. T his pr o p os al pla ns t o elucidat e t he ge netic det er mina nts of palb ociclib effic ac y in p ost -m e n o pa us al w o m e n wi th m et ast atic H R p ositive , H E R 2 ne gative br east c a nc ers u n der g oin g tr eat m e nt in t he par e nt st u d y. P al boci cli b m et a bolis m, cell c ycl e pr ot ei ns, ge n es a n d ge n eti c v ari a nts : P alb ociclib is pri m arily m et a b olize d b y C Y P 3 A e nz y m e a n d u n der g oes s ulf o natio n b y S U L T 2 A1 e nz y me a n d u n der g oes ac ylatio n a n d gluc ur o nidatio n as min or m et a b olic pat he w a ys.1 0 9, 1 1 9 -121 . P a lb ociclib is als o a hig hly s elective in hibit or of C D K4 a n d C D K6 kinas es a n d in lo w na n o m olar c o nc e ntr atio ns bloc ks r etin o blast o m a ( R b) ge ne pr ot ein pr o d uct p R b.108 C yclin -de pe n de nt kinas es ( C D Ks) ar e s erine/t hr e o nine kinas es t hat pla y a ke y r ole in r e g ulatin g c ell c ycle pr o gr essio n b y ass ociatin g wit h c yclins. T he c ell c ycle is a tig htly r e g ulat e d pr oc ess of five distinct p has es: G 0 ( q uies c e nc e) f ollo w e d b y G 1 ( pr e-D N A s y nt hesis), S ( D N A s y nt hesis), G 2 ( pr e-divisio n) a n d M ( c ell divisio n) wit h t he G 1 t o S p has e bein g t he ke y c hec k p oint in pr ot ectin g t he c ell fr o m a b n or m al r e plic atio n.1 0 8 C D K4 a n d C D K6 int er act wit h c yclin D 1 early in t his c hec k p oint p has e r es ultin g in t he p h os p h or ylatio n of p R b a n d allo win g t he r eleas e of tr a ns criptio n f act or E 2 F w hic h lea ds to tr a ns criptio n of ot her t ar get ge nes t o allo w pr o gr essio n t o t he S p has e.1 0 8 C D K activit y is t h us tig htly r e g ulat e d at s e ver al le vels b y C yclin D a n d r etin o blast o m a pr ot eins a n d b y C D K in hibit or y pr ot eins t he I N K4 f a mily ( p 1 6, p 1 5, p 1 8, p 1 9) a n d CI P/ KI P f a mily ( p 2 1, p 2 7, p 5 7).1 2 2 -124 T h us w he n t he c ell c ycle r e g ulat or y m ec ha nis m is alt er e d, u nc o ntr olle d c ell pr olif er atio n oc c urs w hic h is a distinctive f eat ur e of h u m a n c a nc ers.1 25 Cell c ycl e ge n es, pol y m or p his ms a n d c a n ce r : Ma n y of t he ge nes e nc o d in g t he c ell c ycle pr ot eins ar e fr e q ue ntly m ut at e d in h u m a n c a nc ers a n d t his lea ds t o u nc o ntr olle d c ell divisio n a n d t u m or gr o wt h as w ell.1 2 6 F or inst a nc e, in br east c a nc er, alt er atio ns in c ell c ycle r e g ulat ors ha ve bee n r e p ort e d t o inclu de a m plific atio n of c yclin D 1 ge ne ( 1 5-2 0 % c a ncers) a n d o ver e x pr essio n of its pr ot ein pr o d uct w hic h has bee n ass ociat e d wit h p o or clinic al o ut c o m es, t o in d ole nt estr o ge n r ec e pt or p ositive p he n ot y pe a n d t o t a m o xif e n r esist a nce"
68,page_68,"Allia nc e A1 7 1 6 0 1 6 9 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 c yclin D pr ot ein.1 0 8, 1 2 7-13 2 F u rt her m or e, st u dies ha ve bee n r e p ort e d t hat s h o w t hat in hibitin g C D K4 a n d C D K6 kinas es in d uc e G 1 arr est in s e nsitive c ell lines a n d pri m ar y b o ne m arr o w c ells a n d pr e ve nt t u m or gr o wt h in h u m a n m yelo m a xe n o gr afts.1 33-1 37 T he ge nes e nc o din g t he pr ot eins in v olve d in t he G 1 -S p has e inclu de C C N D 1 [ c yclin D 1], C C N D 2 [ c yclin D 2], C C N D 3 [ c yclin D 3], C C N E 1 [ c yclin E] (t he c yclin f a mily w hic h r e g ulat e c yclin-de pe n de nt kinas es); C D K 2 [ p 3 3], C D K 4 , a n d C D K 6 ( c yclin-de pe n de nt kinas es f or t he G 1/ S tr a nsitio n); C D K N 1 A [ p 2 1, Cip 1], C D K N 1 B [ p 2 7, Kip 1] ( CI P/ KI P f a mily c yclin-de pe n de nt kinas e in hibit ors); C D K N 2 A [ p 1 6], C D K N 2 B [ p 1 5], C D K N 2 C [ p 1 8], a n d C D K N 2 D [ p 1 9] (I N K4 f a mily c yclin-de pe n de nt kinas e in hibit ors) a n d R B 1 r etin o blast o m a ge ne. St u dies r elatin g t o ge netic p oly m or p his ms in c ell c ycle ge nes a n d ris k of s o m e c a nc ers inclu din g lu n g, bla d der, pr ost at e, br east, o varia n, e n d o m etrial, pa ncr eas, a n d c olor ect al1 3 8 -1 45 ha ve bee n p u blis he d alt h o u g h n o ne ha ve t a ke n int o c o nsider atio n t he eff ects t hes e in herit e d ge netic varia tio ns m a y ha ve o n t he effic ac y of palb ociclib w hic h s pecific ally in hibits t he C D K4/ 6 c hec k p oint. I n br east c a nc er st u dies, p oly m or p his ms s uc h as C D K N 1 B rs 2 0 6 6 8 2 7 has bee n ass ociat ed wit h s h ort e ne d dis eas e -fr ee s ur vival in patie nts wit h infiltr atin g m et ast asis-fr ee br east c a nc er1 4 6 w hile C C N D 3 rs 2 4 7 9 7 1 7 has bee n ass ociat e d wit h a n incr eas e d ris k of deat h.147 Ot her S N Ps inclu din g C C N E 1 rs 9 9 7 6 6 9, C D K N 1 A rs 3 1 7 6 3 3 6, C D K N 1 B rs 3 4 3 30, C D K N 2 B rs 3 2 1 8 0 0 5 a n d C D K N 2 A rs 3 7 3 1 2 3 9 ha ve bee n ass ociat e d wit h br east c a nc er as w ell.1 4 8 C C N D 1 rs 9 3 4 4 (C C N D 1 -0 2 A8 7 0 G or C C N D 1 G 8 7 0 A) t he m ost st u die d S N P in C C N D 1 a n d pr e vio usly r ef err e d t o as C C N D 1 rs 6 0 3 9 6 5 has bee n s h o w n t o be ass ociat ed wit h br east c a nc er s ur vival in C hines e s u bjects,1 4 9 a n d has als o bee n ass ociat e d wit h br east c a nc er ris k a n d p o or er br east c a nc er s pecific s ur vival in patie nts wit h m et ast atic br east c a nc er .1 5-15 2 P oly m or p his ms in C Y P 3 A 41 5 3, 1 54 a n d in S U L T 2 A 11 5 5, 15 6 ha ve als o bee n ass ociat e d wit h br east a n d ot her c a ncers. T hes e ass ociatio ns of t he c ell c yc le ge ne S N Ps wit h br east c a nc er m a y be influe nc e d b y palb ociclib’s actio n of in hibitin g C D K4/ 6 in t he G 1 -S tr a nsitio n p oint t her e b y m o dif yin g clinic al r es p o ns e a n d t o xicit y o ut c o m es. T his st u d y is ideal t o elucidat e t he ass ociatio ns of c ell c ycle S N Ps in t he pr es e nc e of palb ociclib o n br east c a nc er in t he elderly. We n ot e t hat p oly m or p his ms in ar o m at as e C Y P 1 9 A , C Y P 2 A 6 a n d estr o ge n r ec e pt or E R S 1 ge nes1 5 7-160, t he t ar gets f or AI in hibit ors a n d fulvestr a nt r es pectively, ha ve als o bee n ass ociat e d with br east c a nc er. T her ef or e S N Ps in t hes e 2 ge nes u n der t he influe nc e of t heir s pecific in hibit ors c o m bine d wit h palb ociclib in t he tr eat m e nt ( c h oic e of AI or f ulvestr a nt m a de at t he dis cr etio n of t he tr eatin g in vestigat or) will be st u die d f or ass ociatio ns w it h clinic al r es p o ns e a n d t o xicit y t o palb ociclib. F urt her m ore, t he ge netic varia nts in palb ociclib r elat e d ge nes will be c or r elat e d wit h t he pri m ar y o bjective of t he st u d y w hic h inclu des t oler a bilit y (a d vers e e ve nts ); a n d wit h t he s ec o n dar y o bjectives w hic h inclu de t o xicit y, r es p o ns e t o tr eat m e nt, a n d o ver all s ur vival. We h y p ot hesize t hat in herit e d ge netic p oly m or p his ms in c ell c ycle pat h w a y ge nes a n d in ge nes t hat m et a b olize palb ociclib will c orr elat e wit h clinic al o ut c o m es in elderly patie nts u n der g oin g palb ociclib tr eat m e nt f or estr o ge n r ec e pt or p ositive, H E R 2 ne gative m et ast atic br east c a nc er. We f urt her h y p ot hesize t hat ge nes in C Y P 1 9 A1 , C Y P 2 A6 a n d E S R 1 will als o c orr elat e will t o xicit y o ut c o m es in t his st u d y. We pr o p os e t o ac hie ve t his h y p ot hesis b y ge n ot y pin g patie nt D N A s a m ples f or S N Ps in t he c ell c ycle ge nes inclu din g C C N D 1, C C N D 2, C C N D 3 , C C N E1 , C D K2 , C D K4 , C D K6 , C D K N1 A , C D K N1 B , C D K N2 A , C D K N2 B, C D K N2 C , C D K N2 D , C Y P 3 A 4, C Y P 1 9 A 1, C Y P 2 A 6, E S R 1 R B 1 a n d S U L T 2 A 1 a n d c orr elat e t hes e S N Ps t o effic ac y a n d t o xicit y of palb ociclib."
69,page_69,
70,page_70,"Allia nc e A1 7 1 6 0 1 7 1 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 Ge n ot y pin g T he Age na i P L E X ( pr e vio usly c alle d s e q ue n o m) ge n ot y pin g pr ot oc ol in v olves P C R a m plific atio n of D N A usin g S N P s pecific pri m ers, f ollo w e d b y a bas e e xt e nsio n r eactio n usin g t he i P L E X G old c he mistr y ( Age na Bios cie nc es, S a n Die g o, C A). T he pr ot oc ol has bee n us e d f or years a n d will briefly be des cribe d her e. S N P -s pecific P C R a n d e xt e nsio n pri m ers w er e desig ne d a n d or ga nize d int o p o ols wit h t he Ass a y Desig n S uit e ( Age na). All pri m ers w er e p ur c hase d fr o m I nt e gr at e d D N A T ec h n olo gies ( C or alville, I A). A Q C r u n was perf or m e d wit h C oriell a n d C E P H c o ntr ols, a n d r es ults w er e t est e d f or Me n delia n inc o nsist e ncies. Hot St ar T a q P oly m er as e ( Qia ge n) w as us e d f or all P C Rs. 1 5 n g of D N A w as a d de d t o eac h 5 -ul P C R r eactio n mixt ur e in a 3 8 4 -w ell micr otit er plat e. T he P C R c o n ditio n w as 9 4° C f or 1 5 min f or h ot st art, f ollo w e d b y 4 5 c ycles of de nat urin g at 9 4° C f or 2 0 s ec, a n nealin g at 5 6° C f or 30 s ec, e xt e nsio n at 7 2° C f or 1 min f or 4 5 c ycles, a n d final inc u batio n at 7 2° C f or 3 min. T he P C R pr o d ucts w er e t he n tr eat e d wit h S A P (s hri mp alkaline p h os p hat as e, Age na) f or 4 0 min at 3 7° C t he n r a m pe d t o 8 5° C f or 5 min t o r e m o ve e xc ess d N T Ps. T he final ba s e e xt e nsio n pr o d ucts wer e dilut e d in d o u ble distille d w at er a nd t he n tr eat e d wit h 6 m g of S pectr o C L E A N ( Age na) r esin per w ell t o r e m o ve c o nt a minatin g s alts. 1 0-1 8 nl of tr eat e d e xt e nsio n pr o d uct was s p ott e d t o the a p pr o priat e loc atio n o n a 3 8 4 - pa d S pectr o C HI P II ( Age na) usin g a R S 1 0 0 0 Na n o dis pe ns er ( Age na, S a n Die g o, C A). A Mass A R R A Y Analyzer C o m pact M A L DI -T O F M S ( Age na) w as us e d f or dat a ac q uisitions fr o m t he S pectr o C HI P. All r es ult a nt ge n ot y pin g c alls w er e perf or m e d in r eal ti m e b y t he Mass A R R A Y T y per A nalyzer v 4. 0. 2 6. 7 3 ( Age na) 1 4. 2. 4 A n al ys es S N P a nalysis : Res ults fr o m ge n ot y pin g will be s e nt t o t he bioinf or m atics/st atisticia ns f or a nalys es t o c orr elat e t he S N Ps wit h t he pri m ar y o bjective of t he st u d y w hic h is a d verse e ve nts . T he S N Ps will als o be c orr elat e d t o t he s ec o n dar y o bjectives w hic h inclu de t o xicity, r es p o ns e t o tr eat m e nt a n d o ver all s ur vival. 1 4. 2. 5 Hy pot h es es 1. P atie nts wit h hig her bio m ar ker le vels ha ve a n incr eas e d incide nc e of gr a de 3 + a d verse e ve nts. 2. P atie nts wit h hig her bio m ar ker le vels ha ve hig her r at es of tr eat m e nt m o dific atio n d urin g a dju va n t t her a p y. 3. P atie nts wit h hig her bio m ar ker le vels ha ve p o or er bas eline perf or m a nc e st at us and hig her r at es of perf or m a nce st at us decline d urin g a dju va nt t her a p y. 1 4. 2. 6 St atisti c al a n al yses Tr eat m e nt m o dific atio n is define d as a n y d os e r e d uctio n or o missio n d urin g t he c o urs e of t he st u d y. Bio m ar ker le vels will be c o m par e d t o gr a de 3 + a d vers e e ve nt incide nc e ( as m eas ur e d b y t he C T C A E versio n 5 . 0), rat e of treat m e nt m o dific atio n, baseline perf or m ance st at us a n d perf or m a nc e st at us t hr o u g h o ut t he c o urs e of t he s t u d y des criptively a n d gr a p hic ally. An y t estin g d o ne will be d o ne in a n e x plor at or y m a n ner."
71,page_71,"Allia nc e A1 7 1 6 0 1 7 2 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 1 4. 3 P h ar m ac o ki n eti cs : ( Alli a nce A 1 7 1 60 1-P P 1) P o p ul ati o n P h ar m ac o ki n etics of P al boci cli b Allia n c e A1 7 1 6 0 1 - P P 1 will e valuat e if palb ociclib e x p os ur e ( A U C/ C ma x) is r elat e d t o c ha n ge fr o m bas eline in ne utr o p hil n u m bers i. e. ne utr o pe nia. 1 4. 3. 1 B ac k gr o u n d a n d Hy pot h es es P alb ociclib is a s elective in hibit or of c yclin -de pe n de nt kinas es 4 a n d 6 ( C D K4 a n d C D K6). T he F D A a p pr o ve d r e gi m e n is a 1 2 5 m g c a ps ule of palb ocicl ib t a ke n or ally o nc e daily f or 2 1 c o ns ec utive da ys f ollo w e d b y 7 da ys off tr eat m e nt c o m bine d wit h letr oz ole 2. 5 m g P O daily, o n 2 8 -da y c ycles. P alb ociclib is slo wly a bs or be d wit h a T m a x of 6 -1 2 h f ollo win g a n or al 1 2 5 m g d os e, wi th a m ea n C ma x of 1 3 3 ( +/ -S D 1 8. 6) n g/ m L.. T he t er minal eli minatio n half -lif e is m ea n 2 9 +/- 5 h, a n d st ea d y st at e c o nc e ntr atio ns ar e us ually r eac he d in 8 da ys. T he palb o ciclib is 8 5 % b o u n d t o plas m a pr ot eins a n d its ge o m etric m ea n a p par e nt v olu m e of distrib utio n ( Vz/ F) w as 2 5 8 3 L wit h a c oefficie nt of variatio n ( C V) of 2 6 %. T he ge o m etric m ea n a p par e nt or al clear a nc e ( C L/ F) of palb ociclib w as 6 3. 1 L/ hr ( 2 9 % C V). I n 6 healt h y m ale s u bjects given a sin gle or al d os e of 1 4C - palb ociclib, a m e dia n of 9 1. 6 % of t he t ot al a d minist er e d r a dioactive d os e w as r ec o ver e d in 1 5 da ys; f ec es ( 7 4. 1 % of d os e) w as t he m ajor r o ut e of e xcr etio n, wit h 1 7. 5 % of t he d os e r ec o ver e d in urine. T he m ajorit y of t he m at erial w as e xcr et e d as m et a b olit es. P alb ociclib a bs or ptio n a n d e x p os ur e w ere ver y lo w in a p pr o xi m at ely 1 3 % of t he p o pulation u n der t he f ast e d c o n ditio n. F o o d int a ke incr eas e d t he palb ociclib e x p os ur e in t his s m all s u bs et of t he p o p ulation, b ut did n ot alt er palb ociclib e x p os ur e in t he r est of t he p o p ulatio n t o a clinic ally r ele va nt e xt e nt. T her ef or e, f o o d int a ke r e d uc e d t he int ers u bject varia bilit y of palb ociclib e x p os ur e, w hic h s u p p orts a d ministr atio n of palb ociclib wit h f o o d. C o m par ed t o palb ociclib give n u n der o ver nig ht f ast e d c o n ditio ns, t he p o p ulatio n a ver a ge ar ea u n der t he c o nc e ntr atio n -ti m e c ur ve fr o m zer o t o infinit y ( A U C (i nf)) a n d C ma x of palb ociclib incr eas ed b y 2 1 % a n d 3 8 %, r es pectively, w he n give n wit h hig h -f at, hig h-c alorie f o o d ( a p pr o xi mat ely 8 0 0 t o 1 0 0 0 c alories wit h 1 5 0, 2 5 0, a n d 5 0 0 t o 6 0 0 calories fr o m pr ot ein, car b o h y drat e, and f at, r es pectively), b y 1 2 % a n d 2 7 %, r es pectively, w he n give n wit h lo w -f at, lo w-c alorie f o od ( a p pr o xi m at ely 4 0 0 t o 5 0 0 c alories wit h 1 2 0, 2 5 0, a n d 2 8 t o 3 5 c alories fr o m pr ot ein, c ar b o h y dr at e, a n d f at, res pectively), a n d b y 1 3 % a n d 2 4 %, r es pectively, w he n m o der at e -fat, st a n dar d c alorie f o o d ( a p pr o xi m at ely 5 0 0 t o 7 0 0 calories wit h 7 5 t o 1 0 5, 2 5 0 t o 35 0 a nd 175 t o 2 4 5 c alories fr o m pr ot ein, c ar b o h y dr at e, a n d f at, r es pectively) w as give n 1 h o ur bef ore a n d 2 h o urs aft er palb ociclib d osin g. I n vitr o a n d in viv o st u dies in dic at e t hat palb ociclib u n der g oes he patic m et a b olis m in h u m a ns. F ollo win g or al a d ministr at io n of a sin gle 1 2 5 m g d os e of 1 4C palb ociclib t o h u m a ns, t he pri m ar y m et a b olic pat h w a ys f or palb ociclib in v olve d o xidatio n a n d s ulf o natio n, wit h ac ylatio n a n d gluc ur o nidatio n c o ntrib utin g as min or pat h w a ys. P alb ociclib w as t he m ajor cir c ulatin g dr u g -derive d e ntit y in plas m a ( 2 3 %). T he m ajor cir c ulati n g m et a b olit e w as a gluc ur o nide c o nju gat e of palb ociclib, alt h o u g h it o nly r e pr es e nt e d 1. 5 % of t he a d minist er e d d os e in t he e xcr et a. P alb ociclib w as e xt e nsively m et a b olize d wit h u nc ha n ge d dr u g ac c o u ntin g f or 2. 3 % a n d 6. 9 % of r a dioactivit y in f ec es a n d urin e, r es pectively. I n f ec es, t he s ulf a mic acid c o nju gat e of palb ociclib w as t he m ajor dr u g -r elated c o m p o ne nt, ac c o u ntin g f or 2 6 % of t he a d minist er e d d os e. Dat a fr o m a clinic al trial in patie nts wit h br east c a nc er s h o w e d t hat t her e w as n o dr u g int er actio n bet w ee n palb ociclib a n d letr oz ole w he n t he 2 dr u gs w er e c oa d minist er e d. I n vitr o st u dies wit h h u m a n he pat oc yt es, liver c yt os olic a n d S 9 fr actio ns, a n d r ec o m binant S U L T e nz y m es in dic at e d t hat C Y P 3 A a n d S U L T 2 A1 ar e m ainly in v olve d in t he"
72,page_72,"Allia nc e A1 7 1 6 0 1 7 3 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 m et a b olis m of palb ocicl ib. I n viv o, palb ociclib e x p os ur e w as incr eas e d b y 1. 9-f old w he n i t w as c oa d minist er e d wit h itr ac o naz ole (str o n g C Y P 3 A4 in hibit or), a n d c o -a d ministr atio n of str o n g C Y P 3 A4 in hibit ors s h o uld be a v oide d. If c o -a d ministr atio n wit h a str o n g C Y P 3 A in hibit or c a n not be a v oide d, t he daily palb ociclib d os e s h o uld be r e d uc e d t o 7 5 m g. I n vivo, palb ociclib e x p os ur e w as decr eas e d b y 8 5 % w he n it w as c oa d minist er e d wit h rif a m pin (str o n g C Y P 3 A in d uc er), a n d c o-a d ministr atio n of str o n g C Y P 3 A in d uc ers s h o uld be a v oide d. T he eff ect of m o der at e C Y P 3 A in d uc ers o n palb ociclib e x p os ur e is n ot k n o w n, a n d c o -a d ministr atio n of m o der at e C Y P 3 A4 in d uc ers s h o uld be a v oide d. C o -a d ministr ation of palb ociclib wit h m ultiple d os es of r a be pr az ole ( pr ot o n p u m p in hibit or) u n der f e d c o n ditio ns did n ot ha ve a clinic ally sig nific a nt eff ect o n palb ociclib e x p os ur e. I n vitr o, palb ociclib c a us e d ti m e -de pe n de nt in hibitio n of C Y P 3 A4. P alb ociclib incr eas e d t he midaz ola m ( C Y P 3 A s u bstr at e) A U C b y 6 1 % in healt h y s u bjects, a n d t her ef or e c o - a d ministr atio n of s ensitive C Y P 3 A s u bstr at es wit h narr o w t her a pe utic in dic es s h o uld be a v oide d. Bas e d o n prior p o p ulatio n p har m ac o kinetic a nalysis fr o m m ale a n d f e m ale patie nts tr eat e d wit h palb ociclib, neit her ge n der, a ge n or b o d y w eig ht ha d a clinic ally i m p ort a nt eff ect o n palb ociclib e x p os ur e. F urt her m or e, n o d os e r e d uctio n is nee de d in patie nts wit h mild or m o der at e r e nal i m pair m e nt, or mild he patic i m pair m e nt. N o clinic ally sig nific a nt c ha n ge in t he Q T c int er val w as det ect e d w he n palb ociclib w as a d minist er e d t o st ea d y st at e. Definitive c o nclusio ns r e gar din g a n e x p os ur e -r es p o nse r elatio ns hip f or pr o gr essio n fr ee s ur vival ( P F S) c o uld n ot be m a de bas e d o n t he li mit e d dat a at a fixe d d os e of 1 2 5 m g fr o m prior clinic al st u dies. Ho w e ver, a gr eat er r e d uctio n in a bs olut e ne ut r o p hil c o u nt is s u g gest e d t o be ass ociat e d wit h incr eas e d palb ociclib e x p os ur e. T hes e e x p os ur e eff ect r elatio ns hips f or older patie nts ( o ver 7 0 a n d o ver 7 5 years of a ge) ha ve n ot bee n define d. T he pri m ar y h y p ot hesis of t his p o p ulatio n -p har m ac o kinetic nest e d st u d y is ( 1) T hat palb ociclib e x p os ur e ( A U C/ C ma x) is r elat e d t o c ha n ge fr o m bas eline in ne utr o p hil n u m bers i. e. ne utr o pe nia. S ec o n dar y e x plor at or y h y p ot hes es ar e t hat palb ociclib e x p os ur e is ass ociat e d wit h (i) de gr ee of t hr o m b oc yt o pe nia in older patie nts (ii) p r o gr essio n fr ee s ur vival in older patie nts (iii) t hes e r elatio ns hips will be str e n gt he ne d b y c o nsider atio n of k n o w n p oly m or p his ms in palb ociclib dr u g m et a b olizin g e nz y m es ( es p ecially C Y P 3 A a n d S U L T -2 A1) a n d dr u g tr a ns p ort ers. 1 4. 3. 2 O bje cti ves: • T o r efine a p o p ulatio n p har m ac o kinetic m o del ( of S u n a n d Wa n g) usin g N O N M E M f or palb ociclib t a kin g ac c o u nt of r ele va nt intrinsic a n d e xtrinsic f act ors. • T o det er mine t he intr a patie nt a n d int er patie nt varia bilit y of palb ociclib ( A U C) in older br east c a nc er patie nts r eceivin g palb ociclib plus letr oz ole • T o e x plor e t he e x p os ur e ( A U C/ C ma x) t o xicit y (ne utr o pe nia, t hr o m b oc yt o pe nia) r elatio ns hip f or palb ociclib w he n c o m bine d wit h letr oz ole in older br east c a ncer patie nts 1 4. 3. 3 Met h o ds F or patie nts in t he st u d y w h o ar e r ec eivin g palb ociclib plus letr oz ole or f ulvestr a nt , ve n ous blo o d s a m ples f or palb ocic lib c o nc e ntr atio ns will be o bt aine d at bas eline, a n d at t he s c he d ule d f ollo w -u p clinic visit s o n da y 1 5 of c ycle 1 a n d c ycle 2, w hile still r ec eivin g st u dy dr u g t her a p y. T hes e s a m ples will ha ve t he ti m e of da y t he y w er e o bt aine d d oc u m e nt e d. A t"
73,page_73,"Allia nc e A1 7 1 6 0 1 7 4 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 t hes e f ollow u p visits a P atie nt P ha r m ac o kinetic Q uestio n naire (s ee Ap pe n dix I X ) will be fille d in w hic h will r e q uest inf or m atio n a b o ut t he prior 4 8 h d osin g of palb ociclib a n d t he c o nc o mit a nt m e dic atio ns . T his will det ail t he ti m e of da y t he last t w o d os es of st u d y dr ug w er e t a ke n, a n d r elatio ns hip of w he n t he d os es w er e t a ke n in r elatio n t o m eals. P alb ociclib plas m a c o nc e ntr atio ns will be m eas ur e d usin g a n L C -M S -M S ass a y validat e d in t he Allia nc e P har m ac olo g y/ P har m ac o kinetic c or e la b at t he Univ. of Pitts b ur g h usin g a m o dific atio n of t he validat e d a n d p u blis he d ass a y b y P a ul et al Bio m e d C hr o m at o gr. 2 0 18 Dec 1 3:e 4 4 6 9. P har m ac o kinetic p o p ulatio n dat a m o delin g of t he C mi n (tr o u g h) dr u g c o nce ntratio ns will be perf or m e d usin g N O N M E M t o derive palb ociclib s pecific A U Cs a n d t he intr a a n d int er - patie nt varia bilit y (s ee belo w f or det ails). 1 4. 3. 4 St atisti c al desig n: T he pri m ar y s cie ntific h y p ot hesis is that palb ociclib e x p os ur e ( A U C/ C ma x) is r elat e d t o c ha n ge fr o m bas eline in ne utr o p hil n u m bers i. e. de gr ee of ne utr o pe nia. P o p ul ati o n P h ar m ac oki neti c M o deli n g : We will de velo p par a m etric p o p ulatio n p har m ac o kinetics m o dels f or t he e x p os ur e of palb ociclib . T o c a pt ur e b ot h bet w ee n a n d wit hin -s u bject varia bilities in palb ociclib ex p os ur es, a n o n -linear mixe d eff ects m o del will be us e d. I n partic ular, w e will c o nsider m o dels of t he f or m 𝑦𝑖 [𝑡] = 𝛹 [𝑡,𝜃 ,𝜂𝑖 ;𝐷 ,𝑥 ] + 𝜀𝑖 [𝑡] w her e de n ot es yi [t] t he o bs er ve d plas m a c o nc e ntr atio n at ti m e t, t (t 1, …, t k), o bt aine d t hr o u g h spars e s a m plin g as pr e vio usly des cribe d, f or t he i -t h in divid ual a n d de n ot es t he vect or of p o p ulatio n par a m et ers of size p. T he q ua ntit y D de n ot es t he d os e le vel a n d x is a vect or of a d ditio nal c o variat es. T he r a n d o m vect ors i a n d = (i[t 1], …, i[t k]) ac c o u nt f or the bet w ee n a n d wit hin s u bject varia bilities r es pectively. If p ossible, n o n -linearities wit h r es pect t o ti m e will be e x plor e d. T he m o del will be fitt e d usin g first-or der c o n ditio nal m a xi m u m likelih o o d esti m atio n in t he N O N M E M pr o gr a m ( versio n 5)1 61. F or t his p ur pose it will be ass u m e d t hat t he r a n d o m eff ects i.... n ar e in de pe n de nt q-variat e m ea n -zer o n or mal r a n d o m varia bles wit h c o m m o n varia nc e i w her e q is at m ost e q ual t o p (t he di m e nsio n of t he p o p ulatio n par a m et er vect or 𝜃 ). It is als o ass u m e d t hat t he m eas ur e m e nt err ors 1, …, n ar e in de pe n de nt k -variat e m ea n -zer o n or m al vect ors wit h c o m m o n c o varia nc e m atrix. I n divid ual p har m ac o kinetic par a m et er esti m at es will be o bt aine d fr o m t he esti m at e d p o p ulatio n P K m o del f or palb ociclib . C o variat e t estin g will be perf or m e d t o ide ntif y s o ur c es of varia bilit y in e x p os ur e t o palb ociclib a m o n g in divid uals. C o variat es t hat will be t est e d inclu de: de m o gr a p hic c har act eristics, or ga n f u nctio n m ar kers, dis eas e s e verit y, ge netic m ar kers, a n d c o n c o mit ant m e dic atio ns a n d ti m e r elatio ns hip t o in gestio n of t he pr e vio us m eal. All derive d P K par a m et ers will be s u m m arize d usin g st a n dar d n u m eric al a n d gr a p hic al dis pla ys . P h ar m ac o m et ri c A n al yses: P atie nts wit h p har m ac o kinetic, ke y t o xicit y a n d effic ac y dat a will be inclu de d in t he p har m ac o m etric a nalys es. First a p o p ulatio n p har m ac o kinetic a p pr oac h will be e m plo ye d t o a nalyze t he plas m a c o nc e ntr atio n dat a f or palb ociclib. Rele va nt de m o gr a p hic a n d intrinsic / e xtrinsic f act ors will be e x plor e d f or c o variat e r elatio ns hip. Diff er e nt e m piric al Ba yesia n P K par a m et ers will be c orr elat e d initially wit h t o xicit y a n d lat er wit h effic ac y e n d p oints s uc h as t he o ver all s ur vival. P har m ac o kinetic -bio m ar ker r elatio ns hips usin g ke y m ar kers will als o be c o n d uct e d."
74,page_74,"Allia nc e A1 7 1 6 0 1 7 5 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 P o p ul ati o n P K s a m pli n g s c h e d ul e P atie nts ar e s c he d ule d t o be r e vie w e d in t he clinic o n Da y 1 5 of c ycle 1 a n d 2. Ve n o us blo o d ( 5 ml) will be o bt aine d at t he ti m e of t hes e clinic visits a n d m e dic al e valuatio ns. P atients M U S T be instr uct e d N O T t o t a ke t heir palb ociclib d os e o n t he da y of t he s e visits bef ore bein g s ee n a n d ha vin g t his blo o d s a m ple o bt aine d. Blo o d will be c ollect e d int o p ot assiu m E D T A (la ve n der t o p) t u bes, a n d plas m a s e par at e d b y c e ntrif u gatio n at 1 5 0 0 g f or 1 0 min ut es. Aliq u ots of plas m a will t he n be plac e d in la belle d p oly pr o p yle ne t u bes ( 1 m L in eac h of t w o t u bes) a n d st or e d at -7 0 t o - 8 0 oC u ntil s hip pe d o n dr y ic e t o t he Allia nc e P har m ac olo g y/ P har m ac o kinetic c or e as in dic at e d in S ectio n 6. 2 . 1."
75,page_75,"Allia nc e A1 7 1 6 0 1 7 6 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 1 5. 0 G E N E R A L RE G U L A T O R Y CO N S I D E R A TI O N S A N D CR E D E N TI A LI N G 1 5. 1 Ge ri at ri c Ass ess m e nt Tr ai ni n g At eac h participatin g sit e, a r es ear c h n urs e or clinic al r es ear c h pr of essio nal ( C R P) (pers on w ho int e n ds t o a d minist er t he geriatric ass ess m e nt) will r ec eive tr ainin g o n a d ministr atio n of t he geriatric ass ess m e nt usin g t he o nline vide o tr ainin g m o d ule t hr o u g h t he Alli a nc e w e bsit e, h y perlin k belo w: T o lo gin, s elect “ Me m ber L o gin” o n t he Allia nc e h o m e pa ge a n d e nt er t he C T E P -I A M ac c o unt us er na m e a n d pass w or d. Aft er lo g gin g in, t he tr ainin g m o d ule c a n be f o u n d u n der e d uc atio n a n d tr ainin g > o nline tr ainin g a n d u n der “ F or Sit e St aff. ” O nc e t he tr ainin g is c o m plet e, print a c opy of t he c o m pletio n c ertific at e t o kee p in t he st u d y r ec or ds a n d s u b mit it t o C T S U ac c or din g to S ectio n 4. 2 . 3. Tr ainin g c o m plet e d wit hin t he past t w o years is ac c e pt a b le, as it is n ot st u dy s pecific . An y f urt her q uestio ns or c o nc er ns r e gar din g a d minist erin g t he geriatric ass ess m e nt m a y be dir ect e d t o t he st u d y c hair."
76,page_76,"Allia nc e A1 7 1 6 0 1 7 7 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 1 6. 0 R E F E R E N C ES 1. Fin n R S, Cr o w n J P, La n g I, et al: T he c yclin -de pe n de nt kinas e 4/ 6 in hibit or palb ociclib in c o m binatio n wit h letr oz ole vers us le tr oz ole alo ne as first-line tr eat me nt of oestr o ge n r ec e pt or- p ositive, H E R 2 -ne gative, a d va nc e d br east c a nc er ( P A L O M A -1/ T RI O -1 8): a r a n d o mis e d p has e 2 st u d y. La nc et O nc ol 1 6:2 5-3 5, 2 0 1 5 2. T ur ner N C, R o J, An dr e F, et al: P alb ociclib in Hor m o ne -Rec e pt or -P osi tive Ad va nc e d Br east Ca nc er. N E n gl J Me d 3 7 3:2 0 9 -1 9, 2 0 1 5 3. Hurria A, G u pt a S, Za u der er M, et al: De velo pin g a c a nc er -s pecific geriatric ass ess m e nt. Ca nc er 1 0 4:1 9 9 8 -2 0 0 5, 2 0 0 5 4. Hurria A, Cirrincio ne C T, M uss H B, et al: I m ple m e ntin g a geriatric ass ess m e nt in c o o per ative gr o u p clinic al c a nc er trials: C A L G B 3 6 0 4 0 1. J Clin O nc ol 2 9:1 2 9 0 -6, 2 0 1 1 5. Hurria A, T o ga w a K, M o hile S G, et al: Pr e dictin g c he m ot her a p y t o xicit y in older a d ults wit h c a nc er: a pr os pective m ultic e nt er st u d y. J Clin O nc ol 2 9:3 4 5 7 -6 5, 2 0 1 1 6. Hurria A, Dale W, M o o ne y M, et al: Desig nin g t her a pe utic clinic al trials f or older a n d fr ail a d ults wit h c a nc er: U1 3 c o nf er e nc e r ec o m m e n datio ns. J Clin O nc ol 3 2:2 5 8 7 -9 4, 2 0 1 4 7. Hurria A, Na ylor M, C o he n HJ: I m pr o vin g t he q ualit y of c a nc er c ar e in a n a gin g p o p ulatio n: r ec o m m e n datio ns fr o m a n I O M r e p ort. J A M A 3 1 0:1 7 9 5-6, 2 0 1 3 8. S a w h ne y R, S e hl M, Naei m A: P h ysiolo gic as pects of a gin g: i m pact o n c a nc er m a na ge m e nt a n d decisio n m a kin g, part I. Ca nc er J 1 1:4 4 9 -4 6 0, 2 0 0 5 9. S e hl M, S a w h ne y R, Naei m A: P h ysio lo gic as pects of a gin g: i m pact o n c a nc er m a na ge m e nt a n d decisio n m a kin g, part II. Ca nc er J 1 1:4 6 1 -4 7 3, 2 0 0 5 1 0. D ut hie E: C o m pr e he nsive Geriatric O nc olo g y, T a ylor a n d Fr a ncis, 2 0 0 4 1 1. Yue n G: Alt er e d p har m ac o kinetics in t he elderly. Clin Ger atr Me d 6:2 5 7 -2 6 7, 1 9 9 0 1 2. Ba ker S, Gr oc h o w L: P har m ac olo g y of c he m ot her a p y in t he older pers o n. Clin Ger atr Me d 1 3:1 6 9 -1 8 3, 1 9 9 7 1 3. Kastrissios H, Blas c h ke T: Me dic atio n c o m plia nc e as a f eat ur e in dr u g de velo p m e nt. An n u Re v P har m ac ol T o xic ol 3 7:4 5 1 -4 7 5, 1 9 9 7 1 4. Ves t al R E: Agin g a n d p har m ac olo g y. Ca nc er 8 0:1 3 0 2-1 3 1 0, 1 9 9 7 1 5. Ba ker S, va n S c haik R, Riv or y L, et al: F act ors aff ectin g c ytoc hr o me P -4 5 0 activit y in c a nc er patie nts. Clin Ca nc er Res 1 0:8 3 4 1 -8 3 5 0, 2 0 0 4 1 6. S ot a nie mi E, Arr a nt o A, P elk o ne n O, et al: Age a n d c yt oc hr o m e P 4 5 0 -lin ke d dr u g m et a b olis m in h u m a ns: a n a nalysis of 2 2 6 s u bjects wit h e q ual hist o pat h olo gic al c o n ditio ns. Clin P har m ac ol T her 6 1:3 3 1 -3 3 9, 1 9 9 7 1 7. Br e n ner B M, Me yer T W, Host ett er T H: Diet ar y pr ot ein int a ke a n d t he pr o gr essive nat ur e of kid ne y dis eas e: t he r ole of he m o d y na mic ally m e diat e d glo m er ular injur y in t he pat h o ge nesis of pr o gr essive glo m er ular s cler osis in a gin g, r e nal a blatio n, a n d intrinsic r e nal dis eas e. N E n g J Me d 3 0 7:6 5 2 -6 5 9, 1 9 8 2 1 8. Lic ht m a n S M, Wildiers H, La u na y -Vac her V, et al : I nt er natio nal S ociet y of Geriatric O nc olo g y ( SI O G) r ec o m m e n datio ns f or t he a djust m e nt of d osin g in elderly c a nc er patie nts wit h r e nal ins ufficie nc y. E ur J Ca nc er 4 3:1 4-3 4, 2 0 0 7 1 9. Hurria A, Lic ht m a n S M: P har m ac o kinetics of C he m ot her a p y in t he Older P ati e nt. Ca nc er C o ntr ol 1 4:3 2 -4 3, 2 0 0 7 2 0. Ba ker S, Gr oc h o w L: P har m ac olo g y of c he m ot her a p y in t he older pers o n. Clin Geriatr Me d 1 3:1 6 9 -1 8 3, 1 9 9 7 2 1. Cr o m e P, Fla na ga n R: P har m ac o kinetic st u dies in elderly pe o ple. P har m ac o kinet 2 6:2 4 3 -2 4 7, 1 9 9 4"
77,page_77,"Allia nc e A1 7 1 6 0 1 7 8 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 2 2. Ki m mic k G, Fle min g R, M uss H, et al: Ca nc er c he m ot her a p y in older a d ults: A t oler a bilit y pers pective. Dr u gs Agin g 1 0:3 4 -4 9, 1 9 9 7 2 3. Bald uc ci L, C or c or a n M: Antine o plastic c he m ot her a p y of t he older c a nc er patie nt. He m at ol O nc ol Clin N A m 1 4:1 9 3 -2 1 2, 2 0 0 0 2 4. Maio ne P, P err o ne F, Gallo C, et al: Pr etr eat m e nt q ualit y of lif e a n d f u nctio nal st at us ass ess m e nt sig nific a ntly pr e dict s ur vival of elderly patie nts wit h a d va nc e d n o n -s m all-c ell lu n g c a nc er r ec eivin g c he m ot her a p y: a pr o g n ostic a nalysis of t he m ultic e nt er It alia n lu n g c a nc er st u d y in t he elderly st u d y. J Clin O nc ol 2 3:6 8 6 5 -6 8 7 2, 2 0 0 5 2 5. Fr e yer G, Gea y J, T o uzet S, et al: C o m pr e he nsive geriatric ass ess m e nt pr e dicts t oler a nce t o c he m ot her a p y a n d s ur vival in elderly patie nts wit h a d va nc e d o varia n c ar cin o m a: a GI N E C O st u d y. An n O nc ol 1 6:1 7 9 5-1 8 0 0, 2 0 0 5 2 6. Re pett o L, Fr atin o L, Au disio R, et al: C o m pr e he nsive geriatric ass ess m e nt a d ds inf or m atio n t o East er n C o o per ative Gr o u p perf or m a nc e st at us in elderly c a nc er patie nts; a n It alia n Gr o u p f or Geriatric O nc olo g y St u d y. J Clin O nc ol 2 0:4 9 4 -5 0 2, 2 0 0 2 2 7. Ra o A, Hsie h F, F e uss er J, et al: Geriatric e valuatio n a n d m a na ge m e nt u nits in t he c ar e of t he fr ail elderly patie nt. J Ger o nt ol A Biol S ci Me d S ci 6 0:7 9 8 -8 0 3, 2 0 0 5 2 8. E xt er m a n n M, Aa pr o M, Ber na bei R, et al: Us e o f c o pr e he nsive geriatric ass ess m e nt in older c a nc er patie nts: r ec o m m e n datio n fr o m t he t as k f orce o n C G A of t he I nt er natio nal S ociet y of Geriatric O nc olo g y. Crit Re v O nc ol He m at ol 5 5:2 4 1 -2 5 2, 2 0 0 5 2 9. Giacinti C, Gior da n o A: R B a n d c ell c ycle pr o gr essio n. O nc o ge ne 2 5:5 2 2 0 -7, 2 0 0 6 3 0 Fin n, R. S. et al: Pri m ar y r es ults fr o m a p has e III trial of palb ociclib ( P) wit h letr oz ole ( L) c o m par e d wit h letr oz ole alo ne in p ost m e n o pa us al w o m e n wit h E R +/ H E R 2 – a d va nc e d br east c a nc er ( A B C). N EJ M 2 0 1 6 3 1. Cr o w n J, Fin n R S, Ettl J, et al: Effic ac y a n d s af et y of first -line palb ociclib plus letr oz ole c o m par e d wit h letr oz ole alo ne in patie nts a ge d > = 6 5 years wit h estr o ge n r ec e pt or -p ositive, H E R 2 -ne gative a d va nc e d br east c a nc er: A s u b gr o u p a nalysis b y a ge of t he P A L O M A -1/ T RI O -1 8 trial. J o ur nal of Clinic al O nc olo g y 3 3, 2 0 1 5 3 2. Sla m o n DJ, Cr o w n J, La n g I, et al: L o n g -t er m s af et y pr ofile of palb ociclib ( P) in c o m binatio n wit h letr oz ole ( L) as first -line tr eat m e nt f or p ost m e n o pa us al patie nts wit h E R + a n d H E R 2- a d va nc e d br east c a nc er ( A B C) ( P A L O M A-1/ T RI O -1 8). J o ur nal of Clinic al O nc olo g y 3 3, 2 0 1 5 3 3 Viss er M, G o o d past er B H, Krit c he vs k y S B, et al. M us cle m ass, m us cle str e n gt h, a n d m us cle f at infiltr atio n as pr e dict ors of incide nt m o bilit y li mit atio ns in w ell-f u nctio nin g older pers o ns. T he j o ur n als of ger o nt ol o gy. Seri es A, Bi ol o gi c al sci e nces a n d me di c al sci e nces. 2 0 0 5; 6 0( 3):3 2 4 -3 3 3. 3 4 J a nss e n I, He y msfield S B, R oss R. L o w r elative s kelet al m us cle m ass (s ar c o pe nia) in older pers o ns is ass ociat e d wit h f u nctio nal i m pair m e nt a n d p h ysic al d is a bilit y. J o ur n al of t he A meri c a n Geri atri cs S oci et y. 2 0 0 2; 5 0( 5):8 8 9 -8 9 6. 3 5. R olla n d Y, Czer wins ki S, Abella n Va n Ka n G, et al. S ar c o pe nia: its ass ess m e nt, etiolo g y, pat h o ge nesis, c o ns e q ue nces a n d f ut ur e pers pectives. T he j o ur n al of n utriti o n, he alt h & a gi n g. 2 0 0 8; 1 2( 7):4 3 3 -4 5 0. 3 6. Mett er EJ, C o n wit R, T o bin J, F ozar d J L. Age -ass ociat e d loss of p o wer a n d stre n gt h in t he u p per e xtr e mities in w o m e n a n d m e n. T he j o ur n als of ger o nt ol o gy. Seri es A, Bi olo gi c al sci e nces a n d me di c al sci e nces. 1 9 9 7; 5 2( 5): B2 6 7 -2 7 6 . 3 7. E va ns WJ. S kelet al m us cle loss: c ac he xia, s ar c o pe nia, a n d inactivit y. T he A meri c a n j o ur n al of cli ni c al n utriti o n. 2 0 1 0; 9 1( 4):1 1 2 3 S -1 1 2 7 S. 3 8. M olina -Garrid o MJ, G uille n -P o nc e C, F er na n dez -F elix B M. Relatio ns hip Bet w ee n S ar c o pe nia a n d Fr ailt y in a S pa nis h Ca nc er in t he Elderly Unit: T he O N C O S A R C O Pr oject. J o ur n al of t he A meri c a n M e di c al Direct ors Ass oci ati o n. 2 0 1 6; 1 7( 8):7 6 0 -7 61"
78,page_78,"Allia nc e A1 7 1 6 0 1 7 9 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 3 9. F ear o n K, Ar e n ds J, Bar ac os V. Un derst a n din g t he m ec ha nis ms a n d tr eat m e nt o ptio ns in c a nc er c ac he xia. N at R ev Cli n O nc ol. 2 0 1 3; 1 0( 2):9 0 -9 9. 4 0. E va ns WJ, M orle y J E, Ar giles J, et al. Cac he xia: a ne w definitio n. Cli n N utr. 2 0 0 8; 2 7( 6):7 9 3 - 7 9 9. 4 1. Wein ber g M, S hac har S, Deal A, et al. C har act erizatio n of s kelet al m us cle a n d b o d y m ass in dic es in y o u n ger a n d older w o m e n wit h st a ge II a n d III br east c a ncer. J o ur n al of t he A meri c a n Geri atri cs S oci et y. 2 0 1 6;s u p ple m e nt: S 8 6. 4 2. Str ulo v S hac har S, Deal A M, Wein ber g M, et al. S kelet al M us cle Meas ur es as Pr e dict ors of T o xicit y, Hos pit alizatio n, a n d S ur vival in P atie nts wit h Met ast atic Br east Ca nc er Rec eivin g T a xa ne Bas e d C he m ot her a p y. Cli ni c al c a ncer rese arc h : a n offi ci al j o ur n al of t he A meri c a n Ass oci ati o n f or C a ncer R ese arc h. 2 0 1 6. 4 3. M o urt za kis M, Pr a d o C M M, Lieff ers J R, Rei m a n T, Mc Car gar LJ, Bar ac os V E. A pr actic al a n d pr ecis e a p pr oac h t o q ua ntific atio n of b o d y c o m p ositio n in c a nc er patie nts usin g c o m p ute d t o m o gr a p h y i m a ges ac q uir e d d urin g r o utine c ar e. A p pl P hysi ol N utr M e. 2 0 0 8; 3 3( 5):9 9 7 -1 0 06. 4 4. Au br e y J, Esf a n diari N, Bar ac os V E, et al. Meas ur e m e nt of s kelet al m us cle r a diatio n att e n uatio n a n d basis of its biolo gic al variatio n. A ct a p hysi ol o gi c a. 2 0 1 4; 2 1 0( 3):4 8 9 -4 9 7. 4 5 S ha w J W, J o h ns o n J A, C o o ns SJ ( 2 0 0 5). U S valuatio n of t he E Q -5 D healt h st at es: de velo p m e nt a n d t estin g of t he D 1 valuatio n m o del. Me d Car e; 4 3( 3): 2 0 3 -2 2 0 4 6 R oc k, E. P., D. L. Ke n ne d y, et al. ( 2 0 0 7). "" P atie nt-r e p ort e d o ut c o mes s up p ortin g a ntic a nc er pr o d uct a p pr o vals."" J Clin O nc ol 2 5 ( 3 2): 5 0 9 4-5 0 9 9. 4 7 Bas c h, E., X. Jia, et al. ( 2 0 0 9). "" Ad vers e s y m pt o m e ve nt r e p ortin g b y patie nts vs clinicia ns: r elatio ns hips wit h clinic al o ut c o m es."" J Natl Ca nc er I nst 1 0 1 ( 2 3): 1 6 2 4-1 6 3 2. 4 8 Fr o m m e, E. K., K. M. Eilers, et al. ( 2 0 0 4). "" Ho w ac c ur at e is clinicia n r e p ortin g of c he m ot her a p y a d vers e ef f ects ? A c o m paris o n wit h patie nt-r e p ort e d s y m pt o ms fr o m t he Q ualit y-of -Lif e Q uestio n nair e C 3 0."" J Clin O nc ol 2 2 ( 1 7): 3 4 8 5-3 4 9 0. 4 9 P et ers e n, M. A., H. Lars e n, et al. ( 2 0 0 6). "" Ass essin g healt h-r elat e d q ualit y of lif e in palliative c ar e: c o m parin g patie nt a n d p h ysicia n ass ess m e nts."" E ur J Ca nc er 4 2 ( 8): 1 1 5 9-1 1 6 6. 5 0 Ra bin, R. a n d F. de C harr o ( 2 0 0 1). "" E Q -5 D: a m eas ur e of healt h st at us fr o m t he E ur o Q ol Gr o u p."" An n Me d 3 3 ( 5): 3 3 7-3 4 3. 5 1 Her d m a n, M., C. G u de x, et al. ( 2 0 1 1). "" De velo p m e nt a n d pr eli minar y t estin g of t he ne w five - le vel versio n of E Q-5 D ( E Q -5 D -5 L)."" Q ual Lif e Res 2 0 ( 1 0): 1 7 2 7-1 7 3 6. 5 2 Hurria A, Cirrincio ne C T, M uss H B, et al: I m ple m e ntin g a geriatric ass ess m e nt in c o o per ative gr o u p clinic al c a nc er trials: C A L G B 3 6 0 4 0 1. J Clin O nc ol 2 9:1 2 9 0 -6, 2 0 1 1 5 3. Re pett o L, Fr atin o L, Au disio R A, et al: C o m pr e he nsive geriatric ass ess m e nt a d ds inf or m atio n t o East er n C o o per ative O nc olo g y Gr o u p perf or m a nc e st at us in elderly c a nc er patie nts: a n It alia n Gr o u p f or Geriatric O nc olo g y St u d y. J Clin O nc ol 2 0:4 9 4 -5 0 2, 2 0 0 2 5 4. Ki m mic k G G, Fle min g R, M uss H B, et al: Ca nc er c he m ot her a p y in older a d ults. A t oler a bilit y pers pective. Dr u gs Agin g 1 0:3 4 -4 9, 1 9 9 7 5 5. Maio ne P, P err o ne F, Gallo C, et al: Pr etr eat m e nt q ualit y of lif e a n d f u nctio nal st at us ass ess m e nt sig nific a ntly pr e dict s ur vival of elderly patie nts wit h a d va nc e d n o n-s m all-c ell lu n g c a nc er r ec eivin g c he m ot her a p y: a pr o g n ostic a nalysis of t he m ultic e nt er It alia n lu n g c a nc er in t he elderly st u d y. J Clin O nc ol 2 3:6 8 6 5-7 2, 2 0 0 5 5 6. E xt er m a n n M, Aa pr o M, Ber na bei R, et a l: Us e of c o m pr e he nsive geriatric ass ess me nt in older c a nc er patie nts: r ec o m m e n datio ns fr o m t he t as k f or ce o n C G A of t he I nt er natio nal S ociet y of Geriatric O nc olo g y ( SI O G). Crit Re v O nc ol He m at ol 5 5:2 4 1 -5 2, 2 0 0 5"
79,page_79,"Allia nc e A1 7 1 6 0 1 8 0 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 5 7 S e y m o ur M T, T h o m ps o n L C, Was a n H S, et al. C he m ot her a p y o ptio ns in elderly a n d fr ail patie nts wit h m et ast atic c olor ect al c a nc er ( M R C F O C U S 2): a n o pe n -la bel, r a n d o mis e d f act orial trial. L a ncet. 2 0 1 1; 3 7 7( 9 7 7 9):1 7 4 9 -1 7 59. 5 8 At hert o n, P., et al., W hat Ca n P has e I Clinic al Trials T ell Us Ab o ut Q ualit y Of Lif e? A Pilot St u d y ( Mc 0 1 1 5). Clin Res Trials 1, 2 0 1 5. 5 9 C ha u ha n, C., et al., P atie nt S atisf actio n wit h P articipatio n in P has e II/III N C C T G Clinic al Trials: Was It W ort h It ? ( N 0 3 9 2). J Clin O nc ol, 2 0 1 2. 3 0( 1 5 _ S u p pl): P. 6 1 3 3. 6 0 C ha u ha n, C., et al., P atie nt S atisf actio n wit h P articipatio n, Ad vers e E ve nts a n d Hos pit alizatio ns in P has e II/III N C C T G Clinic al Trials: Was It W ort h It ? ( N 0 3 9 2). Q ualit y Of Lif e Res ear c h, 2 0 1 2. 2 1( Oct 2 0 1 2 S u p ple m e nt): P. Abstr act Nr 2 0 2. 20 4. 6 1 Le -Ra de m ac her, J., et al. Ass ociatio n bet w ee n P atie nt P er c e ptio n of O nc olo g y Clinic al Trial P articipatio n a n d S ur vival. I n As c o An n ual Meetin g. 2 0 1 6. 6 2 Sloa n, J., et al. P atie nt S atisf actio n Wit h P articipatio n, Ad vers e E ve nts An d Hos pit alizatio ns I n P has e II/III N C C T G Clinic al Tri als: Was It W ort h It ? I n S u p p ort Car e Ca nc er. 2 0 1 2. 6 3. Sloa n, J., et al. Was It W ort h It ( WI WI) ? Meas urin g P atie nt S atisf actio n wit h Clinic al Trial P articipatio n. I n S u p p ort Ca nc er Car e. 2 0 1 1. 6 4 Eis e n ha uer E A, T her ass e P, Bo gaert J, S c h wart z L H, S ar ge nt D, F or d R, Da nce y J, Ar b uc k S, G w yt her S, M o o ne y M, R u binst ein L, S ha n kar L, D o d d L, Ka pla n R, Lac o m be D, Ver w eij J. Ne w r es p o ns e e valuatio n crit eria in s olid t u m ors: r e vis e d R E CI S T g uideline ( versio n 1. 1). E ur J Ca nc er 4 5( 2): 2 2 8 -2 4 7, 2 0 0 9. 6 5 Kaze mi -Bajest a ni S M, Maz ur a k V C, Bar ac os V. C o m p ut e d t o m o gr a p h y -define d m us cle a n d f at w astin g ar e ass ociat e d wit h c a ncer clinic al o ut c o m es. Se mi n ars i n cell & devel o p me nt al bi ol o gy. 2 0 1 5. 6 6 Ki m E Y, Ki m Y S, P ar k I, et al. E valuatio n of s ar c o pe nia in s m all -c ell lu n g c a nc er patie nts b y r o utine c hest C T. S u p p ort C are C a ncer. 2 0 1 6; 2 4( 1 1):4 7 2 1 -4 7 2 6. 6 7 R olla n d Y, Czer wins ki S, Abella n Va n Ka n G, et al. S ar c o pe nia: its ass ess m e nt, etiolo g y, pat h o ge nesis, c o ns e q ue nces a n d f ut ur e pers pectives. T he j o ur n al of n utriti o n, he alt h & a gi n g. 2 0 0 8; 1 2( 7):4 3 3 -4 5 0. 6 8 Mett er EJ, C o n wit R, T o bin J, F ozar d J L. Age -ass ociat e d loss of p o wer a n d stre n gt h in t he u p per e xtr e mities in w o m e n a n d m e n. T he j o ur n als of ger o nt ol o gy. Seri es A, Bi olo gi c al sci e nces a n d me di c al sci e nces. 1 9 9 7; 5 2( 5) : B2 6 7-2 7 6. 6 9 E va ns WJ. S kelet al m us cle loss: c ac he xia, s ar c o pe nia, a n d inactivit y. T he A meri c a n j o ur n al of cli ni c al n utriti o n. 2 0 1 0; 9 1( 4):1 1 2 3 S -1 1 2 7 S. 7 0 Martin L, Bir ds ell L, Mac d o nald N, et al. Ca nc er c ac he xia in t he a ge of o besit y: s kelet al m us cle de pletio n is a p o w erf ul pr o g n ostic f act or, in de pe n de nt of b o d y m ass in de x. J o ur n al of cli ni c al o nc ol o gy : offi ci al j o ur n al of t he A meri c a n S oci et y of Cli ni c al O nc ol o gy. 2 0 1 3; 3 1( 1 2):1 5 3 9 -1 547. 7 1 S hac har S S, Deal A M, Wein ber g M, et al. Bo d y C o m p ositio n as a Pr e dict or of T o xicit y in P atie nts Rec eivin g Ant hr ac ycline a n d T a xa ne Bas e d C he m ot her a p y f or Early St a ge Br east Ca nc er. Clinic al c a nc er r es ear c h : a n official jo ur nal of t he A m eric a n Ass ociatio n f or Ca nc er Res ear c h. 2 0 1 7. 7 2 S pie gel m a n D, Hert z m ar k E. Eas y S A S c alc ulatio ns f or ris k or pr e vale nc e r atios a n d diff er e nc es. A m eric a n jo ur nal of e pide miolo g y. 2 0 0 5; 1 6 2( 3):1 9 9 -2 0 0. 7 3 Ers hler W B, S u n W H, Bin kle y N, et al : I nt erle u kin-6 a n d a gin g: blo o d le vels a n d m o n o n uclear c ell pr o d uctio n incr eas e wit h a d va ncin g a ge a n d in vitr o pr o d uctio n is m o difia ble b y diet ar y r estrictio n. L y m p h o kine a n d c yt o kine r es ear c h 1 2:2 2 5-3 0, 1 9 9 3 7 4 F a giolo U, C oss arizza A, S c ala E, et al: I ncr eas e d c yt o kine pr o d uctio n in m o n o n uclear c ells of healt h y elderly pe o ple. E ur o pea n jo ur nal of i m m u n olo g y 2 3:2 3 7 5 -8, 1 9 9 3 7 5 Sin der m a n n J, Kr us e A, Fr er c ks HJ, et al: I n vestigatio ns of t he ly m p h o kine s yst e m in elderly in divid uals. Mec ha nis ms of a gein g a nd de velo p m e nt 7 0:1 4 9 -5 9, 1 9 9 3"
80,page_80,"Allia nc e A1 7 1 6 0 1 8 1 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 7 6 Br u u ns gaar d H, P e ders e n M, P e ders e n B K: Agin g a n d pr oinfla m m at or y c yt o kines. C urr e nt o pinio n in he m at olo g y 8:1 3 1 -6, 2 0 0 1 7 7. Fr a nc es c hi C, Ca pri M, M o nti D, et al: I nfla m m a gin g a n d a nti -infla m m a gin g: a s yst e mic pers pective o n a gin g a n d lo n ge vit y e m er ge d fr o m st u dies in h u m a ns. Mec ha nis ms of a gein g a n d de velo p m e nt 1 2 8:9 2 -1 0 5, 2 0 0 7 7 8 Vast o S, Ca n d or e G, Balistr eri C R, et al: I nfla m m at or y net w or ks in a gein g, a ge -r elat e d dis eas es a n d lo n ge vit y. Mec ha nis ms of a gein g a n d de velo p m e nt 1 2 8:8 3 -9 1, 2 0 0 7 7 9 F ear o n K, Ar e n ds J, Bar ac os V. Un derst a n din g t he m ec ha nis ms a n d tr eat m e nt o ptio ns in c a nc er c ac he xia. N at R ev Cli n O nc ol. 2 0 1 3; 1 0( 2):9 0 -9 9. 8 0 R o bs o n S C, S he p har d E G, Kirs c h R E: Fibrin de gr a datio n pr o d uct D -di m er in d uc es t he s y nt hesi s a n d r eleas e of biolo gic ally active I L -1 bet a, I L -6 a n d plas min o ge n activat or in hibit ors fr o m m o n oc yt es in vitr o. Britis h jo ur nal of hae m at olo g y 8 6:3 2 2 -6, 1 9 9 4 8 1 Cart er R A, Wic ks I P: Vas c ular c ell a d hesio n m olec ule 1 ( C D 1 0 6): a m ultif ac et e d r e g ulat or of joint infla m m atio n. Art hritis a n d r he u m atis m 4 4:9 8 5-9 4, 2 0 0 1 8 2 Hu b bar d R E, O' Ma h o n y M S, S a v va G M, et al: I nfla m m atio n a n d fr ailt y m eas ur es in older pe o ple. J o ur nal of c ellular a n d m olec ular m e dicine 1 3:3 1 0 3 -9, 2 0 0 9 8 3. C o he n HJ, Harris T, Pie per C F: C oa g u latio n a n d activatio n of infla m m at or y pat h w a ys in t he de velo p m e nt of f u nctio nal decline a n d m ort alit y in t he elderly. T he A m eric a n jo ur nal of m e dicine 1 1 4:1 8 0 -7, 2 0 0 3 8 4. De Martinis M, Fr a nc es c hi C, M o nti D, et al: I nfla m m atio n m ar kers pr e dictin g fr ailt y a n d m ort alit y in t he elderly. E x peri m e nt al a n d m olec ular pat h olo g y 8 0:2 1 9 -2 7, 2 0 0 6 8 5. de S aint -Hu bert M, J a m art J, M orr ha ye G, et al: S er u m I L -6 a n d I G F -1 i m pr o ve clinic al pr e dictio n of f u nctio nal decline aft er h os pit alizatio n in older patie nts. Agin g clinic al a n d e x peri m e nt al r es ear c h 2 3:1 0 6 -1 1, 2 0 1 1 8 6. F err uc ci L, Harris T B, G ur alnik J M, et al: S er u m I L -6 le vel a n d t he de velo p m e nt of dis a bilit y in older pers o ns. J o ur nal of t he A m eric a n Geriatrics S ociet y 4 7:6 3 9 -4 6, 1 9 9 9 8 7. F err uc ci L, P e n nin x B W, Volpat o S, et al: C ha n ge in m us cle str e n gt h e x plains ac c eler at e d decline of p h ysic al f u nctio n in older w o m e n wit h hig h int erle u kin -6 s er u m le vels. J A m Geriatr S oc 5 0:1 9 4 7 -5 4, 2 0 0 2 8 8. Huff m a n K M, Pie per C F, Kr a us V B, et al: Relatio ns of a m ar ker of e n d ot helial activatio n (s - V C A M) t o f u nctio n a n d m ort alit y in c o m m u nit y -d w ellin g older a d ults. T he jo ur nals of ger o nt olo g y. S eries A, Biolo gic al s cie nc es a n d m e dic al s cie nc es 6 6:1 3 6 9 -7 5, 2 0 1 1 8 9. P uts M T, Viss er M, T wis k J W, et al: E n d ocrine a n d infla m m at or y m ar kers as pr e dict ors of fr ailt y. Clin E n d ocrin ol ( O xf) 6 3:4 0 3-1 1, 2 0 0 5 9 0. Re u be n D B, C he h AI, Harris T B, et al: P erip her al blo o d m ar kers of infla m m atio n pr e dict m ort alit y a n d f u nctio nal decline in hig h -f u nctio nin g c o m m u nit y-d wellin g older pers o ns. J o ur na l of t he A m eric a n Geriatrics S ociet y 5 0:6 3 8 -4 4, 2 0 0 2 9 1 R o n nin g B, W yller T B, S eljeflot I, et al: Fr ailt y m eas ur es, infla m m at or y bio m ar kers a n d p ost - o per ative c o m plic atio ns in older s ur gic al patie nts. Age a n d a gein g 3 9:7 5 8 -6 1, 2 0 1 0 9 2 Pie per C F, Ra o K M, C u rrie M S, et al: Age, f u nctio nal st at us, a n d r acial diff er e nc es in plas m a D- di m er le vels in c o m m u nit y -d w ellin g elderly pers o ns. T he jo ur nals of ger o nt olo g y. S eries A, Biolo gic al s cie nc es a n d m e dic al s cie nc es 5 5: M 6 4 9 -5 7, 2 0 0 0"
81,page_81,"Allia nc e A1 7 1 6 0 1 8 2 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 9 3 MJ P, M C M, HJ C: Allost atic loa d of cir c ulatin g bio m ar kers o n gait s pee d in c a nc er s ur viv ors. Bet hes da, M D, 2 0 1 2 9 4 Mc Milla n D C: T he s yst e mic infla m m atio n -bas e d Glas g o w Pr o g n ostic S c ore: a dec a de of e x perie nc e in patie nts wit h c a nc er. Ca nc er Treat Re v 3 9:5 3 4 -4 0, 2 0 1 3 9 5. S har m a R, Z u c k nic k M, L o n d o n R, et al: S yst e mic infla m m at or y r es p o ns e pr e dicts pr o g nosis in patie nts wit h a d va nc e d -st a ge c olor ect al c a ncer. Clin C olor ect al Ca nc er 7:3 3 1 -7, 2 0 0 8 9 6. Ca m pisi J: S e nes c e nt c ells, t u m or s u p pressio n, a n d or ga nis m al a gin g: g o o d citize ns, ba d neig h b ors. Cell 1 2 0:5 1 3 -2 2, 2 0 0 5 9 7. C o p pe J P, P atil C K, R o dier F, et al: S e nes c e nc e -ass ociat e d s ecr et or y p he n ot y pes r e veal c ell- n o na ut o n o m o us f u nctio ns of o nc o ge nic R A S a n d t he p 5 3 t u m or s u p pr ess or. P L o S biolo g y 6:2 8 5 3 -6 8, 2 0 0 8 9 8 D o w s ett M, C uzic k J, I n gle J, C oat es A, et al: Met a -a nalysis of br east c a nc er o ut c o m es in a dju va nt trials of ar o m at as e in hibit ors vers us t a m o xif e n. J Clin O nc ol. 2 0 1 0; 2 8( 3):5 0 9 – 5 1 8. 1 0. 1 2 0 0/J C O. 2 0 0 9. 2 3. 12 7 4 [ P u b Me d: 1 9 9 4 9 0 1 7] 9 9 G oss P E, I n gle J N, Ales -Martinez J E, C he u n g A M, C hle b o w s ki R T, et al : E xe m est a ne f or br east -c a nc er pr e ve ntio n in p ost m e n o pa us al w o m e n. N E n gl J Me d. 2 0 1 1; 3 6 4( 2 5):2 3 8 1 – 2 3 9 1. 1 0. 1 0 5 6/ N EJ M oa 1 1 0 3 5 0 7 [ P ub Me d: 2 1 6 3 9 8 0 6] 1 0 0 G oss P E, I n gle J N, Martin o S, R o bert NJ, M uss H B, et al: A r a n d o mize d trial of letr oz ole in p ost m e n o pa us al w o m e n aft er five years of t a m o xif e n t her a p y f or early -st a ge br east ca ncer. N E n gl J Me d. 2 0 0 3; 3 4 9( 1 9):1 7 9 3 – 1 8 0 2.[ P u b Me d: 1 4 5 5 1 3 4 1] 1 0 1 A mir E, S er u ga B, Nir a ula S, Carlss o n L, Oc a na A. T o xicit y of a dju va nt e n d ocrine t her a p y in p ost m e n o pa us al br east c a ncer patie nts: a s yst e m atic r e vie w a n d m et a -a nalysis. J Natl Ca nc er I nst. 2 0 1 1; 1 0 3( 1 7):1 2 9 9 – 1 3 0 9. 1 0. 10 9 3/jnci/ djr 2 4 2 [ P u b Me d: 2 1 7 4 3 0 2 2] 1 0 2 He nr y N L, Giles J T, An g D, M o ha n M, Da da b h o y D, R o bar ge J, Ha y de n J, et al : Pr os pective c har act er izatio n of m us c ulos kelet al s y m pt o ms in early st a ge br east c a ncer patie nts tr eat e d wit h ar o m at as e in hibit ors. Br east Ca nc er Res Tr eat. 2 0 0 8; 1 1 1( 2):3 6 5 – 3 7 2. [ P u b Me d: 1 7 9 2 2 1 8 5] 1 0 3 Barts c h R, Ber ge n E. A S C O 2 0 1 6: hig hlig hts in br east c a nc er. Me m o. 2 01 6; 9( 4):2 1 1 -2 1 4. d oi: 1 0. 1 0 0 7/s 1 2 2 5 4 -0 1 6-0 3 0 0 -6. Re vie w. P u b Me d P MI D: 2 8 0 5 8 0 6 4; P u b Me d Ce ntr al P M CI D: P M C 5 1 6 5 0 2 7 1 0 4 P o g gio F, La m bertini M, Blo n dea u x E, Va glic a M, Le va g gi A, et al: R ole of f ulvestr a nt in t he tr eat m e nt of p ost m e n o pa us al m et ast atic br east c a ncer patie nts. E x pert Re v Clin P har m ac ol. 2 0 1 6 S e p; 9( 9):1 1 5 3 -6 1. d oi:1 0. 1 0 8 0/ 1 7 5 1 2 4 3 3. 2 0 1 6. 1 2 1 5 2 43. P u b Me d P MI D: 2 7 5 4 5 8 1 5. 1 0 5 Fin n R S, Cr o w n J P, La n g I, et al: T he c yclin -de pe n de nt kinas e 4/ 6 in hibit or palb ociclib in c o m binatio n wit h letr oz ole vers us letr oz ole alo ne as first -line tr eat me nt of oestr o ge n r ec e pt or- p ositive, H E R 2 -ne gative, a d va nc e d br east c a nc er ( P A L O M A -1/ T RI O -1 8): a r a n d o mis e d p has e 2 st u d y. La nc et O nc olo g y 1 6:2 5-3 5, 2 0 1 5. 1 0 6 T ur ner N C, R o J, An dr é F, L oi S, Ver m a S, et al: P A L O M A3 St u d y Gr o u p. P alb ociclib in Hor m o ne -Rec e pt or -P ositive Ad va nc e d Br east Ca nc er. N E n gl J Me d. 2 0 1 5 J ul 1 6; 3 7 3( 3):2 0 9 -1 9. d oi: 1 0. 1 0 5 6/ N EJ M oa 1 5 0 5 2 7 0. P u b Me d P MI D:2 6 0 3 0 5 1 8. 1 0 7 Crist of a nilli M, T ur ner N C, Bo n dar e n k o I, R o J, I m S A, et al: F ulvestr a nt plus palb ociclib vers us f ulvestr a nt plus plac e b o f or tr eat m e nt of h or m o ne-r ece pt or-positive, H E R 2 -ne gative m et ast atic br east c a nc er t hat pr o gresse d o n pr e vio us e n d ocrine t her a p y ( P A L O M A -3): final a nalysis of t he m ultic e ntr e, d o u ble -blin d, p has e 3 r a n d o mis e d c o ntr olle d trial. La nc et O nc ol. 2 0 1 6 Apr; 1 7( 4):4 2 5 -3 9. d oi: 1 0. 1 0 1 6/ S 1 4 7 0 -2 0 4 5( 1 5) 0 0 6 1 3-0. P u b Me d P MI D: 2 6 9 4 7 3 3 1. 1 0 8 Fin n R S, Derin g J, C o n klin D, et al. P D 0 3 3 2 9 9 1, a s elective c yclin D kinas e 4/ 6 in hibit or, pr ef er e ntially in hibits pr olif er atio n of lu minal estr o ge n r ec e pt or -p ositive h u m a n br east c a nc er c ell lines i n vitr o. Bre ast C a ncer R ese arc h : B C R . 2 0 0 9; 1 1( 5): R 7 7. d oi:1 0. 1 1 8 6/ bcr 24 1 9"
82,page_82,"Allia nc e A1 7 1 6 0 1 8 3 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 1 0 9 Pfizer I nc. I br a nc e R _ ( palb ociclib): HI G H LI G H T S O F P R E S C RI BI N G I N F O R M A TI O N, Re vis e d: 2/ 2 0 1 6. htt ps:// w w w. pfizer m e dic alinf or m atio n. c o m/e n -us/ibr a nce : HI G H LI G H T S O F P R E S C RI BI N G I N F O R M A TI O N, Re vis e d: 2/ 2 0 1 6 . 1 1 0 Ma n gini N S, Wes olo w s ki R, Ra m as w a m y B, L ust ber g M B, Ber ger MJ. P alb ociclib: A N o vel C yclin -De pe n de nt Kinas e I n hibit or f or Hor m o ne Rec e pt or -P ositive Ad va nc e d Br east Ca nc er. An n P har m ac ot her. 2 0 1 5 N o v; 4 9( 1 1):1 2 5 2 -6 0. d oi:1 0 . 1 1 7 7/ 1 0 60 0 2 8 0 1 5 60 2 2 7 3. Re vie w. P u b Me d P MI D: 2 6 3 2 4 3 5 5 1 1 1 R o berts PJ, Bisi J E, Str u m J C, et al. M ultiple R oles of C yclin -De pe n de nt Kinas e 4/ 6 I n hibit ors in Ca nc er T her a p y. J N CI J o ur n al of t he N ati o n al C a ncer I nstit ut e . 2 0 1 2; 1 0 4( 6):4 7 6-4 8 7. d oi:1 0. 1 0 9 3/jnci / djs 0 0 2. 1 1 2 Mc Cle n d o n A K, Dea n J L, Riva de neir a D B, et al. C D K4/ 6 in hibitio n a nt a g o nizes t he c yt ot o xic r es p o ns e t o a nt hr ac ycline t her a p y. Cell Cycl e . 2 0 1 2; 1 1( 1 4):2 7 4 7-2 75 5. d oi:1 0. 4 1 6 1/ cc. 21 1 2 7. 1 1 3 Ver m a S, Bartlett C H, S c h nell P, De Mic hele A M, L oi S, R o J, C olle o ni M, et al:. P alb ociclib in C o m binatio n Wit h F ulvestr a nt in W o m e n Wit h Hor m o ne Rec e pt or -P ositive/ H E R 2 -Ne gative Ad va nc e d Met ast atic Br east Ca nc er: Det aile d S af et y Analysis Fr o m a M ultic e nt er , Ra n d o mize d, Plac e b o -C o ntr olle d, P has e III St u d y ( P A L O M A -3). O nc olo gist. 2 0 1 6 Oct;2 1( 1 0):1 1 6 5 -1 1 7 5. P u b Me d P MI D: 2 7 3 6 8 8 8 1; P u b Me d Ce ntr al P M CI D: P M C 5 0 6 1 5 4 3. 1 1 4 He nr y N L, S kaar T C, Da nt zer J, Li L, Kid w ell K, et al: Ge netic ass ociatio ns wit h t o xicit y -r elat e d dis c o ntin uatio n of ar o m at as e in hibit or t her a p y f or br east c a nc er. Br east Ca nc er Res Treat. 2 0 1 3 Apr; 1 3 8( 3):8 0 7 -1 6. d oi: 1 0. 1 0 0 7/s 1 0 5 4 9 -0 1 3 -2 5 0 4 3. P u b Me d P MI D: 2 3 5 4 6 5 5 3; P u b Me d Ce ntr al P M CI D: P M C 3 6 4 6 6 2 6. 1 1 5 C olo m er R, M o nz o M, T us q uets I, Rif a J, e t al: A sin gle-n ucle otide p oly m or p his m in t he ar o m at as e ge ne is ass ociat e d wit h t he effic ac y of t he ar o m at as e in hibit or letr oz ole in a d va nc e d br east c ar cin o m a. Clin Ca nc er Res. 2 0 0 8; 1 4( 3):8 1 1 – 8 1 6. 1 0. 11 5 8/ 1 0 78 -0 4 3 2. C C R -0 7 -1 9 2 3 [ P u b Me d: 1 8 2 4 5 5 4 3] 1 1 6 I n gle J N, S c haid DJ, G oss P E, Liu M, M us hir o da T, et al: Ge n o m e -wide ass ociatio ns a n d f u nctio nal ge n o mic st u dies of m us c ulos kelet al a d vers e e ve nts in w o m e n r ec eivin g ar o m at as e in hibit ors. J Clin O nc ol. 2 0 1 0; 2 8( 3 1):4 6 7 4– 4 6 8 2. 1 0. 1 2 0 0/J C O. 2 0 1 0. 2 8. 50 6 4 [ P u b Me d: 2 0 8 7 6 4 2 0] 1 1 7 Ma o JJ, S u HI, F e n g R, D o nels o n M L, et al: . Ass ociatio n of f u nctio nal p oly m or p his ms in C Y P 1 9 A1 wit h ar o m at as e in hibit or ass ociat e d art hr algia in br east c a nc er s ur viv ors. Br east Ca ncer Res. 2 0 1 1; 1 3( 1): R 8. 1 0. 1 1 8 6/ bcr 2 8 1 3 [ P ub Me d: 2 1 2 5 1 3 3 0] 1 1 8 P ar k I H, Lee Y S, Lee K S, Ki m S Y, et al :. Sin gle n ucle otide p oly m or p his ms of C Y P 1 9 A1 pr e dict clinic al o ut c o m es a n d a d vers e e ve nts ass ociat e d wit h letr oz ole in patie nts wit h m et ast atic br east c a nc er. Ca nc er C he m ot her P har m ac ol. 2 0 1 1; 6 8( 5): 1 2 6 3 – 1 2 7 1. 1 0. 10 0 7/s 0 0 2 8 0 -0 1 1 -1 6 1 5 -y [ P u b Me d: 2 1 4 4 2 4 3 9] 1 1 9 Bea ver J A, A miri -Kor dest a ni L, C harla b R, et al. F D A a p pr o val: palb ociclib f or t he tr eat m e nt of p ost m e n o pa us al patie nts wit h estr o ge n r ec e pt or -p ositive, H E R 2 -ne gative m et ast atic br east c a ncer. Cli n C a ncer R es. . 2 01 5; 2 1( 2 1):4 7 6 0 – 4 7 6 6. 1 2 0 D hillo n S. P alb ociclib: first glo bal a p pr o val. Dr u gs . 2 0 1 5; 7 5( 5):5 4 3– 5 5 1. 1 2 1 Yu Y, L oi C M, Hoff m a n J, Wa n g D. P h ysiolo gic ally Bas e d P har m ac o kinetic M o delin g of P alb ociclib. J Clin P har m ac ol. 2 0 1 7 F e b; 5 7( 2):1 7 3 -1 8 4. d oi:1 0. 1 0 0 2/j c p h. 7 9 2. P u b Me d P MI D: 2 7 4 0 2 1 5 7. 1 2 2 M us gr o ve E A, Cald o n C E, Barr aclo u g h J, St o ne A, S ut herla n d R L. C yclin D as a t her a pe utic t ar get in c a nc er. Nat Re v Ca nc er. 2 0 1 1 J ul 7; 1 1( 8):5 5 8-7 2. d oi:1 0. 1 0 3 8/ nr c 3 0 9 0. Re vie w. P u b Me d P MI D: 2 1 7 3 4 7 2 4. 1 2 3 Bess o n A, D o w d y S F, R o berts J M. C D K in hibit ors: c ell c ycle r e g ulat ors a n d be y o n d. De v Cell. 2 0 0 8 F e b; 1 4( 2):1 5 9 -6 9. d oi: 1 0. 1 0 1 6/j. de vc el. 2 0 0 8. 0 1. 0 1 3. Re vie w. P u b Me d P MI D: 1 8 2 6 7 0 8 5. 1 2 4 S herr CJ. A Ne w Cell -C ycle T ar get in Ca nc er - I n hibitin g C yclin D-De pe n de nt Kinas es 4 a n d 6. N E n gl J Me d. 2 0 1 6 N o v 1 7; 3 7 5( 2 0):1 9 2 0 -1 9 2 3. P u b Me d P MI D:2 7 9 5 9 5 9 8."
83,page_83,"Allia nc e A1 7 1 6 0 1 8 4 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 1 2 5 Na m EJ, Ki m Y T. Alt er atio n of c ell -c ycle r e g ulatio n in e pit helial o varia n c a nc er. I nt J G y nec ol Ca nc er. 2 0 0 8 N o v -Dec; 1 8( 6):1 1 6 9 -8 2. d oi:1 0. 1 1 1 1/j. 1 5 2 5 -1 4 3 8. 2 0 0 8. 0 1 1 9 1. x. Re vie w. P u b Med P MI D: 1 8 2 9 8 5 6 6. 1 2 6 Ca na ves e M, S a nt o L, Raje N. C yclin de pe n de nt kinas es in c a nc er: p ot e ntial f or t her a pe utic int er ve ntio n. Ca nc er Biol T her. 2 0 1 2 Ma y; 1 3( 7):4 5 1-7. d oi:1 0. 4 1 6 1/ c bt. 1 9 5 8 9. Re vie w. P u b Med P MI D: 2 2 3 6 1 7 3 4. 1 2 7 Bart k o va J, L u kas J, M uller H, L ut z h oft D, Str a uss M, Bart e k J: C yclin D 1 pr ot ein e x pr essio n a nd f u nctio n in h u m a n br east c a nc er. I nt J C a ncer 1 9 9 4, 5 7:3 5 3 -3 6 1. 1 2 8 Gillett C, F a ntl V, S mit h R, Fis her C, Bart e k J, Dic ks o n C, Bar nes D, P et ers G: A m plific atio n a n d o ver e x pr essio n of c yclin D 1 in br east c a nc er det ect e d b y i m m u n o hist oc he mic al st ainin g. C a ncer R es 1 9 9 4, 5 4:1 8 1 2 -1 8 1 7. 1 2 9 Ke n n y F S, Hui R, M us gr o ve E A, Gee J M, Bla m e y R W, Nic h ols o n RI, S ut herla n d R L, R o berts on J F: O ver e x pr essio n of c yclin D 1 m ess e n ger R N A pr e dicts f or p o or pr o g n osis in estr o ge n r ece ptor - p ositive br east c a nc er. Cli n C a ncer R es 1 9 9 9, 5:2 0 6 9 -2 0 7 6. 1 3 0 H w a n g T S, Ha n H S, Ho n g Y C, Lee HJ, P aik N S: Pr o g n ostic value of c o m bine d a nalysis of c yclin D 1 a n d estr o ge n r ec e pt or st at us in br east c a ncer patie nts. P at h ol I nt 2 0 0 3, 5 3:7 4 -8 0. 1 3 1 R u das M, Le h nert M, Hu y n h A, J a kes z R, Sin ger C, La x S, et al: C yclin D 1 e x pr essio n in br east c a nc er patie nts r ec eiv in g a dju va nt t a m o xif e n-bas e d t her a p y. Cli n C a ncer R es 2 0 0 8, 1 4:1 7 6 7 -1 774. 1 3 2 Jirstr o m K, St e n da hl M, R y de n L, Kr o n bla d A, Be n da hl P O, St al O, La n d ber g G: Ad vers e eff ect of a dju va nt t a m o xif e n in pr e m e n o pa us al br east c a nc er wit h c yclin D 1 ge ne a m plific atio n. C a ncer R es 2 0 0 5, 6 5:8 0 0 9 -8 0 1 6. 1 3 3 Fr y D W, Har ve y PJ, Keller P R, Elliott W L, Mea de M, Tr ac het E, et al: S pecific in hibitio n of c yclin- de pe n de nt kinas e 4/ 6 b y P D 0 3 3 2 9 9 1 a n d ass ociat e d a ntit u m or activit y in h u m a n t u m or xe n o gr afts. M ol C a ncer T her 2 0 0 4, 3:1 4 2 7 -1 4 3 8. 1 3 4 T o o g o o d P L, Har ve y PJ, Re pine J T, S hee ha n DJ, Va n der Wel S N, et al: Dis c o ver y of a p ot e nt a nd s elective in hibit or of c yclin-de pe n de nt kinas e 4/ 6. J M e d C he m 2 0 0 5, 4 8:2 3 8 8 -2 4 0 6. 1 3 5 Mar zec M, Kas pr z yc ka M, Lai R, Gla d de n A B, et al: Ma ntle c ell ly m p h o m a c ells e x pr ess pr e d o mina ntly c yclin D 1a is of or m a n d ar e hig hly s e nsitive t o s elective in hibitio n of C D K4 kinas e activit y. Bl o o d 2 0 0 6, 1 0 8:1 7 4 4 -1 7 5 0. 1 3 6 S aa b R, Bills J L, Mic eli A P, An ders o n C M, et al: P har m ac olo gic in hibitio n of c yclin -de p e n de nt kinas e 4/ 6 activit y arr ests pr olif er atio n in m y o blasts a n d r ha b d o m y os ar c o ma -derive d c ells. M ol C a ncer T her 2 0 0 6, 5:1 2 9 9 -1 3 0 8. 1 3 7 Ba u g h n L B, Di Libert o M, W u K, T o o g o o d P L, L o uie T, G otts c halk R, et al: A n o vel or ally active s m all m olec ule p ot e ntly in d uc es G 1 arr est in pri m ar y m yelo m a c ells a n d pr e ve nts t u m or gr o wth by s pecific in hibitio n of c yclin-de pe n de nt kinas e 4/ 6. C a ncer R es 2 0 0 6, 6 6:7 6 6 1 -7 6 6 7. 1 3 8 De n g Q, G u o H, Dai J, Ya n g L, W u C, Wa n g Q, Hu Z, et al: I m p ut atio n -bas e d ass ociatio n a nalyses ide ntif y ne w lu n g c a nc er s us c e ptibilit y varia nts in C D K6 a n d S H3 R F 1 a n d t heir int er actio ns with s m o kin g in C hines e p o p ulatio ns. Car cin o ge nesis. 2 0 1 3 S e p; 3 4( 9):2 0 1 0 -6. d oi: 1 0. 1 0 9 3/ c ar cin/ b gt 1 4 5. P u b Me d P MI D: 2 3 6 4 4 7 4 4. 1 3 9 Ye Y, Ya n g H, Gr oss m a n H B , Din ne y C, W u X, G u J. Ge netic varia nts in c ell c ycle c o ntr ol pat h w a y c o nf er s us c e ptibilit y t o bla d der c a nc er. Ca nc er. 2 0 0 8 J u n; 1 1 2( 1 1):2 4 6 7 -7 4. d oi: 1 0. 1 0 0 2/ c ncr. 23 4 7 2. P u b Me d P MI D: 1 8 3 6 1 4 2 7. 1 4 0. Kibel A S, Ah n J, Isik ba y M, Kli m A, W u W S, Ha yes R B, Is aacs W B , Da w E W. Ge netic varia nts in c ell c ycle c o ntr ol pat h w a y c o nfer s usce ptibilit y t o a g gr essive pr ost at e c arcin o m a. Pr ost at e. 2016 Apr; 7 6( 5):4 7 9 -9 0. d oi:1 0. 1 0 0 2/ pr os. 2 31 3 9. P u b Me d P MI D: 2 6 7 0 8 9 9 3 1 4 1. Driver K E, S o n g H, Les ue ur F, Ah m e d S, Bar b os a -M or ais N L, T yr er J P, et al: St u dies in E pide miolo g y a n d Ris ks of Ca nc er Her e dit y ( S E A R C H) T ea m.. Ass ociatio n of sin gle -n ucle otide p oly m or p his ms in t he c ell c ycle ge nes wit h br east ca ncer in t he Britis h p o p ulatio n. Car cin o ge nesis. 2 0 0 8 F e b; 2 9( 2):3 3 3 -4 1. d oi: 1 0. 1 0 9 3/ c ar cin/ b g m 2 8 4. P u b Me d P MI D: 1 8 1 7 4 2 4 3; P u b Me d Ce ntr al P M CI D: P M C 2 3 4 6 5 4 6."
84,page_84,"Allia nc e A1 7 1 6 0 1 8 5 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 1 4 2. G o o de E L, Fridle y B L, Vier ka nt R A, C u n nin g ha m J M, et al: Ca n didat e ge ne a nalysis usin g i m p ut e d ge n ot y pes: c ell c ycle sin gle-n ucle otide p oly m or p his ms a n d o varia n c a nc er ris k. Ca nc er E pide miol Bio m ar kers Pr e v. 2 0 0 9 Mar; 1 8( 3):9 3 5 -4 4. d oi: 1 0. 1 1 5 8/ 1 0 5 5 -9 9 6 5. E PI -0 8-0 860. P u b Me d P MI D: 1 9 2 5 8 4 7 7; P u b Me d Ce ntr al P M CI D: P M C 2 7 4 3 1 8 4. 1 4 3. Cai H, Xia n g Y B, Q u S, L o n g J, Cai Q, Ga o J, Z he n g W, S h u X O. Ass ociatio n of ge netic p oly m or p his ms in c ell -c ycle c o ntr ol g e nes a n d s usce ptibilit y t o e n d o m etrial c a nc er a m o n g C hinese w o m e n. A m J E pide miol. 2 0 1 1 J u n 1; 1 7 3( 1 1):1 2 6 3 -7 1. d oi: 1 0. 1 0 9 3/ aje/ k wr 0 0 2. P u b Me d P MI D: 2 1 4 5 4 8 2 6; P u b Me d Ce ntr al P M CI D: P M C 3 1 0 1 0 6 6. 1 4 4. Ca m pa D, P ast or e M, Ge ntilu o m o M, T alar -W ojnar o w s ka R, et al:. F u nctio nal sin gle n ucle otide p oly m or p his ms wit hin t he c yclin -de pe n de nt kinas e in hibit or 2 A/ 2 B r e gio n aff ect pa ncr eatic cancer ris k. O nc ot ar get. 2 0 1 6 Au g 3 0; 7( 3 5):5 7 0 1 1-5 7 0 2 0. d oi:1 0. 1 8 6 3 2/ o nc ot ar get. 1 0 9 3 5. P u b Me d P MI D: 2 7 4 8 6 9 7 9; P u b Me d Ce ntr al P M CI D: P M C 5 3 0 2 9 6 9. 1 4 5. Cacina C, Ya yli m -Er alt a n I, Arika n S, S a gla m E K, Ze y be k U, Is bir T. Ass ociatio n bet w een C D K N 1 A S er 3 1 Ar g a n d C 2 0 T ge ne p oly m or p his ms a n d c olor ect al c a nc er ris k a n d pr o g n osis. I n Viv o. 2 0 1 0 Mar -Apr; 2 4( 2):1 7 9 -8 3. P u b Me d P MI D:2 0 3 6 3 9 9 1. 1 4 6. S c h o n d orf T, Eis e le L, G o hrin g UJ, Valt er M M, et al : T he V1 0 9 G p oly m or p his m of t he p 2 7 ge ne C D K N 1 B in dic at es a w ors e o ut c o m e in n o de -ne gative br east c a nc er patie nts. T u mo ur Biol. 2 0 0 4, 2 5: 3 0 6 -3 1 2. 1 0. 1 1 5 9/ 0 0 0 0 8 13 9 6. P ub Me d P MI D: 1 5 6 2 7 8 9 6. 1 4 7. Azzat o E M, Driver K E, Les ue ur F, S ha h M, et al : Eff ects of c o m m o n ger mline ge netic variatio n in c ell c ycle c o ntr ol ge nes o n breast ca ncer s ur vival: r es ults fr o m a p o p ulatio n-bas e d c o h ort. Br east Ca nc er Res. 2 0 0 8; 1 0( 3): R 4 7. d oi: 1 0. 1 1 8 6/ bcr 2 1 0 0. P u b Me d P MI D: 1 8 5 0 7 8 3 7; P u b Me d Ce ntr al P M CI D: P M C 2 4 8 1 4 9 6. 1 4 8. Driver K E, S o n g H, Les ue ur F, Ah m e d S, Bar b os a -M or ais N L, T yr er J P, P o n der B A, East o n D F, P har oa h P D, D u n nin g A M; St u dies in E pide miolo g y a n d Ris ks of Ca nc er Her e dit y ( S E A R C H) T ea m.. Ass ociatio n of sin gle -n ucle otide p oly m or p his ms in t he c ell c ycle ge nes wit h br east c a ncer in t he Britis h p o p ulatio n. Car cin o ge nesis. 2 0 0 8 F e b; 2 9( 2):3 3 3-4 1. d oi: 1 0. 1 0 9 3/ c ar cin/ b g m 284. P u b Me d P MI D:1 8 1 7 4 2 4 3; P u b Me d Ce ntr al P M CI D: P M C 2 3 4 6 5 4 6. 1 4 9. S h u X O, M o or e D B, Cai Q, C he n g J, We n W, Pier c e L, Cai H, Ga o Y T, Z he n g W: Ass ociatio n of c yclin D 1 ge n ot y pe wit h br east c a nc er ris k a n d s ur vival. Ca nc er E pide miol Bio m ar kers Pr e v. 2 0 05, 1 4: 9 1 -9 7. P u b Me d P MI D: 1 5 6 6 8 4 8 1. 1 5 0. S olei m a ni Z, Kheir k ha h D, S harif M R, S harif A, Kari mia n M, Aft a bi Y. Ass ociatio n of C C N D 1 Ge ne c. 8 7 0 G > A P oly m or p his m wit h Br east Ca nc er Ris k: A Cas e -C o ntr ol St u d y a n d a Met a - Analysis. P at h ol O nc ol Res. 2 0 1 6 Dec 2 1. d oi:1 0. 1 0 0 7/s 1 2 2 5 3 -0 1 6 -0 16 5 -3. [ E p u b a hea d of print] P u b Me d P MI D: 2 8 0 0 4 3 5 3. 1 5 1. Ya yli m -Er alt a n I, Er ge n A, G ör m üs U, Arika n S, Küç üc ü k S, S a h in O, Yigit N, Yildiz Y, Is bir T. Br east c a nc er a n d c yclin D 1 ge ne p oly m or p his m in T ur kis h w o m e n. I n Viv o. 2 0 0 9 S e p - Oct; 2 3( 5):7 6 7 -7 2. P u b Me d P MI D: 1 9 7 7 9 1 1 3. 1 5 2. Be wic k M A, C o nlo n M S, Lafr e nie R M. P oly m or p his ms in X R C C 1, X R C C 3, a n d C C N D 1 a n d s ur vival aft er tr eat m e nt f or m et ast atic br east c a nc er. J Clin O nc ol. 2 0 0 6 Dec 2 0; 2 4( 3 6):5 6 4 5-51. P u b Me d P MI D: 1 7 1 1 6 9 4 3. 1 5 3. Z h o u L P, Ya o F, L ua n H, Wa n g Y L, D o n g X H, Z h o u W W, Wa n g Q H. C Y P 3 A4 * 1 Bp oly m or p his m a n d c a nc er ris k: a Hu G E r e vie w a n d m et a -a nalysis. T u m o ur Biol. 2 0 1 3 Apr; 3 4( 2):6 4 9 -6 0. d oi: 1 0. 1 0 0 7/s 1 3 2 7 7 -0 1 2-0 5 9 2 -z. Re vie w. P ub Me d P MI D: 2 3 1 7 9 4 0 2. 1 5 4. J o h ns o n N, D u d brid ge F, Orr N, Gibs o n L, J o nes M E, S c h oe m a ker MJ, et al. Ge netic variatio n at C Y P 3 A is ass ociat e d wit h a ge at m e nar c he a n d br east c a nc er ris k: a c as e -c o ntr ol st u d y . Br east Ca nc er Res. 2 0 1 4 Ma y 2 6; 1 6( 3): R 5 1. d oi: 1 0. 1 1 8 6/ bcr 36 6 2. P u b Me d P MI D: 2 4 8 8 7 5 1 5; P u b Med Ce ntr al P M CI D: P M C 4 5 2 2 5 9 4."
85,page_85,"Allia nc e A1 7 1 6 0 1 8 6 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 1 5 5. Wilb or n T W, La n g N P, S mit h M, Melet h S, F ala n y C N. Ass ociatio n of S U L T 2 A1 allelic varia nts wit h plas m a a dr e nal a n dr o ge ns a n d pr ost at e c a nc er in Afric a n -A m eric a n m e n. J St er oid Bioc he m M ol Biol. 2 0 0 6 J u n; 9 9( 4 -5):2 0 9 -1 4. P u b Me d P MI D: 1 6 6 1 7 0 1 4. 1 5 6. K w o n E M, Holt S K, F u R, Kolb S, Willia ms G, St a nf or d J L, Ostr a n der E A. An dr o ge n m et a b olis m a n d J A K/ S T A T pat h w a y ge nes a n d pr ost at e c a ncer ris k. Ca nc er E pide miol. 2 0 1 2 Au g; 3 6( 4):3 4 7 -5 3. d oi: 1 0. 1 0 1 6/j. c a ne p. 2 0 1 2. 0 4. 0 0 2. P u b Me d P MI D: 2 2 5 4 2 9 4 9; P u b Me d Ce ntr al P M CI D: P M C 3 3 9 2 4 0 9. 1 5 7. Oest err eic h S, He nr y N L, Kid w ell K M, Va n P oz na k C H, et al: Ass ociatio ns bet w ee n ge netic varia nts a n d t he eff ect of letr oz ole a n d e xe m est a ne o n b o ne m ass a n d b o ne t ur n o ver. Br east Ca nc er Res Tr eat. 2 0 1 5 N o v; 1 5 4( 2):2 6 3 -7 3. d oi: 1 0. 1 0 0 7/s 1 05 4 9 -0 15 -3 6 0 8-8. P u b Me d P MI D: 2 6 5 3 6 8 7 0; P u b Me d Ce ntr al P M CI D: P M C 4 8 0 7 6 1 0. 1 5 8. Le yla n d -J o nes B, Gr a y K P, Abr a m o vit z M, Bo uz y k M, Yo u n g B, et al; BI G 1 -9 8 C olla b or ative Gr o u p.. E S R 1 a n d E S R 2 p oly m or p his ms in t he BI G 1 -9 8 trial c o m parin g a dju va nt letr oz ole vers us t a m o xif e n or t heir s e q ue nc e f or early br east c a ncer. Br east Ca nc er Res Treat. 2 0 1 5 Dec; 1 5 4( 3):5 4 3 -5 5. d oi:1 0. 1 0 0 7/s 10 5 4 9 -0 1 5 -3 63 4 -6. P u b Me d P MI D: 2 6 5 9 0 8 1 3; P u b Me d Ce ntr al P M CI D: P M C 4 7 3 0 9 4 9. 1 5 9. Artigal Ã¡s O, Va n ni T, Hut z M H, As ht o n -Pr olla P, S c h w art z I V. I nflue nce of C Y P 1 9 A1 p oly m or p his ms o n t he tr eat m e nt of br east c a ncer wit h ar o m at as e in hibit ors: a s yst e m atic r e vie w a n d m et a-a nalysis. B M C Me d. 2 0 1 5 J u n 1 1; 1 3:1 3 9. d oi: 1 0. 1 1 8 6/s 1 2 9 1 6-0 1 5 -0 3 7 3 -9. P u b Me d P MI D: 2 6 0 6 7 7 2 1; P u b Me d Ce ntr al P M CI D: P M C 4 4 7 5 2 9 4 1 6 0. Ra u nio H, et al Br J Clin P har m ac ol . 2 0 0 1 Oct; 5 2( 4): 3 5 7 – 3 6 3 1 6 1. Beal, S. a n d L. S heiner, N O N M E M Us ers G uide. 1 9 9 2, N O N M E M Pr oject Gr o u p, Universit y of C alif or nia at S a n Fr a ncis c o: S a n Fr a ncis c o"
86,page_86,"Allia nc e A1 7 1 6 0 1 8 7 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 1 7. 0 MO D E L CO N S E N T F O R M St u d y Title f or St u d y P articipa nts: Testi n g t he effects of p al b o cicli b a n d f ul vestra nt o r letro z ole f o r p atie nts 7 0 ye ars of a ge a n d ol der wit h met ast atic bre ast c a ncer Official St u d y Title f or I nter net Searc h o n htt p:// w w w. Clinical Trials. go v : Alli a nce A 1 7 1 6 0 1: A P h ase II Tri al Assessi n g t he t olera bilit y of P al b o cicli b i n c o m bi n ati o n wit h letro z ole o r f ul vestra nt i n p atie nts a ge d 7 0 a n d ol der wit h estro ge n rece pt o r p ositi ve, H E R -2 ne g ati ve met ast atic bre ast c a ncer T his st u d y is c o n d ucte d b y t he Allia nc e f or Clin ic al Trials in O nc olo g y, a natio nal clinic al res e arc h gr o u p s u p p orte d b y t he N atio nal Ca nc er I nstit ute T his st u d y has p u blic f u n din g fr o m t he N atio nal Ca nc er I nstit ute ( N CI), part of t he N atio nal I nstit utes of H e alt h ( NI H) in t he U nite d States D e part me nt o f H e alt h a n d H u ma n Ser vic es. T he Allia nc e is ma de u p of c a nc er d oct ors, he alt h pr ofessio nals, a n d la b orat or y res e arc hers, w h os e g oal is t o de velo p better tre at me nts f or c a nc er, t o pre ve nt c a nc er, t o re d uc e side effe cts fr o m c a nc er, a n d t o i m pr o ve t he q uali t y of life of c a nc er patie nts. W h at is t he us u al a p pro ac h t o m y bre ast c a ncer ? We are as kin g y o u t o ta ke part in t his st u d y be c a us e y o u are 7 0 ye ars old or o ver a n d ha ve be e n re c e ntly dia g n os e d wit h estr o ge n re c e pt or p ositive, H E R 2 ne gative metastatic bre ast c a nc er. P atie nts wit h t his metastatic bre ast c a nc er are us ually tre ate d wit h a dr u g c alle d palb ociclib alo n g wit h a h or m o nal a ge nt, eit her f ulvestra nt or letr oz ole, as de ter mine d b y y o ur d oct or. P alb ocic lib a n d letr oz ole are give n b y m o ut h a n d f ulvestra nt is a n inje ctio n. T his st u d y f ollo ws t he us ual F o o d a n d Dr u g A d ministratio n ( F D A ) a p pr o ve d tre at me nt, b ut w e are c o n d uctin g t his st u d y be c a us e w e d o n’t k n o w if older patie nts ha ve m ore side effe cts t ha n y o u n ger patie nts. W h at are m y ot her c h oices if I d o n ot t a ke p art i n t his st u d y ? If y o u de cide n ot t o ta ke part in t his st u d y, y o u ha ve ot her c h oic es. F or e xa m ple: • Y o u ma y c h o os e t o ha ve t he us ual a p pr oa c h des cribe d a b o ve wit h o ut bein g in a st u d y. • Y o u ma y c h o os e t o ta ke part in a differe nt st u d y, if o ne is a vaila ble. • Y o u ma y c h o os e n ot t o be tre ate d f or c a nc er a n d ma y w a nt t o re c eive c o mf ort c are t o relie ve s y m pt o ms. W h y is t his st u d y bei n g d o ne ? T he p ur p os e of t his st u d y is t o fin d o ut t he side effe cts t hat t he sta n dar d, F D A -a p pr o ve d c o m binatio n tre at me nt of letr oz ole or f ulvestra nt a n d palb ocicli b has o n patie nts 7 0 ye ars old a n d o ver. P alb oci clib give n alo n g wit h letr oz ole or fulvestra nt inste a d of letr oz ole or f ulvestra nt"
87,page_87,"Allia nc e A1 7 1 6 0 1 8 8 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 alo ne s e e ms t o pre ve nt t he c a nc er fr o m gettin g w ors e. H o w e ver, fe w patie nts a ge d 7 5 a n d older participate d in pre vio us st u dies. T here will be a b o ut 8 8 pe o ple ta kin g part in t his st u d y. W h at are t he st u d y gro u ps ? I n t his st u d y, all st u d y participa nts will get t he s a me tre at me nt. Y o u will ta ke o ne c a ps ule of palb ocicli b o nc e a da y wit h f o o d f or 2 1 da ys. Y o u will n ot ta ke palb ocicli b f or t he ne xt 7 da ys. T his 2 8 da y perio d is c alle d a c ycle. Y o u s h o uld tr y t o ta ke t he palb ociclib c a ps ules at a b o ut t he s a me ti me e a c h da y. Y o u s h o uld n ot ha ve gra pefr uit or gra pefr uit juic e w hile o n t his st u d y. Y o u s h o uld also c he c k wit h y o ur d oct or or p har ma cist bef ore usin g a n y ne w me dicines, inclu din g o ver -t he-c o u nter dr u gs be c a us e of p ossible dr u g intera ctio ns. D urin g t his perio d, y o u will als o be give n eit her letr oz ole or f ulvestra nt bas e d o n w hat y o ur d oct or de cides. If y o ur d oct or pres cribes letr oz ole, y o u will ta ke o ne pill daily f or 2 8 da ys. If y o ur d oct or pres cribes f ulvestra nt y o u will re c eive inje ctio ns o n t he first da y a n d fifte e nt h da y of t he first c ycle a n d t he n o n t he first da y of e ver y c ycle after t hat. Y o u wi ll c o ntin ue o n t his tre at me nt pla n u ntil y o ur c a nc er pr o gress es or if y o u ha ve side effe cts t hat ma y pre ve nt y o u fr o m c o ntin uin g t o ta ke t he tre at me nt. E ac h c ycle is 2 8 d a ys ( 4 we e ks) P al b o cicli b pl us Letr o z ole We e k 1 We e k 2 We e k 3 We e k 4 We e k 5 + P al b o cicli b 1 c a ps ule e ver y da y 1 c a ps ule e ver y da y 1 c a ps ule e ver y da y N o c a ps ule 1 c a ps ule e ver y da y f or 2 1 da ys, t he n 7 da ys n o c a ps ules Letr o z ole 1 pill e ver y da y 1 pill e ver y da y 1 pill e ver y da y 1 pill e ver y da y 1 pill e ver y da y f or 2 8 da ys If y o u f or get t o ta ke a c a ps ule of palb ocicli b or letr oz ole, d o n ot ma ke u p t he miss e d d os e. S kip t hat d os e a n d ta ke t he dr u g o n t he ne xt da y. O r P al b o cicli b pl us F ul v e str a nt We e k 1 We e k 2 We e k 3 We e k 4 We e ks 5 + P al b o cicli b 1 c a ps ule e ver y da y 1 c a ps ule e ver y da y 1 c a ps ule e ver y da y N o c a ps ule 1 c a ps ule e ver y da y f or 2 1 da ys, t he n 7 da ys n o c a ps ules F ul v e str a nt I nje ctio n o n D a y 1 N o inje ctio n I nje ctio n o n D a y 1 5 N o inje ctio n I nje ctio n o n D a y 1 of e ver y 2 8 -da y c ycle If y o u f or get t o ta ke a c a ps ule of palb ocicli b, d o n ot ma ke u p t he miss e d d os e. S kip t hat d os e a n d ta ke t he c a ps ule o n t he ne xt da y."
88,page_88,"Allia nc e A1 7 1 6 0 1 8 9 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 H o w l o n g will I be i n t his st u d y ? Y o u will re c eive t he st u d y tre at me nt f or as lo n g as y o u d o n ot ha ve s e vere side effe cts a n d y o ur c a nc er d oes n ot get w ors e. If y o u de velo p s e vere side effe cts or y o ur c a nc er gets w ors e , y o ur d oct or ma y de cide t o re m o ve y o u fr o m t he st u d y tre at me nt. After y o u st o p t he st u d y tre at me nt, y o ur d oct or will c o ntin ue t o f ollo w y o ur pr o gress e ver y ye ar f or u p t o five ye ars. W h at e xtra tests, a n d pro ce d ures will I h a ve if I t a ke p art i n t his st u d y ? M ost of t he e xa ms, tests, a n d pr oc e d ures y o u will ha ve are part of t he us ual a p pr oa c h f or y o ur c a nc er. H o w e ver, t here are s o me e xtra q uestio n naires t hat y o u will ne e d t o c o m plete if y o u ta ke part in t his st u d y . Y o u will be as ke d t o c o m plete fo ur q uestio n naires a n d perf or m s o me tas ks as part of t his st u d y. T he q uestio n naires will be us e d in t his st u d y in or der t o fin d o ut m ore a b o ut h o w y o u fe el d urin g c a nc er tre at me nt a n d w hat t he effe ct of t he tre at me nt ma y be. T he q uestio n naires will be c o m plete d at t he f ollo win g ti me p oints: Ge ri atric A s s ess me nt: Y o u will be as ke d t o c o m plete t he geriatric ass ess me nt bef ore y o u be gin tre at me nt, prior t o c ycle 4, a n d at t he e n d of y o ur tre at me nt perio d. It will ta ke a b o ut 3 0 min utes t o c o m plete. T he geriatric ass ess me nt in v olves a q uestio n naire, a n inter vie w a n d a t as k. S o me q uestio ns will be as ke d b y a me m ber of t he he alt h c are te a m. Y o u will c o m plete ot her q uestio ns o n y o ur o w n. If y o u ha ve diffic ult y c o m pletin g a n y of t he q uestio ns or tas ks, a me m ber of t he te a m will help y o u. Y o u ma y s kip a n y q uestio ns y o u d o n ot wis h t o a ns w er. T he w alkin g tas k in v olves mini mal risk. It will in v olve y o u gettin g u p fr o m a c hair, w alkin g 1 0 fe et, a n d ret ur nin g t o t he c hair. P ossible ris ks inclu de fe elin g tire d, dizziness, incre as e d he art rate, a n d fallin g. T o mini mize t his ris k y o u will be clos ely m o nit ore d b y a me m ber of t he he alt h c are te a m d urin g t his tas k. If y o u are u nc o mf orta ble wit h w alkin g, y o u ma y s kip t his tas k. Y o u will be as ke d t o c o m plete t hre e ot her q uestio n naires, t w o of w hic h will be re q uire d at t he be gin nin g of e ver y c ycle f or t he first 6 c ycles of tre at me nt, a n d at t he e n d of y o ur tre at me nt perio d. T hes e q uestio n naires will in v olve q uestio ns a b o ut t he side e ffe cts y o u are e x perie ncin g fr o m y o ur tre at me nt a n d a b o ut y o ur ge neral q ualit y of life . T he y will ta ke a b o ut fifte e n t o t w e nt y min utes t o c o m plete. T he ot her q uestio n naire will o nly ne e d t o be c o m plete d at t he e n d of y o ur tre at me nt. It will as k q uestio ns re gar din g h o w t he st u d y helpe d y o u. It will ta ke a b o ut five min utes t o c o m plete."
89,page_89,"Allia nc e A1 7 1 6 0 1 9 0 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 Pill Di ar y Y o u will als o be c o m pletin g a pill diar y e ver y da y , f or t he first t hre e c ycles. Y o u will be as ke d t o brin g t he c o m plete d pill diar y at t he e n d of e ver y c ycle, t o ma ke s ure y o u are ta kin g t he c orre ct d os e a n d n ot m ore t ha n t he sta n dar d d os e. Y o u will re c eive r o utine s c a ns e ve r y 1 2 w e e ks t o s e e if y o ur c a nc er is gettin g w ors e or bet ter, as part of y o ur c a nc er c are. Y o ur d oct or will s e n d c o pies of t hes e s c a ns t o t he Allia nc e, s o t hat res e arc hers c a n e valuate w het her t he tre at me nt y o u are re c eivin g ma y c a us e loss of m us cle tiss ue. W h at p ossi ble ris ks c a n I e x pect fro m t a ki n g p art i n t his st u d y ? If y o u c h o os e t o ta ke part in t his st u d y, t here is a ris k t hat: • Y o u ma y s pe n d m ore ti me in t he h os pital or d oct or’s offic e t ha n us ual • Y o u ma y be as ke d s e nsitive or private q uestio ns w hic h y o u n or mally d o n ot dis c uss T he dr u gs us e d in t his s t u d y ma y affe ct h o w differe nt parts of y o ur b o d y w or k s uc h as y o ur liver, kid ne ys, he art, a n d blo o d. T he st u d y d oct or will test y o ur blo o d a n d let y o u k n o w if c ha n ges oc c ur t hat ma y affe ct y o ur he alt h. T here is als o a ris k t hat y o u c o uld ha ve side effe cts fr o m t he st u d y dr u gs. H ere are i m p orta nt p oints a b o ut side effe cts: • T he st u d y d oct ors d o n ot k n o w w h o will or will n ot ha ve side effe cts. • S o me side effe cts ma y g o a w a y s o o n, s o me ma y last a lo n g ti me, or s o me ma y ne ver g o a w a y. • S o me side effe cts ma y be s erio us a n d ma y e ve n res ult in de at h. Y o u c a n as k t he st u d y d oct or q uestio ns a b o ut side effe cts at a n y ti me. H ere are i m p orta nt p oints a b o ut h o w y o u a n d t he st u d y d oct or c a n ma ke side effe cts less of a pr o ble m: • Tell t he st u d y d oct or if y o u n otic e or fe el a n yt hin g differe nt, s o t he y c a n s e e if y o u are ha vin g a side effe ct. • T he st u d y d oct or ma y be a ble t o tre at s o me side effe cts. • T he st u d y d oct or ma y a djust t he st u d y dr u gs t o tr y t o re d uc e side effe cts. T he ta bles belo w s h o w t he m ost c o m m o n a n d t he m ost s eri o us side effe cts t hat res e arc hers k n o w a b o ut. K e e p in min d t hat t here mig ht be ot her side effe cts t hat res e arc hers d o n ot yet k n o w a b o ut. If i m p orta nt ne w side effe cts are f o u n d, t he st u d y d oct or will dis c uss t hes e wit h y o u. P ossible side effe cts of P alb ociclib, Letr oz ole a n d F ulvestra nt :"
90,page_90,"Allia nc e A1 7 1 6 0 1 9 1 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 P os si ble Si de Effe cts fo r P al b o cicli b ( P D -0 3 3 2 9 9 1) C O M M O N, S O M E M A Y B E S E RI O U S I n 1 0 0 pe o ple r ec eivin g P alb ociclib ( P D -0 3 3 2 9 9 1) , m ore t ha n 2 0 a n d u p t o 1 0 0 m a y ha ve: • Ane mia w hic h m a y r e q uir e blo o d tr a nsf usio n • Na us ea • Tir e d ness • I nf ectio n, es pecially w he n w hit e blo o d c ell c o u nt is lo w O C C A SI O N A L, S O M E M A Y B E S E RI O U S I n 1 0 0 pe o ple r ec eivin g P alb ociclib ( P D -0 3 3 2 9 9 1) , fr o m 4 t o 2 0 m a y ha ve: • Blurr e d visio n, w at erin g e yes • Dr y e ye , s kin • C o nstipatio n, diarr hea, v o mitin g • S or es in t he m o ut h w hic h m a y c a us e diffic ult y s w allo win g • F e ver • Br uisin g, blee din g • L oss of a p petit e • C ha n ges in t ast e • Hea dac he • N os e blee d • Hair loss, r as h R A R E, A N D S E RI O U S I n 1 0 0 pe o ple r ec eivin g P alb ociclib ( P D -0 3 3 2 9 9 1) , 3 or f e wer m a y ha ve: • Da m a ge t o t he lu n gs w hic h m a y c a us e s h ortness of br eat h P os si ble Si de Effe cts of F ul v e str a nt C O M M O N, S O M E M A Y B E S E RI O U S I n 1 0 0 pe o ple re c eivin g F ulvestra nt, m ore t ha n 2 0 a n d u p t o 1 0 0 ma y ha ve: • P ain • Tire d ness • I ncre as e d s w e atin g • H ot flas hes, flus hin g • S w ellin g a n d re d ness at t he site of t he me dic atio n inje ctio n O C C A SI O N A L, S O M E M A Y B E S E RI O U S I n 1 0 0 pe o ple re c eivin g F ulvestra nt, fr o m 4 t o 2 0 ma y ha ve: • C o nstipatio n, diarr he a, na us e a, v o mitin g, loss of a p petite, he art b ur n • S w ellin g of t he b o d y • L oss of b o ne tiss ue, br o ke n b o ne, or de cre as e d heig ht • Dizziness, he a da c he"
91,page_91,"Allia nc e A1 7 1 6 0 1 9 2 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 O C C A SI O N A L, S O M E M A Y B E S E RI O U S I n 1 0 0 pe o ple re c eivin g F ulvestra nt, fr o m 4 t o 2 0 ma y ha ve: • Diffic ult y sle e pin g • Fluid ar o u n d lu n gs • S w ellin g of t he liver w hic h ma y c a us e belly pain • W orr y, de pressio n, m o o d s win gs • H air t hin nin g • C o u g h R A R E, A N D S E RI O U S I n 1 0 0 pe o ple re c eivin g F ulvestra nt, 3 or fe w er ma y ha ve: • Aller gic re a ctio n w hic h ma y c a us e ras h, lo w blo o d press ure, w he e zin g, s h ort ness of bre at h, s w ellin g of t he fa c e or t hr oat • Liver da ma ge w hic h ma y c a us e yello w e yes a n d s kin • V a ginal ble e din g • Blo o d clot w hic h ma y c a us e s w ellin g, pain, s h ort ness of bre at h • H e art atta c k or he art failure w hic h ma y res ult in c hest pain, s h ort ness of bre at h, s w ellin g of a n kles, a n d tire d ness • Str o ke w hic h ma y c a us e w e a k ness, paralysis P os si ble Si de Effe cts of Letr o z ole C O M M O N, S O M E M A Y B E S E RI O U S I n 1 0 0 pe o ple re c eivin g Letr oz ole, m ore t ha n 2 0 a n d u p t o 1 0 0 ma y ha ve: • P ain • Tire d ness • I ncre as e d s w e atin g • H ot flas hes, flus hin g O C C A SI O N A L, S O M E M A Y B E S E RI O U S I n 1 0 0 pe o ple re c eivin g Letr oz ole, fr o m 4 t o 2 0 ma y ha ve: • C o nstipatio n, diarr he a, na us e a, v o mitin g, loss of a p petite, he art b ur n • S w ellin g of t he b o d y • L oss of b o ne tiss ue, br o ke n b o ne, or de cre as e d heig ht • Dizziness, he a da c he • Diffic ult y sle e pin g • Fluid ar o u n d lu n gs • S w ellin g of t he liver w hic h ma y c a us e belly pain • W orr y, de pressio n, m o o d s win gs • H air t hin nin g"
92,page_92,"Allia nc e A1 7 1 6 0 1 9 3 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 R A R E, A N D S E RI O U S I n 1 0 0 pe o ple re c eivin g Letr oz ole, 3 or fe w er ma y ha ve: • Aller gic re a ctio n w hic h ma y c a us e ras h, lo w blo o d press ure, w he e zin g, s h ort ness of bre at h, s w ellin g of t he fa c e or t hr oat • Liver da ma ge w hic h ma y c a us e yello w e yes a n d s kin • V a ginal ble e din g • Blo o d clot w hic h ma y c a us e s w ellin g, pain, s h ort ness of bre at h • H e art atta c k or he art failure w hic h ma y c a us e s h ort ness of bre at h, s w ellin g of a n kles, a n d tire d ness • Str o ke w hic h ma y c a us e w e a k ness, paralysis Ris ks fr o m q ue sti o n n aire s Y o u ma y be c o me tire d fr o m t he a m o u nt of ti me ne e de d t o fill o ut t he q uestio n naires a n d d o t he ot her e valuatio ns. T he q uestio n naire will f oc us o n life iss ues t hat c o uld c a us e y o u t o be c o me e m otio nall y u ps et. If y o u be c o me distress e d a me m ber of t he st u d y te a m will talk wit h y o u. If ne e de d, y o u c a n be referre d t o y o ur d oct or t o deter mine h o w best t o ha n dle y o ur c o nc er ns . Ris ks fr o m wal ki n g t as k As part of t he geriatric ass ess me nt, y o u will be as ke d t o c o m plete a w alkin g tas k. Y o u ma y fe el tire d, dizz y, ha ve a n incre as e d he art rate or fall d urin g t he w alkin g tas k. T o mini mize t his ris k, y o u will be clos ely m o nit ore d b y a me m ber of t he he alt h c are te a m d urin g t his tas k. If y o u are u nc o mf orta ble wit h w alkin g, y o u ma y s kip t his tas k. W h at p ossi ble be nefits c a n I e x pect fro m t a ki n g p art i n t his st u d y ? T his st u d y ma y or ma y n ot help y o u. H o w e ver, t his st u d y ma y help us u n dersta n d h o w t his st u d y dr u g w or ks in older a d ults, a n d ma y help res e arc hers le ar n t hin gs t hat ma y help ot her older pe o ple in t he f u t ure. C a n I st o p t a ki n g p art i n t his st u d y ? Y es. Y o u c a n de cide t o st o p at a n y ti me. If y o u de cide t o st o p f or a n y re as o n, it is i m p orta nt t o let t he st u d y d oct or k n o w as s o o n as p ossible s o y o u c a n st o p s afely. If y o u st o p, y o u c a n de cide w het her or n ot t o let t he st u d y d oct or c o ntin ue t o pr o vide y o ur me dic al inf or matio n t o t he or ga nizatio n r u n nin g t he st u d y. T he st u d y d oct or will tell y o u a b o ut ne w inf or matio n or c ha n ges in t he st u d y t hat ma y affe ct y o ur he alt h or y o ur willin g ness t o c o ntin ue in t he st u d y. I n t ur n, t he st u d y d oct or ma y re m o ve y o u fr o m t he st u d y, if: • Y o ur he alt h c ha n ges a n d t he st u d y is n o lo n ger in y o ur best interest • N e w inf or matio n be c o mes a vaila ble • Y o u d o n ot f ollo w t he st u d y r ules • T he st u d y is st o p pe d b y t he s p o ns or, I nstit utio na l Re vie w B oar d (I R B) or F D A."
93,page_93,"Allia nc e A1 7 1 6 0 1 9 4 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 W h at are m y ri g hts i n t his st u d y ? Ta kin g part in t his st u d y is y o ur c h oic e. N o matter w hat de cisio n y o u ma ke, a n d e ve n if y o ur de cisio n c ha n ges, t here will be n o pe nalt y t o y o u. Y o u will n ot los e me dic al c are or a n y le gal rig hts. F or q uestio ns a b o ut y o ur rig hts w hile in t his st u d y, c all t he _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ (i ns ert n a me of c e nter) I nstit utio nal Re vie w B oar d at _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ (i ns ert tele p h o n e n u mb er). W h at are t he c osts of t a ki n g p art i n t his st u d y ? Y o ur P ote ntia l C osts: Y o u a n d/ or y o ur he alt h pla n/ins ura nc e c o m pa n y will ne e d t o pa y f or all of t he c osts of tre atin g y o ur c a nc er w hile in t his st u d y, inclu din g t he c ost of tests, pr oc e d ures, or me dicines t o ma na ge a n y side effe cts, u nless y o u are t old t hat c ertain tests are s u p plie d at n o c har ge. Bef ore y o u de cide t o be in t he st u d y, y o u s h o uld c he c k wit h y o ur he alt h pl a n or ins ura nc e c o m pa n y t o fin d o ut e xa ctly w hat t he y will pa y f or. Y o u a n d/ or y o ur he alt h pla n/ins ura nc e c o m pa n y will be res p o nsible f or: • P alb ociclib, letr oz ole or f ulvestra nt a n d all pre me dic atio ns, fluids a n d pr oc e d ures. • E xa ms, tests, a n d pr oc e d ures t h at ma y be ne e de d t o ma na ge side effe cts a n d t o m o nit or y o ur s afet y. C osts P aid b y t he St u d y E xa ms, tests, a n d pr oc e d ures d o ne f or res e arc h p ur p os es o nly will n ot be bille d t o y o u or y o ur ins ura nc e pla n. T hes e inclu de b lo o d c olle ctio ns f or t he o ptio nal st u dies a n d s u b missio n of i ma ges t o t he Allia nc e f or e valuatin g w het her t he tre at me nt y o u are rec eivin g ma y c a us e loss of m us cle tiss ue. Y o u will n ot be paid f or ta kin g part in t his st u d y . W h at h a p pe ns if I a m i nj ure d bec a use I t o o k p art i n t his st u d y ? If y o u are injure d as a res ult of ta kin g part in t his st u d y a n d ne e d me dic al tre at me nt, ple as e tell y o ur st u d y d oct or. T he st u d y s p o ns ors will n ot offer t o pa y f or me dic al tre at me nt f or injur y. Y o ur ins ura nc e c o m pa n y ma y n ot be willin g t o pa y f or st u d y-relate d injur y. If y o u ha ve n o ins ura nc e, y o u w o uld be res p o nsible f or a n y c osts. If y o u fe el t his injur y w as a res ult of me dic al err or, y o u ha ve le gal rig hts t o re c eive pa y me nt f or t his injur y e ve n t h o u g h y o u are in a st u d y. W h o will see m y me dic al i nf o r m ati o n ? Y o ur priva c y is ver y i m p orta nt t o us a n d t he res e arc hers will ma ke e ver y eff ort t o pr ote ct it. T he st u d y d oct ors ha ve a priva c y per mit t o help pr ote ct y o ur re c or ds if t here is a c o urt c as e."
94,page_94,"Allia nc e A1 7 1 6 0 1 9 5 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 H o w e ver, y o ur inf or matio n ma y be give n o ut if re q uire d b y la w. F or e xa m ple, c ertain states re q uire d oct ors t o re p ort t o he alt h b oar ds if t he y fin d a dis e as e like t u berc ulosis. H o w e ver, t he res e arc hers will d o t heir best t o ma ke s ure t hat a n y inf or matio n t hat is rele as e d will n ot ide ntif y y o u. S o me of y o ur he alt h inf or matio n a n d inf or matio n a b o ut y o ur s pe ci me n fr o m t his st u d y will be ke pt in a c e ntral data bas e f or res e arc h. Y o ur na me or c o nta ct inf or matio n will n ot be p ut in t he data bas e. T here are or ga nizatio ns t hat ma y lo o k at or re c eive c o pies of s o me of t he inf or matio n in y o ur st u d y re c or ds. Y o ur he alt h inf or matio n in t he data bas e ma y als o be s hare d wit h t hes e or ga nizatio ns. T he y are re q uire d t o ma ke s ure y o ur inf or matio n is ke pt private, u nless re q uire d b y la w t o pr o vide inf or matio n. S o me of t hes e or ga nizatio ns are: • T he Allia nc e f or Clinic al Trials in O nc olo g y • T he N CI Ce ntral I R B is a gr o u p of pe o ple w h o re vie w t he res e arc h wit h t he g oal of pr ote ctin g t he pe o ple w h o ta ke part in t he st u d y. • T he F o o d a n d Dr u g A d ministratio n a n d t he N atio nal Ca nc er I nstit u te in t he U. S., a n d si milar o nes if ot her c o u ntries are in v olve d in t he st u d y. I n a d ditio n t o st orin g data in t he st u d y data bas e, data fr o m st u dies t hat are p u blicly f u n de d ma y als o be s hare d br oa dly f or f ut ure res e arc h wit h pr ote ctio ns f or y o ur priva c y. T he g oal of t his data s harin g is t o ma ke m ore res e arc h p ossible t hat ma y i m pr o ve pe o ple’s he alt h. Y o ur st u d y re c or ds ma y be st ore d a n d s hare d f or f ut ure us e in p u blic data bas es . H o w e ver, y o ur na me a n d ot her pers o nal inf or matio n will n ot be us e d. S o me t y pes of f ut ure res e arc h ma y inclu de lo o kin g at y o ur inf or matio n a n d inf or matio n fr o m ot her patie nts t o s e e w h o ha d side effe cts a cr oss ma n y st u dies or c o m parin g ne w st u d y data wit h older st u d y data. H o w e ver, rig ht n o w w e d o n’t k n o w w hat res e arc h ma y be d o ne in t he f ut ure usin g y o ur inf or matio n. T his me a ns t hat: • Y o u will n ot be as ke d if y o u a gre e t o ta ke part in t he s pe cific f ut ure res e arc h st u dies usin g y o ur he alt h inf or matio n. • Y o u a n d y o ur st u d y d oct or will n ot be t old w he n or w hat t y pe of res e arc h will be d o ne. • Y o u will n ot get re p orts or ot her inf or matio n a b o ut a n y res e arc h t hat is d o ne usin g y o ur inf or matio n. W here c a n I get m o re i nf o r m ati o n ? Y o u ma y visit t he N CI w e b site at htt p://c a nc er. g o v/ f or m ore inf or matio n a b o ut st u dies or ge neral inf or matio n a b o ut c a nc er. Y o u ma y als o c all t he N CI Ca nc er I nf or matio n Ser vic e t o get t he s a me inf or matio n at: 1-8 0 0 -4 -C A N C E R ( 1 -8 0 0 -4 2 2 -6 2 3 7). A des criptio n of t his clinic al trial will be a vaila ble o n htt p:// w w w. Clinic al Trials. g o v , as re q uire d b y U. S. la w. O nc e t he st u d y is o ver, t he site ma y inclu de a s u m mar y of t he res ults. T his s u m mar y will n ot inclu de a n y inf or matio n t hat c a n ide ntif y y o u."
95,page_95,"Allia nc e A1 7 1 6 0 1 9 6 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 W h o c a n a ns wer m y q uesti o ns a b o ut t his st u d y ? Y o u c a n talk t o t he st u d y d oct or a b o ut a n y q u estio ns or c o nc er ns y o u ha ve a b o ut t his st u d y or t o re p ort side effe cts or injuries. Co nta ct t he st u d y d oct or _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ (i ns ert n a me of st u d y d o ct or[s]) at _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ (i ns ert tele p h o n e n u mb er). A d diti o n al St u dies Secti o n: T his secti o n is a b o ut o pti o n al st u dies y o u c a n c h o ose t o t a ke p art i n T his part of t he c o ns e nt f or m is a b o ut o ptio nal st u dies t hat y o u c a n c h o os e t o ta ke part in. T he y are s e parate fr o m t he main st u d y des cribe d a b o ve. T hes e o p tio nal st u dies will n ot be nefit y o ur he alt h. T he res e arc hers le a din g t hes e o ptio nal st u dies h o pe t he res ults will help ot her pe o ple wit h c a nc er in t he f ut ure. T he res ults will n ot be a d de d t o y o ur me dic al re c or ds a n d y o u or y o ur st u d y d oct or will n ot k n o w t he res ults. N eit her y o u n or y o ur ins ura nc e will be bille d f or t hes e o ptio nal st u dies. Y o u c a n still ta ke part in t he main st u d y e ve n if y o u s a y “ n o” t o a n y or all of t hes e st u dies. If y o u sig n u p f or b ut c a n n ot c o m plete a n y of t he o ptio nal st u dies f or a n y re as o n, y o u c a n still ta ke part in t he main st u d y. Circle y o ur c h oic e of “ yes ” or “ n o” f or e a c h of t he f ollo win g st u dies. O pti o n al s a m ple c ollecti o ns f o r l a b o rat ory st u dies a n d bi o b a n ki n g f o r p ossi ble f ut ure st u dies Res e arc hers are tr yin g t o le ar n m ore a b o ut c a nc er a n d ot her he alt h pr o ble ms usin g s a m ples fr o m pe o ple’s tiss ue, blo o d, urine, or ot her fluids. B y c o n d uctin g res e arc h o n t hes e s a m ples, res e arc hers h o pe t o fin d ne w w a ys t o pre ve nt, dete ct, tre at, or c ure he alt h pr o ble ms. S o me of t he s e st u dies ma y be a b o ut h o w ge nes affe ct he alt h a n d dis e as e a n d h o w pe o ple res p o n d t o tre at me nt. Ge nes c arr y inf or matio n a b o ut fe at ures t hat are f o u n d in y o u a n d y o ur fa mily, fr o m t he c olor of y o ur e yes t o he alt h c o n ditio ns f or w hic h y o u ma y be at ris k. Res e arc h t hat st u dies y o ur ge nes is k n o w n as ge n o mics or ge netics. If y o u c h o os e t o ta ke part in t hes e o ptio nal st u dies , t he st u d y d oct or f or t he main st u d y w o uld like t o c olle ct blo o d f or res e arc h o n w h y patie nts ha ve differe nt side effe cts fr o m t he tre at m e nt. I n a d ditio n, t he res e arc hers as k y o ur per missio n t o st ore a n d us e y o ur s a m ples a n d relate d he alt h inf or matio n (f or e xa m ple, y o ur res p o ns e t o c a nc er tre at me nt, res ults of st u d y tests a n d me dicines y o u are give n) f or me dic al res e arc h. T he a d ditio nal r es e arc h t hat ma y be d o ne is u n k n o w n at t his ti me. St orin g s a m ples f or f ut ure st u dies is c alle d “ bio ba n kin g”. T he Bio ba n k is bein g r u n b y t he Allia nc e a n d s u p p orte d b y t he N atio nal Ca nc er I nstit ute."
96,page_96,"Allia nc e A1 7 1 6 0 1 9 7 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 W h at is i n v ol ve d ? If y o u a gre e t o ta ke part, here is w hat will ha p pe n ne xt: 1) A b o ut 6 te as p o o ns of blo o d will be c olle cte d fr o m a vein in y o ur ar m. F o ur te as p o o ns of blo o d will be dra w n bef ore y o u be gin tre at me nt, a n d t w o te as p o o ns will be dra w n after y o u ha ve ta ke n t hre e c ycles of tre at me nt. 2) I n a d ditio n, o ne te as p o o n of blo o d will be c olle cte d bef ore y o u start st u d y tre at me nt, at y o ur c ycle 1 da y 1 a n d da y 1 5 clinic visits, a n d c ycle 2 da y 1 5 clinic visit, f or res e arc h o n h o w t he st u d y dr u g c ha n ges in y o ur b o d y o ver ti me a n d if t hat c a n c ha n ge y o ur side effe cts. Y o u will als o c o m plete a f or m at t hes e visits w he n blo o d is c olle cte d f or t his res e arc h. It will ta ke less t ha n five min utes t o c o m plete t his f or m. F or t his st u d y, y o ur blo o d will be s e nt t o res e arc hers at t he U niversit y of Pitts b ur g h Ca nc er Ce nter wit h y o ur initials a n d c olle ctio n date a n d ti me o n it. 3) Y o ur bas eline blo o d s a m ple a n d s o me relate d he alt h inf or matio n will be s e nt t o a res e arc her f or us e in t he st u d y des cribe d a b o ve. Re mainin g bas eline blo o d s a m ples ma y be st ore d in t he Bio ba n k, alo n g wit h s a m ples fr o m ot her pe o ple w h o ta ke part. T he s a m ples will be ke pt u ntil t he y are us e d u p. 4) O nly q ualifie d res e arc hers c a n re c eive s a m ple s fr o m t he bio ba n k. T here will be s cie ntific a n d et hics re vie ws t o e ns ure t hat t he res e arc h is ne c ess ar y a n d pr o per. Res e arc hers will n ot be give n y o ur na me or a n y ot her inf or matio n t hat c o uld dire ctly ide ntif y y o u. 5) N eit her y o u n or y o ur st u d y d oct or will be n otifie d w he n res e arc h will be c o n d ucte d. Y o u will n ot re c eive re p orts or ot her inf or matio n a b o ut a n y res e arc h t hat is d o ne usin g y o ur s a m ples. 6) S o me of y o ur ge netic a n d he alt h inf or matio n ma y be pla c e d in c e ntral data bas es t hat will be a vaila ble t o q ualifie d res e arc hers. I nf or matio n t hat c o uld dire ctly ide ntif y y o u will n ot be inclu de d. W h at are t he p ossi ble ris ks ? 1) T he m ost c o m m o n ris ks relate d t o dra win g blo o d fr o m y o ur ar m are brief pain a n d ma y be a br uis e. 2) E ve n wit h o ut y o ur na me or ot her ide ntifiers, y o ur ge netic inf or matio n is u niq ue t o y o u. T here is a ris k t hat s o me o ne o utside of t he res e arc h c o uld get a c c ess t o y o ur pers o nal inf or matio n in y o ur me dic al re c or ds or tra c e inf or matio n in a data bas e ba c k t o y ou. T he res e arc hers belie ve t he c ha nc e t hat s o me o ne c o uld re -ide ntif y y o u is ver y s mall, b ut t he ris k ma y c ha n ge in t he f ut ure as pe o ple c o me u p wit h ne w w a ys of tra cin g inf or matio n. 3) I n s o me c as es, t his inf or matio n c o uld be us e d t o ma ke it har der f or y o u to get or ke e p a jo b or ins ura nc e. T here are la ws a gainst t he mis us e of ge netic inf or matio n, b ut t he y ma y n ot give f ull pr ote ctio n. T here c a n als o be a ris k in k n o win g ge netic inf or matio n. N e w he alt h inf or matio n a b o ut in herite d traits t hat mig ht affe ct y o u or y o ur blo o d relatives c o uld be f o u n d d urin g a st u d y. T he res e arc hers belie ve t he c ha nc e t hes e t hin gs will ha p pe n is ver y s mall, b ut c a n n ot pr o mis e t hat t he y will n ot oc c ur."
97,page_97,"Allia nc e A1 7 1 6 0 1 9 8 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 H o w will i nf o r m ati o n a b o ut me be ke pt pri v ate ? Y o ur priva c y is ver y i m p orta nt t o t he res e arc hers a n d t he y will ma ke e ver y eff ort t o pr ote ct it. H ere are just a fe w of t he ste ps t he y will ta ke: 1) W he n y o ur s a m ple s are s e nt b y t he bio ba n k t o t he q ualifie d res e arc hers, n o inf or matio n ide ntif yin g y o u (s uc h as y o ur na me) will be s e nt. Sa m ples will be ide ntifie d b y a u niq ue c o de o nly. 2) T he list t hat lin ks t he u niq ue c o de t o y o ur na me will be ke pt s e parate fr o m y o ur s a m ple a n d he alt h inf or matio n. A n y bio ba n k a n d Allia nc e staff wit h a c c ess t o t he list m ust sig n a n a gre e me nt t o ke e p y o ur ide nti t y c o nfide ntial. 3) Y o ur blo o d s a m ple c olle cte d f or o ne of t he a d ditio nal st u dies will be s e nt t o res e arc hers at t he U niversit y of Pitts b ur g h Ca nc er Ce nter wit h y o ur initials a n d c olle ctio n date a n d ti me o n it . 4) Res e arc hers t o w h o m t he Allia nc e se n ds y o ur s a m ple a n d inf or matio n will n ot k n o w w h o y o u are. T he y m ust als o sig n a n a gre e me nt t hat t he y will n ot tr y t o fin d o ut w h o y o u are. 5) I nf or matio n t hat ide ntifies y o u will n ot be give n t o a n y o ne, u nless re q uire d b y la w. 6) If res e arc h res ults are p u blis he d, y o ur na me a n d ot her pers o nal inf or matio n will n ot be us e d. W h at are t he p ossi ble be nefits ? Y o u will n ot be nefit fr o m ta kin g part. T he res e arc hers, usin g t he s a m ples fr o m y o u a n d ot hers, mig ht ma ke dis c o veries t hat c o uld help pe o ple in t he f ut ure. Are t here a n y c osts o r p a y me nts ? T here are n o c osts t o y o u or y o ur ins ura nc e. Y o u will n ot be paid f or ta kin g part. If a n y of t he res e arc h le a ds t o ne w tests, dr u gs, or ot her c o m mercial pr o d ucts, y o u will n ot s hare in a n y pr ofits. W h at if I c h a n ge m y mi n d ? If y o u de cide y o u n o lo n ger w a nt y o ur s a m ples t o be us e d, y o u c a n c all t he st u d y d oct or, _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _, (i ns ert n a me of st u d y d o ct or f or mai n tri al) at _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ (i ns ert tele p h o ne n u mb er of st u d y d o ct or f or mai n tri al) w h o will let t he res e arc hers k n o w. T he n, a n y s a m ple t hat re mains in t he bio ba n k will n o lo n ger be us e d a n d relate d he alt h inf or matio n will n o lo n ger be c olle cte d. T his will n ot a p ply t o t h os e s a m ples or relate d inf or matio n t hat ha ve alre a d y be e n give n t o or us e d b y q ualifie d res e arc hers."
98,page_98,"Allia nc e A1 7 1 6 0 1 9 9 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 W h at if I h a ve q uesti o ns ? If y o u ha ve q uestio ns a b o ut t he us e of y o ur s a m ples f or res e arc h, c o nta ct t he st u d y d oct or, _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _, (i ns ert n a me of st u d y d oct or f or mai n tri al), at _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ (i ns ert tele p h o n e n u mb er of st u d y d oct or f or mai n tri al). Ple as e circle y o ur a ns w er t o s h o w w het her or n ot y o u w o uld like t o ta ke part in e a c h o ptio n: S a m ples f o r t he l a b o rat o ry st u dies: 1. I a gre e t o ha ve m y s pe ci me n c olle cte d a n d I a gre e t hat m y s pe ci me n s a m ple(s) a n d relate d inf or matio n ma y be us e d f or t he la b orat or y st u dies des cribe d a b o ve. Y E S N O S a m ples f o r f ut ure rese arc h st u dies: 2. M y s a m ples a n d relate d inf or matio n ma y be ke pt in a bio ba n k f or us e in f ut ure he alt h res e arc h. Y E S N O 3. I a gre e t hat m y st u d y d oct or, or t heir re pres e ntative, ma y c o nta ct me or m y p h ysicia n t o s e e if I wis h t o participate in ot her res e arc h in t he f ut ure. Y E S N O T his is t he e n d of t he s e ctio n a b o ut o ptio nal st u dies. M y si g n at ure a greei n g t o t a ke p art i n t he m ai n st u d y I ha ve re a d t his c o ns e nt f or m or ha d it re a d t o me. I ha ve dis c uss e d it wit h t he st u d y d oct or a n d m y q uestio ns ha ve be e n a ns w ere d. I will be give n a sig ne d c o p y of t his f or m. I a gre e t o ta ke part in t he main st u d y a n d a n y a d ditio nal st u dies w here I circle d ‘ yes’. P articipa nt’s sig nat ure _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ D ate of sig nat ure _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ Sig nat ure of pers o n(s) c o n d uctin g t he inf or me d c o ns e nt dis c ussio n _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ D ate of sig nat ure _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _"
99,page_99,"Allia nc e A1 7 1 6 0 1 1 0 0 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 AP P E N DI X I: P A TI E N T I N F O R M A TI O N S H E E T S P ati e nt C o m pl et e d B o o klet A : C ycl e 1 a n d 4, D a y 1 _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __ _ _ _ _ _ _ __ _ _ _ _ _ _ __ _ _ _ _ _ _ __ _ _ _ _ _ _ __ _ _ _ _ _ _ __ _ _ Y o u h a ve be e n gi ve n a bo o kl et t o c o m pl et e f o r t his st u dy. T his bo o kl et c o nt ai ns s o m e q u esti o ns a bo ut y o u r ‘ q u alit y -of -life’ as a pati e nt re cei vi n g t re at me nt f or c a n cer. Y o u r a ns we rs will h el p us t o better u n de rst a n d h o w t h e t re at me nt y o u are receivi n g is aff ecti n g t he wa y y o u f e el. 1. Yo u ar e bei n g as ke d t o c o m plet e a q uestio n nair e b o o klet f or t his st u d y. T his b o o klet m ust be c o m plet e d o n Da y 1 of C ycle 1 a n d 4 of y o ur st u d y tr eat m e nt. It c o nt ains t he f ollo win g q uestio n nair es: • Geriatric Ass ess m e nt • E Q -5 D 3 L • P R O -C T C A E q uestio n nair e Da y 1 • Geriatric Ass ess m e nt: Healt hc ar e Pr of essio nal Q uestio n nair e -Not e: T his f or m is t o be c o m pl et e d by t h e h e alt h c are pr of essio n al, n ot t he pati e nt. 2. Dir ectio ns o n h o w t o c o m plet e eac h s et of q uestio ns ar e writt e n o n t he t o p of eac h s et. 3. It is ver y i m p ort a nt t hat y o u r et ur n t he b o o klets t o us, w het her y o u finis h t he st u d y or n ot. 4. Yo u will be give n t he n urs e’s or st u d y c o or dinat or’s na m e a n d t ele p h o ne n u m ber. Yo u c a n c all a n yti m e wit h a n y c o nc er ns or q uestio ns. 5. Aft er c o m pletin g t his b o o klet, p leas e r et ur n it t o y o ur n urs e or p h ysicia n. T ha n k y o u f or t a ki ng t he ti me t o hel p us."
100,page_100,"Allia nc e A1 7 1 6 0 1 1 0 1 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 P A TI E N T I N F O R M A TI O N S H E E T P ati e nt C o m pl et e d B o o klet B : C ycl es 1 a n d 2, D a y 1 5 _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __ _ _ _ _ _ _ __ _ _ _ _ _ _ __ _ _ _ _ _ _ __ _ _ _ _ _ _ __ _ _ _ _ _ _ __ _ _ Y o u h a ve be e n gi ve n a bo o kl et t o c o m pl et e f or t his st u dy. T his bo o kl et c o nt ai ns s o m e q u esti o ns a bo ut y o u r ‘ q u alit y -of -life’ as a pati e nt re cei vi n g t re at me nt f or c a n cer. Y o u r a ns we rs will h el p us t o better u n de rst a n d h o w t h e t re at me nt y o u are receivi n g is aff ecti n g t he wa y y o u f e el. 1. Y o u are bein g as ke d t o c o m plete a q uestio n naire b o o klet f or t his st u d y. T his b o o klet m ust be c o m plete d o n D a y 1 5 of C ycle s 1 a n d 2 of y o ur st u d y tre at me nt. It c o ntains t he f ollo win g q uestio n naires: • P R O -C T C A E q uestio n naire D a y 1 5 2. Dir ectio ns o n h o w t o c o m plet e eac h s et of q uestio ns ar e writt e n o n t he t o p of eac h s et. 3. It is ver y i m p ort a nt t hat y o u r et ur n t he b o o klets t o us, w het her y o u finis h t he st u d y or n ot. 4. Yo u will be give n t he n urs e’s or st u d y c o or dinat or’s na m e a n d t ele p h o ne n u m ber. Yo u c a n c all a n yti m e wit h a n y c o nc er ns or q uestio ns. 5. Aft er c o m pletin g t his b o o klet, pleas e r et ur n it t o y o ur n urs e or p h ysicia n. T ha n k y o u f or t a ki ng t he ti me t o hel p us."
101,page_101,"Allia nc e A1 7 1 6 0 1 1 0 2 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 P A TI E N T I N F O R M A TI O N S H E E T P ati e nt C o m pl et e d B o o klet C : C ycl e 2, D a y 1, a n d C ycl es 3, 5, a n d 6 _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __ _ _ _ _ _ _ __ _ _ _ _ _ _ __ _ _ _ _ _ _ __ _ _ _ _ _ _ __ _ _ _ _ _ _ __ _ _ Y o u h a ve be e n gi ve n a bo o kl et t o c o m pl et e f or t his st u dy. T his bo o kl et c o nt ai ns s o m e q u esti o ns a bo ut y o u r ‘ q u alit y-of -life’ as a pati e nt re cei vi n g t re at me nt f or c a n cer. Y o u r a ns we rs will h el p us t o better u n de rst a n d h o w t h e t re at me nt y o u are receivi n g is aff ecti n g t he wa y y o u f e el. 1. Yo u ar e bein g as ke d t o c o m plet e a q uestio n nair e b o o klet f or t his st u d y. T h is b oo klet m ust be c o m plet e d o n Da y 1 of C ycle 2 , a n d C ycles 3, 5, a n d 6 of y o ur st u d y tr eat m e nt. It c o nt ains t he f ollo win g q uestio n nair es: • E Q -5 D 3 L • P R O -C T C A E q uestio n nair e Da y 1 2. Dir ectio ns o n h o w t o c o m plet e eac h s et of q uestio ns ar e writt e n o n t he t o p of eac h s et. 3. It is ver y i m p ort a nt t hat y o u r et ur n t he b o o klets t o us, w het her y o u finis h t he st u d y or n ot. 4. Yo u will be give n t he n urs e’s or st u d y c o or dinat or’s na m e a n d t ele p h o ne n u m ber. Yo u c a n c all a n yti m e wit h a n y c o nc er ns or q uestio ns. 5. Aft er c o m pletin g t his b o o klet, pleas e r et ur n it t o y o ur n urs e or p h ysicia n. T ha n k y o u f or t a ki ng t he ti me t o hel p us."
102,page_102,"Allia nc e A1 7 1 6 0 1 1 0 3 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 P A TI E N T I N F O R M A TI O N S H E E T P ati e nt C o m pl et e d B o o klet D: E N D O F T R E A T M E N T _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __ _ _ _ _ _ _ __ _ _ _ _ _ _ __ _ _ _ _ _ _ __ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __ _ _ Y o u h a ve be e n gi ve n a bo o kl et t o c o m pl et e f or t his st u dy. T his bo o kl et c o nt ai ns s o m e q u esti o ns a bo ut y o u r ‘ q u alit y -of -life’ as a pati e nt re cei vi n g t re at me nt f or c a n cer. Y o u r a ns we rs will h el p us t o better u n de rst a n d h o w t h e t re at me nt y o u are receivi n g is aff ecti n g t he wa y y o u f e el. 1. Yo u ar e bein g as ke d t o c o m plet e a q uestio n nair e b o o klet f or t his st u d y. T his b o o klet m ust be c o m plet e d at t he e n d of y o ur tr eat m e nt. It c o ntains t he f ollo win g q uestio n nair es: • Geriatric Ass ess m e nt • P R O -C T C A E q uestio n nair e • E Q -5 D 3 L • Was it W ort h It Q uestio n nair e • Geriatric Ass ess m e nt: Healt hc ar e Pr of essio nal Q uestio n nair e -Not e: T his f or m is t o be c o m pl et e d by t h e h e alt h c are pr of essio n al, n ot t he pati e nt. 2. Dir ectio ns o n h o w t o c o m plet e eac h s et of q uestio ns ar e writt e n o n t he t o p of eac h s et. 3. It is ver y i m p ort a nt t hat y o u r et ur n t he b o o klets t o us, w het her y o u finis h t he st u d y or n ot. 4. Yo u will be give n t he n urs e’s or st u d y c o or dinat or’s na m e a n d t ele p h o ne n u m ber. Yo u c a n c all a n yti m e wit h a n y c o nc er ns or q uestio ns. 5. Aft er c o m pletin g t his b o o klet, pleas e r et ur n it t o y o ur n urs e or p h ysicia n. T ha n k y o u f or t a ki ng t he ti me t o hel p us."
103,page_103,"Allia nc e A1 7 1 6 0 1 1 0 4 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 AP P E N DI X II: GE RI A T RI C AS S ES S M E N T GE RI A T RI C AS S ES S M E N T SU R V E Y T o b e c o mpl et e d b y Ph y si ci a n, N ur s e, or C R A: R e s p o n si bl e p er s o n n a me ( P h y si ci a n, N ur s e, or C R A ) _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ A s s e s s me nt Peri o d ( a s a p pli c a bl e t o t hi s st u d y) □ Pr e -tr e at me nt □ □ Cy cl e # □ En d of Tr e at me nt PA TI E N T QU ES TI O N N AI R E P ati e nt I n str u cti o n s: If y o u ar e u n a bl e t o c o mpl et e t h e q u e sti o n n air e, a me mb er of y o ur h e alt h c ar e t e a m will a s si st y o u. P l e a s e d o n ot h a v e a f a m il y me mb er c o mpl et e t h e q u e sti o n n air e f or y o u. □ M ar k b o x wit h a n “ X ”, if f or m w a s n ot c o m pl et e d at s p e cifi e d ti m e p oi nt a n d s p e cif y r e a s o n: ( M ar k o n e w it h a n X.) □ Pati e nt r ef u s e d □ Pati e nt wit h dr e w c o n s e nt □ N ot d o n e □ Ot h er, s p e cif y _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ ( For a ss e ss m e nt d at e, r e c or d a p pr o xi m at e d at e f or m w a s t o b e c o m pl et e d.) A. B A C K G R O U N D I N F O R M A TI O N 1. W h at i s t h e hi g h e st gr a d e y o u fi ni s h e d i n s c h o ol ? ( M ar k o n e w it h a n X.) □ 8t h gr a d e or l e s s □ V o c ati o n al/ t e c h ni c al s c h o ol □ 9 -1 1t h gr a d e □ B a c h el or’ s d e gr e e □ Hi g h s c h o ol gr a d u at e/ G E D □ A d va n c e d d e gr e e □ A s s o ci at e d e gr e e/ s o m e c oll e g e □ I pr ef er n ot t o a n s w er 2. W h at i s y o ur marit al st at u s ? ( M ar k o n e w it h a n X.) □ M arri e d □ D i v or c e d □ I pr ef er n ot t o a ns w er □ D o m e sti c p art n er s hi p □ S e p ar at e d □ Wi d o w e d □ N e v er marri e d 3. Wit h w h o m d o y o u li v e ? ( M ar k all t h at a p pl y w it h a n X.) □ S p o u s e / p art n er □ Par e nt( s)/ p ar e nt( s) -i n-l a w □ Girlfri e n d / b o yfri e n d □ Li v e al o n e □ C hil dr e n a g e d 1 8 y e ar s or y o u n g er □ Ot h er s, s p e cif y: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ □ C hil dr e n a g e d 1 9 y e ar s or ol d er □ Ot h er r el ati v e, s p e cif y: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _"
104,page_104,"Allia nc e A1 7 1 6 0 1 1 0 5 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 4. W h at i s y o ur c urr e nt e mpl o y me nt st at u s ? ( M ar k o n e w it h a n X.) □ E mpl o y e d 3 2 h o ur s or mor e p er w e e k □ U n e mpl o y e d □ E mpl o y e d l e s s t h a n 3 2 h o ur s p er w e e k □ R etir e d □ H o me ma k er □ F ull -ti me st u d e nt □ D i s a bl e d □ Part -ti me st u d e nt □ O n me di c al l e a v e □ Ot h er, s p e cif y: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ B. D AI L Y A C TI VI TI E S* P A TI E N T I N S T R U C TI O N S: I n di c at e y o ur r e s p o n s e b y mar ki n g a n X i n o n e b o x p er q u e sti o n. 1. C a n y o u u s e t h e t el e p h o n e … □ wit h o ut h el p, i n cl u di n g l o o ki n g u p a n d di ali n g; □ wit h s o me h el p ( c a n a n s w er p h o n e or di al o p er at or i n a n e mer g e n c y, b ut n e e d a s p e ci al p h o n e or h el p i n g etti n g t h e p h o n e n u mb er or di ali n g); or □ ar e y o u c o mpl et el y u n a bl e t o u s e t h e t el e p h o n e ? 2. C a n y o u g et t o pl a c e s o ut of w al ki n g di st a n c e … □ wit h o ut h el p ( c a n tr a v el al o n e o n b u s s e s, t a xi s, or dri v e y o ur o w n c ar); □ wit h s o me h el p ( n e e d s o me o n e t o h el p y o u or g o wit h y o u w h e n tr a v eli n g); or □ ar e y o u u n a bl e t o tr a v el u nl e s s e mer g e n c y arr a n g e me nt s ar e ma d e f or a s p e ci ali z e d v e hi cl e li k e a n a mb ul a n c e ?"
105,page_105,"Allia nc e A1 7 1 6 0 1 1 0 6 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 3. C a n y o u g o s h o p pi n g f or gr o c eri e s or cl ot h e s ( a s s u m i n g y o u h a v e tr a n s p ort ati o n) … □ wit h o ut h el p (t a ki n g c ar e o f all s h o p pi n g n e e d s y o ur s elf, a s s u m i n g y o u h a v e tr a n s p ort ati o n); □ wit h s o me h el p ( n e e d s o me o n e t o g o wit h y o u o n all s h o p pi n g tri p s); or □ ar e y o u c o mpl et el y u n a bl e t o d o a n y s h o p pi n g ? 4. C a n y o u pr e p ar e y o ur o w n me al s … □ wit h o ut h el p ( pl a n a n d c o o k f ull m e al s y o ur s elf); □ wit h s o me h el p ( c a n pr e p ar e s o me t hi n g s b ut u n a bl e t o c o o k f ull me al s y o ur s elf); or □ ar e y o u c o mpl et el y u n a bl e t o pr e p ar e a n y me al s ? 5. C a n y o u d o y o ur h o u s e w or k … □ wit h o ut h el p ( c a n cl e a n fl o or s, et c); □ wit h s o me h el p ( c a n d o li g ht h o u s e w or k b ut n e e d h el p wit h h e a v y w or k); or □ ar e y o u c o mpl et el y u n a bl e t o d o a n y h o u s e w or k ? 6. C a n y o u t a k e y o ur o w n me di ci n e s … □ wit h o ut h el p (i n t h e ri g ht d o s e s at t h e ri g ht ti me); □ wit h s o me h el p ( a bl e t o t a k e me di ci n e if s o me o n e pr e p ar e s it f or y o u a n d/ or r e m i n d s y o u t o t a k e it); or □ ar e y o u c o mpl et el y u n a bl e t o t a k e y o ur me di ci n e s ? 7. C a n y o u h a n dl e y o ur o w n mo n e y … □ wit h o ut h el p ( w rit e c h e c k s, p a y bill s, et c.); □ wit h s o me h el p ( ma n a g e d a y -t o-d a y b u yi n g b ut n e e d h el p wit h ma n a gi n g y o ur c h e c k b o o k a n d p a yi n g y o ur bill s); or □ ar e y o u c o mpl et el y u n a bl e t o h a n dl e mo n e y ? * O A R S I A D L3 3"
106,page_106,"Allia nc e A1 7 1 6 0 1 1 0 7 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 C. P H Y SI C A L A C TI VI TI E S* 1. T h e f oll o wi n g it e ms ar e a cti viti e s y o u m i g ht d o d uri n g a t y pi c al d a y. D o e s y o ur h e alt h li m it y o u i n t h e s e a cti viti e s ? (M a r k a n X i n t h e b o x o n e a c h li n e t h at b e st r efl e ct s y o ur sit u ati o n. ) A cti viti e s Li mit e d a l ot Li mit e d a littl e N ot li mit e d at all a. Vi g or o u s a cti viti e s s u c h a s: r u n ni n g, lifti n g h e a v y o bj e ct s, p arti ci p ati n g i n str e n u o u s s p ort s □ □ □ b. Mo d er at e a cti viti e s s u c h a s: mo vi n g a t a bl e, p u s hi n g a v a c u u m cl e a n er, b o wli n g, or pl a yi n g g olf □ □ □ c. Lifti n g or c arr yi n g gr o c eri e s □ □ □ d. C li mbi n g s e v er al fli g ht s of st air s □ □ □ e. C li mbi n g o n e fli g ht of st air s □ □ □ f. B e n di n g, k n e eli n g, or st o o pi n g □ □ □ g. W al ki n g mor e t h a n a m il e □ □ □ h. W al ki n g s e v er al bl o c k s □ □ □ i. W al ki n g o n e bl o c k □ □ □ j. B at hi n g or dr e s si n g y o ur s elf □ □ □ * M O S, P h y s i c al F u n cti o ni n g S c al e3 4"
107,page_107,"Allia nc e A1 7 1 6 0 1 1 0 8 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 D. C U R R E N T H E A L T H R A TI N G* W hi c h o n e of t h e f oll o wi n g p hr a s e s b e st d e s cri b e s y o u at t hi s ti me ? ( M ar k o n e w it h a n X.) □ N or mal, n o c o mpl ai nt s, n o s y mpt o ms of di s e a s e □ A bl e t o c arr y o n n or mal a cti vit y, m i n or s y mpt o ms of di s e a s e □ N or mal a cti vit y wit h eff ort, s o me s y mpt o ms of di s e a s e □ C ar e f or s elf, u n a bl e t o c arr y o n n or mal a cti vit y or d o a cti v e w or k □ R e q uir e o c c a si o n al a s si st a n c e b ut a bl e t o c ar e f or mo st of p er s o n al n e e d s □ R e q uir e c o n si d er a bl e a s si st a n c e f or p er s o n al c ar e □ D i s a bl e d, r e q uir e s p e ci al c ar e a n d a s si st a n c e □ S e v er el y di s a bl e d, r e q uir e c o nti n u o u s n ur si n g c ar e * P ati e nt K P S3 5 E. F A L L S H o w ma n y ti me s h a v e y o u f all e n i n t h e l a st 6 mo nt h s ? □ □ □ F. Y O U R H E A L T H 1. Y o ur G e n e r al H e alt h* P ati e nt I n str u cti o n s: D o y o u h a v e a n y of t h e f oll o wi n g ill n e s s e s at t h e pr e s e nt ti me, a n d if s o, h o w mu c h d o e s it i nt erf er e wit h y o ur a cti viti e s: N ot at all, S o m e w h at or A Gr e at D e al ? ( M ar k a n X i n t h e b o x t h at b e st r efl e ct s y o ur a n s w er.) If y o u h a v e t hi s ill n e s s: H o w m u c h d o e s it i nt e rf e r e wit h y o ur a cti viti e s ? Ill n e s s N o Y e s N ot at all A littl e A gr e at d e al a. Ot h er c a n c er s or l e u k e m i a □ □ → □ □ □ b. Art hriti s or r h e u mati s m □ □ → □ □ □"
108,page_108,Allia nc e A1 7 1 6 0 1 1 0 9 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 If y o u h a v e t hi s ill n e s s: H o w m u c h d o e s it i nt e rf e r e wit h y o ur a cti viti e s ? Ill n e s s N o Y e s N ot at all A littl e A gr e at d e al c. Gl a u c o ma □ □ → □ □ □ d. E mp h y s e ma or c hr o ni c br o n c hiti s □ □ → □ □ □ e. H i g h bl o o d pr e s s ur e □ □ → □ □ □ f. H e art di s e a s e □ □ → □ □ □ g. C ir c ul ati o n tr o u bl e i n ar ms or l e g s □ □ → □ □ □ h. D i a b et e s □ □ → □ □ □ i. St o ma c h or i nt e sti n al di s or d er s □ □ → □ □ □ j. Ost e o p or o si s □ □ → □ □ □ k. Li v er di s e a s e □ □ → □ □ □ l. Ki d n e y di s e a s e □ □ → □ □ □ m. Str o k e □ □ → □ □ □ n. D e pr e s si o n □ □ → □ □ □ * O A R S I A D L3 3
109,page_109,"Allia nc e A1 7 1 6 0 1 1 1 0 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 2. H o w i s y o ur e y e si g ht ( wit h gl a s s e s or c o nt a ct s) ? ( M ar k o n e w it h a n X.) □ Ex c ell e nt □ G o o d □ F air □ Po or □ T ot all y bl i n d 3. H o w i s y o ur h e ari n g ( wit h a h e ari n g ai d, if n e e d e d) ? ( M ar k o n e w it h a n X.) □ Ex c ell e nt □ G o o d □ F air □ Po or □ T ot all y d e af 4. D o y o u h a v e a n y ot h er p h y si c al pr o bl e ms or ill n e s s e s ( ot h er t h a n li st e d i n q u e sti o n s 1 -4) at t h e pr e s e nt ti me t h at s eri o u sl y aff e ct y o ur h e alt h ? □ N o □ Y e s, s p e cif y: If y e s, h o w mu c h d o e s t hi s i nt erf er e wit h y o ur a cti viti e s ? ( M ar k o n e w it h a n X.) □ N ot at all □ S o me w h at □ A gr e at d e al * O A R S I A D L3 3"
110,page_110,"Allia nc e A1 7 1 6 0 1 1 1 1 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 G. N U T RI TI O N A L S T A T U S 1. H a v e y o u l o st w ei g ht i n v ol u nt aril y o v er t h e p a st 6 mo nt h s ? □ N o □ Y e s If y e s, h o w mu c h ? □ □ □ p o u n d s 2. W h at i s y o ur w ei g ht n o w ? □ □ □ p o u n d s 3. W h at w a s y o ur w ei g ht 6 mo nt h s a g o ? □ □ □ p o u n d s H. H E A L T H Q U E S TI O N N AI R E * I N S T R U C TI O N S: T h e s e q u e sti on s ar e a b o ut h o w y o u h a v e b e e n f e eli n g wit hi n t h e p a st m o nt h. Pl e a s e m ar k a n “ X ” i n t h e b o x o n e a c h li n e t h at b e st r efl e ct s y o ur sit u ati o n. H o w m u c h of t h e ti m e d uri n g t h e p a st m o nt h : All of t h e Ti m e M o st of t h e Ti m e A G o o d Bit of t h e Ti m e S o m e of t h e Ti m e A Littl e of t h e Ti m e N o n e of t h e Ti m e 1. h a s y o ur d ail y lif e b e e n f ull of t hi n g s t h at w er e i nt er e sti n g t o y o u ? □ □ □ □ □ □ 2. di d y o u f e el d e pr e s s e d ? □ □ □ □ □ □ 3. h a v e y o u f elt l o v e d a n d w a nt e d ? □ □ □ □ □ □ 4. h a v e y o u b e e n a v er y n er v o u s p er s o n ? □ □ □ □ □ □ 5. h a v e y o u b e e n i n fir m c o ntr ol of y o ur b e h a vi or, t h o u g ht s, e moti o n s, f e eli n g s ? □ □ □ □ □ □ 6. h a v e y o u f elt t e n s e or hi g h -str u n g ? □ □ □ □ □ □ 7. h a v e y o u f elt c al m a n d p e a c ef ul ? □ □ □ □ □ □ 8. h a v e y o u f elt e moti o n all y st a bl e ? □ □ □ □ □ □ 9. h a v e y o u f elt d o w n h e art e d a n d bl u e ? □ □ □ □ □ □ 1 0. h a v e y o u f elt r e stl e s s, fi d g et y, or i mp ati e nt ? □ □ □ □ □ □ 1 1. h a v e y o u b e e n mo o d y, or br o o d e d a b o ut t hi n g s ? □ □ □ □ □ □"
111,page_111,"Allia nc e A1 7 1 6 0 1 1 1 2 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 1 2. h a v e y o u f elt c h e erf ul, li g ht -h e art e d ? □ □ □ □ □ □ 1 3. h a v e y o u b e e n i n l o w or v er y l o w s pirit s ? □ □ □ □ □ □ 1 4. w er e y o u a h a p p y p er s o n ? □ □ □ □ □ □ 1 5. di d y o u f e el y o u h a d n ot hi n g t o l o o k f or w ar d t o ? □ □ □ □ □ □ 1 6. h a v e y o u f elt s o d o w n i n t h e d u mp s t h at n ot hi n g c o ul d c h e er y o u u p ? □ □ □ □ □ □ 1 7. h a v e y o u b e e n a n xi o u s or w orri e d ? □ □ □ □ □ □ * M HI -1 73 4 - St e w art, A. L. a n d W ar e, J. E., 1 9 9 2"
112,page_112,"Allia nc e A1 7 1 6 0 1 1 1 3 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 I. S O CI A L A C TI VI TI E S* 1. D uri n g t h e p a st 4 w e e k s , h o w mu c h ti me h a s y o ur p h y si c al h e alt h or e moti o n al pr o bl e ms i nt erf er e d wit h y o ur s o ci al a cti viti e s (li k e vi siti n g wit h fri e n d s, r el ati v e s, et c.) ? ( M ar k o n e w it h a n X.) □ All of t h e ti me □ Mo st of t h e ti me □ S o me of t h e ti me □ A littl e of t h e ti me □ N o n e of t h e ti me 2. C o mp ar e d t o y o ur u s u al l e v el of s o ci al a cti vit y , h a s y o ur s o ci al a cti vit y d uri n g t h e p a st 6 mo nt h s d e cr e a s e d, st a y e d t h e s a me, or i n cr e a s e d b e c a u s e of a c h a n g e i n y o ur p h y si c al or e moti o n al c o n diti o n ? ( M ar k o n e w it h a n X.) □ Mu c h l e s s s o ci all y a cti v e t h a n b ef or e □ S o me w h at l e s s s o ci all y a cti v e t h a n b ef or e □ A b o ut a s s o ci all y a cti v e a s b ef or e □ S o me w h at mor e s o ci all y a cti v e a s b ef or e □ Mu c h mor e s o ci all y a cti v e t h a n b ef or e 3. C o mp ar e d t o ot h er s y o ur a g e, ar e y o ur s o ci al a cti viti e s mor e or l e s s li m it e d b e c a u s e of y o ur p h y si c al h e alt h or e moti o n al pr o bl e ms ? ( M ar k o n e w it h a n X.) □ Mu c h mor e li m it e d t h a n ot h er s □ S o me w h at mor e li m it e d t h a n ot h er s □ A b o ut t h e s a me a s ot h er s □ S o me w h at l e s s li m it e d t h a n ot h er s □ Mu c h l e s s li m it e d t h a n ot h er s * M O S, S o ci al A cti viti es3 4"
113,page_113,"Allia nc e A1 7 1 6 0 1 1 1 4 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 J. S O CI A L S U P P O R T * I N S T R U C TI O N S: P e o pl e s o m eti m e s l o o k t o ot h e r s f or c o m p a ni o n s hi p, a s si st a n c e or ot h e r t y p e s of s u p p ort. H o w oft e n i s e a c h of t h e f oll o wi n g ki n d s of s u p p ort a v ail a bl e t o y o u if y o u n e e d it ? ( M a r k a n X i n t h e b o x o n e a c h li n e t h at b e st r efl e ct s y o ur sit u ati o n. ) N o n e of t h e Ti m e A Littl e of t h e Ti m e S o m e of t h e Ti m e M o st of t h e Ti m e All of t h e Ti m e 1. S o me o n e t o h el p y o u if y o u w er e c o nfi n e d t o b e d. □ □ □ □ □ 2. S o me o n e y o u c a n c o u nt o n t o li st e n t o y o u w h e n y o u n e e d t o t al k. □ □ □ □ □ 3. S o me o n e t o gi v e y o u g o o d a d vi c e a b o ut a cri si s. □ □ □ □ □ 4. S o me o n e t o t a k e y o u t o t h e d o ct or if n e e d e d. □ □ □ □ □ 5. S o me o n e t o gi v e y o u i nf or mati o n t o h el p y o u u n d er st a n d a sit u ati o n. □ □ □ □ □ 6. S o me o n e t o c o nfi d e i n or t al k t o a b o ut y o ur s elf or y o ur pr o bl e m. □ □ □ □ □ 7. S o me o n e t o pr e p ar e y o ur me al s if y o u w er e u n a bl e t o d o it y o ur s elf. □ □ □ □ □ 8. S o me o n e w h o s e a d vi c e y o u r e all y w a nt. □ □ □ □ □ 9. S o me o n e t o h el p y o u wit h d ail y c h or e s if y o u w er e si c k. □ □ □ □ □ 1 0. S o me o n e t o s h ar e y o ur mo st pri v at e w orri e s a n d f e ar s wit h. □ □ □ □ □ 1 1. S o me o n e t o t ur n t o f or s u g g e sti o n s a b o ut h o w t o d e al wit h a p er s o n al pr o bl e m. □ □ □ □ □ 1 2. S o me o n e w h o u n d er st a n d s y o ur pr o bl e ms. □ □ □ □ □ * M O S S o ci al S u p p ort S ur v e y 3 6"
114,page_114,"Allia nc e A1 7 1 6 0 1 1 1 5 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 K. S PI RI T U A LI T Y/ R E LI GI O N* Dir e cti o n s: Pl e a s e a n s w e r t h e f oll o wi n g q u e sti o n s a b o ut y o ur r eli gi o u s b eli ef s a n d/ or i n v ol v e m e nt. ( Pl e a s e m ar k a n “ X ” i n t h e b o x o n e a c h li n e t h at b e st r efl e ct s y o ur sit u ati o n.) 1. H o w oft e n d o y o u att e n d c h ur c h, s y n a g o g u e, or ot h er r eli gi o u s me eti n g s ? ( M ar k o n e w it h a n X.) □ Mor e t h a n o n c e p er w e e k □ O n c e a w e e k □ A f e w ti me s a mo nt h □ A f e w ti me s a y e ar □ O n c e a y e ar or l e s s □ N e v er 2. H o w oft e n d o y o u s p e n d ti me i n pri v at e r eli gi o u s a cti viti e s, s u c h a s pr a y er, me dit ati o n, or Bi bl e st u d y ? ( M ar k o n e w it h a n X.) □ Mor e t h a n o n c e a d a y □ D ail y □ T w o or mor e ti me s p er w e e k □ O n c e a w e e k □ A f e w ti me s a mo nt h □ R ar el y or n e v er T h e f oll o w i n g s e cti o n c o nt ai n s 3 st at e m e nt s a b o ut r eli gi o u s b eli ef or e x p eri e n c e. Pl e a s e m ar k t h e e xt e nt t o w hi c h e a c h st at e m e nt i s tr u e or n ot tr u e f or y o u. 3. I n my lif e, I e x p eri e n c e t h e pr e s e n c e of t h e D i vi n e (i. e., G o d). ( M ar k o n e w it h a n X.) □ D efi nit el y tr u e of me □ T e n d s t o b e tr u e □ U n s ur e □ T e n d s n ot t o b e tr u e □ D efi nit el y n ot tr u e 4. My r eli gi o u s b eli ef s ar e w h at r e all y li e b e hi n d my w h ol e a p pr o a c h t o lif e. ( M ar k o n e w it h a n X.) □ D efi nit el y tr u e of me □ T e n d s t o b e tr u e □ U n s ur e □ T e n d s n ot t o b e tr u e □ D efi nit el y n ot tr u e"
115,page_115,"Allia nc e A1 7 1 6 0 1 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 5 . I tri e d h ar d t o c arr y my r eli gi o n o v er i nt o all ot h er d e ali n g s i n my lif e. ( M ar k o n e w it h a n X.) □ D efi nit el y tr u e of me □ T e n d s t o b e tr u e □ U n s ur e □ T e n d s n ot t o b e tr u e □ D efi nit el y n ot tr u e * D U R E L: D u k e U ni v er s it y R eli gi o nI n d e x3 7– K o e ni g et al., 1 9 9 7 L. Y O U R F E E LI N G S* 1. D o y o u oft e n f e el s a d or d e pr e s s e d ? ( M ar k o n e w it h a n X.) □ N o □ Y e s 2. H o w w o ul d y o u d e s cri b e y o ur l e v el of a n xi et y, o n a v er a g e ? P l e a s e cir cl e t h e n u mb er ( 0 -1 0) b e st r efl e cti n g y o ur r e s p o n s e t o t h e f oll o wi n g t h at d e s cri b e s y o ur f e eli n g s d uri n g t h e p a st w e e k, i n cl u di n g t o d a y . 0 1 2 3 4 5 6 7 8 9 1 0 N o a n xi et y A n xi et y a s b a d a s It c a n b e * M a h o n e y et al., 1 9 9 4; L A S A3 8 M. Q U E S TI O N S C O N C E R NI N G T H E Q U E S TI O N N AI R E 1. W er e t h er e a n y q u e sti o n s diffi c ult t o u n d er st a n d ? □ N o □ Y e s If Y e s, w hi c h q u e sti o n s w er e t h e y ? 2. W a s t h e ti me it t o o k t o a n s w er all t h e q u e sti o n s t o o l o n g, j u st ri g ht or t o o s h ort ? □ T o o s h ort → H o w l o n g w o ul d y o u h a v e li k e d t h e q u e sti o n n air e t o b e ? □ □ m i n ut e s □ J u st ri g ht □ T o o l o n g → H o w l o n g w o ul d y o u h a v e li k e d t h e q u e sti o n n air e t o b e ? □ □ m i n ut e s W hi c h it e ms w o ul d y o u r e mo v e ?"
116,page_116,"Allia nc e A1 7 1 6 0 1 1 1 7 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 3. D i d y o u fi n d a n y of t h e q u e sti o n s u p s etti n g ? □ N o □ Y e s If Y e s, w hi c h q u e sti o n s w er e t h e y ? C o ul d y o u t ell me w h y t h e y w er e u p s etti n g ? 4. D o y o u t hi n k t h e q u e sti o n n air e l eft o ut a n y q u e sti o n s t h at w er e i mp ort a nt t o a s k ? T h a n k y o u f or y o ur p arti ci p ati o n."
117,page_117,
118,page_118,"Allia nc e A1 7 1 6 0 1 1 1 9 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 B. Ti me d “ U p a n d G o”* I N S T R U C TI O N S: T h e ti me d “ U p a n d G o” me a s ur e s, i n s e c o n d s, t h e ti me it t a k e s f or a n i n di vi d u al t o st a n d u p fr o m a st a n d ar d ar m c h air ( a p pr o xi mate s e at h ei g ht of 4 6 c m [ a p pr o xi mat el y 1. 5 ft]), w al k a di st a n c e of 3 met er s ( a p pr o xi mat el y 1 0 f e et), t ur n, w al k b a c k t o t h e c h air, a n d sit d o w n a g ai n. T h e s u bj e ct w e ar s hi s/ h er r e g ul ar f o ot w e ar a n d u s e s t h eir c u st o mar y w al ki n g ai d ( n o n e, c a n e, w al k er, et c.) N o p h y si c al a s si st a n c e i s gi v e n. T h e s u bj e ct st art s wit h hi s b a c k a g ai n st t h e c h air, hi s ar m r e sti n g o n t h e c h air’ s ar m, a n d hi s w al ki n g ai d i n h a n d. H e i s i n str u ct e d t h at o n t h e w or d “ g o”, h e i s t o g et u p a n d w al k at a c o mf ort a bl e a n d s af e p a c e t o a lin e o n t h e fl o or 3 met er s ( a p pr o xi mat el y 1 0 f e et) a w a y, t ur n, a n d r et ur n t o t h e c h air a n d sit d o w n a g ai n. T h e s u bj e ct w al k s t hr o u g h t h e t e st o n c e b ef or e b ei n g ti me d i n or d er t o b e c o me f a m ili ar wit h t h e t e st. E it h er a w ri st w at c h wit h a s e c o n d h a n d or a st o p -w at c h c a n b e u s e d t o ti me t h e p erf or ma n c e. Ti me t o p erf or m “ U p a n d G o” □ □. □ s e c o n d s * Ti m e d “ U p a n d G o”4 0 III. C O G NI TI O N T hi s s e cti o n i s o nl y c o m pl et e d Pr etr e at m e n t a n d at t h e e n d of tr e at m e nt 6 -I T E M O RI E N T A TI O N-M E M O R Y -C O N C E N T R A TI O N T E S T** P ati e nt’ s R e s p o n s e M a xi m u m e r r or s Fi n al S c or e W ei g ht s c or e 1. W h at y e ar i s it n o w ? [ wit h o ut l o o ki n g at a c al e n d ar] □ □ □ □ 1 □ □ x 4 = □ □ 2. W h at mo nt h i s it n o w ? [ wit h o ut l o o ki n g at a c al e n d ar] □ □ 1 □ □ x 3 = □ □ M e m or y P hr a s e: R e p e at t hi s p hr a s e aft er me: ‘ J o h n Br o w n, 4 2 Mar k et Str e et, C hi c a g o’ 3. A b o ut w h at ti me i s it ? [ wit hi n 1 h o ur – wit h o ut l o o ki n g at y o ur w at c h] □ □: □ □ 1 □ □ x 3 = □ □ 4. C o u nt b a c k w ar d s 2 0 t o 1. 2 □ □ x 2 = □ □ 5. S a y t h e mo nt h s i n r e v er s e or d er. 2 □ □ x 2 = □ □ 6. R e p e at t h e Me mor y Phr a s e. 5 □ □ x 2 = □ □ T O T A L S C O R E: □ □"
119,page_119,"Allia nc e A1 7 1 6 0 1 1 2 0 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 S c ori n g : F or it e ms 1 t o 3, t h e r e s p o n s e i s eit h er c orr e ct ( s c or e 0) or i n c orr e ct ( s c or e 1). F or it e ms 4 t o 6, a d d o n e p oi nt f or e a c h err or (it e m 4 a n d 5 ma xi mu m err or i s 2; f or it e m 6, ma xi mu m err or i s 5); t ot al all s c or e s i n “ Fi n al S c or e” c ol u mn. D at a fr o m p arti ci p a nt s f o u n d t o h a v e gr o s s c o g niti v e i mp air me nt a s d et er m i n e d b y t h e Ori e nt ati o n -Me mor y - C o n c e ntr ati o n S c or e ≥ 1 1 will b e e x cl u d e d fr o m t h e a n al y si s. Ma xi mu m s c or e = 2 8. ** O M C – K at z ma n, R., et al., 1 9 8 3; K a w a s, C., et al., 1 9 9 5"
120,page_120,"Allia nc e A1 7 1 6 0 1 1 2 1 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 I V. S C O RI N G T hi s s e cti o n i s o nl y a p pli c a bl e if O M C -T e st i s c o m pl et e d Pr etr e at m e nt a n d P o st tr e at m e nt D i d t h e p a ti e nt s c or e ≥ 1 1 o n t h e 6-It e m Ori e nt ati o n-Me m or y -C o n c e ntr ati o n T e st ? □ N o □ Y e s ( If y e s, n otif y t h e p ati e nt’ s tr e ati n g p h y si ci a n.) T hi s q u e sti o n i s o nl y a p pli c a bl e t o q u e sti o n # 1 i n “ S e cti o n K. Y o ur F e eli n g s” fr o m t h e P ati e nt Q u e sti o n n air e. 1. H o w di d t h e p ati e nt a n s w er t h e q u e sti o n “ D o y o u oft e n f e el s a d or d e pr e s s e d ?” i n t h e P ati e nt Q u e sti o n n air e ( S e cti o n K)? N o Y e s (If y e s, n otif y t h e p ati e nt’ s tr e ati n g p h y si ci a n.) V. N U T RI TI O N W h at i s t h e p ati e nt’ s h ei g ht ? ( fr o m p ati e nt’ s c h art) □ □ □ c m W h at i s t h e p ati e nt’ s c urr e nt w ei g ht ? ( fr o m p ati e nt’ s c h art) □ □ □ k g W h at w a s t h e p ati e nt’ s w ei g ht a p pr o xi mat el y 6 mo nt h s a g o ? (fr o m p ati e nt’ s c h art or p ati e nt s s elf r e p ort) □ □ □ k g C al c ul at e d B o d y Ma s s I n d e x: □ □ .□ Per c e nt U ni nt e nti o n al W ei g ht L o s s: □ □ .□% VI. Q U E S TI O N S R E G A R DI N G T H E Q U E S TI O N N AI R E S A. W er e a n y of t h e q u e sti o n n air e s i n t h e “ G eri atri c A s s e s s me nt – H e alt h c ar e Pr of e s si o n al Q u e sti o n n air e” diffi c ult f or y o u t o a d m i ni st er ? □Y e s □N o"
121,page_121,"Allia nc e A1 7 1 6 0 1 1 2 2 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 If n o, pl e a s e pr o c e e d t o t h e n e xt q u e sti o n. If y e s, pl e a s e i n di c at e w hi c h q u e sti o n n air e w a s diffi c ult t o a d m i ni st er ? ( M ar k all t h at a p pl y w it h a n X.) □ K P S H e alt h c ar e Pr of e s si o n al R at e d ( p a g e 1) □ Ti me d U p a n d G o ( p a g e 2) □ 6 -It e m Ori e nt ati o n-Me mor y -C o n c e ntr ati o n T e st ( p a g e 2) □ Ot h er: P l e a s e s p e cif y _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ B. W er e a n y of t h e q u e sti o n n air e s i n t h e “ G eri atri c A s s e s s me nt – Pati e nt Q u e sti o n n air e” diffi c ult f or t h e p ati e nt t o c o mpl et e ? □Y e s □N o B. If n o, pl e a s e pr o c e e d t o t h e n e xt q u e sti o n. If y e s, pl e a s e i n di c at e w hi c h q u e sti o n n air e( s) w a s diffi c ult f or t h e p ati e nt t o c o mpl et e ? ( M ar k all t h at a p pl y w it h a n X.) □ B a c k gr o u n d I nf or mati o n ( p a g e 1) □ D ail y A cti viti e s ( p a g e 2 -3) □ Ph y si c al A cti viti e s ( p a g e 3) □ C urr e nt H e alt h R ati n g ( p a g e 4) □ F all s ( p a g e 4) □ Y o ur H e alt h ( p a g e 4 -5) □ N utriti o n al St at u s ( p a g e 7-8) □ H e alt h Q u e sti o n n air e ( p a g e 9) □ S o ci al A cti viti e s ( p a g e 1 0) □ S o ci al S u p p ort ( p a g e 1 1 ) □ S pirit u alit y or r eli gi o n ( p a g e 1 2 ) □ Y o ur F e eli n g s ( p a g e 1 3 ) C. W a s t h e p ati e nt a bl e t o c o mpl et e “ G eri atri c A s s e s s me nt – Pati e nt Q u e sti o n n air e” o n hi s/ h er o w n ? □Y e s □N o If n o, w h y ? ( M ar k all t h at a p pl y w it h a n X.) □ N ot lit er at e ( d o e s n ot r e a d or w rit e) □ Vi s u al pr o bl e m □ F ati g u e"
122,page_122,"Allia nc e A1 7 1 6 0 1 1 2 3 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 □ Q u e sti o n s t o o diffi c ult ( a b o v e t h e p ati e nt’ s r e a di n g a bilit y) □ Ot h er: s p e cif y _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ D. L e n gt h of ti me t o c o mpl et e b ot h t h e Pati e nt a n d H e alt h c ar e Pr of e s si o n al Q u e sti o n n air e s L e n gt h of ti me t o c o mpl et e h e alt h c ar e pr of e s si o n al q u e sti o n n air e □ □ □ m i n ut e s L e n gt h of ti me t o c o mpl et e p ati e nt q u e sti o n n air e □ □ □ m i n ut e s T ot al l e n gt h of ti me t o c o mpl et e b ot h q u e sti o n n air e s □ □ □ m i n ut e s C o mpl et e d b y: _ _ _ D at e f or m c o mpl et e d: □ □ / □ □ / □ □ □ □ ( L a st n a m e, Fir st n a m e) M M D D Y Y Y Y"
123,page_123,"Allia nc e A1 7 1 6 0 1 1 2 4 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 AP P E N DI X III : WA S IT WO R T H IT QU ES TI O N N AI R E _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __ _ _ _ _ _ _ __ _ _ _ _ _ _ __ _ _ _ _ _ _ __ _ _ _ _ _ _ __ _ _ _ _ _ _ __ _ _ _ _ _ _ __ _ _ _ _ _ _ T o be c o m plet e d b y P h ysicia n, N urs e, or C R A: P atie nt Na m e: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __ _ _ _ _ _ _ Dat e: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __ _ _ _ P atie nt N u m ber: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __ _ _ _ _ _ _ __ _ _ _ _ _ _ __ _ _ _ _ _ _ __ _ _ _ _ _ _ __ _ _ _ _ _ _ __ _ _ _ _ _ _ __ _ _ _ _ ___ P arti ci pati n g i n a cli ni c al t ri al / res e arc h st u dy is a pe rs o n al c h oi ce a n d a n i n di vi d u al e x pe ri e nce. We wo ul d li k e t o get y o u r f ee d bac k o n y o u r e x pe ri e n ce i n t his res e ar c h st u dy. Di re cti o ns : Pleas e a ns w er eac h q uestio n b y cir clin g Y (f or yes), N (f or n o), or U (f or u nc ert ain). 1. Was it w ort h w hile f or y o u t o participat e in t his r es ear c h st u d y ? Y N U 2. If y o u ha d t o d o it o ver, w o uld y o u participa t e in t his r es ear c h st u d y a gain? Y N U 3. W o uld y o u r ec o m m e n d participatin g in t his r es ear c h st u d y t o ot hers ? Y N U 4. O ver all, did y o ur q ualit y of lif e c ha n ge b y participatin g in t his r es ear c h st u d y ? ( circl e o ne res p o nse) It i m pr o ve d It st a ye d t he s a m e It g ot w ors e 5. O ver all h o w w as y o ur e x perie nc e participatin g in t his r es ear c h st u d y ? ( circl e o ne res p o nse) Bett er t ha n I e x pect e d T he s a m e as I e x pect e d W ors e t ha n I e x pect e d 6. If t her e w as o ne t hin g t hat c o uld ha ve bee n d o ne t o i m pr o ve y o ur e x perie nc e in t his r es ear c h st u d y, w hat w o uld it be? 7. W o uld y o u like t o t alk t o s o m e o ne a b o ut y o ur c o nc er ns? Yes N o ( circl e o ne res p o nse)"
124,page_124,"Allia nc e A1 7 1 6 0 1 1 2 5 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 AP P E N DI X IV : OV E R A L L TR E A T M E N T UTI LI T Y O T U is a n o vel clinic al o ut c o m e m eas ur e inc or p oratin g o bjective a n d s u bjective m eas ur es of a ntic a nc er effic ac y, t oler a bilit y, a n d ac c e pt a bilit y, ass ess e d at t he e n d of tr eat m e nt a n d c o n de nse d int o a si m ple 3 p oint s c or e. O T U m a y be r e gar de d as as kin g t he clinicia n: “ Wit h t he be nefit of hin dsig ht, ar e y o u gla d y o u ga ve t his tr eat m e nt ?” a n d as kin g t he patie nt: “ Wit h t he be nefit of hin dsig ht, ar e y o u gla d y o u r ec eive d it ?”. O T U is s c or e d as g o o d, int er m e diat e or p o or, c orr es p o n din g t o “ yes ”, “ u ncert ain” or “ n o” r e plies t o t hes e q uestio ns. T o s c or e t he O T U, t he patie nt is ass ess e d at t he e n d of tr eat m e nt , usin g t he f ollo win g crit eria: 1) Cli ni c al be n efit ? Cat e g orize d as: a. Bot h r a diolo gic ally pr o gr essio n- fr ee ( R E CI S T r es p o nse or st a ble dis eas e) a n d n o clinic al det erior atio n as ass ess e d b y tr eatin g c o ns ult a nt b. Eit her r a diolo gic ally pr o gr essio n- fr ee ( R E CI S T pr o gr essive dis eas e) or clinic al det erior atio n as ass ess e d b y tr eatin g c o ns ult a nt 2) Tol e r a bl e a n d acce pt a bl e ? Cat e g orize d as: a. All of t he f ollo win g: • N o S A E or S U S A R attrib ut e d t o tr eat m e nt • N o e pis o des of gr a de ≥ 3 n o n -he mat olo gic al t o xicit y • P atie nt r es p o ns e t o “ W hic h o ne of t he f ollo win g p hr as es best des cribes y o u at t his ti m e?” in s ectio n D of t he Geriatric Ass ess m e nt at t he e n d of tr eat m e nt is n ot “ Re q uir e c o nsider a ble assist a nc e f or pers o nal c ar e”, “ Dis a ble d, r e q uir e s pecial c ar e a n d assist a nc e” or “ S e ver ely dis a ble d, r e q uir e c o ntin u o us n ursin g c ar e. ” • P atie nt r es p o ns e t o “ Was it w ort h w hile f or y o u t o u n der g o t his c a nc er tr eat m e nt?” fr o m t he Was It W ort h It q uestio n nair e is “ Y” b. An y of t he f ollo win g : • An S A E or S U S A R (s us pect e d u ne x pecte d s erio us a d verse r eactio n) attrib ut e d t o tr eat m e nt • An e pis o de of gr a de ≥ 3 n o n -he m at olo gic al t o xicit y • P atie nt r es p o ns e t o “W hic h o ne of t he f ollo win g p hr as es best des cribes y o u at t his ti m e?” in s ectio n D of t he Geriatric Ass ess m e nt at t he e n d of tr eat m e nt is “ Re q uir e c o nsider a ble assist a nc e f or pers o nal c ar e”, “ Dis a ble d, r e q uir e s pecial c ar e a n d assist a nc e” or “ S e ver ely dis a ble d, r e q uir e c o ntin u o us n ursin g c ar e. ”"
125,page_125,"Allia nc e A1 7 1 6 0 1 1 2 6 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 • P atie nt r es p o ns e t o “Was it w ort h w hile f or y o u t o u n der g o t his c a nc er tr eat m e nt?” fr o m t he Was I t W ort h It q uestio n nair e is n ot “ Y” S c ori n g : G o o d O T U: P atie nt is alive a n d s c or es 1a/ 2a I nt er m e diat e O T U: P atie nt is alive a n d s c or es 1a/ 2 b or 1 b/ 2a P o or O T U: P atie nt is alive a n d s c or es 1 b/ 2 b, or patie nt is dea d"
126,page_126,"Allia nc e A1 7 1 6 0 1 1 2 7 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 AP P E N DI X V : E Q -5 D -3 L HE A L T H QU ES TI O N N AI R E E Q -5 D -3 L Un der eac h hea din g, pleas e c hec k t he O N E b o x t hat best des cribes y o ur healt h T O D A Y. M O BI LI T Y I ha ve n o pr o ble ms w alkin g ❑ I ha ve m o der at e pr o ble ms w alkin g ❑ I a m c o nfine d t o be d ❑ S E L F -C A R E I ha ve n o pr o ble ms w as hin g or dr essin g m ys elf ❑ I ha ve m o der at e pr o ble ms w as hin g or dr essin g m ys elf ❑ I a m u na ble t o w as h or dr ess m ys elf ❑ U S U A L A C TI VI TI E S ( e. g. w ork, st u dy, h o use w ork, f a mily or l eis ure acti viti es) I ha ve n o pr o ble ms d oin g m y us ual activities ❑ I ha ve m o der at e pr o ble ms d oin g m y us ual activities ❑ I a m u na ble t o d o m y us ual activities ❑ P AI N / DI S C O M F O R T I ha ve n o pain or dis c o mf ort ❑ I ha ve m o der at e pain or dis c o mf ort ❑ I ha ve e xtr e m e pain or dis c o mf ort ❑ A N XI E T Y / D E P R E S SI O N I a m n ot a n xio us or de pr ess e d ❑ I a m m o der at ely a n xio us or de pr ess e d ❑ I a m e xtr e m ely a n xio us or de pr ess e d ❑"
127,page_127,"Allia nc e A1 7 1 6 0 1 1 2 8 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 • We w o uld like t o k n o w h o w g o o d or ba d y o ur he alt h is T O D A Y. • T his s c ale is n u m bere d fr o m 0 t o 1 0 0. • 1 0 0 me a ns t he best he alt h y o u c a n i ma gine. 0 me a ns t he w orst he alt h y o u c a n i ma gine. • Mar k a n X o n t he s c ale t o in dic ate h o w y o ur he alt h is T O D A Y. • N o w, ple as e write t he n u m ber y o u mar ke d o n t he s c ale in t he b o x belo w. 1 0 0 2 0 3 0 4 0 5 0 6 0 8 0 7 0 9 0 1 0 0 5 1 5 2 5 3 5 4 5 5 5 7 5 6 5 8 5 9 5 Y O U R H E A L T H T O D A Y ="
128,page_128,
129,page_129,
130,page_130,
131,page_131,
132,page_132,
133,page_133,
134,page_134,
135,page_135,"Allia nc e A1 7 1 6 0 1 1 3 6 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 A P P E N DI X V II: PA TI E N T ME DI C A TI O N DI A R Y - PA L B O C I C LI B To da y’s dat e _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __ _ _ _ _ _ P ati e nt Na m e _ _ _ _ _ _ _ _ _ _ __ _ _ _ _ _ _ _ (initials ac c e pt a ble) P ati e nt St u dy I D _ _ _ _ _ _ _ _ _ _ _ _ I N S T R U C TI O N S T O T H E P A TI E N T: 1. C o m plete t his f or m w hile y o u ta ke palb ociclib a n d if y o u are ta kin g letr oz ole . T his f or m is a 28 da y diar y. Y o u d o n’t ne e d t o c o m plete t he letr oz ole c olu m n if y o u are n ot ta kin g it. Y o u ma y ne e d t o c o m plete m ore t ha n o ne f or m bet w e e n clinic visits. 2. Y o u will ta ke y o ur d os e of palb ocicli b daily f or 2 1 da ys. Y o u will als o ta ke y o ur d os e of letr oz ole daily f or 2 8 da ys. 3. P alb ociclib intera cts wit h ot her me dic atio ns. D o n ot start a n y ne w pres criptio n or o ver t he c o u nter me dic atio ns wit h o ut dis c ussin g wit h y o ur d oct or or p har ma cist. 4 Ta ke t he palb ociclib c a ps ule wit h f o o d at a b o ut t he s a me ti me e ver y da y . Letr oz ole c a n be ta ke n o nc e daily wit h o ut re gar d t o f o o d. 5 . Re c or d t he date, a n d w he n y o u t o o k t he c a ps ule a n d pill. Re c or d d os es as s o o n as y o u ta ke t he m; d o n ot batc h e ntries t o get her at a later ti me. 6 . If y o u v o mit or miss a d os e , d o n ot ma ke u p t hat d os e; res u me d osin g wit h t he ne xt s c he d ule d d os e at t he us ual ti me. 7 . S w allo w c a ps ule w h ole, d o n ot cr us h or c he w. It s h o uld be ta ke n in c o m binatio n wit h e n d ocrine t hera p y (if ta kin g Letr oz ole) . T he c o m binatio n t hat y o u are bein g tre ate d wit h ma y be palb ociclib alo n g wit h letr oz ole pill or f ulvestra nt inje ctio n. D o n ot ta ke gra pefr uit or gra pefr uit juic e w he n y o u are ta kin g t his dr u g. 8 . If y o u ha ve a n y c o m me nts or n otic e a n y side effe cts, ple as e re c or d t he m in t he C o m me nts c olu m n. If y o u ma ke a mista ke w hile y o u write, ple as e cr oss it o ut wit h o ne line, p ut y o ur initials ne xt t o it, a n d t he n write t he c orre cte d inf or matio n ne xt t o y o ur initials. E xa m ple: 1 0:3 0 a m S B 9:3 0 a m 9 . If y o u d o n’t ta ke y o ur palb ociclib d os e f or a n y re as o n, c o nta ct y o ur p h ysicia n. 1 0 . Ple as e ret ur n t his f or m t o y o ur p h ysicia n at y o ur ne xt a p p oint me nt. Y o u ma y ne e d t o ret ur n m ore t ha n o ne f or m per clinic visit."
136,page_136,"Allia nc e A1 7 1 6 0 1 1 3 7 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 D a y D ate Ti me of d ail y d os e - P al b o cicli b ( 2 1 d a ys) Ti me of d ail y d os e - Letr o z ole( 2 8 d a ys ) If y o u mis s e d a d os e, R e as o n fo r n ot t a ki n g t he c a ps ule C o m me nts 1 2 3 4 5 6 7 8 9 1 0 1 1 1 2 1 3 1 4 1 5 1 6 1 7 1 8 1 9 2 0 2 1 2 2 N o c a ps ule 2 3 N o c a ps ule 2 4 N o c a ps ule 2 5 N o c a ps ule 2 6 N o c a ps ule 2 7 N o c a ps ule 2 8 N o c a ps ule P atie nt’s sig nat ure D ate Ad ditio nal s pac e f or C o m m e nts:"
137,page_137,
138,page_138,
139,page_139,"Allia nc e A1 7 1 6 0 1 1 4 0 N CI Versi o n D at e: 5/ 2 9 / 2 0 2 0 U p d at e 5 AP P E N DI X I X: PA TI E N T P H A R M A C O KI N E T I C Q U ES TI O N N AI R E N ot e: T his f or m is r e q uir e d t o be c o m plet e d at all blo o d dr a w ti m e p oints ass ociat e d wit h t he p har m ac o kinetic s u bst u d y ( A1 7 1 6 0 1 -P P 1). O n pr e -st u d y tr eat m e nt visit ( bas eline), C ycle 1 Da y 1 5 a n d C ycle 2 Da y 1 5, t his f or m is t o be a d minist er e d b y a n urs e/ C R P , c o m plet e d b y t he patie nt, a n d e nt er e d int o Ra ve b y sit e st aff. F or bas eli n e visit: T h e pati e nt m ay i n di c at e N/ A f or t h e q u esti o ns t hat are n ot a p pli c a bl e. Not e: st u dy m e di c ati o n s ho ul d O N L Y be t a k e n o n t h e da y of t h e cli ni c visit after pr o vi di n g t h e P K bl o o d s a m pl e . P atie nt I nitials: _ _ _ _ _ _ _ _ _ _ _ P atie nt I D #: _ _ _ _ _ _ _ _ _ _ _ _ _ St u d y #: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ C ycle #: _ _ _ _ _ _ _ Da y #: _ _ _ _ _ _ _ _ _ Dat e: _ _ _ _ _ _ _ _ _ _ T he f ollo win g q uestio n r ef ers t o t he da y bef or e yest er da y ( 2 da ys a g o): W hat ti m e did y o u t a ke y o ur or al st u d y m e dic atio n ( palb ociclib) ? _ _ _ _:_ _ _ _ A M / P M W hat d os e of or al st u d y m e dic atio n ( palb ociclib) did y o u t a ke o n t he da y bef or e yest er da y ------ m g T he f ollo win g q uestio n r ef ers t o yest er da y ( 1 da y a g o): W hat ti m e did y o u t a ke y o ur or al st u d y m e dic atio n ( palb ociclib) ? _ _ _ _:_ _ _ _ A M / P M W hat d os e of or al st u d y m e dic atio n ( palb ociclib) did y o u t a ke yest er da y ------ m g T he f ollo win g q uestio n r ef ers t o t o da y ( T HI S O N L Y A P P LI E S I F Y O U H A V E T A K E N Y O U R S T U D Y M E DI C A T I O N B E F O R E B EI N G S E E N I N T H E C LI NI C T O D A Y): W hat ti m e did y o u t a ke y o ur st u d y m e dic atio n ( palb ociclib) ? _ _ _ _:_ _ _ _ A M / P M W hat d os e of or al st u d y m e dic atio n ( palb ociclib) did y o u t a ke t o da y? -------- m g List c o n c o mit a nt m e di c ati o ns pati e nt is t a ki n g at bas eli ne st u dy visit O N L Y:"
